

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the Month of May, 2008

1-15240

(Commission File Number)

JAMES HARDIE INDUSTRIES N.V.

(Translation of registrant's name into English)

Atrium, 8th floor
Strawinskylaan 3077
1077 ZX Amsterdam, The Netherlands
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): Not Applicable

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): Not Applicable

Indicate by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): Not Applicable

TABLE OF CONTENTS

Safe Harbor Statement	3
Exhibit Index	4
Signatures	5
EXHIBIT 99.1	
EXHIBIT 99.2	
EXHIBIT 99.3	

Safe Harbor Statement

The exhibits attached to this Form 6-K contain forward-looking statements. We may from time to time make forward-looking statements in our periodic reports filed with or furnished to the United States Securities and Exchange Commission on Forms 20-F and 6-K, in our annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by our officers, directors or employees to analysts, institutional investors, lenders and potential lenders, representatives of the media and others. Examples of forward-looking statements include:

- expectations about the timing and amount of payments to the Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven asbestos-related personal injury and death claims;
- expectations concerning the costs associated with the suspension of operations at our Blandon, Pennsylvania and Plant City, Florida plants;
- statements as to the possible consequences of proceedings brought against us and certain of our former directors and officers by the Australian Securities and Investments Commission;
- statements regarding tax liabilities and related proceedings;
- expectations that our credit facilities will be extended or renewed;
- projections of our operating results or financial condition;
- statements regarding our plans, objectives or goals, including those relating to competition, acquisitions, dispositions and our products;
- statements about our future performance; and
- statements about product or environmental liabilities.

Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “target,” “estimate,” “project,” “predict,” “forecast,” “guideline,” “should,” “aim” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent risks and uncertainties. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors, some of which are discussed under “Risk Factors” beginning on page 6 of our Form 20-F filed on 6 July 2007 with the Securities and Exchange Commission, include but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former James Hardie subsidiaries; required contributions to the AICF and the effect of foreign exchange on the amount recorded in our financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which we operate; the consequences of product failures or defects; exposure to environmental, asbestos or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; the success of our research and development efforts; our reliance on a small number of product customers; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; foreign exchange risks and the effect of natural disasters. We caution you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those in forward-looking statements. Forward-looking statements speak only as of the date they are made and we undertake no duty to update or revise any such statements.

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	James Hardie Appoints New Director — Filed with the Australian Stock Exchange on May 20, 2008
Exhibit 99.2	James Hardie Q4 FY08 — Filed with the Australian Stock Exchange on May 22, 2008
Exhibit 99.3	KPMG report — Filed with the Australian Stock Exchange on May 22, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

James Hardie Industries N.V.

Date: May 23, 2008

By: /s/ Russell Chenu

Russell Chenu
Managing Director

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	James Hardie Appoints New Director — Filed with the Australian Stock Exchange on May 20, 2008
Exhibit 99.2	James Hardie Q4 FY08 — Filed with the Australian Stock Exchange on May 22, 2008
Exhibit 99.3	KPMG report — Filed with the Australian Stock Exchange on May 22, 2008

COMPANY STATEMENT

20 May 2008

For media and analyst enquiries please
call Steve Ashe on: Tel: (02) 8274 5246
Mob: 0408 164 011.

James Hardie appoints new Director

The Supervisory Board of James Hardie Industries has appointed David Harrison to the company's Supervisory and Joint Boards (the Board) and to the Board's Remuneration Committee, effective May 19, 2008.

Mr Harrison is an experienced company director and has a distinguished finance background, having served with special expertise in corporate finance roles as well as international operations and information technology.

He is Managing Partner of the US financial investor, HCI Inc. and previously spent seven years at Pentair, Inc., as Executive Vice President and Chief Financial Officer. His experience also includes roles as Vice President and Chief Financial Officer at Scotts, Inc. and Coltec Industries, Inc. and numerous accounting and financial roles held during 22 years at Borg-Warner/GE, culminating in his appointment as Vice President Finance Europe/Canada and Director, Finance North America.

Mr Harrison is a Director and Chairman of the Audit Committee for National Oilwell Varco (since 2003) and a Director and member of the Audit & Finance Committee for Navistar International (since 2007).

Announcing Mr Harrison's appointment, James Hardie Chairman, Michael Hammes, said his experience would further enhance the Board's finance and business skills, and was particularly relevant given the planned retirement of long-serving director, James Loudon, later this year.

"David's focus on corporate finance and international operations are especially relevant to James Hardie and we welcome the additional depth he brings to the Board," said Mr Hammes.

As required by the company's Articles of Association, Mr Harrison will stand for election at the Annual General Meeting to be held in Amsterdam in August 2008.

End

Contact details follow

Media, Investor and Analyst Enquiries:

Steve Ashe — Vice President Investor Relations

Telephone: 61 2 8274 5246
Mobile: 61 408 164 011
Email: steve.ashe@jameshardie.com.au
Facsimile: 61 2 8274 5218

www.jameshardie.com

Disclaimer

This company statement contains forward-looking statements. James Hardie may from time to time make forward-looking statements in its periodic reports filed with or furnished to the United States Securities and Exchange Commission on Forms 20-F and 6-K, in the annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the company's officers, directors or employees to analysts, institutional investors, lenders and potential lenders, representatives of the media and others. Examples of forward-looking statements include:

- expectations about the timing and amount of payments to the Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven asbestos-related personal injury and death claims;
- expectations concerning the costs associated with the suspension of operations at the company's Blandon, Pennsylvania plant;
- statements as to the possible consequences of proceedings brought against the company and certain of its former directors and officers by the Australian Securities and Investments Commission;
- statements regarding tax liabilities and related proceedings;
- expectations that the company's credit facilities will be extended or renewed;
- projections of the company's operating results or financial condition;
- statements regarding the company's plans, objectives or goals, including those relating to competition, acquisitions, dispositions and the company's products;
- statements about the company's future performance; and
- statements about product or environmental liabilities.

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "should," "aim" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent risks and uncertainties. The company cautions that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors, some of which are discussed under "Risk Factors" beginning on page 6 of the Form 20-F filed on 6 July 2007 with the Securities and Exchange Commission, include but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former James Hardie subsidiaries; required contributions to the AICF and the effect of foreign exchange on the amount recorded in the company's financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the company operates; the consequences of product failures or defects; exposure to environmental, asbestos or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; the success of research and development efforts; reliance on a small number of product distributors; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; foreign exchange risks; the successful implementation of new software systems; and the effect of natural disasters. The company cautions that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those in forward-looking statements. Forward-looking statements speak only as of the date they are made and the company undertakes no duty to update or revise any such statements.

Results for Announcement to the Market

James Hardie Industries N.V.

ARBN 097 829 895

Appendix 4E – Preliminary Final Report Year Ended 31 March 2008

Key Information	Year Ended 31 March			
	2008 US\$M	2007 US\$M	Movement	
Net Sales From Ordinary Activities	1,468.8	1,542.9	Down	5%
Operating (Loss) Profit From Continuing Operations After Tax Attributable to Shareholders	(71.6)	150.8	Down	—
Operating (Loss) Profit Including Cumulative Change In Accounting Principle For Stock-Based Compensation	(71.6)	151.7	Down	—
Net Tangible (Liabilities) Assets per Ordinary Share	US\$ (0.47)	US\$ 0.55	Down	—

Dividend Information

- A dividend of US 8.0 cents per share/CUFS is payable to share/CUFS holders on 11 July 2008. A dividend of US 12 cents per share/CUFS was paid on 18 December 2007 and a dividend of US 15 cents per share/CUFS was paid on 10 July 2007.
- Record Date is 4 June 2008 to determine entitlements to the dividend payable to share /CUFS holders on 10 July 2007 (ie, on the basis of proper instruments of transfer received by the Company's registrar, Computershare Investor Services Pty Ltd, Level 3, 60 Carrington Street, Sydney NSW 2000, Australia, by 5:00 pm if securities are not CHESS approved, or security holding balances established by 5:00 pm or such later time permitted by SCH Business Rules if securities are CHESS approved).
- This dividend and future dividends will be unfranked for Australian taxation purposes.
- This dividend is subject to Dutch withholding tax of 15%. For withholding tax information see: www.Jameshardie.com (select Investor Relations, then Shareholder services then Tax Information) or contact Computershare.
- The Australian currency equivalent amount of dividend to be paid to CUFS holders will be announced to the ASX on or about 5 June 2008.
- No dividend reinvestment plans are available for this dividend.

Movements in Controlled Entities during the year ended 31 March 2008

The following entities were liquidated: James Hardie FC Pty Ltd (20 April 2007), James Hardie Windows (Holdings) Pty Ltd (20 April 2007), (James Hardie US Holdings, Inc. (9 August 2007) and James Hardie Building Products LLC (9 August 2007).

ABTCO Road LLC was dissolved on 21 November 2007.

Audit

The results and financial information included within this Preliminary Final Report have been prepared using US GAAP and have been subject to an independent audit by external auditors.

Results for the 4th Quarter and Year Ended 31 March 2008**Contents**

1. Media Release
2. Management's Analysis of Results
3. Management Presentation
4. Consolidated Financial Statements

James Hardie Industries N.V. is incorporated in The Netherlands with corporate seat in Amsterdam. The liability of members is limited. The information contained in the above documents comprise the information required by ASX Listing Rule 4.2A and should be read in conjunction with the James Hardie 2007 Annual Report which can be found on the company website at www.jameshardie.com.

MEDIA RELEASE

22 May 2008

For analyst and media enquiries please
call Steve Ashe on: Tel: (02) 8274 5246
Mob: 0408 164 011.

4th quarter net operating profit US\$20.1m
Full year net operating profit US\$169.7m
(both excluding asbestos, asset impairments and tax adjustments)

James Hardie today announced a US\$20.1 million net operating profit, excluding asbestos, asset impairments and tax adjustments for the quarter ended 31 March 2008, a decrease of 61% compared to the same period last year.

For the quarter, net operating loss including asbestos, asset impairments and tax adjustments was US\$146.9 million compared to a net operating profit of US\$103.1 million for the same quarter last year.

For the full year, net operating profit excluding asbestos, asset impairments and tax adjustments decreased 20% to US\$169.7 million from US\$211.8 million. Including asbestos, asset impairments and tax adjustments, the company incurred a net operating loss of US\$71.6 million for the full year compared to a net operating profit of US\$151.7 million for last year.

Operating Performance

Fourth quarter net sales decreased 13% to US\$312.9 million, gross profit was down 20% to US\$107.2 million and EBIT excluding asbestos and asset impairments was 39% lower at US\$43.2 million. EBIT including asbestos and asset impairments improved from a loss of US\$215.8 million to a loss of US\$181.5 million.

For the full year, net sales decreased 5% to US\$1,468.8 million, gross profit was down 8% to US\$530.0 million and EBIT excluding asbestos and asset impairments decreased 12% to US\$281.7 million. EBIT including asbestos and asset impairments increased 58% from an EBIT loss of US\$86.6 million in fiscal year 2007 to an EBIT loss of US\$36.6 million in fiscal year 2008.

In this Media Release, James Hardie may present financial measures, sales volume terms, financial ratios, and Non-US GAAP financial measures included in the Definitions section of this document starting on page 8. The company presents financial measures that it believes are customarily used by its Australian investors. Specifically, these financial measures, which are equivalent to or derived from certain US GAAP measures as explained in the definitions, include "EBIT", "EBIT margin", "Operating profit" and "Net operating profit". The company may also present other terms for measuring its sales volumes ("million square feet" or "mmsf" and "thousand square feet" or "msf"); financial ratios ("Gearing ratio", "Net interest expense cover", "Net interest paid cover", "Net debt payback", "Net debt (cash)"; and Non-US GAAP financial measures ("EBIT excluding asbestos and asset impairments", "EBIT margin excluding asbestos and asset impairments", "Net operating profit excluding asbestos, asset impairments and tax adjustments", "Diluted earnings per share excluding asbestos, asset impairments and tax adjustments", "Operating profit before income taxes excluding asbestos and asset impairments" and "Effective tax rate excluding asbestos, asset impairments and tax adjustments" and EBITDA). Unless otherwise stated, results and comparisons are of the 4th quarter and the full year of the current fiscal year versus the 4th quarter and the full year of the prior fiscal year.

Media Release: James Hardie - 4th Quarter and Full Year FY08

The slump in the US housing market, our largest market, deepened during the quarter as builders continued to reduce the pace of new home construction in an environment of weak sales and high inventories of new homes for sale. New housing starts are now running around 55% off their peak levels of 2006. Despite this, the business was able to partly offset the impact of the much weaker housing market during the year through market penetration against alternative materials. USA Fibre Cement net sales fell 20% for the quarter and 9% for the full year. EBIT was down 41% to US\$50.3 million and 13% to \$313.6 million for the quarter and full year, respectively, due to lower volumes and higher costs, partially offset by lower SG&A spending for the full year.

Asia Pacific Fibre Cement net sales were up 14% for the quarter due to a stronger Australian dollar against the US dollar and a higher average net sales price. Asia Pacific Fibre Cement EBIT increased 22% to US\$10.7 million for the quarter and 28% to US\$50.3 million for the full year due to an improved operating performance in the Australia and New Zealand Fibre Cement business and favourable currency movements.

Diluted earnings per share for the quarter decreased to a loss of US33.8 cents per share from earnings of US22.0 cents in the same period last year and decreased from US32.5 cents to a loss of US15.7 cents for fiscal year 2008. Weighted average shares outstanding were 8% lower at 31 March 2008 as compared to 31 March 2007 as a result of the company's share buy-back program.

Diluted earnings per share excluding asbestos, asset impairments and tax adjustments decreased by 58% from US11.0 cents to US4.6 cents for the quarter and decreased by 18% from US45.4 cents to US37.2 cents for fiscal year 2008. Diluted earnings per share excluding asbestos, asset impairments and tax adjustments benefited from the share buy-back program commenced during fiscal year 2008.

4th Quarter and Full Year at a Glance

US\$ Million	Q4 FY 2008	Q4 FY 2007	% Change	FY 2008	FY 2007	% Change
Net sales	\$ 312.9	\$ 360.9	(13)	\$1,468.8	\$1,542.9	(5)
Gross profit	107.2	133.8	(20)	530.0	573.0	(8)
SCI and other related expenses	—	(5.4)	—	—	(13.6)	—
EBIT excluding asbestos and asset impairments	43.2	70.5	(39)	281.7	318.9	(12)
AICF SG&A expenses	(1.3)	—	—	(4.0)	—	—
Asbestos adjustments	(182.3)	(286.3)	36	(240.1)	(405.5)	41
Impairment charges	(38.6)	—	—	(71.0)	—	—
EBIT	(181.5)	(215.8)	16	(36.6)	(86.6)	58
Net interest (expense) income	(2.2)	(4.2)	48	1.1	(6.5)	—
Income tax benefit (expense)	36.8	323.1	(89)	(36.1)	243.9	—
Net operating (loss) profit	(146.9)	103.1	—	(71.6)	151.7	—

Media Release: James Hardie - 4th Quarter and Full Year FY08

Net operating profit excluding asbestos, asset impairments and tax adjustments decreased 61% for the quarter to US\$20.1 million, and was 20% lower for the full year at US\$169.7 million, as shown in the following table:

US\$ Million	Q4 FY 2008	Q4 FY 2007	% Change	FY 2008	FY 2007	% Change
Net operating (loss) profit	\$(146.9)	\$ 103.1	—	\$(71.6)	\$ 151.7	—
Excluding:						
Asbestos:						
Asbestos adjustments	182.3	286.3	(36)	240.1	405.5	(41)
AICF SG&A expenses	1.3	—	—	4.0	—	—
AICF interest income	(2.4)	—	—	(9.4)	—	—
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(86)	(45.8)	(335.0)	(86)
Asset impairments:						
Impairment charges (net of tax)	24.6	—	—	44.6	—	—
Impairment related costs (net of tax)	1.6	—	—	2.0	—	—
Tax adjustments	5.8	(3.0)	—	5.8	(10.4)	—
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	(61)	\$169.7	\$ 211.8	(20)

Commentary

James Hardie's CEO, Mr Louis Gries said: "Overall, our major businesses performed relatively well for the year in very challenging market conditions, particularly in the United States. However, fourth quarter results were disappointing.

"In the US, the housing market continued to deteriorate in all four quarters of this past year. New housing starts were down 37% from last year and 55% from their peak in 2006.

"Our USA Fibre Cement business again outperformed the broader market for the year with sales down only 9%. It achieved these results mainly through further market penetration at the expense of alternative materials.

"The normal seasonal pickup in new housing activity expected in the latter part of the fourth quarter did not occur, adversely affecting fourth quarter performance in our US business.

"Indicators of future housing construction activity suggest some further weakness is to be expected. However, early first quarter sales for the US business indicate a slight pick up in demand, although not to the extent experienced in previous years.

"In our Asia Pacific Fibre Cement business, continued acceptance of our new differentiated products by builders, developers and architects in Australia and New Zealand helped lift sales performance for the year," said Mr Gries.

Dividend

The company today announced a final dividend of US8 cents a share. The dividend will be paid on 11 July 2008 to shareholders registered on 4 June 2008. The full year dividend for FY08 will be US20 cents a share, consistent with the full year dividend for FY07.

Media Release: James Hardie - 4th Quarter and Full Year FY08

Share Buy-Back Program

On 15 August 2007, the company announced a share buy-back program of up to 10% of the company's issued capital, approximately 46.8 million shares. The company bought back 2.2 million shares and 35.7 million shares of common stock during the three months and full year ended 31 March 2008, respectively. The bought back shares had an aggregate cost of A\$12.7 million (US\$11.7 million) and A\$236.4 million (US\$208.0 million) during the three months and full year ended 31 March 2008, respectively. The average price paid per share of common stock was A\$5.77 (US\$5.32) and A\$6.62 (US\$5.83) during the three months and full year ended 31 March 2008, respectively. The US dollar amounts were determined using the weighted average spot rates for the days on which shares were purchased. The company did not purchase any shares during the period between 1 April 2008 and 22 May 2008. The company cancelled 35.0 million shares on 31 March 2008.

USA Fibre Cement

Fourth quarter net sales were down 20% compared to the same quarter last year, to US\$232.5 million. Sales volume decreased 19% to 393.9 million square feet, and the average net sales price decreased 1% from US\$598 to US\$590 per thousand square feet.

For the full year, net sales were down 9% compared to the same period last year, to US\$1,144.8 million. Sales volume decreased 11% to 1,916.6 million square feet, and the average net sales price was 2% higher at US\$597 per thousand square feet.

Despite improved housing affordability as a result of further interest rate cuts, the US housing market continued to deteriorate during the quarter as weaker consumer confidence, tighter mortgage lending standards and falling house prices weighed heavily on demand for new homes. Housing construction starts for the quarter were at near record lows as builders again slowed the pace of new home construction in an attempt to reduce very high inventory levels, and as increased foreclosures placed more existing homes for sale.

Sales volumes were lower across all divisions and in each key region, other than Canada. Most of the decrease in sales volumes came from our exterior products category with only the ColorPlus® collection of products recording sales growth for the quarter. Sales of our interior products category were slightly weaker for the quarter.

The seasonal pickup in demand that was expected in the latter part of the quarter did not occur and this led to inventory levels for the business at the end of the quarter being higher than expected.

EBIT for the quarter was 41% lower at US\$50.3 million, primarily due to lower volume and higher manufacturing costs. The EBIT margin was 21.6%. For the full year, EBIT was 13% lower at US\$313.6 million and the EBIT margin was 27.4%.

Asia Pacific Fibre Cement

Net sales increased 14% to US\$73.5 million for the quarter. In Australian dollars, net sales decreased 1% due to a 3% decrease in sales volume, partially offset by an increase of 2% in the average Australian dollar net sales price.

For the full year, net sales increased 19% to US\$298.3 million. In Australian dollars, net sales increased 4% due to a 2% increase in sales volumes and a 2% increase in the average Australian dollar net sales price.

Media Release: James Hardie - 4th Quarter and Full Year FY08

Residential construction activity was slightly weaker in both Australia and New Zealand compared to the same quarter last year. There was a small decrease in sales volumes in Australia and New Zealand mainly due to the impact of less production days associated with Easter falling in March, compared with it falling in April last year. In Australia, sales of Scyon™ branded differentiated products continued to grow and increase as a proportion of the sales mix. For the full year, sales of Scyon™ branded products were up 150% compared to the previous fiscal year. In New Zealand, differentiated products, including Linea® weatherboards, also continued to grow as a proportion of the sales mix. In the Philippines, net sales were down 4%, in local currency, compared to the same quarter last year due to a small decrease in both sales volumes and the average sales price, primarily due to a reduction in export sales.

EBIT was 22% higher for the quarter at US\$10.7 million and 28% higher at US\$50.3 million for the full year due to an increased gross margin together with the appreciation of Asia Pacific currencies against the US dollar. The EBIT margin was 14.6% for the quarter and 16.9% for the full year.

USA Hardie Pipe

Net sales for the quarter and full year decreased compared to the same periods last year due to materially lower sales volume as a result of weaker residential and non-residential construction activity in Florida. The business also experienced a greater EBIT loss for the quarter and full year compared to a small EBIT loss in the same quarter last year and a small positive EBIT for the full year last year.

The recent downturn in construction activity and the outlook for our USA Hardie Pipe business in the Southeast of the United States has prompted the company to close the business, resulting in an impairment charge of US\$25.4 million in the fourth quarter, as discussed below. Production in the Plant City, Florida manufacturing facility discontinued in May 2008.

Europe Fibre Cement

The Europe Fibre Cement business incurred significantly reduced EBIT losses for the quarter and full year as it continued to build sales and improve operating margins.

Impairment Charges

The downturn in US construction activity has prompted the company to review the carrying value of certain long-lived assets. As a result of these reviews, asset impairments of US\$38.6 million and US\$71.0 million have been taken in the fourth quarter and the full year, respectively.

On 31 October 2007, the company announced plans to suspend production at its Blandon, Pennsylvania plant in the US. The company recorded an asset impairment of US\$32.4 million in the quarter ended 31 December 2007 and the year ended 31 March 2008 in its USA Fibre Cement segment. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. These assets are being held for use by the company. Between the date of the announcement and 31 March 2008, the company has incurred US\$1.4 million of impairment related costs. These impairment related costs are not included in the impairment charge of US\$32.4 million and have been included in cost of goods sold and selling, general and administrative expenses in the period in which they were incurred.

Media Release: James Hardie - 4th Quarter and Full Year FY08

On 22 May 2008, the company announced plans to cease production at its Plant City, Florida Hardie Pipe manufacturing facility in the US. As a result, the company recorded an asset impairment of US\$25.4 million in the fourth quarter and the year ended 31 March 2008 in its Other segment. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. In addition to the impairment charge, the company has recorded US\$1.8 million of impairment related costs in the year ended 31 March 2008.

The company also recorded an asset impairment of US\$13.2 million in the fourth quarter and the year ended 31 March 2008 related to buildings and machinery used to produce materials for the company's products. This impairment charge was recorded in its USA Fibre Cement segment. The impaired assets were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows.

Asbestos Adjustments

The effect of asbestos adjustments on EBIT for the quarter and full year ended 31 March 2008 are as follows:

US\$ Million	Q4 FY08	Q4 FY07	FY 2008	FY 2007
Change in estimates	\$(154.1)	\$ 70.3	\$(152.9)	\$ 28.5
Effect of foreign exchange	(28.2)	(17.1)	(87.2)	(94.5)
Impact of tax-effecting the net Amended FFA liability	—	(335.0)	—	(335.0)
Other adjustments	—	(4.5)	—	(4.5)
Asbestos adjustments	\$(182.3)	\$(286.3)	\$(240.1)	\$(405.5)

Readers are referred to Note 12 of the company's 31 March 2008 Consolidated Financial Statements for further information on the asbestos adjustments.

ASIC Proceedings

In February 2007, the Australian Securities and Investments Commission (ASIC) commenced civil proceedings against the company, a former subsidiary and ten then-present or former officers and directors of the James Hardie group. The civil proceedings concern alleged contraventions of certain provisions of the Corporations Law and/or the Corporations Act connected with the affairs of the company and certain subsidiaries during the period February 2001 to June 2003.

Readers are referred to Note 13 of the company's 31 March 2008 Consolidated Financial Statements for further information on the ASIC Proceedings.

Cash Flow

Operating cash flow for the full year ended 31 March 2008 increased from cash used of US\$67.1 million to cash generated of US\$319.3 million. The increase was driven primarily by the payment of a deposit with the Australian Taxation Office pending a disputed amended assessment and payments made to fund the AICF during the year ended 31 March 2007 totalling US\$154.8 million and US\$151.9 million, respectively, compared to payments of US\$9.7 million and nil, respectively, in the current full year. Capital expenditures for the purchase of property, plant and equipment decreased from US\$92.6 million to US\$38.5 million.

Media Release: James Hardie - 4th Quarter and Full Year FY08

Outlook

In North America, factors such as high inventory levels of new homes for sale, an increased rate of foreclosures placing more existing properties on the market, weaker economic conditions and consumer sentiment, and tighter mortgage lending standards, all suggest that further weakness in the level of new housing construction activity is likely in the short-term.

To address the prospect of further market weakness, the USA Fibre Cement business underwent a further business reset in April to enable its cost base to better reflect expected market demand.

The business remains committed to investing in key growth initiatives and expects to further increase market share at the expense of alternative materials and outperform the broader market. However, as a result of the severe decline in housing construction activity and the prospect of a further decline in the short-term, the business has increased its focus on initiatives that build EBIT performance.

In Asia Pacific Fibre Cement, the short-term outlook is for residential construction activity to be flat in Australia, slightly weaker in New Zealand and for construction activity in the Philippines to be stronger. The business expects to continue to grow primary demand for fibre cement and increase market shares through its range of differentiated products in Australia and New Zealand. Non-differentiated products are expected to remain subject to strong competition.

Changes to the company's asbestos liability to reflect changes in foreign exchange rates or updates to the actuarial estimate and the other matters referred to in the disclaimer at the end of this document may have a material impact on the company's consolidated financial statements. Readers are referred to Note 12 of the company's 31 March 2008 Consolidated Financial Statements for more information about the company's asbestos liability.

END

Media/Analyst Enquiries:

Steve Ashe
Vice President Investor Relations

Telephone: +61 2 8274 5246
Mobile: +61 408 164 011
Email: steve.ashe@jameshardie.com.au
Facsimile: +61 2 8274 5218

This Media Release forms part of a package of information about the company's results. It should be read in conjunction with the other parts of the package, including Management's Analysis of Results, a Management Presentation and a Financial Report.

These documents, along with a webcast of the management presentation on 22 May 2008, are available from the Investor Relations area of James Hardie's website at: www.jameshardie.com

The company lodged its annual filing for the year ended 31 March 2007 with the SEC on 6 July 2007.

All holders of the company's securities may receive, on request, a hard copy of our complete audited financial statements, free of charge. Requests can be made via the company website or by contacting one of the company's corporate offices. Contact details are available on the company's website.

Media Release: James Hardie - 4th Quarter and Full Year FY08

Definitions

Financial Measures – US GAAP equivalents

EBIT and EBIT margin – EBIT, as used in this document, is equivalent to the US GAAP measure of operating income. EBIT margin is defined as EBIT as a percentage of net sales. James Hardie believes EBIT and EBIT margin to be relevant and useful information as these are the primary measures used by management to measure the operating profit or loss of its business. EBIT is one of several metrics used by management to measure the earnings generated by the company's operations, excluding interest and income tax expenses. Additionally, EBIT is believed to be a primary measure and terminology used by its Australian investors. EBIT and EBIT margin should be considered in addition to, but not as a substitute for, other measures of financial performance reported in accordance with accounting principles generally accepted in the United States of America. EBIT and EBIT margin, as the company has defined them, may not be comparable to similarly titled measures reported by other companies.

Operating profit – is equivalent to the US GAAP measure of income.

Net operating profit – is equivalent to the US GAAP measure of net income.

Sales Volumes

mmsf – million square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

msf – thousand square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

Financial Ratios

Gearing Ratio – Net debt (cash) divided by net debt (cash) plus shareholders' equity.

Net interest expense cover – EBIT divided by net interest expense.

Net interest paid cover – EBIT divided by cash paid during the period for interest, net of amounts capitalised.

Net debt payback – Net debt (cash) divided by cash flow from operations.

Net debt (cash) – short-term and long-term debt less cash and cash equivalents.

Media Release: James Hardie - 4th Quarter and Full Year FY08

Non-US GAAP Financial Measures

EBIT and EBIT margin excluding asbestos and asset impairments – EBIT and EBIT margin excluding asbestos and asset impairments are not measures of financial performance under US GAAP and should not be considered to be more meaningful than EBIT and EBIT margin. James Hardie has included these financial measures to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations and provides useful information regarding its financial condition and results of operations. The company uses these non-US GAAP measures for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
EBIT	\$(181.5)	\$(215.8)	\$ (36.6)	\$ (86.6)
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	—	4.0	—
Asset impairments:				
Impairment charges	38.6	—	71.0	—
Impairment related costs	2.5	—	3.2	—
EBIT excluding asbestos and asset impairments	43.2	70.5	281.7	318.9
Net Sales	\$ 312.9	\$ 360.9	\$1,468.8	\$1,542.9
EBIT margin excluding asbestos and asset impairments	13.8%	19.5%	19.2%	20.7%

Net operating profit excluding asbestos, asset impairments and tax adjustments – Net operating profit excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than net income. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
Net operating (loss) profit	\$(146.9)	\$ 103.1	\$(71.6)	\$ 151.7
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	—	4.0	—
AICF interest income	(2.4)	—	(9.4)	—
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(45.8)	(335.0)
Asset impairments:				
Impairment charges (net of tax)	24.6	—	44.6	—
Impairment related costs (net of tax)	1.6	—	2.0	—
Tax adjustments	5.8	(3.0)	5.8	(10.4)
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	\$169.7	\$ 211.8

Media Release: James Hardie - 4th Quarter and Full Year FY08

Diluted earnings per share excluding asbestos, asset impairments and tax adjustments – Diluted earnings per share excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than diluted earnings per share. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company's management uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	\$169.7	\$211.8
Weighted average common shares outstanding — Diluted (millions)	434.6	469.0	456.1	466.4
Diluted earnings per share excluding asbestos, asset impairments and tax adjustments (US cents)	4.6	11.0	37.2	45.4

Effective tax rate excluding asbestos, asset impairments and tax adjustments – Effective tax rate excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than effective tax rate. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company's management uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
Operating loss before income taxes	\$(183.7)	\$(220.0)	\$ (35.5)	\$ (93.1)
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	—	4.0	—
AICF interest income	(2.4)	—	(9.4)	—
Asset impairments:				
Impairment charges	38.6	—	71.0	—
Impairment related costs	2.5	—	3.2	—
Operating profit before income taxes excluding asbestos and asset impairments	\$ 38.6	\$ 66.3	\$ 273.4	\$ 312.4
Income tax benefit (expense)	36.8	323.1	(36.1)	243.9
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(45.8)	(335.0)
Tax benefit related to asset impairments	(14.9)	—	(27.6)	—
Tax adjustments	5.8	(3.0)	5.8	(10.4)
Income tax expense excluding asbestos, asset impairments and tax adjustments	(18.5)	(14.9)	(103.7)	(101.5)
Effective tax rate excluding asbestos, asset impairments and tax adjustments	48.0%	22.5%	37.9%	32.5%

Media Release: James Hardie - 4th Quarter and Full Year FY08

EBITDA – is not a measure of financial performance under US GAAP and should not be considered an alternative to, or more meaningful than, income from operations, net income or cash flows as defined by US GAAP or as a measure of profitability or liquidity. Not all companies calculate EBITDA in the same manner as James Hardie has and, accordingly, EBITDA may not be comparable with other companies. The company has included information concerning EBITDA because it believes that this data is commonly used by investors to evaluate the ability of a company's earnings from its core business operations to satisfy its debt, capital expenditure and working capital requirements.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
EBIT	\$(181.5)	\$(215.8)	\$(36.6)	\$(86.6)
Depreciation and amortisation	14.4	13.7	56.5	50.7
EBITDA	\$(167.1)	\$(202.1)	\$ 19.9	\$(35.9)

Media Release: James Hardie - 4th Quarter and Full Year FY08

Disclaimer

This Media Release contains forward-looking statements. We may from time to time make forward-looking statements in our periodic reports filed with or furnished to the United States Securities and Exchange Commission on Forms 20-F and 6-K, in our annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by our officers, directors or employees to analysts, institutional investors, lenders and potential lenders, representatives of the media and others. Examples of forward-looking statements include:

- expectations about the timing and amount of payments to the Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven asbestos-related personal injury and death claims;
- expectations concerning the costs associated with the suspension of operations at our Blandon, Pennsylvania and Plant City, Florida plants;
- statements as to the possible consequences of proceedings brought against us and certain of our former directors and officers by the Australian Securities and Investments Commission;
- statements regarding tax liabilities and related proceedings;
- expectations that our credit facilities will be extended or renewed;
- projections of our operating results or financial condition;
- statements regarding our plans, objectives or goals, including those relating to competition, acquisitions, dispositions and our products;
- statements about our future performance; and
- statements about product or environmental liabilities.

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "should," "aim" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent risks and uncertainties. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors, some of which are discussed under "Risk Factors" beginning on page 6 of our Form 20-F filed on 6 July 2007 with the Securities and Exchange Commission, include but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former James Hardie subsidiaries; required contributions to the AICF and the effect of foreign exchange on the amount recorded in our financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which we operate; the consequences of product failures or defects; exposure to environmental, asbestos or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; the success of our research and development efforts; our reliance on a small number of product customers; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; foreign exchange risks; and the effect of natural disasters. We caution you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those in forward-looking statements. Forward-looking statements speak only as of the date they are made and we undertake no duty to update or revise any such statements.

Media Release: James Hardie - 4th Quarter and Full Year FY08

MANAGEMENT'S ANALYSIS OF RESULTS

22 May 2008

**James Hardie Industries N.V.
Results for the 4th Quarter and Full Year Ended 31 March 2008**

US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY08	Q4 FY07	% Change	FY08	FY07	% Change
Net Sales						
USA Fibre Cement	\$ 232.5	\$ 289.9	(20)	\$1,144.8	\$1,262.3	(9)
Asia Pacific Fibre Cement	73.5	64.3	14	298.3	251.7	19
Other	6.9	6.7	3	25.7	28.9	(11)
Total Net Sales	\$ 312.9	\$ 360.9	(13)	\$1,468.8	\$1,542.9	(5)
Cost of goods sold	(205.7)	(227.1)	9	(938.8)	(969.9)	3
Gross profit	107.2	133.8	(20)	530.0	573.0	(8)
Selling, general and administrative expenses	(60.3)	(52.3)	(15)	(228.2)	(214.6)	(6)
Research & development expenses	(7.5)	(5.6)	(34)	(27.3)	(25.9)	(5)
Impairment charges	(38.6)	—	—	(71.0)	—	—
SCI and other related expenses	—	(5.4)	—	—	(13.6)	—
Asbestos adjustments	(182.3)	(286.3)	36	(240.1)	(405.5)	41
EBIT	(181.5)	(215.8)	16	(36.6)	(86.6)	58
Net interest (expense) income	(2.2)	(4.2)	48	1.1	(6.5)	—
Operating loss before income taxes	(183.7)	(220.0)	17	(35.5)	(93.1)	62
Income tax benefit (expense)	36.8	323.1	(89)	(36.1)	243.9	—
Operating (loss) profit before cumulative effect of change in accounting principle	(146.9)	103.1	—	(71.6)	150.8	—
Cumulative effect of change in accounting principle for stock-based compensation, net of income tax expense of nil and US \$0.4 million, respectively	—	—	—	—	0.9	—
Net operating (loss) profit	\$(146.9)	\$ 103.1	—	\$ (71.6)	\$ 151.7	—
(Loss) earnings per share — diluted (US cents)	(33.8)	22.0	—	(15.7)	32.5	—
Volume (mmsf)						
USA Fibre Cement	393.9	484.9	(19)	1,916.6	2,148.0	(11)
Asia Pacific Fibre Cement	95.3	98.2	(3)	398.2	390.8	2
Average net sales price per unit (per mmsf)						
USA Fibre Cement	US\$ 590	US\$ 598	(1)	US\$ 597	US\$ 588	2
Asia Pacific Fibre Cement	A\$ 848	A\$ 833	2	A\$ 862	A\$ 842	2

In this Management's Analysis of Results, James Hardie may present financial measures, sales volume terms, financial ratios, and Non-US GAAP financial measures included in the Definitions section of this document starting on page 15. The company presents financial measures that it believes are customarily used by its Australian investors. Specifically, these financial measures, which are equivalent to or derived from certain US GAAP measures as explained in the definitions, include "EBIT", "EBIT margin", "Operating profit" and "Net operating profit". The company may also present other terms for measuring its sales volumes ("million square feet" or "mmsf" and "thousand square feet" or "msf"); financial ratios ("Gearing ratio", "Net interest expense cover", "Net interest paid cover", "Net debt payback", "Net debt (cash)"); and Non-US GAAP financial measures ("EBIT excluding asbestos and asset impairments", "EBIT margin excluding asbestos and asset impairments", "Net operating profit excluding asbestos, asset impairments and tax adjustments", "Diluted earnings per share excluding asbestos, asset impairments and tax adjustments", "Operating profit before income taxes excluding asbestos and asset impairments" and "Effective tax rate excluding asbestos, asset impairments and tax adjustments" and EBITDA). Unless otherwise stated, results and comparisons are of the 4th quarter and current full fiscal year versus the 4th quarter and full year of the prior fiscal year.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Total Net Sales

Total net sales for the quarter decreased 13% compared to the same quarter of the previous year, from US\$360.9 million to US\$312.9 million. For the full year, total net sales decreased 5% from US\$1,542.9 million to US\$1,468.8 million.

Net sales from USA Fibre Cement for the quarter decreased 20% from US\$289.9 million to US\$232.5 million due to a reduction in sales volume and a slight reduction in average net sales price. For the full year, net sales from USA Fibre Cement decreased 9% from US\$1,262.3 million to US\$1,144.8 million due to reduced sales volume, partially offset by a higher average net sales price.

Net sales from Asia Pacific Fibre Cement for the quarter increased 14% from US\$64.3 million to US\$73.5 million due to favourable currency exchange rates and a higher average net sales price, partially offset by a reduction in sales volume. For the full year, net sales from Asia Pacific Fibre Cement increased 19% from US\$251.7 million to US\$298.3 million due to favourable currency exchange rates, increased sales volumes and a higher average net sales price.

Other net sales for the quarter increased 3% from US\$6.7 million to US\$6.9 million, and for the full year decreased 11% from US\$28.9 million to US\$25.7 million. The decrease was due to reduced sales in the USA Hardie Pipe business, partially offset by improved sales performance in the Europe Fibre Cement business.

USA Fibre Cement

Quarter

Net sales decreased 20% from US\$289.9 million in the fourth quarter of the prior fiscal year to US\$232.5 million due to decreased sales volume and a slight decrease in the average net sales price.

Sales volume decreased 19% from 484.9 million square feet to 393.9 million square feet for the quarter, as the continued decline in housing construction activity and deteriorating economic conditions led to weaker demand for the company's products.

The average net sales price decreased 1% from US\$598 per thousand square feet to US\$590 per thousand square feet.

Full year

Net sales decreased 9% from US\$1,262.3 million to US\$1,144.8 million due to decreased sales volume, partially offset by a higher average net sales price.

Sales volume decreased 11% from 2,148.0 million square feet to 1,916.6 million square feet for the full year, as the decline in housing construction activity and deteriorating economic conditions led to weaker demand for the company's products.

The average net sales price increased 2% from US\$588 per thousand square feet to US\$597 per thousand square feet due to price increases and a shift in the product mix.

Discussion

Despite improved housing affordability as a result of further interest rate cuts, the housing market continued to deteriorate during the quarter as weaker consumer confidence, tighter lending standards and falling house prices weighed heavily on demand for new homes. Housing construction starts for the quarter were at near record lows as builders again attempted to reduce high inventory levels of new homes for sale, and as increased foreclosures placed more existing homes for sale.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

The decline in net sales compared to the same quarter last year was primarily due to lower sales volumes in our exterior products category. The decline was across the entire range of exterior products other than ColorPlus® collection of products, which has continued growing. Sales were lower across all divisions and in each key region with the exception of Canada.

Artisan® Lap, the business' new premium exterior product launched in Atlanta last September, is continuing to be well received by architects, developers and builders who work in the custom home segment of the market. Artisan® Lap has now been launched in regions of the Western and Southern Divisions.

Repair and remodelling activity has not been affected to the same extent as the new construction segment of the housing market, however some weakness in repair and remodelling activity has led to sales of our interior products being slightly lower compared to the same quarter last year.

The overall rate of market penetration slowed during the quarter and the business did not buffer the impact of the downturn in housing construction activity to the extent expected.

The usual seasonal pickup in demand that was expected in the latter part of the quarter did not occur and this led to inventory levels for the business at the end of the quarter being higher than expected.

Although the business is continuing to perform well at the EBIT line relative to other participants in the housing sector, it has shifted its focus for the next fiscal year to increase margins. The company believes that this shift in focus will not result in funding cuts for key growth initiatives.

For the full year, market penetration in the interior and exterior product categories and an increase in the average net sales price helped to partly off-set the unfavourable impact of significantly weaker housing construction activity.

Asia Pacific Fibre Cement

Quarter

Net sales for the quarter increased 14% from US\$64.3 million to US\$73.5 million due to a 17% increase in the average net sales price, partly offset by a 3% decrease in sales volume. Favourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar accounted for the increase in net sales in US dollars. In Australian dollars, net sales decreased 1% due to a 3% decrease in the sales volume offset by a 2% increase in the average net sales price.

Full year

Net sales for the full year increased 19% from US\$251.7 million to US\$298.3 million due to a 17% increase in the average net sales price and 2% increase in sales volumes. Favourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar accounted for 15% of the increase in net sales in US dollars. In Australian dollars, net sales increased 4% due to a 2% increase in sales volume and a 2% increase in the average Australian dollar net sales price.

Discussion

Residential construction activity was slightly weaker in both Australia and New Zealand compared to the same quarter last year. Net sales in the Australia and New Zealand business increased 14% due to favourable foreign currency exchange rates. In Australian dollars, net sales decreased 1% due to a 3% decline in sales volume and a 2% increase in the average net sales price. The decrease in sales volumes was mainly due to the impact of less production days associated with Easter falling in March, compared with April last year. In Australia, sales of Scyon™ branded differentiated products continued to grow and increased as a proportion of the sales mix. Sales of Scyon™ branded products for the year increased 150% compared to the previous fiscal year.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Non-differentiated products remain subject to strong price competition. In New Zealand, differentiated products, including Linea[®] weatherboards, also continued to grow as a proportion of the sales mix. The increase in the average net sales price for the quarter was due to the shift in the Australia and New Zealand sales mix. In the Philippines, net sales were 4% lower, in local currency, compared to the same quarter last year due to a small decrease in sales volumes and the average sales price, largely related to a reduction in export sales.

For the full year, the increase in net sales was driven by stronger primary demand for fibre cement in Australia and New Zealand mainly due to growth in sales of the Scyon[™] product range in Australian and Linea[®] weatherboards in New Zealand, a higher average net sales price and favourable foreign currency movements.

Other

USA Hardie Pipe

Net sales for the quarter and full year decreased compared to the same periods last year due to materially lower sales volume resulting from weaker residential and non-residential construction activity in Florida.

Europe Fibre Cement

Sales continued to grow steadily during the quarter and the full year.

Gross Profit

Quarter

Gross profit decreased 20% from US\$133.8 million to US\$107.2 million. The gross profit margin decreased 2.8 percentage points from 37.1% to 34.3%.

USA Fibre Cement gross profit decreased 28% compared to the same quarter last year due to lower sales volume, higher freight costs, higher average unit costs and a slightly lower average net sales price. The gross profit margin of the USA Fibre Cement business decreased by 4.1 percentage points.

Asia Pacific Fibre Cement gross profit increased 41% compared to the same period last year. Favourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar accounted for 16% of this increase while the underlying Australian dollar business results accounted for the remaining 25% increase. In Australian dollars, gross profit increased 25% due to lower manufacturing costs, including an insurance claim recovery recorded in the period accounting for 10% of the increase. The gross profit margin of the Asia Pacific Fibre Cement business increased by 6.2 percentage points.

Full year

Gross profit decreased 8% from US\$573.0 million to US\$530.0 million. The gross profit margin decreased 0.9 of a percentage point from 37.1% to 36.2%.

USA Fibre Cement gross profit decreased 12% compared to the same period last year due to lower sales volumes, higher freight costs and higher average unit costs, partially offset by a higher average net sales price. The gross profit margin decreased by 1.3 percentage points.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Asia Pacific Fibre Cement gross profit increased 24% compared to the same period last year. Favourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar accounted for 14% of this increase while the underlying Australian dollar business results accounted for the remaining 10% increase. In Australian dollars, gross profit increased 10% due to increased sales volumes, a higher average net sales price and an insurance claim recovery which accounted for 2% of the increase. The gross profit margin increased by 1.4 percentage points.

Selling, General and Administrative (SG&A) Expenses

SG&A expenses increased 15% for the quarter, from US\$52.3 million to US\$60.3 million, due to the costs associated with the Australian Securities and Investments Commission (ASIC) proceedings, non-claims handling related operating expenses of the Asbestos Injuries Compensation Fund (AICF) and increased SG&A spending of the USA Fibre Cement and the Asia Pacific Fibre Cement segments. As a percentage of sales, SG&A expenses increased 4.8 percentage points to 19.3%.

For the full year, SG&A expenses increased 6% from US\$214.6 million to US\$228.2 million, primarily due to higher warranty provisions relating to non-US activities, costs associated with the ASIC proceedings, non-claims handling related operating expenses of the AICF and the impact of the unfavourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar. These increases were partially offset by improved SG&A performance of the USA Fibre Cement and Other segments. As a percentage of sales, SG&A expense increased 1.6 percentage points to 15.5%.

SG&A expenses for the full year include non-claims handling related operating expenses of the AICF of US\$4.0 million.

ASIC Proceedings

In February 2007, ASIC commenced civil proceedings against JHI NV, a former subsidiary and ten then-present or former officers and directors of the James Hardie group. The civil proceedings concern alleged contraventions of certain provisions of the Corporations Law and/or the Corporations Act connected with the affairs of the company and certain subsidiaries during the period February 2001 to June 2003.

There remains considerable uncertainty surrounding the likely outcome of the ASIC proceedings in the longer term and there is a possibility that the company could become responsible for other amounts in addition to the defence costs. However, at this stage, the company believes that, while incurring such amounts is reasonably possible, the actual amount or range of amounts is not estimable.

Readers are referred to Note 13 of the company's 31 March 2008 Consolidated Financial Statements for further information on the ASIC Proceedings.

Research and Development Expenses

Research and development expenses include costs associated with "core" research projects that are designed to benefit all business units. These costs are recorded in the Research and Development segment rather than being attributed to individual business units. These costs were 87% higher for the quarter at US\$5.6 million and 38% higher for the full year at US\$18.0 million.

Other research and development costs associated with commercialisation projects in business units are included in the business unit segment results. In total, these costs were 27% lower for the quarter at US\$1.9 million and 28% lower for the full year at US\$9.3 million.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Impairment Charges

The downturn in US construction activity has prompted the company to review the carrying value of certain long-lived assets. As a result of these reviews, impairments charges of US\$38.6 million and US\$71.0 million have been taken in the fourth quarter and the full year.

On 31 October 2007, the company announced plans to suspend production at its Blandon, Pennsylvania plant in the US. The company recorded an asset impairment of US\$32.4 million in the quarter ended 31 December 2007 and the year ended 31 March 2008 in its USA Fibre Cement segment. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. These assets are being held for use by the company. Between the date of the announcement and 31 March 2008, the company has incurred US\$1.4 million of impairment related costs. These impairment related costs are not included in the impairment charge of US\$32.4 million and have been included in cost of goods sold and selling, general and administrative expenses in the period in which they were incurred.

On 22 May 2008, the company announced plans to cease production at its Plant City, Florida Hardie Pipe manufacturing facility in the US. As a result, the company recorded an asset impairment of US\$25.4 million in the fourth quarter and the year ended 31 March 2008 in its Other segment. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. In addition to the impairment charge, the company has recorded US\$1.8 million of impairment related costs in the year ended 31 March 2008.

The company recorded an asset impairment of US\$13.2 million in the fourth quarter and the year ended 31 March 2008 related to buildings and machinery used to produce materials for the company's products. This impairment charge was recorded in its USA Fibre Cement segment. The impaired assets were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows.

Special Commission of Inquiry (SCI) and Other Related Expenses

During the fourth quarter, SCI and other related expenses were nil compared to US\$5.4 million for the same period last year. For the full year, SCI and other related expenses were nil compared to US\$13.6 million for the same period last year. Now that the Amended & Restated Final Funding Agreement (Amended FFA) has been implemented, the company anticipates no significant SCI and other related expenses going forward.

Asbestos Adjustments

The asbestos adjustments are derived from an estimate of future Australian asbestos-related liabilities in accordance with the Amended FFA that was signed with the NSW Government on 21 November 2006 and approved by the company's security holders on 7 February 2007.

The asbestos-related assets and liabilities are denominated in Australian dollars. Therefore the reported value of these asbestos-related assets and liabilities in the company's consolidated balance sheets in US dollars is subject to adjustment, with a corresponding effect on the company's consolidated statement of operations, depending on the closing exchange rate between the two currencies at the balance sheet date.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

The asbestos adjustments for the quarter and full year ended 31 March 2008 are as follows:

US\$ Million	Q4 FY08	Q4 FY07	FY08	FY07
Change in estimates	\$(154.1)	\$ 70.3	\$(152.9)	\$ 28.5
Effect of foreign exchange	(28.2)	(17.1)	(87.2)	(94.5)
Impact of tax-effecting the net Amended FFA liability	—	(335.0)	—	(335.0)
Other adjustments	—	(4.5)	—	(4.5)
Asbestos adjustments	<u>\$(182.3)</u>	<u>\$(286.3)</u>	<u>\$(240.1)</u>	<u>\$(405.5)</u>

Readers are referred to Note 12 of the company's 31 March 2008 Consolidated Financial Statements for further information on the asbestos adjustments.

EBIT

EBIT loss for the quarter decreased from US\$215.8 million for the same quarter last year to US\$181.5 million for the current quarter. EBIT loss for the quarter includes net unfavourable asbestos adjustments of US\$182.3 million, AICF SG&A expenses of US\$1.3 million, asset impairments of US\$38.6 million and impairment related costs of US\$2.5 million. For the same period in the prior year, EBIT loss includes net unfavourable asbestos adjustments of US\$286.3 million, as shown in the table below.

EBIT loss for the full year decreased from US\$86.6 million for last year to US\$36.6 million for the current year. EBIT loss for the full year includes net unfavourable asbestos adjustments of US\$240.1 million, AICF SG&A expenses of US\$4.0 million, asset impairments of US\$71.0 million and impairment related costs of US\$3.2 million. For the same period in the prior year, EBIT includes net unfavourable asbestos adjustments of US\$405.5 million, as shown in the table below.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

EBIT - US\$ Millions	Three Months and Full Year Ended 31 March					
	Q4 FY08	Q4 FY07	% Change	FY08	FY07	% Change
USA Fibre Cement	\$ 50.3	\$ 84.6	(41)	\$ 313.6	\$ 362.4	(13)
Asia Pacific Fibre Cement	10.7	8.8	22	50.3	39.4	28
Other	(2.8)	(2.7)	(4)	(7.3)	(9.3)	22
Research & Development	(5.0)	(3.5)	(43)	(18.1)	(17.1)	(6)
General Corporate	(12.5)	(16.7)	25	(60.0)	(56.5)	(6)
Asset Impairments	(38.6)	—	—	(71.0)	—	—
Asbestos adjustments	(182.3)	(286.3)	36	(240.1)	(405.5)	41
AICF SG&A expenses	(1.3)	—	—	(4.0)	—	—
EBIT	(181.5)	(215.8)	16	(36.6)	(86.6)	58
Excluding:						
Asbestos:						
Asbestos adjustments	182.3	286.3	(36)	240.1	405.5	(41)
AICF SG&A expenses	1.3	—	—	4.0	—	—
Asset impairments:						
Impairment charges	38.6	—	—	71.0	—	—
Impairment related costs	2.5	—	—	3.2	—	—
EBIT excluding asbestos and asset impairments	\$ 43.2	\$ 70.5	(39)	\$ 281.7	\$ 318.9	(12)
Net sales	\$ 312.9	\$ 360.9	(13)	\$1,468.8	\$1,542.9	(5)
EBIT margin excluding asbestos and asset impairments	13.8%	19.5%		19.2%	20.7%	

USA Fibre Cement EBIT

USA Fibre Cement EBIT for the quarter decreased 41% from US\$84.6 million to US\$50.3 million, primarily due to reduced gross profit performance which resulted from lower sales volume, higher freight costs, higher average unit costs and a slightly lower average net sales price. For the full year, EBIT decreased 13% from US\$362.4 million to US\$313.6 million, primarily due to lower volume and higher freight costs, partially offset by lower SG&A spending. The quarter and full year USA Fibre Cement EBIT margin was lower by 7.6 percentage points at 21.6% and 1.3 percentage points at 27.4%, respectively.

Asia Pacific Fibre Cement EBIT

Asia Pacific Fibre Cement EBIT for the quarter increased 22% from US\$8.8 million to US\$10.7 million. Favourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar accounted for 17% of this increase while the underlying Australian dollar business results accounted for the remaining 5% increase. In Australian dollars, Asia Pacific Fibre Cement EBIT for the quarter increased 5% due to an improved gross margin performance partially offset by increased SG&A expenses. The EBIT margin was 0.9 of a percentage point higher at 14.6% for the quarter.

Asia Pacific Fibre Cement EBIT for the full year increased 28% from US\$39.4 million to US\$50.3 million. Favourable currency exchange rates of the Asia Pacific business' currencies compared to the US dollar accounted for 16% of this increase while the underlying Australian dollar business results accounted for the remaining 12% increase. In Australian dollars, Asia Pacific Fibre Cement EBIT for the full year increased 12% due to an improved gross margin performance partially offset by increased SG&A expenses. The EBIT margin was 1.2 percentage points higher at 16.9% for the full year.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Other EBIT

The USA Hardie Pipe business recorded a significantly greater EBIT loss for the quarter and full year compared to a small EBIT loss in the same quarter last year and a small positive EBIT for the full year last year.

The Europe Fibre Cement business incurred significantly reduced EBIT losses for the quarter and the full year as it continued to build sales and improve operating margins.

General Corporate Costs

General corporate costs for the quarter decreased by US\$4.2 million from US\$16.7 million to US\$12.5 million primarily due to there being no SCI costs in the current quarter and a reduction in earnings related bonuses, partially offset by costs associated with the ASIC proceedings.

For the full year, general corporate costs increased by US\$3.5 million from US\$56.5 million to US\$60.0 million. The increase was primarily due to higher warranty provisions relating to non-US activities and costs associated with the ASIC proceedings, partially offset by the decrease in SCI costs.

Net Interest (Expense) Income

Net interest expense for the quarter decreased from US\$4.2 million to US\$2.2 million. The decrease was primarily due to interest income of US\$2.4 million earned on investments and cash balances held by the AICF in the current quarter.

For the full year, net interest (expense) income increased from an expense of US\$6.5 million to income of US\$1.1 million. The increase was primarily due to interest income of US\$9.4 million earned on investments and cash balances held by the AICF and the lack of a make-whole payment in the current year compared to the US\$6.0 million make-whole payment made in the prior year. These increases were partially offset by reduced capitalised interest and reduced interest income due to lower cash balances.

Income Tax Benefit (Expense)

Income tax benefit for the quarter decreased from a benefit of US\$323.1 million to US\$36.8 million. For the full year, income tax decreased from an income tax benefit of US\$243.9 million to an income tax expense of US\$36.1 million.

The company's effective tax rate on earnings excluding asbestos, asset impairments and tax adjustments was 37.9% for this fiscal year compared to 32.5% for the previous fiscal year. The increase in the effective tax rate excluding asbestos, asset impairments and tax adjustments over the same period in the prior year is due to the impact of the change in the geographical mix of earnings and a reduction in capital expenditures.

With effect from 1 April 2007, the company was required to adopt the provisions of FASB Interpretation No. 48 (FIN 48), "Accounting for Uncertainty in Income Taxes, an interpretation of Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes". The adoption of FIN 48 resulted in the reduction of the company's consolidated beginning retained earnings of US\$78.0 million.

Readers are referred to Note 14 of the company's 31 March 2008 Consolidated Financial Statements for further information on the adoption of FIN 48.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Tax adjustments

The company recorded unfavourable tax adjustments of US\$5.8 million for the three months ended 31 March 2008 compared to favourable tax adjustments of US\$3.0 million in the same period last year. For the full year ended 31 March 2008 the company recorded unfavourable tax adjustments of US\$5.8 million compared to favourable tax adjustments of US\$10.4 million in the prior fiscal year. The US\$5.8 million tax adjustments in the current year relate to FIN48 adjustments. The tax adjustments made in fiscal year 2007 relate to tax provision write-backs.

Disputed Amended Australian Income Tax Assessment

As announced on 22 March 2006, RCI Pty Ltd (RCI), a wholly owned subsidiary of the company, received an amended assessment from the Australian Taxation Office (ATO) in respect of RCI's income tax return for the year ended 31 March 1999. The amended assessment relates to the amount of net capital gains arising as a result of an internal corporate restructure carried out in 1998 and has been issued pursuant to the discretion granted to the Commissioner of Taxation under Part IVA of the Income Tax Assessment Act 1936. The original amended assessment issued to RCI was for a total of A\$412.0 million.

However, after subsequent remissions of general interest charges (GIC) by the ATO, the total was changed to A\$368.0 million, comprising A\$172.0 million of primary tax after allowable credits, A\$43.0 million of penalties (representing 25% of primary tax) and A\$153.0 million of GIC.

RCI is appealing the amended assessment. During fiscal year 2007, the company agreed with the ATO that in accordance with the ATO Receivables Policy, the company would pay 50% of the total amended assessment being A\$184.0 million. The company also agreed to guarantee the payment of the remaining 50% of the amended assessment should its appeal not be successful and to pay GIC accruing on the unpaid balance of the amended assessment in arrears on a quarterly basis. Up to 31 March 2008, GIC totalling A\$95.2 million has been paid to the ATO. On 15 April 2008, the company paid A\$3.3 million in GIC in respect of the quarter ended 31 March 2008. However, the company has not recorded any liability at 31 March 2008 for the remainder of the amended assessment because, at this time, the company believes it is more likely than not that RCI's view of its tax position will be upheld on appeal.

On 30 May 2007, the ATO issued a Notice of Decision disallowing the company's objection to the amended assessment. On 11 July 2007, the company filed an application appealing the Objection Decision with the Federal Court of Australia. On 18 February 2008, RCI filed its appeal statement and on 19 February 2008, its amended appeal statement. The hearing date for RCI's trial is presently scheduled for 8 December 2008.

Readers are referred to Note 15 of the company's 31 March 2008 Consolidated Financial Statements for further information on the ATO amended assessment.

Net Operating (Loss) Profit

Net operating profit for the quarter decreased from a net operating profit of US\$103.1 million to a net operating loss of US\$146.9 million. Net operating profit excluding asbestos, asset impairments and tax adjustments decreased 61% from US\$51.4 million to US\$20.1 million as shown in the table below.

For the full year, net operating profit decreased from a net operating profit of US\$151.7 million to a net operating loss of US\$71.6 million. Net operating profit excluding asbestos, asset impairments and tax adjustments decreased 20% from US\$211.8 million to US\$169.7 million as shown in the table below.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Net Operating Profit - US \$millions	Three Months and Full Year Ended 31 March					
	Q4 FY08	Q4 FY07	% Change	FY08	FY07	% Change
Net operating (loss) profit	\$(146.9)	\$ 103.1	—	\$ (71.6)	\$ 151.7	—
Excluding:						
Asbestos:						
Asbestos adjustments	182.3	286.3	(36)	240.1	405.5	(41)
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	—	(45.8)	(335.0)	—
AICF SG&A costs	1.3	—	—	4.0	—	—
AICF interest income	(2.4)	—	—	(9.4)	—	—
Asset impairments:						
Impairment charges (net of tax)	24.6	—	—	44.6	—	—
Impairment related costs (net of tax)	1.6	—	—	2.0	—	—
Tax adjustments	5.8	(3.0)	—	5.8	(10.4)	—
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	(61)	\$169.7	\$ 211.8	(20)

Liquidity and Capital Resources

The company has historically met its working capital needs and capital expenditure requirements through a combination of cash flow from operations, proceeds from the divestiture of businesses, credit facilities and other borrowings, proceeds from the sale of property, plant and equipment, and proceeds from the redemption of investments. Seasonal fluctuations in working capital generally have not had a significant impact on its short-term or long-term liquidity. The company anticipates it will have sufficient funds to meet its planned working capital and other cash requirements for the next 12 months based on its existing cash balances and anticipated operating cash flows arising during the year. The company anticipates that any cash requirements arising from the Amended FFA will be met from existing cash, unused committed facilities and anticipated future net operating cash flows.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Excluding restricted cash, the company had cash and cash equivalents of US\$35.4 million as of 31 March 2008. At that date, it also had credit facilities totalling US\$490.0 million, of which US\$264.5 million was drawn. The credit facilities are all uncollateralised and consist of the following:

Description (US\$ millions)	Effective Interest Rate	At 31 March 2008 Total Facility	Principal Drawn
364-day facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until December 2008	3.61%	\$ 110.0	\$ 90.0
Term facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until June 2010	3.64%	245.0	174.5
Term facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until February 2011	—	45.0	—
Term facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until February 2013	—	90.0	—
Total		\$ 490.0	\$ 264.5

At 31 March 2008, the company had net debt of US\$229.1 million, compared with net debt of US\$153.9 million at 31 March 2007.

The company's credit facilities as of 31 March 2008 consist of 364-day facilities in the amount of US\$110.0 million which, as of 31 March 2008, expire in December 2008 and extensions to the maturity date to June 2009 have been requested. The company also has term facilities in the amount of US\$245.0 million, which expire in June 2010; US\$45.0 million, which expire in February 2011; and US\$90.0 million, which expire in February 2013. At 31 March 2008, US\$264.5 million was drawn under the combined facilities and US\$225.5 million was available, but unused.

The weighted average remaining term of the total credit facilities, US\$490.0 million, at 31 March 2008 was 2.4 years.

In July 2006, pursuant to an agreement negotiated with the ATO and in accordance with the ATO Receivable Policy, the company made a payment of A\$184.0 million (US\$162.5 million) along with the provision of a guarantee from JHI NV in favour of the ATO for the unpaid balance of the assessment. The company has also agreed to pay GIC accruing on the unpaid balance of the assessment in arrears on a quarterly basis. Even if the company is ultimately successful in its appeal and the cash deposit is refunded, this procedural requirement to post a cash deposit materially and adversely affects the company's financial position and liquidity in the intervening period. See "Disputed Amended Australian Income Tax Assessment" above for further information on the ATO amended assessment.

If the company is unable to extend its credit facilities, or is unable to renew its credit facilities on terms that are substantially similar to the ones it presently has, it may experience liquidity issues and will have to reduce its levels of planned capital expenditures, reduce or eliminate dividend payments and stock buy-backs or take other measures to conserve cash in order to meet its future cash flow requirements. The company anticipates being able to meet its future payment obligations for the next 12 months from existing cash, unused committed facilities and anticipated future net operating cash flows.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Share Buy-Back Program

On 15 August 2007, the company announced a share buy-back program of up to 10% of the company's issued capital, approximately 46.8 million shares. The company bought back 2.2 million shares and 35.7 million shares of common stock during the three months and full year ended 31 March 2008, respectively. The bought back shares had an aggregate cost of A\$12.7 million (US\$11.7 million) and A\$236.4 million (US\$208.0 million) during the three months and full year ended 31 March 2008, respectively. The average price paid per share of common stock was A\$5.77 (US\$5.32) and A\$6.62 (US\$5.83) during the three months and full year ended 31 March 2008, respectively. The US dollar amounts were determined using the weighted average spot rates for the days on which shares were purchased. The company did not purchase any shares during the period between 1 April 2008 and 22 May 2008. The company officially cancelled 35.0 million shares on 31 March 2008.

Cash Flow

Operating cash flow for the full year ended 31 March 2008 increased from cash used of US\$67.1 million to cash generated of US\$319.3 million. The increase was driven primarily by the payment of a deposit with the ATO pending a disputed amended assessment and payments made to fund the AICF during the year ended 31 March 2007 totaling US\$154.8 million and US\$151.9 million, respectively, compared to payments of US\$9.7 million and nil, respectively, in the current full year. Capital expenditures for the purchase of property, plant and equipment decreased from US\$92.6 million to US\$38.5 million.

END

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Media/Analyst Enquiries:

Steve Ashe
Vice President Investor Relations

Telephone: +61 2 8274 5246
Mobile: +61 0408 164 011
Email: steve.ashe@jameshardie.com.au
Facsimile: +61 2 8274 5218

This Management's Analysis of Results forms part of a package of information about James Hardie's results. It should be read in conjunction with the other parts of this package, including a Media Release, a Management Presentation and a Financial Report.

These documents, along with a webcast of the presentation on 22 May 2008, are available from the Investor Relations area of the James Hardie website at www.jameshardie.com

The company lodged its annual filing for the year ended 31 March 2007 with the SEC on 6 July 2007.

All holders of the company's securities may receive, on request, a hard copy of our complete audited financial statements, free of charge. Requests can be made via the Investor Relations area of the company's website or by contacting one of the company's corporate offices. Contact details are available on the company's website.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Definitions

Financial Measures – US GAAP equivalents

EBIT and EBIT margin – EBIT, as used in this document, is equivalent to the US GAAP measure of operating income. EBIT margin is defined as EBIT as a percentage of net sales. James Hardie believes EBIT and EBIT margin to be relevant and useful information as these are the primary measures used by management to measure the operating profit or loss of its business. EBIT is one of several metrics used by management to measure the earnings generated by the company's operations, excluding interest and income tax expenses. Additionally, EBIT is believed to be a primary measure and terminology used by its Australian investors. EBIT and EBIT margin should be considered in addition to, but not as a substitute for, other measures of financial performance reported in accordance with accounting principles generally accepted in the United States of America. EBIT and EBIT margin, as the company has defined them, may not be comparable to similarly titled measures reported by other companies.

Operating profit – is equivalent to the US GAAP measure of income.

Net operating profit – is equivalent to the US GAAP measure of net income.

Sales Volumes

mmsf – million square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

msf – thousand square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

Financial Ratios

Gearing Ratio – Net debt (cash) divided by net debt (cash) plus shareholders' equity.

Net interest expense cover – EBIT divided by net interest expense.

Net interest paid cover – EBIT divided by cash paid during the period for interest, net of amounts capitalised.

Net debt payback – Net debt (cash) divided by cash flow from operations.

Net debt (cash) – short-term and long-term debt less cash and cash equivalents.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Non-US GAAP Financial Measures

EBIT and EBIT margin excluding asbestos and asset impairments – EBIT and EBIT margin excluding asbestos and asset impairments are not measures of financial performance under US GAAP and should not be considered to be more meaningful than EBIT and EBIT margin. James Hardie has included these financial measures to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations and provides useful information regarding its financial condition and results of operations. The company uses these non-US GAAP measures for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
EBIT	\$(181.5)	\$(215.8)	\$ (36.6)	\$ (86.6)
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	—	4.0	—
Asset impairments:				
Impairment charges	38.6	—	71.0	—
Impairment related costs	2.5	—	3.2	—
EBIT excluding asbestos and asset impairments	43.2	70.5	281.7	318.9
Net Sales	\$ 312.9	\$ 360.9	\$1,468.8	\$1,542.9
EBIT margin excluding asbestos and asset impairments	13.8%	19.5%	19.2%	20.7%

Net operating profit excluding asbestos, asset impairments and tax adjustments – Net operating profit excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than net income. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
Net operating (loss) profit	\$(146.9)	\$ 103.1	\$(71.6)	\$ 151.7
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	—	4.0	—
AICF interest income	(2.4)	—	(9.4)	—
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(45.8)	(335.0)
Asset impairments:				
Impairment charges (net of tax)	24.6	—	44.6	—
Impairment related costs (net of tax)	1.6	—	2.0	—
Tax adjustments	5.8	(3.0)	5.8	(10.4)
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	\$169.7	\$ 211.8

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Diluted earnings per share excluding asbestos, asset impairments and tax adjustments – Diluted earnings per share excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than diluted earnings per share. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company's management uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	\$169.7	\$211.8
Weighted average common shares outstanding — Diluted (millions)	434.6	469.0	456.1	466.4
Diluted earnings per share excluding asbestos, asset impairments and tax adjustments (US cents)	4.6	11.0	37.2	45.4

Effective tax rate excluding asbestos, asset impairments and tax adjustments – Effective tax rate excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than effective tax rate. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company's management uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
Operating loss before income taxes	\$(183.7)	\$(220.0)	\$ (35.5)	\$ (93.1)
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	—	4.0	—
AICF interest income	(2.4)	—	(9.4)	—
Asset impairments:				
Impairment charges	38.6	—	71.0	—
Impairment related costs	2.5	—	3.2	—
Operating profit before income taxes excluding asbestos and asset impairments	\$ 38.6	\$ 66.3	\$ 273.4	\$ 312.4
Income tax benefit (expense)	36.8	323.1	(36.1)	243.9
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(45.8)	(335.0)
Tax benefit related to asset impairments	(14.9)	—	(27.6)	—
Tax adjustments	5.8	(3.0)	5.8	(10.4)
Income tax expense excluding asbestos, asset impairments and tax adjustments	(18.5)	(14.9)	(103.7)	(101.5)
Effective tax rate excluding asbestos, asset impairments and tax adjustments	48.0%	22.5%	37.9%	32.5%

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

EBITDA – is not a measure of financial performance under US GAAP and should not be considered an alternative to, or more meaningful than, income from operations, net income or cash flows as defined by US GAAP or as a measure of profitability or liquidity. Not all companies calculate EBITDA in the same manner as James Hardie has and, accordingly, EBITDA may not be comparable with other companies. The company has included information concerning EBITDA because it believes that this data is commonly used by investors to evaluate the ability of a company's earnings from its core business operations to satisfy its debt, capital expenditure and working capital requirements.

US\$ Millions	Q4 FY08	Q4 FY07	FY08	FY07
EBIT	\$(181.5)	\$(215.8)	\$(36.6)	\$(86.6)
Depreciation and amortisation	14.4	13.7	56.5	50.7
EBITDA	\$(167.1)	\$(202.1)	\$ 19.9	\$(35.9)

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Supplemental Financial Information

James Hardie's management measures its operating performance and analyses year-over-year changes in operating results with and without the effect of the net Amended FFA liability recorded in the fourth quarter of fiscal year 2006 and believes that security holders will do the same.

As set forth in Note 12 of the 31 March 2008 Financial Report, the net Amended FFA liability, while recurring, is based on periodic actuarial determinations, claims experience and currency fluctuations. It has no relation to the results of the company's operations. Accordingly, management believes that the following information is useful to it and investors in evaluating ongoing operating financial performance.

The following tables are considered non-GAAP and are not intended to be used or viewed in any respect as substitutes for the company's GAAP consolidated financial statements. These non-GAAP measures should only be viewed as a supplement to reported GAAP financial statements, and, in all cases, the corresponding GAAP amounts are shown on the same line as the non-GAAP measure, to avoid any possible confusion.

The following tables should be read in conjunction with JHI NV's financial statements and related notes contained in the company's 31 March 2008 Consolidated Financial Statements.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

James Hardie Industries N.V.
Consolidated Balance Sheet
31 March 2008
(unaudited)

US\$ Millions	Total Fibre Cement Operations - excluding Asbestos Compensation	Asbestos Compensation	As Reported
ASSETS			
Current assets			
Cash and cash equivalents	\$ 185.0	\$ (149.6)	\$ 35.4
Restricted cash and cash equivalents	5.0	—	5.0
Restricted cash and cash equivalents — Asbestos	—	37.4	37.4
Restricted short-term investments — Asbestos	—	77.7	77.7
Accounts and notes receivable, net of allowance for doubtful accounts of \$2.0m	130.9	0.5	131.4
Inventories	179.7	—	179.7
Prepaid expenses and other current assets	27.6	0.4	28.0
Insurance receivable — Asbestos	—	14.1	14.1
Workers' compensation — Asbestos	—	6.9	6.9
Deferred income taxes	8.2	—	8.2
Deferred income taxes — Asbestos	—	9.1	9.1
Total current assets	536.4	(3.5)	532.9
Property, plant and equipment, net	755.8	0.6	756.4
Insurance receivable — Asbestos	—	194.3	194.3
Workers' compensation — Asbestos	—	78.5	78.5
Deferred income taxes	13.2	—	13.2
Deferred income taxes — Asbestos	—	397.1	397.1
Deposit with Australian Taxation Office	205.8	—	205.8
Other assets	1.7	—	1.7
Total assets	\$ 1,512.9	\$ 667.0	\$ 2,179.9
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Accounts payable and accrued liabilities	\$ 106.1	\$ 1.5	\$ 107.6
Short-term debt	90.0	—	90.0
Accrued payroll and employee benefits	36.9	0.1	37.0
Accrued product warranties	6.9	—	6.9
Income taxes payable	33.4	(20.4)	13.0
Asbestos liability	—	78.7	78.7
Workers' compensation — Asbestos	—	6.9	6.9
Other liabilities	9.1	—	9.1
Total current liabilities	282.4	66.8	349.2
Long-term debt	174.5	—	174.5
Deferred income taxes	84.2	—	84.2
Accrued product warranties	10.8	—	10.8
Asbestos liability	—	1,497.8	1,497.8
Workers' compensation — Asbestos	—	78.5	78.5
Other liabilities	184.2	3.3	187.5
Total liabilities	736.1	1,646.4	2,382.5
Commitments and contingencies			
Shareholders' equity			
Common stock	219.7	—	219.7
Additional paid-in capital	19.3	—	19.3
Retained earnings (accumulated deficit)	520.5	(975.0)	(454.5)
Common stock in treasury	(4.0)	—	(4.0)
Accumulated other comprehensive income	21.3	(4.4)	16.9
Total shareholders' equity	776.8	(979.4)	(202.6)
Total liabilities and shareholders' equity	\$ 1,512.9	\$ 667.0	\$ 2,179.9

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

James Hardie Industries N.V.
Consolidated Statement of Operations
For the full year ended 31 March 2008
(unaudited)

US\$ Millions	Total Fibre Cement Operations - excluding Asbestos Compensation	Asbestos Compensation	As Reported
Net Sales			
USA Fibre Cement	\$ 1,144.8	\$ —	\$ 1,144.8
Asia Pacific Fibre Cement	298.3	—	298.3
Other	25.7	—	25.7
Total Net Sales	1,468.8	—	1,468.8
Cost of goods sold	(938.8)	—	(938.8)
Gross profit	530.0	—	530.0
Selling, general and administrative expenses	(224.2)	(4.0)	(228.2)
Research and development expenses	(27.3)	—	(27.3)
Impairments charges	(71.0)	—	(71.0)
Asbestos adjustments	—	(240.1)	(240.1)
EBIT	207.5	(244.1)	(36.6)
Net Interest (expense) income	(8.3)	9.4	1.1
Operating profit (loss) before income taxes	199.2	(234.7)	(35.5)
Income tax expense	(81.9)	45.8	(36.1)
Net Operating Profit (Loss)	\$ 117.3	\$ (188.9)	\$ (71.6)

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

James Hardie Industries N.V.
Consolidated Statement of Cash Flows
For the full year ended 31 March 2008
(unaudited)

US\$ Millions	Total Fibre Cement Operations - excluding Asbestos Compensation	Asbestos Compensation	As Reported
Cash Flows from Operating Activities			
Net Income (loss)	\$ 117.3	\$ (188.9)	\$ (71.6)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:			
Depreciation	56.5	—	56.5
Deferred income taxes	(8.2)	(45.8)	(54.0)
Prepaid pension cost	1.0	—	1.0
Stock-based compensation	7.7	—	7.7
Asbestos adjustments	—	240.1	240.1
Impairment charges	71.0	—	71.0
Other	(3.4)	—	(3.4)
Changes in operating assets and liabilities:			
Restricted cash and cash equivalents	—	44.7	44.7
Accounts and notes receivable	39.6	—	39.6
Inventories	(26.6)	—	(26.6)
Prepaid expenses and other current assets	4.7	0.2	4.9
Insurance receivable — Asbestos	—	16.7	16.7
Accounts payable and accrued liabilities	2.6	—	2.6
Asbestos liability	—	(67.0)	(67.0)
Deposit with Australian Taxation Office	(9.7)	—	(9.7)
Other accrued liabilities and other liabilities	66.8	—	66.8
Net cash provided by operating activities	\$ 319.3	\$ —	\$ 319.3
Cash Flows From Investing Activities			
Purchases of property, plant and equipment	(38.5)	—	(38.5)
Net cash used in investing activities	\$ (38.5)	\$ —	\$ (38.5)
Cash Flows from Financing Activities			
Proceeds from short term borrowings	7.0	—	7.0
Proceeds from long term borrowings	69.5	—	69.5
Proceeds from issuance of shares	3.3	—	3.3
Tax benefit from stock options exercised	—	—	—
Treasury stock purchased	(208.0)	—	(208.0)
Dividends paid	(126.2)	—	(126.2)
Net cash used in financing activities	\$ (254.4)	\$ —	\$ (254.4)
Effects of exchange rate changes on cash	(25.1)	—	(25.1)
Net increase in cash and cash equivalents	1.3	—	1.3
Cash and cash equivalents at beginning of period	34.1	—	34.1
Cash and cash equivalents at end of period	\$ 35.4	\$ —	\$ 35.4
Components of Cash and Cash Equivalents			
Cash at bank and on hand	21.6	—	21.6
Short-term deposits	13.8	—	13.8
Cash and cash equivalents at end of period	\$ 35.4	\$ —	\$ 35.4

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

Disclaimer

This Management's Analysis of Results contains forward-looking statements. We may from time to time make forward-looking statements in our periodic reports filed with or furnished to the United States Securities and Exchange Commission on Forms 20-F and 6-K, in our annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by our officers, directors or employees to analysts, institutional investors, lenders and potential lenders, representatives of the media and others. Examples of forward-looking statements include:

- expectations about the timing and amount of payments to the Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven asbestos-related personal injury and death claim;
- expectations concerning the costs associated with the suspension of operations at our Blandon, Pennsylvania and Plant City, Florida plants;
- statements as to the possible consequences of proceedings brought against us and certain of our former directors and officers by the Australian Securities and Investments Commission;
- statements regarding tax liabilities and related proceedings;
- expectations that our credit facilities will be extended or renewed;
- projections of our operating results of financial condition;
- statements regarding our plans, objectives or goals, including those relating to competition, acquisitions dispositions and our products;
- statements about our future performance; and
- statements about product or environmental liabilities.

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "should," "aim" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent risks and uncertainties. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors, some of which are discussed under "Risk Factors" beginning on page 6 of our Form 20-F filed on 6 July 2007 with the Securities and Exchange Commission, include but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former James Hardie subsidiaries; required contributions to the AICF and the effect of foreign exchange on the amount recorded in our financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which we operate; the consequences of product failures or defects; exposure to environmental, asbestos or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; the success of our research and development efforts; our reliance on a small number of product customers; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; foreign exchange risks; and the effect of natural disasters. We caution you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those in forward-looking statements. Forward-looking statements speak only as of the date they are made and we undertake no duty to update or revise any such statements.

Management's Analysis of Results: James Hardie - 4th Quarter and Full Year FY08

James Hardie

FY08 4th Quarter and Full Year Results

22 May 2008

In this Management Presentation, James Hardie may present financial measures, sales volume terms, financial ratios, and Non-US GAAP financial measures included in the Definitions section of this document starting on page 59. The company presents financial measures that it believes are customarily used by its Australian investors. Specifically, these financial measures, which are equivalent to or derived from certain US GAAP measures as explained in the definitions, include "EBIT", "EBIT margin", "Operating profit" and "Net operating profit". The company may also present other terms for measuring its sales volumes ("million square feet or mmsf" and "thousand square feet or msf"), financial ratios ("Gearing ratio", "Net interest expense cover", "Net interest paid cover", "Net debt payback", "Net debt (cash)"), and Non-US GAAP financial measures ("EBIT excluding asbestos and asset impairments", "EBIT margin excluding asbestos and asset impairments", "Net operating profit excluding asbestos, asset impairments and tax adjustments", "Diluted earnings per share excluding asbestos, asset impairments and tax adjustments", "Operating profit before income taxes excluding asbestos and asset impairments", "Effective tax rate excluding asbestos, asset impairments and tax adjustments" and EBITDA). Unless otherwise stated, results and comparisons are of the 4th quarter and current full fiscal year versus the 4th quarter and full year of the prior fiscal year.

Agenda

- Overview and Operating Review – Louis Gries, CEO
- Financial Review – Russell Chenu, CFO
- Questions and Answers

Overview

- Major businesses performed relatively well over the full year in challenging market conditions, particularly in the US
- Net operating line for the quarter and full year affected by material asbestos adjustments, asset impairments and tax adjustments

US\$ Millions	Q4	Q4	%	FY 2008	FY 2007	%
	FY 2008	FY 2007	Change			
Net operating (loss) profit	(146.9)	103.1	-	(71.6)	151.7	-
Net operating profit excluding asbestos, asset impairments and tax adjustments	20.1	51.4	(61)	169.7	211.8	(20)
Diluted earnings per share excluding asbestos, asset impairments and tax adjustments (US cents)	4.6	11.0	(58)	37.2	45.4	(18)

Overview

4th Quarter

USA Fibre Cement

- The housing market deteriorated further during the quarter
- Sales and EBIT were much lower than the same quarter last year

Asia Pacific Fibre Cement

- EBIT was up, primarily due to favourable currency movements and improved operating performance in Australia and New Zealand

Overview

Full Year

- USA Fibre Cement – Price growth and market penetration helped partly buffer the unfavourable impact of significantly weaker housing construction activity and deliver a good EBIT performance, considering the conditions
- Asia Pacific Fibre Cement – Strong sales and EBIT performance
- Operating businesses continued to generate strong cash flows

Overview

- Announced final dividend of US 8 cents a share. Total dividend for year consistent at US 20 cents
- Announced closure of USA Hardie Pipe business

Operating Review

Louis Gries, CEO

USA Fibre Cement



James Hardie lap and shingle siding with ColorPlus® Technology featured in *MidWest Homes' Minnesota Top Homes Volume 2*. The home was built by Mark Anthony Homes in Hudson, Wisconsin.

USA Fibre Cement

4th Quarter Result

Net Sales	down	20% to US\$232.5 million
Sales Volume	down	19% to 393.9 mmsf
Average Price	down	1% to US\$590 per msf
EBIT	down	41% to US\$50.3 million
EBIT Margin	down	7.6 pts to 21.6%

USA Fibre Cement

Full Year Result

Net Sales down 9% to US\$1,144.8 million

Sales Volume down 11% to 1,916.6 mmsf

Average Price up 2% to US\$597 per msf

EBIT down 13% to US\$313.6 million

EBIT Margin down 1.3 pt to 27.4%

USA Fibre Cement

4th Quarter Market Conditions

- Further deterioration in new housing construction activity
 - Starts down 26% and 30% for the December and March quarters, respectively
- Market demand affected by weaker economic conditions, tighter lending standards and falling house prices
- Inventory levels of new homes remain high
- More existing homes for sale due to increase in foreclosures
- Builder confidence levels remain very low
- Repair and remodelling activity down, but much less than new construction

USA Fibre Cement

4th Quarter Key Points

- Sales down due to further deterioration in US housing construction activity
 - Normal seasonal pickup in demand not evident in March orders
 - Inventory build higher than required due to lower than forecasted Q4 shipments
- Market penetration did not buffer the market decline as it has in previous quarters
- Sales volumes were lower across all divisions and in each key region, other than Canada
- Exterior products accounted for most of the decline in sales. Only ColorPlus® collection of products recorded sales growth
- Sales volumes of interior products were down slightly
- Higher costs – pulp, freight in particular
- Continued to hold average net sales price
- Further business reset carried out in April – based on lower starts forecast and high inventory levels


USA Fibre Cement

Outlook

- Further weakness in housing construction activity
- Softer repair and remodelling activity expected in short to medium-term
- Increased focus in FY09 on initiatives that build EBIT performance.
- Further market penetration against alternative materials

USA Fibre Cement


Top Line Growth



Rolling 12 month average of seasonally adjusted estimate of housing starts by US Census Bureau.

USA Fibre Cement


Primary Growth Performance



Sources: Dodge US addressable starts (SF & MF-low); US Census R&R \$expenditures less CPI
 Note: R&R growth for Q408 assumed to be flat

USA Fibre Cement

Average Net Selling Price




USA Fibre Cement

Strategy

- Aggressively grow demand for our products in targeted market segments
- Grow our overall market position while defending our share in existing market segments
- Offer products with superior value to that of our competitors
- Introduce differentiated products to reduce direct price competition

USA Fibre Cement

EBIT and EBIT Margin*



*Excludes restructuring and other operating expenses of US\$12.6 million in Q3 FY02 and impairment charges of US\$45.6 million in Q4 FY08

USA Fibre Cement

Managing through the housing downturn - Update

- Reset business in February 2008 based on housing starts of 1 million per annum
- Continued market deterioration resulted in a further business reset in April based on housing starts of 800,000 per annum
- Reset included manufacturing and SG&A adjustments
 - Manufacturing
 - changes to plant manning based on lowest landed cost

USA Fibre Cement

Managing through the housing downturn – Update (continued)

- SG&A adjustments
 - Reviewed activities and projects across the organisation
 - Changes made to SG&A cost base considering:
 - Ability to make a significant impact during FY09
 - Impact on ability to enable business to compete and grow as the housing market recovers
 - Long term strategic value
 - Cost reductions were made in HR, Marketing, R&D, Finance and Business Development
- Employee numbers in US business reduced by 9% or 170, down 19% from 2174 at its peak in 2006

Asia Pacific Fibre Cement



James Hardie ExoTec® Facade Panel and fixing system has been used on the Queensland University of Technology.
Architect: Conrad & Gargett.

Asia Pacific Fibre Cement

4th Quarter Result

Net Sales	up	14% to US\$73.5 million
Sales Volume	down	3% to 95.3 mmsf
Average Price	up	2% to A\$848 per msf
EBIT	up	22% to US\$10.7 million
EBIT Margin	up	0.9 pts to 14.6%

Asia Pacific Fibre Cement

Full Year Result

Net Sales	up	19% to US\$298.3 million
Sales Volume	up	2% to 398.2 mmsf
Average Price	up	2% to A\$862 per msf
EBIT*	up	28% to US\$50.3 million
EBIT* Margin	up	1.2 pts to 16.9%

* EBIT includes US\$2.7m lease cost adjustment related to prior periods

Asia Pacific Fibre Cement

Strategy

- Grow primary demand for our products
- Leverage our superior technology to offer differentiated products and systems with superior value to those of competitors
- Promote a smarter way to build composite construction houses using our products
- Vigorously defend our position in existing market segments

Asia Pacific Fibre Cement

Key Points

- Residential construction activity was slightly weaker in both Australia and New Zealand
- US\$ financial results again assisted by appreciation of Asia Pacific currencies
- Q4 net sales down 1% in A\$ due to 3% decrease in sales volume, partly offset by a 2% increase in the average Australian dollar net sales price
- In Australia and New Zealand, differentiated value-added products continue to increase as a proportion of the sales mix
- Non-differentiated products remain subject to strong competitive pressures
- Stronger EBIT performance in A\$, up 5% for the quarter and 12% for the year

Asia Pacific Fibre Cement

Outlook

- Residential construction activity is expected to be flat in Australia and slightly weaker in New Zealand
- Further primary demand growth for fibre cement in Australia and New Zealand
- Growth in differentiated products
- Non-differentiated products in Australia are expected to remain subject to strong competition
- In the Philippines, construction activity is expected to be stronger in the short-term

Other

USA Hardie Pipe

- Q4 net sales lower due to weaker residential and non-residential construction activity in Florida
- EBIT loss for both the quarter and full year
- Announced closure of business today
 - EBIT losses mainly incurred since commencement in 2001
 - Significant deterioration in market conditions in Florida
 - Average selling prices significantly less than for the USA Fibre Cement business
 - Estimated future financial returns not sufficient to warrant further investment
- Impairment charge of US\$25.4 million and impairment related costs of US\$1.8 million recorded in Q4

Europe Fibre Cement

- Sales continuing to grow steadily
- Significantly reduced EBIT loss for the quarter and full year

Financial Review

Russell Chenu, CFO

Overview

- Solid operating performance for the year considering further significant decline in US housing construction activity
- Net operating line affected by asbestos, asset impairments and tax adjustments:
 - Asbestos adjustments :
 - US\$182.3m in Q4 and US\$240.1m in full year – change in KPMG Actuaries' estimate and unfavourable currency movement on A\$ asbestos liability
 - Asset impairments of US\$41.1m (US\$26.2m net of tax) in Q4 and US\$74.2m (US\$46.6m net of tax) in full year
 - Q4 – USA Hardie Pipe closure US\$25.4m impairment charge and US\$1.8 million impairment related costs
 - Q4 – USA Fibre Cement (buildings and machinery) US\$13.2m impairment charge
 - Q3 – USA Fibre Cement (Blandon, Pennsylvania plant) US\$32.4m impairment charge and US\$1.4 million impairment related costs
 - Unfavourable tax adjustments of US\$5.8 million related to FIN48

Overview

- Increase in inventory levels – normal seasonal pickup in demand did not occur in Q4
- Strong cash generation for the year – US\$319.3 million
- Final dividend of US8 cents a share declared
 - Payable 11 July 2008
 - Record date 4 June 2008
- Total dividend consistent at US20 cents a share

Share Buy-Back

- Announced share buy-back of up to 10% of issued capital (up to approximately 46.8 million shares) on 15 August 2007
- Purchased 7.6% of issued capital between 18 September 2007 and 31 March 2008 at average price of A\$6.62/ US\$5.83
 - 35.7 million shares purchased as at 31 March 2007 - total cost US\$208 million
 - no shares purchased between 1 April 2008 and 22 May 2008
- Material benefits
 - > 3% EPS accretion
 - 0.5% WACC reduction

Results – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>% Change</u>
Net sales	312.9	360.9	(13)
Gross profit	107.2	133.8	(20)
SG&A expenses	(60.3)	(52.3)	(15)
Research & development expenses	(7.5)	(5.6)	(34)
Impairment charges	(38.6)	-	-
SCI and other related expenses	-	(5.4)	-
Asbestos adjustments	(182.3)	(286.3)	36
EBIT	(181.5)	(215.8)	16
Net interest expense	(2.2)	(4.2)	48
Income tax benefit	36.8	323.1	(89)
Net operating (loss) profit	(146.9)	103.1	-

Results – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>% Change</u>
Net operating (loss) profit	(146.9)	103.1	-
Asbestos:			
Asbestos adjustments	182.3	286.3	(36)
AICF SG&A expenses	1.3	-	-
AICF interest income	(2.4)	-	-
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(86)
Asset impairments:			
Impairment charges (net of tax)	24.6	-	-
Impairment related costs (net of tax)	1.6	-	-
Tax adjustments	5.8	(3.0)	-
Net operating profit excluding asbestos, asset impairments and tax adjustments	20.1	51.4	(61)

Results – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
Net sales	1,468.8	1,542.9	(5)
Gross profit	530.0	573.0	(8)
SG&A expenses	(228.2)	(214.6)	(6)
Research & development expenses	(27.3)	(25.9)	(5)
Impairment charges	(71.0)	-	-
SCI and other related expenses	-	(13.6)	-
Asbestos adjustments	(240.1)	(405.5)	41
EBIT	(36.6)	(86.6)	58
Net interest income (expense)	1.1	(6.5)	-
Income tax (expense) benefit	(36.1)	243.9	-
Effect of change in accounting principle – net of tax	-	0.9	-
Net operating (loss) profit	(71.6)	151.7	-

Results – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
Net operating (loss) profit	(71.6)	151.7	-
Asbestos:			
Asbestos adjustments	240.1	405.5	(41)
AICF SG&A expenses	4.0	-	-
AICF interest income	(9.4)	-	-
Tax benefit related to asbestos adjustments	(45.8)	(335.0)	(86)
Asset impairments:			
Impairment charges (net of tax)	44.6	-	-
Impairment related costs (net of tax)	2.0	-	-
Tax adjustments	5.8	(10.4)	-
Net operating profit excluding asbestos, asset impairments and tax adjustments	169.7	211.8	(20)

Segment Net Sales – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>% Change</u>
USA Fibre Cement	232.5	289.9	(20)
Asia Pacific Fibre Cement	73.5	64.3	14
Other	6.9	6.7	3
Total	312.9	360.9	(13)

Segment Net Sales – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
USA Fibre Cement	1,144.8	1,262.3	(9)
Asia Pacific Fibre Cement	298.3	251.7	19
Other	25.7	28.9	(11)
Total	1,468.8	1,542.9	(5)

Segment EBIT – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>% Change</u>
USA Fibre Cement	50.3	84.6	(41)
Asia Pacific Fibre Cement	10.7	8.8	22
Other	(2.8)	(2.7)	(4)
R & D ¹	(5.0)	(3.5)	(43)
Total segment EBIT excluding impairment charges	53.2	87.2	(39)
General Corporate	(12.5)	(16.7)	25
Total EBIT excluding asbestos and impairment charges	40.7	70.5	(42)
Asbestos adjustments	(182.3)	(286.3)	(36)
AICF SG&A expenses	(1.3)	-	-
Impairment charges	(38.6)	-	-
Total EBIT	(181.5)	(215.8)	16

¹ R&D includes "core" R&D expenses and administrative expenses, but excludes product development expenses

Segment EBIT – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
USA Fibre Cement	313.6	362.4	(13)
Asia Pacific Fibre Cement	50.3	39.4	28
Other	(7.3)	(9.3)	22
R & D ¹	(18.1)	(17.1)	(6)
Total segment EBIT excluding impairment charges	338.5	375.4	(10)
General Corporate	(60.0)	(56.5)	(6)
Total EBIT excluding asbestos and impairment charges	278.5	318.9	(13)
Asbestos adjustments	(240.1)	(405.5)	41
AICF SG&A expenses	(4.0)	-	-
Impairment charges	(71.0)	-	-
Total EBIT	(36.6)	(86.6)	58

¹ R&D includes "core" R&D expenses and administrative expenses, but excludes product development expenses

Corporate Costs – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>% Change</u>
Stock compensation expenses	2.7	1.7	(59)
SCI and other related expenses	-	5.4	-
ASIC proceedings	1.1	-	-
Australian pension plan	1.2	0.5	-
Other costs	7.5	9.1	18
Total	12.5	16.7	25

Corporate Costs – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
Stock compensation expenses	7.7	5.8	(33)
SCI and other related expenses	-	13.6	-
Non-US warranty provision	4.0	-	-
ASIC proceedings	5.5	-	-
Australian pension plan	3.2	2.8	(14)
Other costs	39.6	34.3	(15)
Total	60.0	56.5	(6)

Net Interest Income (Expense)

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>FY '08</u>	<u>FY '07</u>
Gross interest expense	(4.6)	(4.7)	(11.7)	(12.1)
Make-whole payment	-	-	-	(6.0)
Capitalised interest	-	-	0.6	6.1
Interest (expense) income	-	0.5	2.8	5.5
Net interest expense excluding AICF net interest income	(4.6)	(4.2)	(8.3)	(6.5)
AICF net interest income	2.4	-	9.4	-
Net interest (expense) income	(2.2)	(4.2)	1.1	(6.5)

Income Tax Expense – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>
Operating loss before income taxes	\$(183.7)	\$(220.0)
Asbestos:		
Asbestos adjustments	182.3	286.3
AICF SG&A expenses	1.3	-
AICF interest income	(2.4)	-
Asset impairments:		
Impairment charges	38.6	-
Impairment related costs	2.5	-
Operating profit before income taxes excluding asbestos and asset impairments	\$38.6	\$66.3
Income tax expense excluding asbestos, asset impairments and tax adjustments	(18.5)	(14.9)
Effective tax rate excluding asbestos, asset impairments and tax adjustments	48.0%	22.5%

Income Tax Expense – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>
Operating loss before income taxes	\$(35.5)	\$(93.1)
Asbestos:		
Asbestos adjustments	240.1	405.5
AICF SG&A expenses	4.0	-
AICF interest income	(9.4)	-
Asset impairments:		
Impairment charges	71.0	-
Impairment related costs	3.2	-
Operating profit before income taxes excluding asbestos and asset impairments	\$273.4	\$312.4
Income tax expense excluding asbestos, asset impairments and tax adjustments	(103.7)	(101.5)
Effective tax rate excluding asbestos, asset impairments and tax adjustments	37.9%	32.5%

EBITDA – Q4

<u>US\$ Millions</u>	<u>Q4'08</u>	<u>Q4'07</u>	<u>% Change</u>
EBIT			
USA Fibre Cement	50.3	84.6	(41)
Asia Pacific Fibre Cement	10.7	8.8	22
Other	(2.8)	(2.7)	(4)
R & D	(5.0)	(3.5)	(43)
General Corporate	(12.5)	(16.7)	25
Depreciation and Amortisation			
USA Fibre Cement	10.2	10.2	-
Asia Pacific Fibre Cement	3.9	2.6	50
Other	0.3	0.8	(63)
Total EBITDA excluding asbestos & asset impairments	55.1	84.1	(34)
Asbestos adjustments	(182.3)	(286.3)	36
AICF SG&A expenses	(1.3)	-	-
Asset impairments	(38.6)	-	-
Total EBITDA	(167.1)	(202.2)	17

EBITDA – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
EBIT			
USA Fibre Cement	313.6	362.4	(13)
Asia Pacific Fibre Cement	50.3	39.4	28
Other	(7.3)	(9.3)	22
R & D	(18.1)	(17.1)	(6)
General Corporate	(60.0)	(56.5)	(6)
Depreciation and Amortisation			
USA Fibre Cement	42.8	37.8	13
Asia Pacific Fibre Cement	10.3	10.1	2
Other	3.4	2.8	21
Total EBITDA excluding asbestos & asset impairments	335.0	369.6	(9)
Asbestos adjustments	(240.1)	(405.5)	41
AICF SG&A expenses	(4.0)	-	-
Asset impairments	(71.0)	-	-
Total EBITDA	19.9	(35.9)	-

Cash Flow – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
EBIT	(36.6)	(86.6)	58
Non-cash items			
- Asbestos adjustments	240.1	405.5	(41)
- Asset impairments	71.0	-	-
- Other non-cash items	7.8	54.8	(86)
Net working capital movements	115.0	(52.6)	-
Cash generated by trading activities	397.3	321.1	24
Tax payments	(55.5)	(80.8)	31
Deposit with ATO	(9.7)	(154.8)	94
Initial Payment to AICF	-	(148.7)	-
Interest paid (net)	(12.8)	(3.9)	-
Net Operating Cash Flow	319.3	(67.1)	-
Purchases of property, plant & equipment	(38.5)	(92.6)	58
Dividends paid	(126.2)	(42.1)	-
Share buy-back	(208.0)	-	-
Equity issued	3.3	18.5	(82)
Other	(25.1)	17.0	-
Movement in Net Cash (Debt)	(75.2)	(166.3)	55
Net Cash (Debt) – 31 March 2007	(153.9)	12.4	-
Net Cash (Debt) – 31 March 2008	(229.1)	(153.9)	(49)

Capital Expenditure – Full Year

<u>US\$ Millions</u>	<u>FY '08</u>	<u>FY '07</u>	<u>% Change</u>
USA Fibre Cement	31.3	78.8	60
Asia Pacific Fibre Cement	5.6	10.5	47
Other	1.6	3.3	52
Total	38.5	92.6	58

Key Ratios

	<u>FY08</u>	<u>FY07</u>	<u>FY06</u>
EPS (Diluted) ¹	36.9c	49.3c	45.7c
Dividend Paid per share	27.0c	9.0c	10.0c
Return on Shareholders' Funds ¹	17.7%	24.0%	28.7%
Return on Capital Employed ²	24.2%	27.7%	32.0%
EBIT/ Sales (EBIT margin) ²	19.2%	21.6%	20.9%
Gearing Ratio ¹	21.5%	12.5%	(1.5)%
Net Interest Expense Cover ³	33.9x	51.2x	-
Net Interest Paid Cover ²	22.0x	65.2x	89.0x
Net Debt Payback ⁴	0.7 yrs	1.9 yrs	-

¹ Excludes asbestos adjustments, tax expense/benefit related to asbestos adjustments, AICF SG&A expenses, AICF interest income, asset impairments and tax adjustments

² Excludes asbestos adjustments, AICF SG&A expenses and impairments.

³ Excludes asbestos adjustments, AICF SG&A expenses, AICF interest income and impairments.

⁴ Excludes payments under the Amended FFA

Summary

- Solid overall operating performance for the year considering business environment
- Strong cash generation
- Net operating line affected by asbestos adjustments, impairments and tax adjustments
- The company's financial position remains strong
- Results remain subject to fluctuation in A\$: US\$ exchange rate for foreseeable future

Asbestos Compensation Funding Arrangement

- Updated actuarial report completed as at 31 March 2008
- Discounted central estimate increased to A\$1,426.3 million
- Annual contribution to AICF will be approximately US\$100 - US\$110.0 million dependent on the A\$/US\$ exchange rate
 - Payment in A\$ due 1 July 2008 or in quarterly installments through FY2009

Updated Actuarial Estimate

A\$ Millions

KPMG Actuaries expected estimate for 31 March 2008, based on 31 March 2007 estimate (allowing for cost savings in NSW only)	A\$1,375.0
Change in discount rate	40.4
	<hr/>
	1,334.6
Reduced by:	
Reduction in average claims cost and legal costs	(72.2)
Increase in claim numbers	144.5
Incidence pattern (change in peak year)	29.6
Settlement patterns	(6.9)
Emerging claims experience	(2.8)
Insurance recoveries	0.2
Cross claim recoveries	12.0
Nil cost claims	(12.7)
	<hr/>
Total increase in net liability	91.7
	<hr/>
Actuarial estimate at 31 March 2008	A\$1,426.3
	<hr/>

Updated Actuarial Estimate

Net accounting liability under Amended FFA

<u>A\$ millions</u> (except where stated)	31 March 2007	31 March 2008
Central Estimate – Discounted	1,355.1	1,426.3
Discounting and inflation allowance	(82.1)	(40.1)
Provision for claims handling costs of AICF	69.2	73.5
Other US GAAP adjustments	39.6	32.0
Net (assets) liabilities of AICF (excl funding payment)	2.2	0.1
Contributions to asbestos research and education	5.6	3.5
Effect of tax	(415.2)	(465.1)
Net post-tax liability	974.4	1,030.2
Exchange rate A\$ to US\$	1.2395	1.0903
Net post-tax liability in US\$ millions	786.1	944.9

Updated Actuarial Estimate

Comparison

<u>A\$ Billions</u>	<u>30 Jun 04</u>	<u>31 Mar 05</u>	<u>30 Jun 05</u>	<u>31 Mar 06</u>	<u>30 Sept 06</u>	<u>31 Mar 07</u>	<u>31 Mar 08</u>
Central Estimate – Discounted	1.536	1.685	1.568	1.517	1.555	1.355	1.426
Central Estimate – Undiscounted	3.586	3.604	3.131	3.079	3.169	2.811	3.027
Range - Undiscounted	2.0-5.7	2.0-5.9	1.5-5.5	1.7-5.3	1.8-5.7	1.6-5.1	1.9-5.4

Asbestos Fund Update

- AICF holdings at 31 March 2008
 - A\$123.4m – cash and short-term investments

- Net claims paid FY08:

<u>A\$ millions</u>	AICF FY08*	KPMG Actuarial Estimate	MRCF/AICF FY07
Claims Paid	67.2	70.6	67.5
Legal Costs	7.1	5.6	7.6
Insurance and cross claim recoveries	(19.2)	(11.9)	(17.7)
Total net claims costs	55.1*	64.3	57.4

* Source: Amaca Claims Service and AICF management reports

Questions & Answers

Disclaimer

This Management Presentation contains forward-looking statements. We may from time to time make forward-looking statements in our periodic reports filed with or furnished to the United States Securities and Exchange Commission on Forms 20-F and 6-K, in our annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by our officers, directors or employees to analysts, institutional investors, lenders and potential lenders, representatives of the media and others. Examples of forward-looking statements include:

- *expectations about the timing and amount of payments to the Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven asbestos-related personal injury and death claims;*
- *expectations concerning the costs associated with the suspension of operations at our Blandon Pennsylvania and Plant City, Florida plants;*
- *statements as to the possible consequences of proceedings brought against us and certain of our former directors and officers by the Australian Securities and Investments Commission;*
- *statements regarding tax liabilities and related proceedings.*
- *expectations that our credit facilities will be extended or renewed;*
- *projections of our operating results or financial condition;*
- *statements regarding our plans, objectives or goals, including those relating to competition, acquisitions, dispositions and our products;*
- *statements about our future performance; and*
- *statements about product or environmental liabilities.*

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "should," "aim" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent risks and uncertainties. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors, some of which are discussed under "Risk Factors" beginning on page 6 of our Form 20-F filed on 6 July 2007 with the Securities and Exchange Commission, include but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former James Hardie subsidiaries; required contributions to the AICF and the effect of foreign exchange on the amount recorded in our financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which we operate; the consequences of product failures or defects; exposure to environmental, asbestos or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; the success of our research and development efforts; our reliance on a small number of product distributors; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; foreign exchange risks; and the effect of natural disasters. We caution you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those in forward-looking statements. Forward-looking statements speak only as of the date they are made and we undertake no duty to update or revise any such statements.

Endnotes

This Management Presentation forms part of a package of information about the company's results. It should be read in conjunction with the other parts of this package, including Management's Analysis of Results, a Media Release and a Financial Report.

Definitions

Financial Measures – US GAAP equivalents

EBIT and EBIT Margin - EBIT, as used in this document, is equivalent to the US GAAP measure of operating income. EBIT margin is defined as EBIT as a percentage of net sales. We believe EBIT and EBIT margin to be relevant and useful information as these are the primary measures used by our management to measure the operating profit or loss of our business. EBIT is one of several metrics used by our management to measure the earnings generated from our operations, excluding interest and income tax expenses. Additionally, EBIT is believed to be a primary measure and terminology used by our Australian investors. EBIT and EBIT margin should be considered in addition to, but not as a substitute for, other measures of financial performance reported in accordance with accounting principles generally accepted in the United States of America. EBIT and EBIT margin, as we have defined them, may not be comparable to similarly titled measures reported by other companies.

Operating profit - is equivalent to the US GAAP measure of income.

Net operating profit - is equivalent to the US GAAP measure of net income.

Sales Volumes

mmsf – million square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

msf – thousand square feet, where a square foot is defined as a standard square foot of 5/16" thickness.

Endnotes

Financial Ratios

Gearing Ratio – Net debt (cash) divided by net debt (cash) plus shareholders' equity.

Net interest expense cover – EBIT divided by net interest expense.

Net interest paid cover – EBIT divided by cash paid during the period for interest, net of amounts capitalised.

Net debt payback – Net debt (cash) divided by cash flow from operations.

Net debt (cash) – Short-term and long-term debt less cash and cash equivalents.

Non-US GAAP Financial Measures

EBIT and EBIT margin excluding asbestos and asset impairments – EBIT and EBIT margin excluding asbestos and asset impairments are not measures of financial performance under US GAAP and should not be considered to be more meaningful than EBIT and EBIT margin. James Hardie has included these financial measures to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations and provides useful information regarding its financial condition and results of operations. The company uses these non-US GAAP measures for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY '08	FY '07
EBIT	\$ (181.5)	\$ (215.8)	\$ (36.6)	\$ (86.6)
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	-	4.0	-
Asset impairments:				
Impairment charges	38.6	-	71.0	-
Impairment related costs	2.5	-	3.2	-
EBIT excluding asbestos and asset impairments	43.2	70.5	281.7	318.9
Net Sales	\$ 312.9	\$ 360.9	\$ 1,468.8	\$ 1,542.9
EBIT margin excluding asbestos and asset impairments	13.8%	19.5%	19.2%	20.7%

Non-US GAAP Financial Measures (continued)

Net operating profit excluding asbestos, asset impairments and tax adjustments – Net operating profit excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than net income. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company uses this non-US GAAP measure for the same purposes.

US\$ Millions	FY08	FY07	FY08	FY07
Net operating (loss) profit	\$ (146.9)	\$ 103.1	\$ (71.6)	\$ 151.7
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	-	4.0	-
AICF interest income	(2.4)	-	(9.4)	-
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(45.8)	(335.0)
Asset impairments:				
Impairment charges (net of tax)	24.6	-	44.6	-
Impairment related costs (net of tax)	1.6	-	2.0	-
Tax adjustments	5.8	(3.0)	5.8	(10.4)
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	\$ 169.7	\$ 211.8

Non-US GAAP Financial Measures (continued)

Diluted earnings per share excluding asbestos, asset impairments and tax adjustments – Diluted earnings per share excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than diluted earnings per share. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company's management uses this non-US GAAP measure for the same purposes.

US\$ Millions	Q4 FY08	Q4 FY07	FY '08	FY '07
Net operating profit excluding asbestos, asset impairments and tax adjustments	\$ 20.1	\$ 51.4	\$ 169.7	\$ 211.8
Weighted average common shares outstanding - Diluted (millions)	434.6	469.0	456.1	466.4
Diluted earnings per share excluding asbestos, asset impairments and tax adjustments (US cents)	4.6	11.0	37.2	45.4

Non-US GAAP Financial Measures (continued)

Effective tax rate excluding asbestos, asset impairments and tax adjustments – Effective tax rate excluding asbestos, asset impairments and tax adjustments is not a measure of financial performance under US GAAP and should not be considered to be more meaningful than effective tax rate. The company has included this financial measure to provide investors with an alternative method for assessing its operating results in a manner that is focussed on the performance of its ongoing operations. The company's management uses this non-US GAAP measure for the same purposes.

Non-US GAAP Financial Measures (continued)

US\$ Millions	Q4 FY08	Q4 FY07	FY '08	FY' 07
Operating loss before income taxes	\$ (183.7)	\$ (220.0)	\$ (35.5)	\$ (93.1)
Asbestos:				
Asbestos adjustments	182.3	286.3	240.1	405.5
AICF SG&A expenses	1.3	-	4.0	-
AICF interest income	(2.4)	-	(9.4)	-
Asset impairments:				
Impairment charges	38.6	-	71.0	-
Impairment related costs	2.5	-	3.2	-
Operating profit before income taxes excluding asbestos and asset impairments	\$ 38.6	\$ 66.3	\$ 273.4	\$ 312.4
Income tax benefit (expense)	36.8	323.1	(36.1)	243.9
Asbestos:				
Tax benefit related to asbestos adjustments	(46.2)	(335.0)	(45.8)	(335.0)
Impairments:				
Tax benefit related to asset impairments	(14.9)	-	(27.6)	-
Tax adjustments	5.8	(3.0)	5.8	(10.4)
Income tax expense excluding asbestos, asset impairments and tax adjustments	(18.5)	(14.9)	(103.7)	(101.5)
Effective tax rate excluding asbestos, asset impairments and tax adjustments	48.0%	22.5%	37.9%	32.5%

Non-US GAAP Financial Measures (continued)

EBITDA – is not a measure of financial performance under US GAAP and should not be considered an alternative to, or more meaningful than, income from operations, net income or cash flows as defined by US GAAP or as a measure of profitability or liquidity. Not all companies calculate EBITDA in the same manner as James Hardie has and, accordingly, EBITDA may not be comparable with other companies. The company has included information concerning EBITDA because it believes that this data is commonly used by investors to evaluate the ability of a company's earnings from its core business operations to satisfy its debt, capital expenditure and working capital requirements.

US\$ Millions	FY08	FY07	FY08	FY07
EBIT	\$ (181.5)	\$ (215.8)	\$ (36.6)	\$ (86.6)
Depreciation and amortisation	14.4	13.7	56.5	50.7
EBITDA	\$ (167.1)	\$ (202.1)	\$ 19.9	\$ (35.9)

James Hardie FY08 4th Quarter and Full Year Results

22 May 2008

In this Management Presentation, James Hardie may present financial measures, sales volume terms, financial ratios, and Non-US GAAP financial measures included in the Definitions section of this document starting on page 59. The company presents financial measures that it believes are customarily used by its Australian investors. Specifically, these financial measures, which are equivalent to or derived from certain US GAAP measures as explained in the definitions, include "EBIT", "EBIT margin", "Operating profit" and "Net operating profit". The company may also present other terms for measuring its sales volumes ("million square feet or mmsf" and "thousand square feet or msf"), financial ratios ("Gearing ratio", "Net interest expense cover", "Net interest paid cover", "Net debt payback", "Net debt (cash)"), and Non-US GAAP financial measures ("EBIT excluding asbestos and asset impairments", "EBIT margin excluding asbestos and asset impairments", "Net operating profit excluding asbestos, asset impairments and tax adjustments", "Diluted earnings per share excluding asbestos, asset impairments and tax adjustments", "Operating profit before income taxes excluding asbestos and asset impairments", "Effective tax rate excluding asbestos, asset impairments and tax adjustments" and EBITDA). Unless otherwise stated, results and comparisons are of the 4th quarter and current full fiscal year versus the 4th quarter and full year of the prior fiscal year.

**James Hardie Industries N.V.
and Subsidiaries**
Consolidated Financial Statements
As of 31 March 2008 and 2007

James Hardie Industries N.V. and Subsidiaries

Index


	<u>Page</u>
Item 1. Financial Statements	
Report of Independent Registered Public Accounting Firm	F-3
Consolidated Balance Sheets as of 31 March 2008 and 2007	F-4
Consolidated Statements of Operations for the Years Ended 31 March 2008, 2007 and 2006	F-5
Consolidated Statements of Cash Flows for the Years Ended 31 March 2008, 2007 and 2006	F-7
Consolidated Statements of Changes in Shareholders' Equity for the Years Ended 31 March 2008, 2007 and 2006	F-9
Notes to Consolidated Financial Statements	F-10

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of
James Hardie Industries N.V.

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, cash flows, and changes in shareholders' equity present fairly, in all material respects, the financial position of James Hardie Industries N.V. and its subsidiaries at 31 March 2008 and 31 March 2007, and the results of their operations and their cash flows for each of the three years in the period ended 31 March 2008 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

As discussed in Note 14 to the consolidated financial statements, during the year ended 31 March 2008, the Company changed the manner in which it accounts for uncertain tax positions. Also, as discussed in Note 2 to the consolidated financial statements, during the year ended 31 March 2007, the Company changed its method of accounting for stock-based compensation and defined benefit pension plans.



PricewaterhouseCoopers LLP
Los Angeles, California
19 May 2008

Item 1. Financial Statements

James Hardie Industries N.V. and Subsidiaries Consolidated Balance Sheets

	(Millions of US dollars)		(Millions of Australian dollars)	
	31 March 2008	31 March 2007	31 March 2008 (Unaudited)	31 March 2007 (Unaudited)
Assets				
Current assets:				
Cash and cash equivalents	\$ 35.4	\$ 34.1	A\$ 38.6	A\$ 42.3
Restricted cash and cash equivalents	5.0	5.0	5.5	6.2
Restricted cash and cash equivalents — Asbestos	37.4	146.9	40.8	182.1
Restricted short-term investments — Asbestos	77.7	—	84.7	—
Accounts and notes receivable, net of allowance for doubtful accounts of \$2.0 million (A\$2.2 million) and \$1.5 million (A\$1.9 million) as of 31 March 2008 and 31 March 2007, respectively	131.4	163.4	143.3	202.5
Inventories	179.7	147.6	195.9	183.0
Prepaid expenses and other current assets	28.0	32.4	30.5	40.2
Insurance receivable — Asbestos	14.1	9.4	15.4	11.7
Workers' compensation — Asbestos	6.9	2.7	7.5	3.3
Deferred income taxes	8.2	27.3	8.9	33.8
Deferred income taxes — Asbestos	9.1	7.8	9.9	9.7
Total current assets	<u>532.9</u>	<u>576.6</u>	<u>581.0</u>	<u>714.8</u>
Property, plant and equipment, net	756.4	827.7	824.7	1,025.9
Insurance receivable — Asbestos	194.3	165.1	211.8	204.6
Workers' compensation — Asbestos	78.5	76.5	85.6	94.8
Deferred income taxes	13.2	6.9	14.4	8.6
Deferred income taxes — Asbestos	397.1	318.2	433.0	394.4
Deposit with Australian Taxation Office	205.8	154.8	224.4	191.9
Other assets	1.7	2.3	1.9	2.9
Total assets	<u>\$ 2,179.9</u>	<u>\$ 2,128.1</u>	<u>A\$ 2,376.8</u>	<u>A\$ 2,637.9</u>
Liabilities and Shareholders' Equity				
Current liabilities:				
Accounts payable and accrued liabilities	\$ 107.6	\$ 100.8	A\$ 117.3	A\$ 124.9
Short-term debt	90.0	83.0	98.1	102.9
Accrued payroll and employee benefits	37.0	42.0	40.3	52.1
Accrued product warranties	6.9	5.7	7.5	7.1
Income taxes payable	13.0	10.6	14.2	13.1
Asbestos liability	78.7	63.5	85.8	78.7
Workers' compensation — Asbestos	6.9	2.7	7.5	3.3
Other liabilities	9.1	9.3	9.9	11.5
Total current liabilities	<u>349.2</u>	<u>317.6</u>	<u>380.6</u>	<u>393.6</u>
Long-term debt	174.5	105.0	190.3	130.1
Deferred income taxes	84.2	93.8	91.8	116.3
Accrued product warranties	10.8	9.5	11.8	11.8
Asbestos liability	1,497.8	1,225.8	1,633.1	1,519.4
Workers' compensation — Asbestos	78.5	76.5	85.6	94.8
Other liabilities	187.5	41.2	204.4	51.1
Total liabilities	<u>2,382.5</u>	<u>1,869.4</u>	<u>A\$ 2,597.6</u>	<u>A\$ 2,317.1</u>
Commitments and contingencies (Note 13)				
Shareholders' equity:				
Common stock, Euro 0.59 par value, 2.0 billion shares authorised; 432,214,668 shares issued at 31 March 2008 and 467,295,391 shares issued at 31 March 2007	219.7	251.8		
Additional paid-in capital	19.3	180.2		
Accumulated deficit	(454.5)	(178.7)		
Common stock in treasury, at cost, 708,695 shares and nil shares at 31 March 2008 and 31 March 2007, respectively	(4.0)	—		
Accumulated other comprehensive income	16.9	5.4		
Total shareholders' (deficit) equity	<u>(202.6)</u>	<u>258.7</u>		
Total liabilities and shareholders' equity	<u>\$ 2,179.9</u>	<u>\$ 2,128.1</u>		

The accompanying notes are an integral part of these consolidated financial statements.

James Hardie Industries N.V. and Subsidiaries
Consolidated Statements of Operations

(Millions of US dollars, except per share data)	Years Ended 31 March		
	2008	2007	2006
Net sales	\$ 1,468.8	\$ 1,542.9	\$ 1,488.5
Cost of goods sold	(938.8)	(969.9)	(937.7)
Gross profit	530.0	573.0	550.8
Selling, general and administrative expenses	(228.2)	(214.6)	(209.8)
Research and development expenses	(27.3)	(25.9)	(28.7)
Impairment charges	(71.0)	—	(13.4)
SCI and other related expenses	—	(13.6)	(17.4)
Asbestos adjustments	(240.1)	(405.5)	(715.6)
Other operating expense	—	—	(0.8)
Operating loss	(36.6)	(86.6)	(434.9)
Interest expense	(11.1)	(12.0)	(7.2)
Interest income	12.2	5.5	7.0
Loss before income taxes	(35.5)	(93.1)	(435.1)
Income tax (expense) benefit	(36.1)	243.9	(71.6)
(Loss) income before cumulative effect of change in accounting principle	(71.6)	150.8	(506.7)
Cumulative effect of change in accounting principle for stock-based compensation, net of income tax expense of nil, \$0.4 million and nil, respectively	—	0.9	—
Net (loss) income	\$ (71.6)	\$ 151.7	\$ (506.7)
Net (loss) income per share — basic	\$ (0.16)	\$ 0.33	\$ (1.10)
Net (loss) income per share — diluted	\$ (0.16)	\$ 0.33	\$ (1.10)
Weighted average common shares outstanding (Millions):			
Basic	455.0	464.6	461.7
Diluted	455.0	466.4	461.7

The accompanying notes are an integral part of these consolidated financial statements.

James Hardie Industries N.V. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)

(Millions of Australian dollars, except per share data)	Years Ended 31 March		
	2008	2007	2006
Net sales	A\$ 1,689.6	A\$ 2,016.0	A\$ 1,977.5
Cost of goods sold	(1,079.9)	(1,267.3)	(1,245.7)
Gross profit	609.7	748.7	731.8
Selling, general and administrative expenses	(262.5)	(280.4)	(278.7)
Research and development expenses	(31.4)	(33.8)	(38.1)
Impairment charges	(81.7)	—	(17.8)
SCI and other related expenses	—	(17.8)	(23.1)
Asbestos adjustments	(276.2)	(529.8)	(1,000.0)
Other operating expense	—	—	(1.1)
Operating loss	(42.1)	(113.1)	(627.0)
Interest expense	(12.8)	(15.7)	(9.6)
Interest income	14.0	7.2	9.3
Loss before income taxes	(40.9)	(121.6)	(627.3)
Income tax (expense) benefit	(41.5)	318.7	(95.1)
(Loss) income before cumulative effect of change in accounting principle	(82.4)	197.1	(722.4)
Cumulative effect of change in accounting principle for stock-based compensation, net of income tax expense of nil, A\$0.5 million and nil, respectively	—	1.2	—
Net (loss) income	A\$ (82.4)	A\$ 198.3	A\$ (722.4)
Net (loss) income per share — basic	A\$ (0.18)	A\$ 0.43	A\$ (1.56)
Net (loss) income per share — diluted	A\$ (0.18)	A\$ 0.43	A\$ (1.56)
Weighted average common shares outstanding (Millions):			
Basic	455.0	464.6	461.7
Diluted	455.0	466.4	461.7

The accompanying notes are an integral part of these consolidated financial statements.

James Hardie Industries N.V. and Subsidiaries
Consolidated Statements of Cash Flows

(Millions of US dollars)	Years Ended 31 March		
	2008	2007	2006
Cash Flows From Operating Activities			
Net (loss) income	\$ (71.6)	\$ 151.7	\$ (506.7)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:			
Depreciation	56.5	50.7	45.3
Deferred income taxes	(54.0)	(310.4)	4.3
Prepaid pension cost	1.0	(0.4)	2.9
Stock-based compensation	7.7	4.5	5.9
Asbestos adjustments	240.1	405.5	715.6
Cumulative effect of change in accounting principle	—	(0.9)	—
Impairment charges	71.0	—	13.4
Other	(3.4)	1.3	1.7
Changes in operating assets and liabilities:			
Restricted cash and cash equivalents	44.7	(151.9)	—
Accounts and notes receivable	39.6	(4.8)	(24.0)
Inventories	(26.6)	(19.5)	(26.6)
Prepaid expenses and other current assets	4.9	(0.1)	(24.8)
Insurance receivable — Asbestos	16.7	—	—
Accounts payable and accrued liabilities	2.6	(18.4)	24.4
Asbestos liability	(67.0)	—	—
Deposit with Australian Taxation Office	(9.7)	(154.8)	—
Other accrued liabilities and other liabilities	66.8	(19.6)	7.0
Net cash provided by (used in) operating activities	319.3	(67.1)	238.4
Cash Flows From Investing activities			
Purchases of property, plant and equipment	(38.5)	(92.6)	(162.0)
Proceeds from disposal of subsidiaries and businesses, net of cash divested	—	—	8.0
Net cash used in investing activities	(38.5)	(92.6)	(154.0)
Cash Flows From Financing activities			
Proceeds from short-term borrowings	7.0	—	181.0
Repayments of short-term borrowings	—	(98.0)	—
Proceeds from long-term borrowings	69.5	105.0	—
Repayments of long-term borrowings	—	(121.7)	(37.6)
Proceeds from issuance of shares	3.3	18.5	18.7
Tax benefit from stock options exercised	—	1.8	2.2
Treasury stock purchased	(208.0)	—	—
Dividends paid	(126.2)	(42.1)	(45.9)
Collections on loans receivable	—	0.1	0.3
Net cash (used in) provided by financing activities	(254.4)	(136.4)	118.7
Effects of exchange rate changes on cash	(25.1)	15.1	(1.5)
Net increase (decrease) in cash and cash equivalents	1.3	(281.0)	201.6
Cash and cash equivalents at beginning of period	34.1	315.1	113.5
Cash and cash equivalents at end of period	\$ 35.4	\$ 34.1	\$ 315.1
Components of Cash and Cash Equivalents			
Cash at bank and on hand	\$ 21.6	\$ 26.1	\$ 24.9
Short-term deposits	13.8	8.0	290.2
Cash and cash equivalents at end of period	\$ 35.4	\$ 34.1	\$ 315.1
Supplemental Disclosure of Cash Flow Activities			
Cash paid during the year for interest, net of amounts capitalised	\$ 12.8	\$ 3.9	\$ 3.5
Cash paid during the year for income taxes, net	\$ 70.4	\$ 80.8	\$ 93.4

The accompanying notes are an integral part of these consolidated financial statements.

James Hardie Industries N.V. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)

(Millions of Australian dollars)	Years Ended 31 March		
	2008	2007	2006
Cash Flows From Operating Activities			
Net (loss) income	A\$ (82.4)	A\$ 198.3	A\$ (722.4)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:			
Depreciation	65.0	66.2	60.2
Deferred income taxes	(62.1)	(405.6)	5.7
Prepaid pension cost	1.2	(0.5)	3.9
Stock-based compensation	8.9	5.9	7.8
Asbestos adjustments	276.2	529.8	1,000.0
Cumulative effect of change in accounting principle	—	(1.2)	—
Impairment charges	81.7	—	17.8
Other	(3.9)	1.7	2.3
Changes in operating assets and liabilities:			
Restricted cash and cash equivalents	51.4	(198.5)	—
Accounts and notes receivable	45.6	(6.3)	(31.9)
Inventories	(30.6)	(25.5)	(35.3)
Prepaid expenses and other current assets	5.6	(0.1)	(32.9)
Insurance receivable — Asbestos	19.2	—	—
Accounts payable and accrued liabilities	3.0	(24.0)	32.4
Asbestos liability	(77.1)	—	—
Deposit with Australian Taxation Office	(11.2)	(202.3)	—
Other accrued liabilities and other liabilities	76.8	(25.6)	9.3
Net cash provided by (used in) operating activities	367.3	(87.7)	316.9
Cash Flows From Investing Activities			
Purchases of property, plant and equipment	(44.3)	(121.0)	(215.2)
Proceeds from disposal of subsidiaries and businesses, net of cash divested	—	—	10.6
Net cash used in investing activities	(44.3)	(121.0)	(204.6)
Cash Flows From Financing Activities			
Proceeds from short-term borrowings	8.1	—	240.5
Repayments of short-term borrowings	—	(128.0)	—
Proceeds from long-term borrowings	79.9	137.2	—
Repayments of long-term borrowings	—	(159.0)	(50.0)
Proceeds from issuance of shares	3.8	24.2	24.8
Tax benefit from stock options exercised	—	2.4	2.9
Treasury stock purchased	(239.3)	—	—
Dividends paid	(145.2)	(55.0)	(61.0)
Collections on loans receivable	—	0.1	0.3
Net cash (used in) provided by financing activities	(292.7)	(178.1)	157.5
Effects of exchange rate changes on cash	(34.0)	(11.3)	23.7
Net (decrease) increase in cash and cash equivalents	(3.7)	(398.1)	293.5
Cash and cash equivalents at beginning of period	42.3	440.4	146.9
Cash and cash equivalents at end of period	A\$ 38.6	A\$ 42.3	A\$ 440.4
Components of Cash and Cash Equivalents			
Cash at bank and on hand	A\$ 23.6	A\$ 32.4	A\$ 34.8
Short-term deposits	15.0	9.9	405.6
Cash and cash equivalents at end of period	A\$ 38.6	A\$ 42.3	A\$ 440.4
Supplemental Disclosure of Cash Flow Activities			
Cash paid during the year for interest, net of amounts capitalised	A\$ 14.7	A\$ 4.8	A\$ 4.9
Cash paid during the year for income taxes, net	A\$ 81.0	A\$ 100.2	A\$ 130.5

The accompanying notes are an integral part of these consolidated financial statements.

James Hardie Industries N.V. and Subsidiaries
Consolidated Statements of Changes in Shareholders' Equity

(Millions of US dollars)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Total
Balances as of 31 March 2005	\$ 245.8	\$ 138.7	\$ 264.3	\$ (24.1)	\$ —	\$ 624.7
Comprehensive income (loss):						
Net loss	—	—	(506.7)	—	—	(506.7)
Amortisation of unrealised transition gain on derivative instruments	—	—	—	0.5	—	0.5
Foreign currency translation loss	—	—	—	(4.8)	—	(4.8)
Other comprehensive loss	—	—	—	(4.3)	—	(4.3)
Total comprehensive loss	—	—	—	—	—	(511.0)
Stock-based compensation	—	5.9	—	—	—	5.9
Tax benefit from stock options exercised	—	2.2	—	—	—	2.2
Employee loans repaid	—	0.3	—	—	—	0.3
Stock options exercised	7.4	11.3	—	—	—	18.7
Dividends paid	—	—	(45.9)	—	—	(45.9)
Balances as of 31 March 2006	\$ 253.2	\$ 158.4	\$ (288.3)	\$ (28.4)	\$ —	\$ 94.9
Comprehensive income (loss):						
Net income	—	—	151.7	—	—	151.7
Foreign currency translation gain	—	—	—	36.5	—	36.5
Other comprehensive income	—	—	—	36.5	—	36.5
Total comprehensive income	—	—	—	—	—	188.2
Adoption of FAS 158, net of tax	—	—	—	(2.7)	—	(2.7)
Stock-based compensation	—	4.5	—	—	—	4.5
Tax benefit from stock options exercised	—	1.8	—	—	—	1.8
Employee loans repaid	—	0.1	—	—	—	0.1
Stock options exercised	3.1	15.4	—	—	—	18.5
Dividends paid	—	—	(42.1)	—	—	(42.1)
Other	(4.5)	—	—	—	—	(4.5)
Balances as of 31 March 2007	\$ 251.8	\$ 180.2	\$ (178.7)	\$ 5.4	\$ —	\$ 258.7
Comprehensive income (loss)						
Net loss	—	—	(71.6)	—	—	(71.6)
Pension and post-retirement benefit adjustments	—	—	—	0.6	—	0.6
Unrealised loss on investments	—	—	—	(4.4)	—	(4.4)
Foreign currency translation gain	—	—	—	15.3	—	15.3
Other comprehensive income	—	—	—	11.5	—	11.5
Total comprehensive loss	—	—	—	—	—	(60.1)
Adoption of FIN 48	—	—	(78.0)	—	—	(78.0)
Stock-based compensation	—	7.7	—	—	—	7.7
Stock options exercised	0.5	2.8	—	—	—	3.3
Dividends paid	—	—	(126.2)	—	—	(126.2)
Treasury stock purchased	—	—	—	—	(208.0)	(208.0)
Treasury stock retired	(32.6)	(171.4)	—	—	204.0	—
Balances as of 31 March 2008	\$ 219.7	\$ 19.3	\$ (454.5)	\$ 16.9	\$ (4.0)	\$ (202.6)

The accompanying notes are an integral part of these consolidated financial statements.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

1. Background and Basis of Presentation

Nature of Operations

The Company manufactures and sells fibre cement building products for interior and exterior building construction applications primarily in the United States, Australia, New Zealand, Philippines and Europe.

Background

On 2 July 1998, ABN 60 000 009 263 Pty Ltd, formerly James Hardie Industries Limited ("JHIL"), then a public company organised under the laws of Australia and listed on the Australian Stock Exchange, announced a plan of reorganisation and capital restructuring (the "1998 Reorganisation"). James Hardie N.V. ("JHNV") was incorporated in August 1998, as an intermediary holding company, with all of its common stock owned by indirect subsidiaries of JHIL. On 16 October 1998, JHIL's shareholders approved the 1998 Reorganisation. Effective as of 1 November 1998, JHIL contributed its fibre cement businesses, its US gypsum wallboard business, its Australian and New Zealand building systems businesses and its Australian windows business (collectively, the "Transferred Businesses") to JHNV and its subsidiaries. In connection with the 1998 Reorganisation, JHIL and its non-transferring subsidiaries retained certain unrelated assets and liabilities.

On 24 July 2001, JHIL announced a further plan of reorganisation and capital restructuring (the "2001 Reorganisation"). Completion of the 2001 Reorganisation occurred on 19 October 2001. In connection with the 2001 Reorganisation, James Hardie Industries N.V. ("JHI NV"), formerly RCI Netherlands Holdings B.V., issued common shares represented by CHESS Units of Foreign Securities ("CUFS") on a one for one basis to existing JHIL shareholders in exchange for their shares in JHIL such that JHI NV became the new ultimate holding company for JHIL and JHNV.

Following the 2001 Reorganisation, JHI NV controls the same assets and liabilities as JHIL controlled immediately prior to the 2001 Reorganisation.

Previously deconsolidated entities have been consolidated beginning 31 March 2007 as part of the accounting for the asbestos liability. Upon approval of the Restated and Amended Final Funding Agreement on 7 February 2007 (the "Amended FFA"), the Asbestos Injuries Compensation Fund (the "AICF") was deemed a special purpose entity and, as such, it was consolidated with the results for JHI NV. See Note 2 and Note 12 for additional information.

Basis of Presentation

The consolidated financial statements represent the financial position, results of operations and cash flows of JHI NV and its current wholly owned subsidiaries and special purpose entities, collectively referred to as either the "Company" or "James Hardie" and JHI NV together with its subsidiaries as of the time relevant to the applicable reference, the "James Hardie Group," unless the context indicates otherwise. Operating loss for the twelve months ended 31 March 2008 includes a charge of US\$2.7 million relating to prior period lease costs. The impact of this adjustment on prior periods' financial statements is not material.

The assets, liabilities, statements of operations and statements of cash flows of the Company have been presented with accompanying Australian dollar (A\$) convenience translations as the majority of the Company's shareholder base is Australian. These A\$ convenience translations are not prepared in accordance with accounting principles generally accepted in the United States of America and have not been audited. The exchange rates used to calculate the convenience translations are as follows:

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

(US\$1 = A\$)	2008	31 March 2007	2006
Assets and liabilities	1.0903	1.2395	1.3975
Statements of operations	1.1503	1.3066	1.3285
Cash flows — beginning cash	1.2395	1.3975	1.2946
Cash flows — ending cash	1.0903	1.2395	1.3975
Cash flows — current period movements	1.1503	1.3066	1.3285

2. Summary of Significant Accounting Policies

Accounting Principles

The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The US dollar is used as the reporting currency. All subsidiaries and special purpose entities are consolidated and all significant intercompany transactions and balances are eliminated.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Reclassifications

Certain prior year balances have been reclassified to conform with the current year presentation. The reclassifications do not impact shareholders' equity.

Foreign Currency Translation

All assets and liabilities are translated into US dollars at current exchange rates while revenues and expenses are translated at average exchange rates in effect for the period. The effects of foreign currency translation adjustments are included directly in other comprehensive income in shareholders' equity. Gains and losses arising from foreign currency transactions are recognised in income currently.

Cash and Cash Equivalents

Cash and cash equivalents include amounts on deposit in banks and cash invested temporarily in various highly liquid financial instruments with original maturities of three months or less when acquired.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents include amounts on deposit with insurance companies.

Accounts Receivable

The Company reviews trade receivables and estimates of the allowance for doubtful accounts each period. The allowance is determined by analysing specific customer accounts and assessing the risk of uncollectability based on insolvency, disputes or other collection issues.

Inventories

Inventories are valued at the lower of cost or market. Cost is generally determined under the first-in, first-out method, except that the cost of raw materials and supplies is determined using actual or average costs. Cost includes the costs of materials, labour and applied factory overhead. On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analysing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are written down, if necessary.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Property, plant and equipment of businesses acquired are recorded at their estimated cost based on fair value at the date of acquisition. Depreciation of property, plant and equipment is computed using the straight-line method over the following estimated useful lives:

	Years
Buildings	40
Building improvements	5 to 10
Manufacturing machinery	20
General equipment	5 to 10
Computer equipment, software and software development	3 to 7
Office furniture and equipment	3 to 10

The costs of additions and improvements are capitalised, while maintenance and repair costs are expensed as incurred. Interest is capitalised in connection with the construction of major facilities. Capitalised interest is recorded as part of the asset to which it relates and is amortised over the asset's estimated useful life. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation amounts with any resulting gain or loss reflected in the consolidated statements of operations.

In accordance with Statement of Financial Accounting Standards ("SFAS") No. 143, "Accounting for Asset Retirement Obligations", the Company accrues for all asset retirement obligations in the period in which the liability is incurred. The initial measurement of an asset retirement obligation is based upon the present value of estimated cost and a related long-lived asset retirement cost is capitalised as part of the asset's carrying value and allocated to expense over the asset's useful life.

Impairment of Long-Lived Assets

In accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," long-lived assets, such as property, plant and equipment, and purchased intangibles subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognised by the amount by which the carrying amount of the asset exceeds the fair value of the assets.

Environmental

Environmental remediation expenditures that relate to current operations are expensed or capitalised, as appropriate. Expenditures that relate to an existing condition caused by past operations, and which do not contribute to current or future revenue generation, are expensed. Liabilities are recorded when environmental assessments and/or remedial efforts are probable and the costs can be reasonably estimated. Estimated liabilities are not discounted to present value. Generally, the timing of these accruals coincides with completion of a feasibility study or the Company's commitment to a formal plan of action.

Revenue Recognition

The Company recognises revenue when the risks and obligations of ownership have been transferred to the customer, which generally occurs at the time of delivery to the customer. The Company records estimated reductions to sales for customer rebates and discounts including volume, promotional, cash and other discounts. Rebates and discounts are recorded based on management's best estimate when products are sold. The estimates are based on historical experience for similar programs and products. Management reviews these rebates and discounts on an ongoing basis and the related accruals are adjusted, if necessary, as additional information becomes available.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Cost of Goods Sold

Cost of goods sold is primarily comprised of cost of materials, labour and manufacturing. Cost of goods sold also includes the cost of inbound freight charges, purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs and shipping and handling costs.

Shipping and Handling

Shipping and handling costs are charged to cost of goods sold as incurred. Recovery of these costs is incorporated in the Company's sales price per unit and is therefore classified as part of net sales.

Selling, General and Administrative

Selling, general and administrative expenses primarily include costs related to advertising, marketing, selling, information technology and other general corporate functions. Selling, general and administrative expenses also include certain transportation and logistics expenses associated with the Company's distribution network.

Advertising

The Company expenses the production costs of advertising the first time the advertising takes place. Advertising expense was US\$11.9 million, US\$17.0 million and US\$19.1 million during the years ended 31 March 2008, 2007 and 2006, respectively.

Research and Development

Research and development costs are charged to expense when incurred.

Accrued Product Warranties

An accrual for estimated future warranty costs is recorded based on an analysis by the Company, including the historical relationship of warranty costs to sales.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognised by applying enacted statutory rates applicable to future years to differences between the tax bases and financial reporting amounts of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognised in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that all or some portion of deferred tax assets will not be realised. Interest and penalties related to uncertain tax positions are recognised in income tax expense.

Financial Instruments

To meet the reporting requirements of SFAS No. 107, "Disclosures About Fair Value of Financial Instruments", the Company calculates the fair value of financial instruments and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments. When the fair value reasonably approximates the carrying value, no additional disclosure is made. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realise in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

Periodically, interest rate swaps, commodity swaps and forward exchange contracts are used to manage market risks and reduce exposure resulting from fluctuations in interest rates, commodity prices and foreign currency exchange rates. Where such contracts are designated as, and are effective as, a hedge, gains and losses arising on such contracts are accounted for in accordance with SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities," as amended. Specifically, changes in the fair value of derivative instruments designated as cash flow hedges are deferred and recorded in other comprehensive income. These deferred gains or losses are recognised in income when the transactions being hedged are recognised. The ineffective portion of

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

these hedges is recognised in income currently. Changes in the fair value of derivative instruments designated as fair value hedges are recognised in income, as are changes in the fair value of the hedged item. Changes in the fair value of derivative instruments that are not designated as hedges for accounting purposes are recognised in income. The Company does not use derivatives for trading purposes.

Stock-based Compensation

The Company recognised stock-based compensation expense (included in selling, general and administrative expense) of US\$7.7 million, US\$5.8 million and US\$5.9 million for the years ended 31 March 2008, 2007 and 2006, respectively.

Upon adoption of SFAS No. 123R, "Accounting for Stock-Based Compensation", at the beginning of fiscal year 2007, the Company analysed forfeiture rates on all of its 2001 Stock Option Plan grants for which vesting was complete, resulting in an estimated weighted average forfeiture rate of 30.7%. Based on this estimated rate, a cumulative adjustment to stock-based compensation expense of US\$1.3 million net of an income tax benefit of US\$0.4 million was recorded effective 1 April 2006. The adjustment is presented on the consolidation statements of operations as a cumulative effect of change in accounting principle (net of income tax). The portion of the cumulative adjustment that relates to USA-based employees caused a reduction in the deferred tax asset previously recorded. For the twelve months ended 31 March 2007, the amount of the cumulative adjustment related to USA-based employees was US\$1.0 million for which the related USA income tax adjustment was US\$0.4 million.

Employee Benefit Plans

In fiscal year 2007, the Company implemented the provisions of SFAS No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans". Adopting this standard resulted in the recognition of an increase in non-current liabilities of US\$3.9 million and a reduction in shareholders' equity of US\$2.7 million, at 31 March 2007.

The Company sponsors both defined benefit and defined contribution retirement plans for its employees. Employer contributions to the defined contribution plans are recognised as periodic pension expense in the period that the employees' salaries or wages are earned. The defined benefit plan covers all eligible employees and takes into consideration the following components to calculate net periodic pension expense: (a) service cost; (b) interest cost; (c) expected return on plan assets; (d) amortisation of unrecognised prior service cost; (e) recognition of net actuarial gains or losses; and (f) amortisation of any unrecognised net transition asset. If the amount of the Company's total contribution to its pension plan for the period is not equal to the amount of net periodic pension cost, the Company recognises the difference either as a prepaid or accrued pension cost.

Dividends

Dividends are recorded as a liability on the date the Board of Directors formally declares the dividend.

Earnings Per Share

The Company is required to disclose basic and diluted earnings per share ("EPS"). Basic EPS is calculated using net income divided by the weighted average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional common shares calculated using the treasury method that would have been outstanding if the dilutive potential common shares, such as options, had been issued. Accordingly, basic and dilutive common shares outstanding used in determining net (loss) income per share are as follows:

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

(Millions of shares)	Years Ended 31 March		
	2008	2007	2006
Basic common shares outstanding	455.0	464.6	461.7
Dilutive effect of stock options	—	1.8	—
Diluted common shares outstanding	<u>455.0</u>	<u>466.4</u>	<u>461.7</u>
(US dollars)	2008	2007	2006
Net (loss) income per share — basic	\$(0.16)	\$0.33	\$(1.10)
Net (loss) income per share — diluted	\$(0.16)	\$0.33	\$(1.10)

Potential common shares of 10.4 million, 7.7 million and 6.6 million for the years ended 31 March 2008, 2007 and 2006, respectively, have been excluded from the calculation of diluted common shares outstanding because the effect of their inclusion would be anti-dilutive. Due to the net loss for the years ended 31 March 2008 and 2006, the assumed net exercise of stock options was excluded, as the effect would have been anti-dilutive.

Repurchased Common Stock

The Company accounts for repurchased common stock under the cost method and includes such treasury stock as a component of shareholders' equity. Retirement of treasury stock is recorded as a reduction of common stock and additional paid-in capital, as applicable.

Accumulated Other Comprehensive Income

Accumulated other comprehensive income includes foreign currency translation gains and losses, unrealised losses on investments and unrecognised pension costs, and is presented as a separate component of shareholders' equity.

Asbestos

At 31 March 2006, the Company recorded an asbestos provision based on the estimated economic reality of the Original Final Funding Agreement ("Original FFA") entered into on 1 December 2005. The amount of the asbestos provision of US\$715.6 million was based on the terms of the Original FFA, which included an actuarial estimate prepared by KPMG Actuaries as of 31 March 2006 of the projected future cash outflows, undiscounted and uninflated, and the anticipated tax deduction arising from Australian legislation which came into force on 6 April 2006. The amount represented the net economic impact that the Company was prepared to assume as a result of its voluntary funding of the asbestos liability which was under negotiation with various parties.

In February 2007, the shareholders approved the Amended FFA entered into on 21 November 2006 to provide long-term funding to the AICF, a special purpose fund that provides compensation for Australian-related personal injuries for which certain former subsidiary companies of James Hardie in Australia (being Amaca Pty Ltd ("Amaca"), Amaba Pty Ltd ("Amaba") and ABN 60 Pty Limited ("ABN 60") (collectively, the "Liable Entities")) are found liable.

Upon shareholder approval of the Amended FFA, in accordance with Financial Accounting Standards Board ("FASB") Interpretation No. 46R, the Company consolidated the AICF with the Company resulting in a separate recognition of the asbestos liability and certain other items including the related Australian income tax benefit. Among other items, the Company recorded a deferred tax asset for the anticipated tax benefit related to asbestos liabilities and a corresponding increase in the asbestos liability. As stated in "Deferred Income Taxes" below, the Company's Performing Subsidiary will be able to claim a taxable deduction for contributions to the asbestos fund. For the year ended 31 March 2007, the Company classified the expense related to the increase of the asbestos liability as asbestos adjustments and the Company classified the benefit related to the recording of the related deferred tax asset as an income tax benefit (expense) on its consolidated statements of operations.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Amaca and Amaba separated from the James Hardie Group in February 2001. ABN 60 separated from the James Hardie Group in March 2003. Upon shareholder approval of the Amended FFA in February 2007, shares in the Liable Entities were transferred to the AICF. The Company appoints three of the AICF directors and the NSW state government appoints two of the AICF directors. The AICF manages Australian asbestos-related personal injury claims made against the Liable Entities, and makes compensation payments in respect of those proven claims.

AICF

Under the terms of the Amended FFA, James Hardie 117 Pty Ltd (the "Performing Subsidiary") has a contractual liability to make payments to the AICF. This funding to the AICF results in the Company having a pecuniary interest in the AICF. The interest is considered variable because the potential impact on the Company will vary based upon the annual actuarial assessments obtained by the AICF with respect to asbestos-related personal injury claims against the Liable Entities. Due to the Company's variable interest in the AICF, it consolidates the AICF in accordance with FASB, Interpretation No. 46R, "Consolidation of Variable Interest Entities".

The AICF has operating costs that are claims related and non-claims related. Claims related costs incurred by the AICF are treated as reductions to the accrued asbestos liability balances previously reflected in the consolidated balance sheets. Non-claims related operating costs incurred by the AICF are expensed as incurred in the line item *Selling, general and administrative expenses* in the consolidated statements of operations. The AICF earns interest on its cash and cash equivalents and on its short-term investments; these amounts are included in the line item *Interest income* in the consolidated statements of operations.

Asbestos-Related Assets and Liabilities

The Company has recorded on its consolidated balance sheets certain assets and liabilities under the terms of the Amended FFA. These items are Australian dollar-denominated and are subject to translation into US dollars at each reporting date. These assets and liabilities are commonly referred to by the Company as *Asbestos-Related Assets and Liabilities* and include:

Asbestos Liability

The amount of the asbestos liability reflects the terms of the Amended FFA, which has been calculated by reference to (but is not exclusively based upon) the most recent actuarial estimate of projected future cash flows prepared by KPMG Actuaries. Based on KPMG Actuaries' assumptions, KPMG Actuaries arrived at a range of possible total cash flows and proposed a central estimate which is intended to reflect an expected outcome. The Company views the central estimate as the basis for recording the asbestos liability in the Company's financial statements, which under US GAAP, it considers the best estimate under SFAS No. 5. The asbestos liability includes these cash flows as undiscounted and uninflated on the basis that it is inappropriate to discount or inflate future cash flows when the timing and amounts of such cash flows is not fixed or readily determinable.

Adjustments in the asbestos liability due to changes in the actuarial estimate of projected future cash flows and changes in the estimate of future operating costs of the AICF are reflected in the consolidated statements of operations during the period in which they occur. Claims paid by the AICF and claims-handling costs incurred by the AICF are treated as reductions in the accrued balances previously reflected in the consolidated balance sheets.

Insurance Receivable

There are various insurance policies and insurance companies with exposure to the asbestos claims. The insurance receivable determined by KPMG Actuaries reflects the recoveries expected from all such policies based on the expected pattern of claims against such policies less an allowance for credit risk based on credit agency ratings. The insurance receivable generally includes these cash flows as undiscounted and uninflated on the basis that it is inappropriate to discount or inflate future cash flows when the timing and amounts of such cash flows are not fixed or readily determinable. The Company only records insurance receivables that it deems to be probable.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Included in insurance receivable is US\$16.2 million recorded on a discounted basis because the timing of the recoveries has been agreed with the insurer.

Adjustments in insurance receivable due to changes in the actuarial estimate, or changes in the Company's assessment of recoverability are reflected in the consolidated statements of operations during the period in which they occur. Insurance recoveries are treated as a reduction in the insurance receivable balance.

Workers' Compensation

Workers' compensation claims are claims made by former employees of the Liable Entities. Such past, current and future reported claims were insured with various insurance companies and the various Australian State-based workers' compensation schemes (collectively "workers' compensation schemes or policies"). An estimate of the liability related to workers' compensation claims is prepared by KPMG Actuaries as part of the annual actuarial assessment. This estimate contains two components, amounts that will be met by a workers' compensation scheme or policy, and amounts that will be met by the Liable Entities.

The portion of the KPMG Actuaries estimate that is expected to be met by the Liable Entities is included as part of the *Asbestos Liability*. Adjustments to this estimate are reflected in the consolidated statements of operations during the period in which they occur.

The portion of the KPMG Actuaries estimate that is expected to be met by the workers' compensation schemes or policies of the Liable Entities is recorded by the Company as a workers' compensation liability. Since these amounts are expected to be paid by the workers' compensation schemes or policies, the Company records an equivalent workers' compensation receivable.

Adjustments to the workers' compensation liability result in an equal adjustment in the workers' compensation receivable recorded by the Company and have no effect on the consolidated statements of operations.

Asbestos-Related Research and Education Contributions

The Company agreed to fund asbestos-related research and education initiatives for a period of 10 years, beginning in fiscal year 2007. The liabilities related to these agreements are included in "Other Liabilities" on the consolidated balance sheets.

Restricted Cash and Cash Equivalents

Cash and cash equivalents of the AICF are reflected as restricted assets, as the use of these assets is restricted to the settlement of asbestos claims and payment of the operating costs of the AICF.

Restricted Short-Term Investments

Short-term investments consist of highly liquid investments held in the custody of major financial institutions. All short-term investments are classified as available for sale and are recorded at market value using the specific identification method. Unrealised gains and losses on the market value of these investments are included as a separate component of accumulated other comprehensive income.

AICF – Other Assets and Liabilities

Other assets and liabilities of the AICF, including fixed assets, trade receivables and payables are included on the consolidated balance sheets under the appropriate captions and their use is restricted to the operations of the AICF.

Deferred Income Taxes

The Performing Subsidiary is able to claim a taxation deduction for its contributions to the AICF over a five-year period from the date of contribution. Consequently, a deferred tax asset has been recognised equivalent to the anticipated tax benefit over the life of the Amended FFA. Adjustments are made to the deferred income tax asset as adjustments to the asbestos-related assets and liabilities are recorded.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Foreign Currency Translation

The asbestos-related assets and liabilities are denominated in Australian dollars and thus the reported values of these asbestos-related assets and liabilities in the Company's consolidated balance sheets in US dollars are subject to adjustment depending on the closing exchange rate between the two currencies at the balance sheet date. The effect of foreign exchange rate movements between these currencies is included in *Asbestos Adjustments* in the consolidated statements of operations.

Recent Accounting Pronouncements

Fair Value Measurements

In September 2006, the FASB issued Statement No. 157, "Fair Value Measurements" ("SFAS No. 157"), which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles ("GAAP") and expands disclosures about fair value measurements. The expanded disclosures in this statement about the use of fair value to measure assets and liabilities should provide users of financial statements with better information about the extent to which fair value is used to measure recognised assets and liabilities, the inputs used to develop the measurements, and the effect of certain measurements on earnings (or changes in net assets) for the period. Certain provisions of SFAS No. 157 are effective for the Company on 1 April 2008 and it is currently evaluating the impact on its financial statements of adopting SFAS No. 157.

Fair Value Option for Financial Assets and Financial Liabilities

In February 2007, the FASB issued Statement No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS No. 159"), which allows for voluntary measurement of financial assets and liabilities as well as certain other items at fair value. Unrealised gains and losses on financial instruments for which the fair value option has been elected are reported in earnings. The provisions of SFAS No. 159 are effective for the Company on 1 April 2008 and it is currently evaluating the impact on its financial statements of adopting SFAS No. 159.

Business Combinations

In December 2007, the FASB issued SFAS No. 141 (revised 2007), "Business Combinations" ("SFAS No. 141R"), which replaces SFAS No. 141. The statement establishes principles and requirements for how the acquirer in a business combination recognises and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any controlling interest; recognises and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The provisions of SFAS No. 141R are effective for business combinations for which the acquisition date is on or after 1 April 2009.

Noncontrolling Interests in Consolidated Financial Statements – an amendment to ARB No. 51

In December 2007, the FASB approved the issuance of SFAS No. 160 "Noncontrolling Interests in Consolidated Financial Statements – an amendment to ARB No. 51" ("SFAS No. 160"). SFAS No. 160 establishes accounting and reporting standards that require the ownership interest in subsidiaries held by parties other than the entity be clearly identified and presented in the Consolidated Balance Sheets within equity, but separate from the entity's equity; the amount of consolidated net income attributable to the entity and the noncontrolling interest be clearly identified and presented on the face of the Consolidated Statement of Earnings; and changes in the entity's ownership interest while the entity retains its controlling financial interest in its subsidiary be accounted for consistently. The provisions of SFAS No. 160 are effective for the Company on 1 April 2009, and it is currently evaluating the impact on its financial statements of adopting SFAS No. 160.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Disclosures about Derivative Instruments and Hedging Activities

In March 2008, the FASB issued SFAS No. 161, "Disclosures about Derivative Instruments and Hedging Activities" ("SFAS No. 161"). SFAS No. 161 is intended to improve financial reporting of derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity's financial position, financial performance, and cash flows. SFAS No. 161 is effective for the Company April 1, 2009. and it is currently evaluating the impact on its financial statements of adopting SFAS No. 161.

3. Cash and Cash Equivalents

Cash and cash equivalents include amounts on deposit in banks and cash invested temporarily in various highly liquid financial instruments with original maturities of three months or less.

Cash and cash equivalents consist of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Cash at bank and on hand	\$ 21.6	\$ 26.1
Short-term deposits	13.8	8.0
Total cash and cash equivalents	<u>\$ 35.4</u>	<u>\$ 34.1</u>

Short-term deposits are placed at floating interest rates varying between 2.14% to 2.93% and 4.85% to 5.25% as of 31 March 2008 and 2007, respectively.

4. Restricted Cash and Cash Equivalents

Included in restricted cash is US\$5.0 million related to an insurance policy as of 31 March 2008 and 2007.

5. Accounts and Notes Receivable

Accounts and notes receivable consist of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Trade receivables	\$ 122.7	\$ 152.4
Other receivables and advances	10.7	12.5
Allowance for doubtful accounts	(2.0)	(1.5)
Total accounts and notes receivable	<u>\$ 131.4</u>	<u>\$ 163.4</u>

The collectability of accounts receivable, consisting mainly of trade receivables, is reviewed on an ongoing basis and an allowance for doubtful accounts is provided for known and estimated bad debts. The following are changes in the allowance for doubtful accounts:

(Millions of US dollars)	31 March	
	2008	2007
Balance at beginning of period	\$ 1.5	\$ 1.3
Charged to expense	0.6	0.5
Costs and deductions	(0.1)	(0.3)
Balance at end of period	<u>\$ 2.0</u>	<u>\$ 1.5</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

6. Inventories

Inventories consist of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Finished goods	\$ 127.4	\$ 101.5
Work-in-process	8.4	12.3
Raw materials and supplies	51.0	37.8
Provision for obsolete finished goods and raw materials	(7.1)	(4.0)
Total inventories	\$ 179.7	\$ 147.6

7. Property, Plant and Equipment

Property, plant and equipment consist of the following components:

	Land	Buildings	Machinery and Equipment	Construction in Progress	Total
Balance at 31 March 2006:					
Cost	\$ 15.6	\$ 147.5	\$ 669.8	\$ 228.1	\$ 1,061.0
Accumulated depreciation	—	(31.7)	(253.7)	—	(285.4)
Net book value	15.6	115.8	416.1	228.1	775.6
Changes in net book value:					
Capital expenditures	1.3	70.8	131.3	(110.8)	92.6
Retirements and sales	—	—	(0.6)	—	(0.6)
Depreciation	—	(8.3)	(42.4)	—	(50.7)
Other movements	—	—	0.6	—	0.6
Foreign currency translation adjustments	—	—	10.2	—	10.2
Total changes	1.3	62.5	99.1	(110.8)	52.1
Balance at 31 March 2007:					
Cost	16.9	218.3	811.3	117.3	1,163.8
Accumulated depreciation	—	(40.0)	(296.1)	—	(336.1)
Net book value	\$ 16.9	\$ 178.3	\$ 515.2	\$ 117.3	\$ 827.7
Changes in net book value:					
Capital expenditures	0.3	7.3	65.8	(34.9)	38.5
Retirements and sales	—	—	(1.2)	—	(1.2)
Depreciation	—	(12.0)	(44.5)	—	(56.5)
Impairment	—	(16.7)	(54.3)	—	(71.0)
Other movements	—	—	5.2	—	5.2
Foreign currency translation adjustments	—	—	13.7	—	13.7
Total changes	0.3	(21.4)	(15.3)	(34.9)	(71.3)
Balance at 31 March 2008:					
Cost	17.2	208.9	840.5	82.4	1,149.0
Accumulated depreciation	—	(52.0)	(340.6)	—	(392.6)
Net book value	\$ 17.2	\$ 156.9	\$ 499.9	\$ 82.4	\$ 756.4

Construction in progress consists of plant expansions and upgrades.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Interest related to the construction of major facilities is capitalised and included in the cost of the asset to which it relates. Interest capitalised was US\$0.6 million, US\$5.3 million and US\$5.7 million for the years ended 31 March 2008, 2007 and 2006, respectively. Depreciation expense for continuing operations was US\$56.5 million, US\$50.7 million and US\$45.3 million for the years ended 31 March 2008, 2007 and 2006, respectively.

Included in property, plant and equipment are restricted assets of the AICF with a net book value of US\$0.6 million and US\$0.4 million as of 31 March 2008 and 2007, respectively.

Asset Impairments

The Company recorded an asset impairment charge of US\$13.4 million for the year ended 31 March 2006 related to the closure of its pilot roofing plant. This asset impairment charge was recorded in the Company's Other segment. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows.

On 31 October 2007, the Company announced plans to suspend production at its Blandon, Pennsylvania plant in the US. The Company recorded an asset impairment charge of US\$32.4 million in the year ended 31 March 2008 in its USA Fibre Cement segment. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. These assets are being held for use by the Company. Since the date of the announcement through 31 March 2008, the Company has incurred US\$1.4 million of closure related costs. The closure related costs are not included in the asset impairment charge of US\$32.4 million and have been included in cost of goods sold and selling, general and administrative expenses in the period incurred.

The Company recorded an asset impairment charge of US\$25.4 million in the year ended 31 March 2008 in its Other segment, related to the closure of its Plant City, Florida Hardie Pipe plant. The impaired assets include buildings and machinery, which were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. These assets are being held for use by the Company.

The Company recorded an asset impairment charge of US\$13.2 million in the year ended 31 March 2008 related to buildings and machinery utilised to produce materials for the Company's products. This asset impairment was recorded in its USA Fibre Cement segment. The impaired assets were reduced to their estimated fair value based on valuation methods including quoted market prices and discounted future cash flows. These assets are being held for use by the Company.

8. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Trade creditors	\$ 73.7	\$ 57.7
Other creditors and accruals	33.9	43.1
Total accounts payable and accrued liabilities	<u>\$ 107.6</u>	<u>\$ 100.8</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

9. Short and Long-Term Debt

Debt consists of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Short-term debt	\$ 90.0	\$ 83.0
Long-term debt	174.5	105.0
Total debt ¹	<u>\$ 264.5</u>	<u>\$ 188.0</u>

¹ Total debt at 3.63% and 5.91% weighted average rates at 31 March 2008 and 2007, respectively.

At 31 March 2008, the Company's credit facilities currently consist of :

Description (US\$ millions)	At 31 March 2008	
	Total Facility	Principal Drawn
364-day facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until December 2008	\$110.0	\$ 90.0
Term facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until June 2010	245.0	174.5
Term facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until February 2011	45.0	—
Term facilities, can be drawn in US\$, variable interest rates based on LIBOR plus margin, can be repaid and redrawn until February 2013	90.0	—
Total	<u>\$490.0</u>	<u>\$ 264.5</u>

For all facilities, the interest rate is calculated two business days prior to the commencement of each draw-down period based on the US\$ London Interbank Offered Rate ("LIBOR") plus the margins of individual lenders and is payable at the end of each drawn-down period. The Company paid commitment fees in the amount of US\$0.4 million and US\$0.7 million, respectively for the years ended 31 March 2008 and 2007. At 31 March 2008, there was US\$264.5 million drawn under the combined facilities and US\$225.5 million was available.

Short-term debt at 31 March 2008 and 31 March 2007 comprised US\$90.0 million and US\$83.0 million, respectively, drawn under the 364-day facilities. Long-term debt at 31 March 2008 and 31 March 2007 comprised US\$174.5 million and US\$105.0 million, respectively, drawn under the term facilities.

At 31 March 2008, management believes that the Company was in compliance with all restrictive covenants contained in its credit facility agreements. Under the most restrictive of these covenants, the Company (i) is required to maintain certain ratios of indebtedness to equity which do not exceed certain maximums, excluding assets, liabilities and other balance sheet items of the AICF, Amaba Pty Limited, Amaca Pty Limited, ABN 60 Pty Limited and Marlew Mining Pty Limited, (ii) must

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

maintain a minimum level of net worth, excluding assets, liabilities and other balance sheet items of the AICF, (iii) must meet or exceed a minimum ratio of earnings before interest and taxes to net interest charges, excluding all income, expense and other profit and loss statement impacts of the AICF, Amaba Pty Limited, Amaca Pty Limited, ABN 60 Pty Limited and Marlew Mining Pty Limited and (iv) has limits on how much it can spend on an annual basis in relation to asbestos payments to the AICF. Such limits are consistent with the contractual liabilities of the Performing Subsidiary and the Company under Amendment FFA.

The Company anticipates being able to meet its future payment obligations for the next 12 months from existing cash, unutilised committed facilities and anticipated future net operating cash flows.

10. Non-Current Other Liabilities

Non-current other liabilities consist of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Employee entitlements	\$ 6.4	\$ 11.9
Uncertain tax positions	123.7	0.7
Other	<u>57.4</u>	<u>28.6</u>
Total non-current other liabilities	<u>\$ 187.5</u>	<u>\$ 41.2</u>

11. Product Warranties

The Company offers various warranties on its products, including a 50-year limited warranty on certain of its fibre cement siding products in the United States. A typical warranty program requires the Company to replace defective products within a specified time period from the date of sale. The Company records an estimate for future warranty related costs based on an analysis of actual historical warranty costs as they relate to sales. Based on this analysis and other factors, the adequacy of the Company's warranty provisions are adjusted as necessary. While the Company's warranty costs have historically been within its calculated estimates, it is possible that future warranty costs could differ from those estimates.

Additionally, the Company includes in its accrual for product warranties amounts for a Class Action Settlement Agreement (the "Settlement Agreement") related to its previous roofing products, which are no longer manufactured in the United States. On 14 February 2002, the Company signed the Settlement Agreement for all product, warranty and property related liability claims associated with these previously manufactured roofing products. These products were removed from the marketplace between 1995 and 1998 in areas where there had been any alleged problems. The total amount included in the product warranty provision relating to the Settlement Agreement is US\$2.7 million and US\$3.5 million as of 31 March 2008 and 2007, respectively.

The following are the changes in the product warranty provision:

(Millions of US dollars)	Years Ended 31 March	
	2008	2007
Balance at beginning of period	\$ 15.2	\$ 15.5
Accruals for product warranties	10.2	4.4
Settlements made in cash or in kind	(7.9)	(4.9)
Foreign currency translation adjustments	<u>0.2</u>	<u>0.2</u>
Balance at end of period	<u>\$ 17.7</u>	<u>\$ 15.2</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

The “Accruals for product warranties” line item above includes a reduction in the accrual of US\$0.5 million and an additional accrual of US\$2.0 million for the years ended 31 March 2008 and 2007, respectively, related to the Settlement Agreement. The “Settlements made in cash or in kind” line item above includes settlements related to the Settlement Agreement of US\$0.3 million and US\$0.2 million for the years ended 31 March 2008 and 2007, respectively.

12. Asbestos

The Amended FFA to provide long-term funding to the AICF was approved by shareholders in February 2007. The accounting policies utilised by the Company to account for the Amended FFA are described in Note 2, *Summary of Significant Accounting Policies*.

Asbestos Adjustments

The asbestos adjustments included in the consolidated statements of operations comprise the following:

(Millions of US dollars)	2008	Years Ended 31 March 2007	2006
Change in estimates:			
Change in actuarial estimate — asbestos liability	\$ (175.0)	\$ 50.3	\$ —
Change in actuarial estimate — insurance receivable	27.4	(22.6)	—
Change in estimate — AICF claims-handling costs	(6.5)	0.8	—
Change in estimate — other	1.2	—	—
Subtotal — Change in estimates	<u>(152.9)</u>	<u>28.5</u>	<u>—</u>
Effect of foreign exchange	(87.2)	(94.5)	—
Tax impact related to the implementation of the Amended FFA	—	(335.0)	—
Initial recording of provision at 31 March 2006	—	—	(715.6)
Other adjustments	—	(4.5)	—
Total Asbestos Adjustments	<u>\$ (240.1)</u>	<u>\$ (405.5)</u>	<u>\$ (715.6)</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Asbestos-Related Assets and Liabilities

Under the terms of the Amended FFA, the Company has included on its consolidated balance sheets certain asbestos-related assets and liabilities. These amounts are detailed in the table below, and the net total of these asbestos-related assets and liabilities is commonly referred to by the Company as the "Net Amended FFA Liability".

(Millions of US dollars)	31 March	
	2008	2007
Asbestos liability – current	\$ (78.7)	\$ (63.5)
Asbestos liability – non-current	<u>(1,497.8)</u>	<u>(1,225.8)</u>
Asbestos liability – Total	<u>(1,576.5)</u>	<u>(1,289.3)</u>
Insurance receivable – current	14.1	9.4
Insurance receivable – non-current	<u>194.3</u>	<u>165.1</u>
Insurance receivable – Total	<u>208.4</u>	<u>174.5</u>
Workers' compensation asset – current	6.9	2.7
Workers' compensation asset – non-current	78.5	76.5
Workers' compensation liability – current	(6.9)	(2.7)
Workers' compensation liability – non-current	<u>(78.5)</u>	<u>(76.5)</u>
Workers' compensation – Total	<u>—</u>	<u>—</u>
Deferred income taxes – current	9.1	7.8
Deferred income taxes – non-current	<u>397.1</u>	<u>318.2</u>
Deferred income taxes – Total	<u>406.2</u>	<u>326.0</u>
Income tax payable (reduction in income tax payable)	20.4	9.0
Other net liabilities	<u>(3.4)</u>	<u>(6.3)</u>
Net Amended FFA liability	(944.9)	(786.1)
Restricted cash and cash equivalents and restricted short-term investment assets of the AICF	115.1	146.9
Unfunded Net Amended FFA liability	<u>\$ (829.8)</u>	<u>\$ (639.2)</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Asbestos Liability

The amount of the asbestos liability reflects the terms of the Amended FFA, which has been calculated by reference to (but is not exclusively based upon) the most recent actuarial estimate of the projected future asbestos-related cash flows prepared by KPMG Actuaries. The asbestos liability also includes an allowance for the future claims-handling costs of the AICF. The Company will receive an updated actuarial estimate as of 31 March each year. The last actuarial assessment was performed as of 31 March 2008.

The changes in the asbestos liability for the year ended 31 March 2008 are detailed in the table below:

	AS Millions	AS to US\$ rate	US\$ Millions
Asbestos liability – 31 March 2007	A\$ (1,598.1)	1.2395	\$ (1,289.3)
Asbestos claims paid ¹	74.3	1.1503	64.6
AICF claims-handling costs incurred ¹	2.8	1.1503	2.4
Change in actuarial estimate ²	(190.8)	1.0903	(175.0)
Change in estimate of AICF claims-handling costs ²	(7.1)	1.0903	(6.5)
Effect of foreign exchange			(172.7)
Asbestos liability – 31 March 2008	<u>A\$ (1,718.9)</u>	1.0903	<u>\$ (1,576.5)</u>

Insurance Receivable – Asbestos

The changes in the insurance receivable for the year ended 31 March 2008 are detailed in the table below:

	AS Millions	AS to US\$ rate	US\$ Millions
Insurance receivable – 31 March 2007	A\$ 216.3	1.2395	\$ 174.5
Insurance recoveries ¹	(19.2)	1.1503	(16.7)
Change in estimate ³	0.2	1.1782	0.2
Change in actuarial estimate ²	29.9	1.0903	27.4
Effect of foreign exchange			23.0
Insurance receivable – 31 March 2008	<u>A\$ 227.2</u>	1.0903	<u>\$ 208.4</u>

Deferred Income Taxes – Asbestos

The changes in the deferred income taxes — asbestos for the year ended 31 March 2008 are detailed in the table below:

	AS Millions	AS to US\$ rate	US\$ Millions
Deferred tax assets – 31 March 2007	A\$ 404.1	1.2395	\$ 326.0
Amounts offset against income tax payable ¹	(11.1)	1.1503	(9.6)
Impact of change in actuarial estimates ²	50.4	1.0903	46.2
Impact of other asbestos adjustments ¹	(0.5)	1.1503	(0.4)
Effect of foreign exchange			44.0
Deferred tax assets – 31 March 2008	<u>A\$ 442.9</u>	1.0903	<u>\$ 406.2</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Income Tax Payable

A portion of the deferred income tax asset is applied against the Company's income tax payable. At 31 March 2008 and 2007, this amount was US\$20.4 million and US\$9.0 million, respectively. During the year ended 31 March 2008, there was a US\$1.7 million favourable effect of foreign exchange.

Other Net Liabilities

Other net liabilities include a provision for asbestos-related education and medical research contributions of US\$3.3 million and US\$4.6 million at 31 March 2008 and 2007, respectively. Also included in other net liabilities are the other assets and liabilities of the AICF including trade receivables, prepayments, fixed assets, trade payables and accruals. These other assets and liabilities of the AICF were a net liability of US\$0.1 million and US\$1.7 million at 31 March 2008 and 2007, respectively. During the year ended 31 March 2008, there was a US\$1.0 million favourable adjustment related to changes in estimates of the other net liabilities and a US\$0.5 million unfavourable effect of foreign exchange.

Restricted Cash and Short-term Investment Assets of the AICF

Cash and cash equivalents and short-term investments of the AICF are reflected as restricted assets as these assets are restricted for use in the settlement of asbestos claims and payment of the operating costs of the AICF. During the year ended 31 March 2008, no short-term investments were purchased or sold.

The changes in the restricted cash and cash equivalents and restricted short-term investment assets of the AICF for the year ended 31 March 2008 are detailed in the table below:

	AS Millions	AS to US\$ rate	US\$ Millions
Restricted cash and cash equivalents and restricted short-term investment assets – 31 March 2007	A\$ 182.1	1.2395	\$ 146.9
Asbestos claims paid ¹	(74.3)	1.1503	(64.6)
AICF operating costs paid — claims-handling ¹	(2.8)	1.1503	(2.4)
AICF operating costs paid — non claims-handling ¹	(4.6)	1.1503	(4.0)
Insurance recoveries ¹	19.2	1.1503	16.7
Interest and investment income ¹	10.8	1.1503	9.4
Unrealised loss on investments ¹	(5.1)	1.1503	(4.4)
Other ¹	0.2	1.1503	0.2
Effect of foreign exchange			17.3
Restricted cash and cash equivalents and restricted short-term investment assets – 31 March 2008	<u>A\$ 125.5</u>	1.0903	<u>\$ 115.1</u>

¹ The average exchange rate for the period is used to convert the Australian dollar amount to US dollars based on the assumption that these transactions occurred evenly throughout the period.

² The spot exchange rate at 31 March 2008 is used to convert the Australian dollar amount to US dollars as the adjustment to the estimate was made on that date.

³ The spot exchange rate at 30 June 2007 is used to convert the Australian dollar amount to US dollars as the adjustment to the estimate was made on that date.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Actuarial Study; Claims Estimate

The AICF commissioned an updated actuarial study of potential asbestos-related liabilities as of 31 March 2008. Based on KPMG Actuaries' assumptions, KPMG Actuaries arrived at a range of possible total cash flows and proposed a central estimate which is intended to reflect an expected outcome. The Company views the central estimate as the basis for recording the asbestos liability in the Company's financial statements, which under US GAAP, it considers the best estimate under SFAS No. 5. Based on the results of these studies, it is estimated that the discounted (but inflated) value of the central estimate for claims against the Former James Hardie Companies was approximately A\$1.4 billion (US\$1.3 billion). The undiscounted (but inflated) value of the central estimate of the asbestos-related liabilities of Amaca and Amaba as determined by KPMG Actuaries was approximately A\$3.0 billion (US\$2.8 billion). Actual liabilities of those companies for such claims could vary, perhaps materially, from the central estimate described above. The asbestos liability includes projected future cash flows as undiscounted and uninflated on the basis that it is inappropriate to discount or inflate future cash flows when the timing and amounts of such cash flows is not fixed or readily determinable.

The asbestos liability has been revised to reflect the most recent actuarial estimate prepared by KPMG Actuaries as of 31 March 2008 and to adjust for payments made to claimants during the year then ended.

In estimating the potential financial exposure, KPMG Actuaries made assumptions related to the total number of claims which were reasonably estimated to be asserted through 2071, the typical cost of settlement (which is sensitive to, among other factors, the industry in which a plaintiff claims exposure, the alleged disease type and the jurisdiction in which the action is brought), the legal costs incurred in the litigation of such claims, the rate of receipt of claims, the settlement strategy in dealing with outstanding claims and the timing of settlements.

Further, KPMG Actuaries relied on the data and information provided by the AICF and Amaca Claims Services, Amaca Pty Ltd (under NSW External Administration) ("ACS") and assumed that it is accurate and complete in all material respects. The actuaries have not verified the information independently nor established the accuracy or completeness of the data and information provided or used for the preparation of the report.

Due to inherent uncertainties in the legal and medical environment, the number and timing of future claim notifications and settlements, the recoverability of claims against insurance contracts, and estimates of future trends in average claim awards, as well as the extent to which the above named entities will contribute to the overall settlements, the actual amount of liability could differ materially from that which is currently projected.

A sensitivity analysis has been performed to determine how the actuarial estimates would change if certain assumptions (i.e., the rate of inflation and superimposed inflation, the average costs of claims and legal fees, and the projected numbers of claims) were different from the assumptions used to determine the central estimates. This analysis shows that the discounted (but inflated) central estimates could be in a range of A\$1.0 billion (US\$0.9 billion) to A\$2.1 billion (US\$1.9 billion) (undiscounted, but inflated, estimates of A\$1.9 billion (US\$1.7 billion) to A\$5.4 billion (US\$5.0 billion)), as of 31 March 2008. It should be noted that the actual cost of the liabilities could be outside of that range depending on the results of actual experience relative to the assumptions made.

The potential range of costs as estimated by KPMG Actuaries is affected by a number of variables such as nil settlement rates (where no settlement is payable by the Former James Hardie Companies because the claim settlement is borne by other asbestos defendants (other than the former James Hardie subsidiaries) which are held liable), peak year of claims, past history of claims numbers, average settlement rates, past history of Australian asbestos-related medical injuries, current number of claims, average defence and plaintiff legal costs, base wage inflation and superimposed inflation. The potential range of losses disclosed includes both asserted and unasserted claims. While no assurances can be provided, the Company believes that it is likely to be able to partially recover losses from various insurance carriers. As of 31 March 2008, KPMG

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Actuaries' undiscounted central estimate of asbestos-related liabilities was A\$3.0 billion (US\$2.8 billion). This undiscounted (but inflated) central estimate is net of expected insurance recoveries of A\$497.8 million (US\$456.6 million) after making a general credit risk allowance for bad debt insurance carriers and an allowance for A\$72.7 million (US\$66.7 million) of "by claim" or subrogation recoveries from other third parties. In accordance with FIN 39, the Company has not netted the insurance receivable against the asbestos liability on its consolidated balance sheets.

Claims Data

The AICF provides compensation payments for Australian asbestos-related personal injury claims against the Liable Entities. The claims data in this section are only reflective of these Australian asbestos-related personal injury claims against the Liable Entities.

For the years ended 31 March 2008, 2007 and 2006, the following table, provided by KPMG Actuaries, shows the claims filed, the number of claims dismissed, settled or otherwise resolved for each period and the average settlement amount per claim:

	2008	Years Ended 31 March	
		2007	2006 ¹
Number of claims filed	552	463	346
Number of claims dismissed	74	121	97
Number of claims settled or otherwise resolved	445	416	405
Average settlement amount per settled claim	A\$147,349	A\$166,164	A\$151,883
Average settlement amount per settled claim	US\$128,096	US\$127,165	US\$114,322

The following table, provided by KPMG Actuaries, shows the activity related to the numbers of open claims, new claims and closed claims during each of the past five years and the average settlement per settled claim and case closed:

	2008	2007	Years Ended 31 March		
			2006 ¹	2005	2004
Number of open claims at beginning of period	490	564	712	687	743
Number of new claims	552	463	346	489	379
Number of closed claims	519	537	502	464	435
Number of open claims at end of period	523	490	556	712	687
Average settlement amount per settled claim	A\$147,349	A\$166,164	A\$151,883	A\$157,594	A\$167,450
Average settlement amount per case closed	A\$126,340	A\$128,723	A\$122,535	A\$136,536	A\$121,642
Average settlement amount per settled claim	US\$128,096	US\$127,163	US\$114,318	US\$116,572	US\$116,123
Average settlement amount per case closed	US\$109,832	US\$ 98,510	US\$ 92,229	US\$100,996	US\$ 84,356

¹ Information includes claims data for only 11 months ended 28 February 2006. Claims data for the 12 months ended 31 March 2006 were not available at the time the Company's financial statements were prepared.

Under the terms of the Amended FFA, the Company has obtained rights of access to actuarial information produced for the AICF by the actuary appointed by the AICF (the "Approved Actuary"). The Company's future disclosures with respect to claims statistics are subject to it obtaining such information from the Approved Actuary. The Company has had no general right (and has not obtained any right under the Amended FFA) to audit or otherwise require independent verification of such information or the methodologies to be adopted by the Approved Actuary. As such, the Company will need to rely on the accuracy and completeness of the information and analysis of the Approved Actuary when making future disclosures with respect to claims statistics.

13. Commitment and Contingencies

ASIC Proceedings

In February 2007, the Australian Securities and Investments Commission ("ASIC") commenced civil proceedings in the Supreme Court of New South Wales (the "Court") against the Company, ABN 60 and ten then-present or former officers and directors of the James Hardie Group. While the subject matter of the allegations varies between individual defendants, the allegations against the Company are confined to alleged contraventions of provisions of the Australian Corporations Act/Law relating to continuous disclosure, a director's duty of care and diligence, and engaging in misleading or deceptive conduct in respect of a security.

In the proceedings, ASIC seeks:

- declarations regarding the alleged contraventions;
- orders for pecuniary penalties in such amount as the Court thinks fit up to the limits specified in the Corporations Act;
- orders that former James Hardie group directors or officers Michael Brown, Michael Gillfillan, Meredith Hellicar, Martin Koffel, Peter Macdonald, Philip Morley, Geoffrey O'Brien, Peter Shafron, Gregory Terry and Peter Willcox be prohibited from managing an Australian corporation for such period as the Court thinks fit;
- an order that the Company execute a deed of indemnity in favour of ABN 60 providing that the Company indemnify ABN 60 for an amount up to a maximum of AS\$1.9 billion, for such amount as ABN 60, or its directors, consider, after giving careful consideration, is necessary to ensure that ABN 60 is able to pay its debts, as and when they fall due, and for such amount as ABN 60, or its directors, reasonably believe is necessary to ensure that ABN 60 remains solvent; and
- its costs of the proceedings.

The Company is defending each of the allegations made by ASIC and the orders sought against it in the proceedings, as are the other former directors and officers.

ASIC has indicated that its investigations into other related matters continue and may result in further actions, both civil and criminal. However, it has not indicated the possible defendants to any such actions.

The Company has entered into deeds of indemnity with certain of its directors and officers, as is common practice for publicly listed companies. The Company's articles of association also contain an indemnity for directors and officers and the Company has granted indemnities to certain of its former related corporate bodies which may require the Company to indemnify those entities against indemnities they have granted their directors and officers. To date, claims for payments of expenses incurred have been received from certain former directors and officers in relation to the ASIC investigation, and in relation to the examination of these persons by ASIC delegates. Now that proceedings have been brought against former directors and officers of the James Hardie Group, the Company has and will continue to incur further costs under these indemnities which may be significant. Initially, the Company has obligations, or has offered, to advance funds in respect of defence costs and such advances have been and will continue to be made. Currently, a portion of the defence costs of former directors are being advanced by third parties, with the Company paying the balance. Based upon the information available to it presently, the Company expects this to continue absent any finding of dishonesty against any former director or officer. The Company notes that other recoveries may be available, depending upon the outcome of the ASIC proceedings, including either as a result of a costs order being made against ASIC or, if ASIC is successful in securing civil penalty declarations, as a result of repayments by former directors and officers in accordance with the terms of their indemnities. It is the Company's policy to expense legal costs as incurred.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

There remains considerable uncertainty surrounding the likely outcome of the ASIC proceedings in the longer term and there is a possibility that the Company could become responsible for other amounts in addition to the defence costs. However, at this stage, the Company believes that although such losses are reasonably possible, the amount or range of such losses are not estimable.

Environmental and Legal

The operations of the Company, like those of other companies engaged in similar businesses, are subject to a number of federal, state and local laws and regulations on air and water quality, waste handling and disposal. The Company's policy is to accrue for environmental costs when it is determined that it is probable that an obligation exists and the amount can be reasonably estimated. In the opinion of management, based on information presently known except as set forth above, the ultimate liability for such matters should not have a material adverse effect on either the Company's consolidated financial position, results of operations or cash flows.

The Company is involved from time to time in various legal proceedings and administrative actions incidental or related to the normal conduct of its business. Although it is impossible to predict the outcome of any pending legal proceeding, management believes that such proceedings and actions should not, except those items specifically described within these consolidated financial statements, individually or in the aggregate, have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Operating Leases

As the lessee, the Company principally enters into property, building and equipment leases. The following are future minimum lease payments for non-cancellable operating leases having a remaining term in excess of one year at 31 March 2008:

Years ending 31 March:	(Millions of US dollars)
2009	\$ 14.8
2010	13.3
2011	12.4
2012	12.0
2013	8.6
Thereafter	56.7
Total	\$ 117.8

Rental expense amounted to US\$10.2 million, US\$12.1 million and US\$12.5 million for the years ended 31 March 2008, 2007 and 2006, respectively.

Capital Commitments

Commitments for the acquisition of plant and equipment and other purchase obligations, primarily in the United States, contracted for but not recognised as liabilities and generally payable within one year, were US\$9.0 million at 31 March 2008.

Readers are referred to Note 12 *Asbestos* and Note 15 *Amended ATO Assessment* for additional disclosures of commitments and contingencies.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

14. Income Taxes

Income tax expense includes income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Income tax benefit (expense) for continuing operations consists of the following components:

(Millions of US dollars)	2008	Years Ended 31 March	
		2007	2006
(Loss) income from continuing operations before income taxes:			
Domestic ¹	\$ 80.1	\$ 110.9	\$ 113.7
Foreign	(115.6)	(204.0)	(548.8)
(Loss) income from continuing operations before income taxes	<u>\$ (35.5)</u>	<u>\$ (93.1)</u>	<u>\$ (435.1)</u>
Income tax (expense) benefit:			
Current:			
Domestic ¹	\$ (7.1)	\$ 0.4	\$ (9.0)
Foreign	(102.1)	(63.7)	(91.5)
Current income tax (expense) benefit	<u>(109.2)</u>	<u>(63.3)</u>	<u>(100.5)</u>
Deferred:			
Domestic ¹	(0.2)	0.1	(0.3)
Foreign	73.3	307.1	29.2
Deferred income tax (expense) benefit	<u>73.1</u>	<u>307.2</u>	<u>28.9</u>
Total income tax (expense) benefit for continuing operations	<u>\$ (36.1)</u>	<u>\$ 243.9</u>	<u>\$ (71.6)</u>

¹ Since JHI NV is the Dutch parent holding company, domestic represents The Netherlands.

Income tax benefit (expense) computed at the statutory rates represents taxes on income applicable to all jurisdictions in which the Company conducts business, calculated as the statutory income tax rate in each jurisdiction multiplied by the pre-tax income attributable to that jurisdiction. Income tax benefit (expense) from continuing operations is reconciled to the tax at the statutory rates as follows:

(Millions of US dollars)	2008	Years Ended 31 March	
		2007	2006
Income tax benefit (expense) computed at statutory tax rates	\$ 7.8	\$ 16.2	\$ 121.0
US state income taxes, net of the federal benefit	(1.9)	(6.5)	(7.1)
Asbestos provision	—	242.0	(214.7)
Asbestos — effect of foreign exchange	(27.5)	(24.1)	—
Benefit from Dutch financial risk reserve regime	7.3	8.1	12.7
Expenses not deductible	(3.2)	(1.7)	(3.4)
Non-assessable items	2.7	1.8	1.4
Losses not available for carryforward	(1.4)	(3.2)	(2.6)
Change in reserves	(18.5)	10.4	—
Result of tax audits	—	—	20.7
Change in tax law	—	3.0	—
Other items	(1.4)	(2.1)	0.4
Total income tax (expense) benefit	<u>\$ (36.1)</u>	<u>\$ 243.9</u>	<u>\$ (71.6)</u>
Effective tax rate	<u>101.7%</u>	<u>262.0%</u>	<u>16.5%</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Deferred tax balances consist of the following components:

(Millions of US dollars)	31 March	
	2008	2007
Deferred tax assets:		
Asbestos liability	\$ 406.2	\$ 326.0
Other provisions and accruals	27.0	33.3
Net operating loss carryforwards	6.3	7.8
Capital loss carryforwards	40.0	35.2
Taxes on intellectual property transfer	6.5	6.5
Prepayments	2.9	7.5
Other	0.8	—
Total deferred tax assets	<u>489.7</u>	<u>416.3</u>
Valuation allowance	<u>(45.1)</u>	<u>(39.7)</u>
Total deferred tax assets, net of valuation allowance	<u>444.6</u>	<u>376.6</u>
Deferred tax liabilities:		
Property, plant and equipment	(93.4)	(108.4)
Foreign currency movements	(15.2)	(5.2)
Other	—	(0.1)
Total deferred tax liabilities	<u>(108.6)</u>	<u>(113.7)</u>
Net deferred tax liabilities	<u>\$ 336.0</u>	<u>\$ 262.9</u>

Under SFAS No. 109, "Accounting for Income Taxes", the Company establishes a valuation allowance against a deferred tax asset if it is more likely than not that some portion or all of the deferred tax asset will not be realised. The Company has established a valuation allowance pertaining to all of its Australian net operating loss carryforwards and all of its Australian capital loss carryforwards. The valuation allowance increased by US\$5.4 million during the fiscal year 2008 due to foreign currency movements.

At 31 March 2008, the Company had Australian tax loss carryforwards of approximately US\$17.7 million that will never expire. At 31 March 2008, the Company had a 100% valuation allowance against the Australian tax loss carryforwards.

At 31 March 2008, the Company had US\$133.2 million in Australian capital loss carryforwards which will never expire. At 31 March 2008, the Company had a 100% valuation allowance against the Australian capital loss carryforwards.

At 31 March 2008, the undistributed earnings of non-Dutch subsidiaries approximated US\$744.7 million. The Company intends to indefinitely reinvest these earnings, and accordingly, has not provided for taxes that would be payable upon remittance of those earnings. The amount of the potential deferred tax liability related to undistributed earnings is impracticable to determine at this time.

Due to the size of the Company and the nature of its business, the Company is subject to ongoing reviews by taxing jurisdictions on various tax matters, including challenges to various positions the Company asserts on its income tax returns. The Company accrues for tax contingencies based upon its best estimate of the taxes ultimately expected to be paid, which it updates over time as more information becomes available. Such amounts are included in taxes payable or other non-current liabilities, as appropriate. If the Company ultimately determines that payment of these amounts is unnecessary, the Company reverses the liability and recognises a tax benefit during the period in which the Company determines that the liability is no longer necessary. The Company records additional tax expense in the period in which it determines that the recorded tax liability is less than the ultimate assessment it expects.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

In fiscal years 2008, 2007 and 2006, the Company recorded income tax benefit of nil, US\$10.4 million and US\$20.7 million, respectively, as a result of the finalisation of certain tax audits (whereby certain matters were settled), the expiration of the statute related to certain tax positions and adjustments to income tax balances based on the filing of amended income tax returns, which give rise to the benefit recorded by the Company.

The Company or one of its subsidiaries files income tax returns in the US federal jurisdiction, and various states and foreign jurisdictions including Australia and the Netherlands. The Company is no longer subject to US federal examinations by US Internal Revenue Service ("IRS") for tax years prior to and including tax year 2004. The Company is no longer subject to examinations by the Netherlands tax authority, for tax years prior to tax year 2002. With certain limited exceptions, the Company is no longer subject to Australian federal examinations by the Australian Taxation Office ("ATO") for tax years prior to tax year 2000. The Company is currently subject to audit and review in a number of jurisdictions in which it operates and has been advised that further audits will commence in the next 12 months. In particular, the IRS is currently conducting an audit to determine whether the Company is in compliance with the revised US – Netherlands Tax Treaty Limitations on Benefits ("LOB") provision that entitles it to beneficial withholding tax rates on payments from the US to the Netherlands. The IRS audit determination should be forthcoming during fiscal year 2009. In addition, the ATO is auditing the Company's Australian income tax returns for the years ended 31 March 2002 and 31 March 2004 through 31 March 2006. The ATO is working with the Company and the Company's advisors to conclude its inquiries. It is anticipated that the audits and reviews currently being conducted will be completed within the next 24 months.

Of the audits currently being conducted, none have progressed sufficiently to predict their ultimate outcome. The Company accrues income tax liabilities for these audits based upon knowledge of all relevant facts and circumstances, taking into account existing tax laws, its experience with previous audits and settlements, the status of current tax examinations and how the tax authorities view certain issues.

The Company currently derives significant tax benefits under the US-Netherlands tax treaty. The treaty was amended during fiscal year 2005 and became effective for the Company on 1 February 2006. The amended treaty provides, among other things, new requirements that the Company must meet for the Company to continue to qualify for treaty benefits and its effective income tax rate. During fiscal year 2006, the Company made changes to its organisational and operational structure to satisfy the requirements of the amended treaty and believes that it is in compliance and should continue qualifying for treaty benefits. However, if during a subsequent tax audit or related process, the Internal Revenue Service ("IRS") determines that these changes do not meet the new requirements, the Company may not qualify for treaty benefits, its effective income tax rate could significantly increase beginning in the fiscal year that such determination is made and it could be liable for taxes owed from the effective date of the amended treaty provisions.

In June 2006, the FASB issued FASB Interpretation No. 48 ("FIN 48"), "Accounting for Uncertainty in Income Taxes, an interpretation of SFAS No. 109", "Accounting for Income Taxes". FIN 48 clarifies the accounting for uncertainty in income taxes recognised in an enterprise's financial statements in accordance with SFAS No. 109. Unlike SFAS No. 109, FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Additionally, FIN 48 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

The Company adopted FIN 48 on 1 April 2007. The adoption of FIN 48 resulted in the reduction of the Company's consolidated beginning retained earnings of US\$78.0 million. As of the adoption date, the Company had US\$39.0 million of gross unrecognised tax benefits that, if recognised, would affect the effective tax rate. As of the adoption date, the Company's opening accrual for interest and penalties is US\$39.7 million.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

During the fourth quarter of fiscal 2008, the Company identified an error in the FIN 48 liability presented in its consolidated financial statements for the quarterly periods ended June 30, 2007, September 30, 2007 and December 31, 2007. The Company incorrectly recorded the interest expense associated with the potential tax liability at the gross amount rather than net of tax. The impacted financial statement line items were correctly stated for the year ended March 31, 2008. Management has concluded that the errors are not material to the financial statements for those periods and that the quarterly financial statement filings for those periods can continue to be relied upon. A summary of the revisions are as follows:

	First Quarter Ended 30 June 2007		Second Quarter Ended 30 September 2007		Third Quarter Ended 31 December 2007	
	Previously Reported	Revised	Previously Reported	Revised	Previously Reported	Revised
Income tax expense	(36.4)	(35.6)	(27.6)	(26.8)	(8.9)	(8.0)
Net income	39.1	39.9	19.1	19.9	17.1	18.0
Total liabilities	2,070.1	2,056.2	2,085.5	2,070.2	2,208.5	2,192.3
Total other comprehensive income	46.2	47.7	10.2	12.3	33.9	36.0
Shareholders' equity (deficit)	147.7	161.6	112.4	127.7	(52.6)	(36.4)

A reconciliation of the beginning and ending amount of unrecognised tax benefits is as follows:

Unrecognised tax benefits at 1 April 2007	\$ 39.0
Additions for tax positions of the current year	1.3
Additions for tax positions of prior year	16.0
Foreign translation adjustment	5.6
Unrecognised tax benefits at 31 March 2008	<u>\$ 61.9</u>

The Company recognises penalties and interest accrued related to unrecognised tax benefits in income tax expense. During 2008, the total amount of interest and penalties recognised in tax expense was US\$7.3 million.

As of 31 March, 2008 the total amount of unrecognised tax benefits and the total amount of interest and penalties accrued related to unrecognised tax benefits that, if recognised, would affect the effective tax rate is US\$61.9 million and US\$47.0 million, respectively.

A number of years may elapse before an uncertain tax position is audited and ultimately settled. It is difficult to predict the ultimate outcome or the timing of resolution for uncertain tax positions. It is reasonably possible that the amount of unrecognised tax benefits could significantly increase or decrease within the next twelve months. These changes could result from the settlement of ongoing litigation, the completion of ongoing examinations, the expiration of the statute of limitations, or other circumstances. At this time, an estimate of the range of the reasonably possible change cannot be made.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

15. Amended ATO Assessment

In March 2006, RCI Pty Ltd ("RCI"), a wholly owned subsidiary of the Company, received an amended assessment from the ATO in respect of RCI's income tax return for the year ended 31 March 1999. The amended assessment relates to the amount of net capital gains arising as a result of an internal corporate restructure carried out in 1998 and has been issued pursuant to the discretion granted to the Commissioner of Taxation under Part IVA of the Australian Income Tax Assessment Act 1936. The original amended assessment issued to RCI was for a total of A\$412.0 million. However, after two remissions of general interest charges ("GIC") made by the ATO during fiscal year 2007, the total was revised to A\$368.0 million and is comprised of the following as of 31 March 2008:

(Millions of dollars)	US\$ (1)	A\$
Primary tax after allowable credits	\$ 157.8	A\$172.0
Penalties (2)	39.4	43.0
General interest charges	<u>140.3</u>	<u>153.0</u>
Total amended assessment	<u>\$ 337.5</u>	<u>A\$368.0</u>

1 US\$ amounts calculated using the A\$/US\$ foreign exchange spot rate at 31 March 2008.

2 Represents 25% of primary tax.

During fiscal year 2007, the Company agreed with the ATO that in accordance with the ATO Receivable Policy, the Company would pay 50% of the total amended assessment being A\$184.0 million (US\$168.8 million), and provide a guarantee from James Hardie Industries N.V. in favour of the ATO for the remaining unpaid 50% of the amended assessment, pending outcome of the appeal of the amended assessment. The Company also agreed to pay GIC accruing on the unpaid balance of the amended assessment in arrears on a quarterly basis. Up to 31 March 2008, GIC totalling A\$95.2 million has been paid to the ATO. On 15 April 2008, the Company paid A\$3.3 million in GIC in respect of the quarter ended 31 March 2008.

On 30 May 2007, the ATO issued a Notice of Decision disallowing the Company's objection to the amended assessment. On 11 July 2007, the Company filed an application appealing the Objection Decision with the Federal Court of Australia. The hearing date for RCI's trial is presently scheduled for 8 December 2008.

RCI strongly disputes the amended assessment and is pursuing all avenues of appeal to contest the ATO's position in this matter. The ATO has confirmed that RCI has a reasonably arguable position that the amount of net capital gains arising as a result of the corporate restructure carried out in 1998 has been reported correctly in the fiscal year 1999 tax return and that Part IVA does not apply. As a result, the ATO reduced the amount of penalty from an automatic 50% of primary tax that would otherwise apply in these circumstances, to 25% of primary tax. In Australia, a reasonably arguable position means that the tax position is about as likely to be correct as it is not correct. The Company and RCI received legal and tax advice at the time of the transaction, during the ATO enquiries and following receipt of the amended assessment. The Company believes that it is more likely than not that the tax position reported in RCI's tax return for the 1999 fiscal year will be upheld on appeal. Therefore, the Company believes that the requirements under FIN 48 for recording a liability have not been met and therefore it has not recorded any liability at 31 March 2008 for the amended assessment.

The Company expects that amounts paid in respect of the amended assessment will be recovered by RCI (with interest) at the time RCI is successful in its appeal against the amended assessment. As a result, the Company has treated all payments in respect of the amended assessment that have been made up to 31 March 2008 as a deposit and it is the Company's intention to treat any payments to be made at a later date as a deposit.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

16. Stock-Based Compensation

At 31 March 2008, the Company had the following stock-based compensation plans: the Executive Share Purchase Plan; the Managing Board Transitional Stock Option Plan; the JHI NV 2001 Equity Incentive Plan; the Supervisory Board Share Plan 2006 and the Long-Term Incentive Plan.

Executive Share Purchase Plan

Prior to July 1998, James Hardie Industries Limited ("JHIL") issued stock under an Executive Share Purchase Plan (the "Plan"). Under the terms of the Plan, eligible executives purchased JHIL shares at their market price when issued. Executives funded purchases of JHIL shares with non-recourse, interest-free loans provided by JHIL and collateralised by the shares. In such cases, the amount of indebtedness is reduced by any amounts payable by JHIL in respect of such shares, including dividends and capital returns. These loans are generally repayable within two years after termination of an executive's employment. Variable plan accounting under the provisions of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," has been applied to the Executive Share Purchase Plan shares granted prior to 1 April 1995 and fair value accounting, pursuant to the requirements of SFAS No. 123R, has been applied to shares granted after 31 March 1995. The Company recorded no compensation expense during the years ended 31 March 2008, 2007 and 2006. No shares were issued under this plan during years ended 31 March 2008, 2007 and 2006.

Managing Board Transitional Stock Option Plan

The Managing Board Transitional Stock Option Plan provides an incentive to the members of the Managing Board. The maximum number of ordinary shares that may be issued and outstanding or subject to outstanding options under this plan shall not exceed 1,380,000 shares. At 31 March 2008 and 2007, there were 1,320,000 options outstanding under this plan.

On 22 November 2005, the Company granted options to purchase 1,320,000 shares of the Company's common stock at an exercise price per share equal to A\$8.53 to the Managing Directors under the Managing Board Transitional Stock Option Plan. As set out in the plan rules, the exercise price and the number of shares available on exercise may be adjusted on the occurrence of certain events, including new issues, share splits, rights issues and capital reconstructions. 50% of these options become exercisable on the first business day on or after 22 November 2008 if the total shareholder returns ("TSR") (essentially its dividend yield and common stock performance) from 22 November 2005 to that date were at least equal to the median TSR for the companies comprising the Company's peer group, as set out in the plan. In addition, for each 1% increment that the Company's TSR is above the median TSR, an additional 2% of the options become exercisable. If any options remain unvested on the last business day of each six month period following 22 November 2008 and 22 November 2010, the Company will reapply the vesting criteria to those options on that business day.

JHI NV 2001 Equity Incentive Plan

On 19 October 2001 (the grant date), JHI NV granted options to purchase 5,468,829 shares of the Company's common stock under the JHI NV 2001 Equity Incentive Plan (the "2001 Equity Incentive Plan") to key US executives in exchange for their previously granted Key Management Equity Incentive Plan ("KMEIP") shadow shares that were originally granted in November 2000 and 1999 by JHIL. These options may be exercised in five equal tranches (20% each year) starting with the first anniversary of the original shadow share grant.

Original Shadow Share Grant Date	Original Exercise Price	October 2001 Number of Options Granted	Option Expiration Date
November 1999	A\$ 3.82	1,968,544	November 2009
November 2000	A\$ 3.78	3,500,285	November 2010

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

As set out in the plan rules, the exercise prices and the number of shares available on exercise are adjusted on the occurrence of certain events, including new issues, share splits, rights issues and capital reconstructions. Consequently, the exercise prices were reduced by A\$0.21, A\$0.38 and A\$0.10 for the November 2003, November 2002 and December 2001 returns of capital, respectively.

Under the 2001 Equity Incentive Plan, additional grants have been made at fair market value to management and other employees of the Company. Each option confers the right to subscribe for one ordinary share in the capital of JHI NV. The options may be exercised as follows: 25% after the first year; 25% after the second year; and 50% after the third year. All unexercised options expire 10 years from the date of issue or 90 days after the employee ceases to be employed by the Company.

The following table summarises the additional option grants:

Share Grant Date	Original Exercise Price	Number of Options Granted	Option Expiration Date
December 2001	A\$ 5.65	4,248,417	December 2011
December 2002	A\$ 6.66	4,037,000	December 2012
December 2003	A\$ 7.05	6,179,583	December 2013
December 2004	A\$ 5.99	5,391,100	December 2014
February 2005	A\$ 6.30	273,000	February 2015
December 2005	A\$ 8.90	5,224,100	December 2015
March 2006	A\$ 9.50	40,200	March 2016
November 2006	A\$ 8.40	3,499,490	November 2016
March 2007	A\$ 8.90	179,500	March 2017
March 2007	A\$ 8.35	151,400	March 2017
December 2007	A\$ 6.38	5,031,310	December 2017

As set out in the plan rules, the exercise prices and the number of shares available on exercise may be adjusted on the occurrence of certain events, including new issues, share splits, rights issues and capital reconstructions. Consequently, the exercise prices on the December 2002 and December 2001 option grants were reduced by A\$0.21 for the November 2003 return of capital and the December 2001 option grant was reduced by A\$0.38 for the November 2002 return of capital.

The Company is authorised to issue 45,077,100 shares under the 2001 Equity Incentive Plan.

JHI NV Stock Appreciation Rights Incentive Plan

On 14 December 2004, 527,000 stock appreciation rights were granted under the terms and conditions of the JHI NV Stock Appreciation Rights Incentive Plan ("Stock Appreciation Rights Plan") with an exercise price of A\$5.99. In April 2005, 27,000 stock appreciation rights were cancelled. In December 2006, 250,000 of these stock appreciation rights vested and were exercised at A\$8.99, the closing price of the Company's stock on the exercise day. In December 2007, the remaining 250,000 of these stock appreciation rights vested and were exercised at A\$6.52, the closing price of the Company's stock on the exercise day. These rights are accounted for as stock appreciation rights under SFAS No. 123R and, accordingly, compensation expense of US\$0.1 million, US\$0.5 million and US\$0.5 million was recognised in the years ended 31 March 2008, 2007 and 2006, respectively.

Supervisory Board Share Plan

At the 2002 Annual General Meeting, the Company's shareholders approved a Supervisory Board Share Plan ("SBSP"), which required that all non-executive directors on the Joint Board and Supervisory Board receive shares of the Company's common stock as payment for a portion of their director fees. The SBSP required that the directors take at least US\$10,000 of their fees in shares and allowed directors to receive additional shares in lieu of fees at their discretion. Shares issued under the US\$10,000 compulsory component of the SBSP were subject to a two-year escrow that

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

required members of the Supervisory Board to retain those shares for at least two years following issue. The issue price for the shares is the market value at the time of issue. No loans were entered into by the Company in relation to the grant of shares pursuant to the SBSP. During fiscal year 2007, this plan was replaced with the Supervisory Board Share Plan 2006. All remaining shares issued under the SBSP were released from escrow in November 2007.

Supervisory Board Share Plan 2006

At the 2006 Annual General Meeting, the Company's shareholders approved the replacement of its SBSP with a new plan called the Supervisory Board Share Plan 2006 ("SBSP 2006"). Participation by members of the Supervisory Board in the SBSP 2006 is not mandatory. The SBSP 2006 allows the Company to issue new shares or acquire shares on the market on behalf of the participant. The total remuneration of a Supervisory Board member will take into account any participation in the SBSP 2006 and shares under the SBSP 2006. At 31 March 2008, 61,792 shares had been acquired under this plan.

Long-Term Incentive Plan

At the 2006 Annual General Meeting, the Company's shareholders approved the establishment of a Long-Term Incentive Plan ("LTIP") to provide incentives to members of the Company's Managing Board and to certain members of its management ("Executives"). The shareholders also approved, in accordance with certain LTIP rules, the issue of options in the Company to members of the Company's Managing Board and to Executives. In November 2006, 1,132,000 options were granted under the LTIP to the Managing Board. In August 2007 an additional 1,016,000 options were granted to the Managing Board under the LTIP. The vesting of these options are subject to 'performance hurdles' as outlined in the LTIP rules. Unexercised options expire 10 years from the date of issue. At 31 March 2008, there were 2,148,000 options outstanding under this plan.

Valuation and Expense Information Under SFAS No. 123R

The Company accounts for stock options in accordance with the fair value provisions of SFAS No. 123R, which requires the Company to estimate the value of stock options issued based upon an option-pricing model and recognise this estimated value as compensation expense over the periods in which the options vest.

The Company estimates the fair value of each option grant on the date of grant using either the Black-Scholes option-pricing model or a lattice model that incorporates a Monte Carlo Simulation (the "Monte Carlo method"). Options granted under the 2001 Equity Incentive Plan and the Managing Board Transitional Stock Option Plan are valued using the Black-Scholes option-pricing model since the vesting of these options is based solely on a requisite service condition. Options granted under the LTIP were valued using the Monte Carlo method since vesting of these options requires that certain target 'performance hurdles' are achieved.

The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free rate and expected dividends. We estimate the expected term of options granted by calculating the average term from our historical stock option exercise experience. We estimate the volatility of our common stock based on historical daily stock price volatility. We base the risk-free interest rate on US Treasury notes with terms similar to the expected term of the options. We calculate dividend yield using the current management dividend policy at the time of option grant.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

The following table includes the weighted average assumptions and weighted average fair values used for grants valued using the Black-Scholes option-pricing model during the year ended 31 March:

	2008	2007	2006
Dividend yield	5.0%	1.5%	0.9%
Expected volatility	30.0%	28.1%	27.9%
Risk free interest rate	3.4%	4.6%	4.5%
Expected life in years	4.4	5.1	5.6
Weighted average fair value at grant date	A\$1.13	A\$2.40	A\$2.78
Number of stock options	5,031,310	3,830,390	6,584,300

The following table includes the weighted average assumptions and weighted average fair values used for grants valued using the Monte Carlo method during the year ended 31 March:

	2008	2007	2006
Dividend yield	5.0%	1.6%	N/A
Expected volatility	32.1%	28.1%	N/A
Risk free interest rate	4.2%	4.6%	N/A
Weighted average fair value at grant date	A\$3.14	A\$3.30	N/A
Number of stock options	1,016,000	1,132,000	N/A

Compensation expense arising from stock option grants as estimated using option-pricing models was US\$7.7 million, US\$5.8 million and US\$5.9 million for the years ended 31 March 2008, 2007 and 2006, respectively. As of 31 March 2008, the unrecorded deferred stock-based compensation balance related to stock options was US\$9.6 million after estimated forfeitures and will be recognised over an estimated weighted average amortisation period of 1.5 years.

General Share-Based Award Information

The following table summarises all of the Company's shares available for grant and the movement in all of the Company's outstanding options:

	Shares Available for Grant	Outstanding Options	
		Number	Weighted Average Exercise Price
Balance at 31 March 2006	19,836,233	19,513,257	A\$6.99
Newly Authorised	3,000,000	—	
Granted	(4,962,390)	4,962,390	A\$8.42
Exercised	—	(3,988,880)	A\$5.96
Forfeited	1,546,950	(1,546,950)	A\$7.70
Balance at 31 March 2007	19,420,793	18,939,817	A\$7.52
Newly Authorised	—	—	
Granted	(6,047,310)	6,047,310	A\$6.62
Exercised	—	(606,079)	A\$6.33
Forfeited	2,190,811	(2,190,811)	A\$7.79
Balance at 31 March 2008	15,564,294	22,190,237	A\$7.29

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

The total intrinsic value of stock options exercised was A\$1.2 million, A\$10.3 million and A\$11.5 million for the years ended 31 March 2008, 2007 and 2006, respectively.

The weighted average grant-date fair value of stock options granted was A\$1.47, A\$2.61 and A\$2.78 during the years ended 31 March 2008, 2007 and 2006, respectively.

Windfall tax benefits realised in the United States from stock options exercised and included in cash flows from financing activities in the consolidated statements of cash flows were nil, US\$1.8 million and US\$2.2 million for the years ended 31 March 2008, 2007 and 2006, respectively.

The following table summarises outstanding and exercisable options as of 31 March 2008:

Exercise Price	(In Australian dollars)						
	Options Outstanding			Options Exercisable			
	Number	Weighted Average Remaining Life (in Years)	Weighted Average Exercise Price	Aggregate Intrinsic Value	Number	Weighted Average Exercise Price	Aggregate Intrinsic Value
A\$3.09	409,907	2.6	A\$3.09	A\$1,295,306	409,907	A\$3.09	A\$1,295,306
3.13	100,435	1.6	3.13	313,357	100,435	3.13	313,357
5.06	660,582	3.7	5.06	787,017	660,582	5.06	787,017
5.99	2,745,625	6.7	5.99	713,862	2,745,625	5.99	713,862
6.30	93,000	6.9	6.30	—	93,000	6.30	—
6.38	4,822,398	9.7	6.38	—	14,286	6.38	—
6.45	901,500	4.6	6.45	—	901,500	6.45	—
7.05	2,280,750	5.7	7.05	—	2,280,750	7.05	—
7.83	1,016,000	9.4	7.83	—	—	—	—
8.35	151,400	9.0	8.35	—	37,850	8.35	—
8.40	3,747,340	8.6	8.40	—	686,349	8.40	—
8.53	1,320,000	7.7	8.53	—	—	—	—
8.90	3,901,100	7.7	8.90	—	2,000,425	8.90	—
9.50	40,200	7.9	9.50	—	20,100	9.50	—
Total	22,190,237	7.7	A\$7.29	A\$3,109,542	9,950,809	A\$6.83	A\$3,109,542

The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value based on stock options with an exercise price less than the Company's closing stock price of A\$6.25 as of 31 March 2008, which would have been received by the option holders had those option holders exercised their options as of that date.

17. Share Repurchase Program

On 15 August 2007, the Company announced a share repurchase program of up to 10% of the Company's issued capital, approximately 46.8 million shares. The Company repurchased 35.7 million shares of common stock during the year ended 31 March 2008. The repurchased shares had an aggregate cost of A\$236.4 million (US\$208.0 million) and the average price paid per share of common stock was A\$6.62 (US\$5.83). The US dollar amounts were determined using the weighted average spot rates for the days on which shares were purchased. The Company had not purchased any shares during the period between 1 April 2008 and 22 May 2008. The Company officially cancelled 35.0 million shares on 31 March 2008.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

18. Financial Instruments

Foreign Currency

As a multinational corporation, the Company maintains significant operations in foreign countries. As a result of these activities, the Company is exposed to changes in exchange rates which affect its results of operations and cash flows.

The Company purchases raw materials and fixed assets and sells some finished product for amounts denominated in currencies other than the functional currency of the business in which the related transaction is generated. In order to protect against foreign exchange rate movements, the Company may enter into forward exchange contracts timed to mature when settlement of the underlying transaction is due to occur. At 31 March 2008, there were no material contracts outstanding.

Credit Risk

Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents, investments and trade accounts receivable.

The Company maintains cash and cash equivalents, investments and certain other financial instruments with various major financial institutions. At times, these financial instruments may be in excess of insured limits. To minimise this risk, the Company performs periodic evaluations of the relative credit standing of these financial institutions and, where appropriate, places limits on the amount of credit exposure with any one institution.

The Company is exposed to losses on forward exchange contracts in the event that counterparties fail to deliver the contracted amount. The credit exposure to the Company is calculated as the mark-to-market value of all contracts outstanding with that counterparty. At 31 March 2008 and 2007, total credit exposure arising from forward exchange contracts was not material.

Credit risk with respect to trade accounts receivable is concentrated due to the concentration of the distribution channels for the Company's fibre cement products. Credit is extended based on an evaluation of each customer's financial condition and, generally, collateral is not required. The Company has historically not incurred significant credit losses.

Fair Values

The carrying values of cash and cash equivalents, short-term investments, accounts receivable, short-term borrowings and accounts payable and accrued liabilities are a reasonable estimate of their fair value due to the short-term nature of these instruments. The following table summarises the estimated fair value of the Company's long-term debt (including current portion of long-term debt):

(Millions of US dollars)	2008		31 March		2007	
	Carrying Value	Fair Value	Carrying Value	Fair Value	Carrying Value	Fair Value
Long-term debt:						
Floating	\$ 174.5	\$ 174.5	\$ 105.0	\$ 105.0	\$ 105.0	\$ 105.0
Fixed	—	—	—	—	—	—
Total	<u>\$ 174.5</u>	<u>\$ 174.5</u>	<u>\$ 105.0</u>	<u>\$ 105.0</u>	<u>\$ 105.0</u>	<u>\$ 105.0</u>

Fair values of long-term debt were determined by reference to the 31 March 2008 and 2007 market values for comparably rated debt instruments.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

19. Operating Segment Information and Concentrations of Risk

The Company has reported its operating segment information in the format that the operating segment information is available to and evaluated by the Managing Board of Directors. USA Fibre Cement manufactures and sells fibre cement interior linings, exterior siding and related accessories products in the United States. Asia Pacific Fibre Cement includes all fibre cement manufactured in Australia, New Zealand and the Philippines and sold in Australia, New Zealand and Asia. Research and Development represents the cost incurred by the research and development centres. Other includes the manufacture and sale of fibre cement reinforced pipes in the United States, fibre cement operations in Europe and roofing operations in the United States. The roofing plant was closed and the business ceased operations in April 2006. On 22 May 2008, the Company announced plans to cease production at its Plant City, Florida Hardie Pipe plant in the US. The Company's operating segments are strategic operating units that are managed separately due to their different products and/or geographical location.

Operating Segments

The following are the Company's operating segments and geographical information:

(Millions of US dollars)	Net Sales to Customers ¹		
	2008	2007	2006
USA Fibre Cement	\$ 1,144.8	\$ 1,262.3	\$ 1,218.4
Asia Pacific Fibre Cement	298.3	251.7	241.8
Other	25.7	28.9	28.3
Worldwide total	<u>\$ 1,468.8</u>	<u>\$ 1,542.9</u>	<u>\$ 1,488.5</u>

(Millions of US dollars)	Loss Before Income Taxes		
	2008	2007	2006
USA Fibre Cement ^{2,3}	\$ 268.0	\$ 362.4	\$ 342.6
Asia Pacific Fibre Cement ²	50.3	39.4	41.7
Research and Development ²	(18.1)	(17.1)	(15.7)
Other ⁴	(32.8)	(9.3)	(26.5)
Segments total	267.4	375.4	342.1
General Corporate ^{5,6}	(304.0)	(462.0)	(777.0)
Total operating loss	(36.6)	(86.6)	(434.9)
Net interest income (expense) ⁷	1.1	(6.5)	(0.2)
Worldwide total	<u>\$ (35.5)</u>	<u>\$ (93.1)</u>	<u>\$ (435.1)</u>

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

(Millions of US dollars)	Total Identifiable Assets Years Ended 31 March	
	2008	2007
USA Fibre Cement	\$ 835.8	\$ 893.0
Asia Pacific Fibre Cement	218.3	199.3
Research and Development	13.9	10.9
Other	10.6	41.6
Segments total	1,078.6	1,144.8
General Corporate ^{8,9}	1,101.3	983.3
Worldwide total	<u>\$ 2,179.9</u>	<u>\$ 2,128.1</u>

Geographic Areas

(Millions of US dollars)	Net Sales to Customers ¹ Years Ended 31 March		
	2008	2007	2006
USA	\$ 1,153.1	\$ 1,279.4	\$ 1,233.7
Australia	198.6	169.0	164.5
New Zealand	67.3	54.4	53.6
Other Countries	49.8	40.1	36.7
Worldwide total	<u>\$ 1,468.8</u>	<u>\$ 1,542.9</u>	<u>\$ 1,488.5</u>

(Millions of US dollars)	Total Identifiable Assets Years Ended 31 March	
	2008	2007
USA	\$ 846.6	\$ 935.7
Australia	139.0	127.1
New Zealand	26.1	23.1
Other Countries	66.9	58.9
Segments total	1,078.6	1,144.8
General Corporate ^{8,9}	1,101.3	983.3
Worldwide total	<u>\$ 2,179.9</u>	<u>\$ 2,128.1</u>

¹ Export sales and inter-segmental sales are not significant.

² Research and development costs of US\$7.4 million, US\$10.8 million and US\$13.2 million in fiscal years 2008, 2007 and 2006, respectively, were expensed in the USA Fibre Cement segment. Research and development costs of US\$1.6 million, US\$1.8 million and US\$2.3 million in fiscal years 2008, 2007 and 2006, respectively, were expensed in the Asia Pacific Fibre Cement segment. Research and development costs of US\$18.0 million, US\$13.0 million and US\$12.3 million in fiscal years 2008, 2007 and 2006, respectively, were expensed in the Research and Development segment. Research and Development costs of US\$0.3 million, US\$0.3 million and US\$0.9 million in fiscal years 2008, 2007 and 2006, respectively, were expensed in the Other segment. The Research and Development segment also included selling, general and administrative expenses of US\$0.1 million, US\$4.1 million and US\$3.4 million in fiscal years 2008, 2007 and 2006, respectively.

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Research and development expenditures are expensed as incurred and in total amounted to US\$27.3 million, US\$25.9 million and US\$28.7 million for the years ended 31 March 2008, 2007 and 2006, respectively.

- 3 Included in USA Fibre Cement for the year ended 31 March 2008 are asset impairment charges of US\$45.6 million and impairment related costs totaling US\$ 1.4 million.
- 4 Included in the Other segment for the years ended 31 March 2008 and 2006 are asset impairment charges of US\$25.4 million and US\$13.4 million, respectively. Also included in the Other segment for the year ended 31 March 2008, are impairment related costs totaling US\$1.8 million.
- 5 The principal components of General Corporate are officer and employee compensation and related benefits; professional and legal fees; administrative costs; and rental expense, net of rental income, on the Company's corporate offices. Also included in General Corporate are unfavourable asbestos adjustments of US\$240.1 million, US\$405.5 million and US\$715.6 million in fiscal years 2008, 2007 and 2006, respectively and AICF SG&A expenses of US\$4.0 million, nil and nil in fiscal years 2008, 2007 and 2006, respectively.
- 6 Includes costs of nil, US\$13.6 million and US\$17.4 million for SCI and other related expenses in fiscal years 2008, 2007 and 2006, respectively.
- 7 The Company does not report net interest expense for each operating segment as operating segments are not held directly accountable for interest expense. Included in net interest income (expense) is AICF interest income of US\$9.4 million, nil and nil in fiscal years 2008, 2007 and 2006, respectively. See Note 12.
- 8 The Company does not report deferred tax assets and liabilities for each operating segment as operating segments are not held directly accountable for deferred income taxes. All deferred income taxes are included in General Corporate.
- 9 Asbestos-related assets at 31 March 2008 and 31 March 2007 are US\$817.1 million and US\$727.6 million, respectively, and are included in the General Corporate segment. See Note 12.

Concentrations of Risk

The distribution channels for the Company's fibre cement products are concentrated. If the Company were to lose one or more of its major customers, there can be no assurance that the Company will be able to find a replacement. Therefore, the loss of one or more customers could have a material adverse effect on the Company's consolidated financial position, results of operations and cash flows. The Company has three major customers that individually account for over 10% of the Company's net sales.

These three customers' accounts receivable represented 42% and 58% of the Company's trade accounts receivable at 31 March 2008 and 2007, respectively. The following are gross sales generated by these three customers, which are all from the USA Fibre Cement segment:

(Millions of US dollars)	2008		Years Ended 31 March 2007		2006	
	\$	%	\$	%	\$	%
Customer A	431.3	27.9	446.3	26.7	426.2	35.0
Customer B	108.2	7.0	172.3	10.3	168.5	13.8
Customer C	167.3	10.8	168.9	10.1	156.6	12.9
Total	<u>706.8</u>		<u>787.5</u>		<u>751.3</u>	

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Approximately 22% of the Company's fiscal year 2008 net sales from continuing operations were derived from outside the United States. Consequently, changes in the value of foreign currencies could significantly affect the consolidated financial position, results of operations and cash flows of the Company's non-US operations on translation into US dollars.

20. Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) consists of the following components:

(Millions of US dollars)	2008	Years Ended 31 March 2007	2006
Pension and post-retirement benefit adjustments (net of US\$1.0 million and US\$1.2 million tax benefit, respectively)	\$ (2.1)	\$ (2.7)	\$ —
Unrealised loss on restricted short-term investments	(4.4)	—	—
Foreign currency translation adjustments	23.4	8.1	(28.4)
Total accumulated other comprehensive income	<u>\$ 16.9</u>	<u>\$ 5.4</u>	<u>\$ (28.4)</u>

21. Related Party Transactions

JHI NV Directors' and Former Directors' Securities Transactions

The Company's Directors (and Former Directors' for the relevant year) and their director-related entities held an aggregate of 275,426 ordinary shares and 210,530 ordinary shares at 31 March 2008 and 2007, respectively, and options to acquire 4,750,544 ordinary shares and 3,914,544 ordinary shares at 31 March 2008 and 2007, respectively.

Supervisory Board members (other than Mr J Loudon) on 14 March 2008 participated in an acquisition of shares at A\$5.7352, under the terms of the Supervisory Board Share Plan 2006 which was approved by JHI NV shareholders on 17 August 2007. Mr J Loudon, Mr M Hammes and Mr R Chenu also made on market-purchases during fiscal year 2008. Directors' acquisitions were as follows:

	On Market Purchases/(Sales)	SBSP
Non-Executive Directors		
M Hammes	9,000	6,859
B Anderson	—	6,124
D Andrews	—	3,903
D DeFosset	—	10,377
J Loudon	6,300	—
D McGauchie AO	—	5,803
R van der Meer	—	4,410
C Walter AM	—	5,032
Executive Directors		
L Gries	—	n/a
R Chenu	5,000	n/a
Former Directors		
J Barr	—	7,667
B Butterfield	(90,000)	n/a

James Hardie Industries N.V. and Subsidiaries
Notes to Consolidated Financial Statements

Mr B Butterfield separated from the company and resigned as a Managing Board member effective 30 September 2007. As a result of the separation, 90,000 of his 621,000 options to acquire ordinary shares were cancelled. In December 2007, Mr Butterfield exercised options to acquire 90,000 additional ordinary shares and sold the underlying shares.

Other than Mr Butterfield, no Director or Former Director, or their director-related entities, disposed of any shares in the Company.

The JHI NV dividends paid to Directors and their related entities were on the same terms and conditions that applied to other holders.

Existing Loans to the Company's Directors and Directors of James Hardie Subsidiaries

At 31 March 2008 and 2007, loans totaling US\$29,267 and US\$30,774, respectively, were outstanding from certain executive directors or former directors of subsidiaries of JHI NV under the terms and conditions of the Executive Share Purchase Plan (the "Plan"). Loans under the Plan are interest free and repayable from dividend income earned by, or capital returns from, securities acquired under the Plan. The loans are collateralised by CUFS under the Plan. No new loans to Directors or executive officers of JHI NV, under the Plan or otherwise, and no modifications to existing loans have been made since December 1997.

During fiscal year 2008, repayments totaling US\$5,419 were received in respect of the Plan from AT Kneeshaw and DAJ Salter. During fiscal year 2005, an executive director of a subsidiary resigned with loans outstanding of US\$117,688. Under the terms of the Plan, this director had two years from the date of his resignation to repay such loan. The loan was repaid in full in the year ended 31 March 2007. During fiscal year 2007, an executive director of a subsidiary resigned with loans outstanding of US\$14,123 and during fiscal year 2008, an executive director of a subsidiary resigned with loans outstanding of US\$16,075. Under the terms of the Plan, each loan must be repaid within two years from the date of their respective resignations.

Payments Made to Directors and Director Related Entities of JHI NV during the Year

Deputy Chairman DG McGauchie AO is a director of Telstra Corporation Limited from whom the Company purchases communications services. Supervisory Board Director R van der Meer is Supervisory Board director of ING Bank Nederland N.V. and ING Verzekeringen (Insurance) Nederland N.V. Entities in the ING Group provide various financial services to the Company. All transactions were in accordance with normal commercial terms and conditions. It is not considered that these Directors had significant influence over these transactions.

Payments made to Director and Director Related Entities of Subsidiaries of JHI NV

The Company has subsidiaries located in various countries, many of which require that at least one director be a local resident. All payments described below arise because of these requirements.

Payments of US\$4,507 and US\$4,507 for the years ended 31 March 2008 and 2007, respectively, were made to Grech, Vella, Tortell & Hyzler Advocates. Dr JJ Vella was a director of one of the Company's subsidiaries. The payments were in respect of legal services and were negotiated in accordance with usual commercial terms and conditions.

Payments totaling US\$5,979 and US\$5,364 for the years ended 31 March 2008 and 2007, respectively, were made to Bernaldo, Mirador and Directo Law Offices. R Bernaldo is a director of a subsidiary of the Company. The payments were in respect of professional services and were negotiated in accordance with usual commercial terms and conditions.

James Hardie Industries N.V. and Subsidiaries

This Financial Report forms part of a package of information about the Company's results. It should be read in conjunction with the other parts of this package, including the Media Release, Management Presentation and Management's Analysis of Results.

Disclaimer

This Financial Report of results contains forward-looking statements. James Hardie may from time to time make forward-looking statements in its periodic reports filed with or furnished to the United States Securities and Exchange Commission on Forms 20-F and 6-K, in the annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the Company's officers, directors or employees to analysts, institutional investors, lenders and potential lenders, representatives of the media and others. Examples of forward-looking statements include:

- expectations about the timing and amount of payments to the Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven asbestos-related personal injury and death claims;
- expectations concerning the costs associated with the suspension of operations at the Company's Blandon, Pennsylvania and Plant City, Florida plants;
- statements as to the possible consequences of proceedings brought against the Company and certain of its former directors and officers by the Australian Securities and Investments Commission;
- statements regarding tax liabilities and related proceedings;
- expectations that the Company's credit facilities will be extended or renewed;
- projections of the Company's operating results or financial condition;
- statements regarding the Company's plans, objectives or goals, including those relating to competition, acquisitions, dispositions and the Company's products;
- statements about the Company's future performance; and
- statements about product or environmental liabilities.

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "should," "aim" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. These factors, some of which are discussed under "Risk Factors" beginning on page 6 of the Form 20-F filed on 6 July 2007 with the Securities and Exchange Commission, include but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former James Hardie subsidiaries; required contributions to the AICF and the effect of foreign exchange on the amount recorded in the Company's financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the Company operates; the consequences of product failures or defects; exposure to environmental, asbestos or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; the success of research and development efforts; reliance on a small number of product customers; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; foreign exchange risks; and the effect of natural disasters. The Company cautions that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those in forward-looking statements. Forward-looking statements speak only as of the date they are made and the Company undertakes no duty to update or revise any such statements.



KPMG Actuaries Pty Limited

Australian Financial Services Licence No: 227 328

10 Shelley Street
Sydney NSW 2000
Australia

PO Box H67
Australia Square
Sydney NSW 1213
Australia

ABN: 77 002 882 000

Telephone: +61 2 9335 8900
Facsimile: +61 2 9335 8911
Email: actuaries@kpmg.com.au

**VALUATION OF
ASBESTOS RELATED DISEASE LIABILITIES
OF FORMER JAMES HARDIE ENTITIES
("THE LIABLE ENTITIES")
TO BE MET BY THE AICF TRUST
EFFECTIVE AS AT 31 MARCH 2008
PREPARED FOR ASBESTOS INJURIES COMPENSATION
FUND LIMITED (AICFL)
22 MAY 2008**

KPMG Actuaries Pty Limited is a sub-licensee of KPMG, an Australian partnership that is part of the KPMG International network. KPMG International is a Swiss cooperative.



KPMG Actuaries Pty Limited

Australian Financial Services Licence No: 227 328

10 Shelley Street
Sydney NSW 2000
Australia

PO Box H67
Australia Square
Sydney NSW 1213
Australia

ABN: 77 002 882 000

Telephone: +61 2 9335 8900
Facsimile: +61 2 9335 8911
Email: actuaries@kpmg.com.au

22 May 2008

Dallas Booth
Chief Executive Officer
Asbestos Injuries Compensation Fund Limited
c/-Level 3, 22 Pitt Street
Sydney NSW 2000

Cc Russell Chenu, Chief Financial Officer, James Hardie Industries NV
Leigh Sanderson, Deputy-Director General (Legal), The State of New South
Wales, c/- The Cabinet Office
The Board of Directors, Asbestos Injuries Compensation Fund Limited

Dear Dallas

**Valuation of asbestos-related disease liabilities of former
James Hardie entities ("The Liable Entities") to be met by the AICF Trust**

We are pleased to provide you with our actuarial valuation report relating to the asbestos-related disease liabilities of the Liable Entities which are to be met by the AICF Trust.

This report is effective as at 31 March 2008 and has taken into account claims data and information provided to us by AICFL as at 31 March 2008. If you have any questions with respect to the contents of this report, please do not hesitate to contact us. Yours sincerely

Neil Donlevy MA FIA FIAA
Director
KPMG Actuaries Pty Limited
*Fellow of the Institute of Actuaries
(London)*
*Fellow of the Institute of Actuaries of
Australia*

Richard Wilkinson BSc FIA FIAA
Director
KPMG Actuaries Pty Limited
*Fellow of the Institute of Actuaries
(London)*
*Fellow of the Institute of Actuaries of
Australia*

KPMG Actuaries Pty Limited is a sub-licensee of KPMG, an Australian partnership that is part of the KPMG International network. KPMG International is a Swiss cooperative.



EXECUTIVE SUMMARY

Important Note: Basis of Report

This valuation report ("the Report") has been prepared by KPMG Actuaries Pty Limited (A.B.N. 77 002 882 000) ("KPMG Actuaries") in accordance with an "Amended and Restated Final Funding Agreement in respect of the provision of long-term funding for compensation arrangements for certain victims of Asbestos-related diseases in Australia" (hereafter referred to as "the Amended Final Funding Agreement") between James Hardie Industries NV ("JHINV"), James Hardie 117 Pty Limited, the State of New South Wales and Asbestos Injuries Compensation Fund Limited ("AICFL") which was signed on 21 November 2006.

This Report is intended to meet the requirements of the Amended Final Funding Agreement and values the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

This Report is not intended to be used for any other purpose and may not be suitable, and should not be used, for any other purpose. Opinions and estimates contained in the Report constitute our judgement as of the date of the Report.

In preparing the Report, KPMG Actuaries has relied on information supplied to it from various sources and has assumed that that information is accurate and complete in all material respects. KPMG Actuaries has not independently verified the accuracy or completeness of the data and information used for this Report.

Except insofar as liability under statute cannot be excluded, KPMG Actuaries, its directors, employees and agents will not be held liable for any loss or damage of any kind arising as a consequence of any use of the Report or purported reliance on the Report including any errors in, or omissions from, the valuation models.

The Report must be read in its entirety. Individual sections of the Report, including the Executive Summary, could be misleading if considered in isolation. In particular, the opinions expressed in the Report are based on a number of assumptions and qualifications which are set out in the full Report.



Introduction

The Amended Final Funding Agreement requires the completion of an Annual Actuarial Report evaluating the potential asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust. KPMG Actuaries has been retained by AICFL to provide this actuarial valuation report as required under the Amended Final Funding Agreement and this is detailed in our Engagement Letter dated 29 January 2008.

The Liable Entities are defined as being the following entities:

- Amaca Pty Ltd (formerly James Hardie & Coy);
- Amaba Pty Ltd (formerly Jsekarb, James Hardie Brakes and Better Brakes); and
- ABN60 Pty Ltd (formerly James Hardie Industries Ltd).

In addition, the Board of JHINV agreed that Personal Asbestos Claims arising out of mining activities at Baryulgil would also be met by the AICF Trust (these liabilities are referred to in the Amended Final Funding Agreement as liabilities in relation to Marlew Claims and they are deemed to be liabilities of Amaca).

Our valuation is on a central estimate basis and is intended to be effective as at 31 March 2008. It has been based on claims data and information as at 31 March 2008 provided to us by AICFL.

Overview of Recent Claims Experience and comparison with previous forecasts

Claim Numbers

Claims reporting for mesothelioma has shown a significant increase in the year. There were 266 claims reported in 2007/08, compared with 215 claims reported in 2006/07 and 216 claims in 2005/06.

The increase in claims reporting activity has been systemic across a number of States, rather than specific to any one State. However, in 2007/08 there has been an apparent "backlog clearance" from WorkCover Queensland which has contributed to these trends.

Claims experience was particularly heavy during the first and third quarters of the 2007/08 financial year, including 37 claims reported in November 2007.



At the same time, asbestosis has also shown a moderate increase in activity to 169 claims in 2007/08, compared with 164 claims in 2006/07 and 103 claims in 2005/06. Again, the increase has been widespread rather than specific to any one State.

The increased number of mesothelioma and asbestosis claims have been systemic to known overall Australian experience rather than specifically related to the experience of the Liable Entities. However, it is not clear what the drivers are that have given rise to this experience.

As a consequence, claims activity in 2007/08 reached its highest annual level to date. There were 552 claims reported in 2007/08, up from 488 claims reported in 2006/07, 406 in 2005/06 and 512 in 2004/05.

The following table shows the comparison of actual experience with that which had previously been forecast:

Table E.1: Comparison of claim numbers

	<u>Actual</u>	<u>Expected</u>	<u>Ratio of Actual to Expected (%)</u>
Mesothelioma	266	222	120%
Asbestosis	169	156	108%
Lung cancer	24	30	80%
ARPD & Other	40	30	133%
Wharf	7	6	117%
Workers	46	48	96%
Total	552	492	112%

Note: Actual experience in 2007/08 is expected to develop further, in line with previous years where additional claims have emerged after the end of the financial year (e.g. 2006/07 has seen the claims numbers reported increase by 24 from 464 to 488, with mesothelioma increasing by 13 from 202 to 215; and asbestosis increasing by 9 from 155 to 164).



Average Claim Awards

Claim awards for mesothelioma have shown a degree of stability in the last five years and remain below prior expectations. For other disease types, average claim awards have exhibited greater volatility, which is not unexpected given the smaller numbers of claim settlements of those disease types. However, claims awards in 2007/08 for other disease types have typically been below expectations this year.

There has been only 1 large mesothelioma claim settlement (being claims in excess of \$1m) in 2007/08, considerably lower than our expected annual allowance of 5 large claims.

The following table shows the comparison of actual experience with that which had previously been forecast:

Table E.2: Comparison of average claim size

	Actual (\$)	Expected (\$)	Ratio of Actual to Expected (%)
Mesothelioma	236,635	266,500	89%
Asbestosis	80,343	101,300	79%
Lung cancer	117,184	133,300	88%
ARPD & Other	46,461	95,900	48%
Wharf	31,633	106,600	30%
Workers	243,749	133,300	183%
Mesothelioma Large Claims Costs	1 claim @ \$1,354,240 = \$1,354,240	5 claims @ 1,758,900 = 8,794,500	15%



Cashflow expenditure: gross and net

Gross cashflow expenditure, at \$74m, was slightly below our prior expectations. However, net cashflow expenditure, at \$55m, has been significantly lower than our prior expectations.

Table E.3: Comparison of cashflow

	<u>Actual</u>	<u>Expected</u>	<u>Ratio of Actual to Expected (%)</u>
Gross Cashflow	74.3	78.3	95%
Insurance and Other Recoveries	19.3	14.0	138%
Net cashflow	55.0	64.3	86%

The primary reason for this experience has been the significant level of insurance and other recoveries that have been made by AICFL in 2007/08.

In the 2007/08 financial year, recoveries totalled more than \$19m, with around \$18m arising from collections from insurers of the Liable Entities and \$1.4m arising from cross-claim recoveries.

The main contributors to this level of activity have been the collections from Equitas, ACE Insurance and the annual payment by QBE, together with some Scheme of Arrangement receipts.



Liability Assessment

At 31 March 2008, our central estimate of the liabilities of the Liable Entities (the Discounted Central Estimate) to be met by the AICF Trust is \$1,426.3m (March 2007: \$1,355.1m).

We have not allowed for the future Operating Expenses of the AICF Trust or the Liable Entities in the liability assessment.

Table E.4: Comparison of central estimate of liabilities

	March 2008 \$m			March 2007 \$m
	Gross of insurance recoveries	Insurance recoveries	Net of insurance recoveries	Net of insurance recoveries
Total projected cashflows (uninflated)	1,614.3	228.1	1,386.2	1,273.0
Future inflation allowance	1,910.8	269.7	1,641.1	1,537.8
Total projected cash-flows with inflation	3,525.2	497.8	3,027.3	2,810.8
Discounting allowance	(1,879.5)	(278.5)	(1,601.0)	(1,455.6)
Net present value liabilities	1,645.7	219.4	1,426.3	1,355.1



Comparison with previous valuation

In the absence of any change to the claim projection assumptions from our 31 March 2007 valuation, other than allowing for the changes in the discount rate, we would have projected a Discounted Central Estimate liability of \$1,334.6m as at 31 March 2008.

Consequently, our revised assessment at 31 March 2008 represents an increase of \$91.7m from that assessment.

The increase in that net liability estimate is principally a consequence of:

- An increase in the projected number of future mesothelioma and asbestosis claims recognising the higher reporting activity in the last year;
- Increases to the incidence pattern of notifications, particularly in relation to the assumed peak year of notification for asbestosis; and
- A reduction in the assumed cross-claim recovery rate.

offset by

- A reduction in average claim awards and legal costs for some disease types;
- An increase in the assumed rate of nil settlements;
- A change to the settlement pattern of claims; and
- Actual experience in the 12-month period being better than forecast, with savings being achieved on claims which were not settled as at the previous valuation.

The following table shows an analysis of the change in our liability assessments from March 2007 to March 2008.



Table E.5: Analysis of change

	<u>\$m</u>
Net liability at start of valuation period	1,355.1
Expected net claims payments	(64.3)
Unwind of discount / interest charge	84.2
Expected liability at end of valuation period	1,375.0
Change in discount rate	(40.4)
Expected net liability at end of valuation period adjusted for discount rate	1,334.6
Impact of Change in valuation bases:	
- Claim numbers	144.5
- Incidence pattern of notifications (change in peak year)	29.6
- Nil settlement rate	(12.7)
- Average claims costs and legal costs	(72.2)
- Settlement patterns	(6.9)
- Insurance recoveries	0.2
- Cross-claim recoveries	12.0
- Emerging experience on reported claims and pending claims	(2.8)
Total development in net liability	91.7
Net liability at end of valuation period	1,426.3



Amended Final Funding Agreement calculations

The Amended Final Funding Agreement sets out the basis on which payments will be made to the AICF Trust.

Additionally, there are a number of other figures specified within the Amended Final Funding Agreement that we are required to calculate. These are ¹:

- Discounted Central Estimate;
- Term Central Estimate; and
- Period Actuarial Estimate.

Table E.6: Amended Final Funding Agreement calculations

	<u>\$ m</u>
Discounted Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,426.3
Period Actuarial Estimate (net of cross-claim recoveries, gross of Insurance and Other Recoveries) comprising:	249.8
Discounted value of cashflow in 2008/09	81.0
Discounted value of cashflow in 2009/10	83.1
Discounted value of cashflow in 2010/11	85.7
Term Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,422.4

It should be noted that the actual funding required at a particular date will depend upon a number of factors, including:

- the net asset position of the AICF Trust at that time;
- the free cash flow amount of the JHINV Group in the preceding financial year; and
- the Period Actuarial Estimate in the latest Annual Actuarial Report.

¹ See Glossary of Terms in Appendix G for description of these items

Uncertainty


Estimates of asbestos-related disease liabilities are subject to considerable uncertainty, significantly more than personal injury liabilities in relation to other causes, such as CTP or Workers Compensation claims. This includes uncertainty due to:

- The difficulty in quantifying the extent and pattern of past asbestos exposures and the number and incidence of the ultimate number of lives that may be affected by asbestos related diseases arising from such past asbestos exposures;
- The propensity of individuals affected by diseases arising from such exposure to file common law claims against defendants;
- The extent to which the Liable Entities will be joined in such future common law claims;
- The fact that the ultimate severity of the impact of the disease and the quantum of the claims that will be awarded will be subject to the outcome of events that have not yet occurred, including:
 - medical and epidemiological developments;
 - court interpretations;
 - legislative changes;
 - changes to the form and range of benefits for which compensation may be awarded (“heads of damage”);
 - public attitudes to claiming;
 - the potential for future procedural reforms in NSW and other States affecting the legal costs incurred in managing and settling claims;
 - potential third-wave exposures; and
 - social and economic conditions such as inflation.

It should therefore be expected that the actual emergence of the liabilities will vary from any estimate. As indicated in Figure E.1, depending on the actual out-turn of experience relative to that currently forecast the variation could potentially be substantial. Thus, no assurance can be given that the actual liabilities of the Liable Entities to be met by the AICF Trust will not ultimately exceed the estimates contained in this report and any such variation may be significant.

Given this, we provide the following sensitivity tests of the actuarial assessment of the liabilities to changes in some key assumptions.

Figure: E.1 Sensitivity testing results — Impact around the Discounted Central Estimate (in \$m)



* The superimposed inflation sensitivity tests are for 6.25% per annum for 5 years reducing to 2.25% per annum; and 2.25% per annum for 5 years reducing to 0% per annum.

The above chart implies that the single most sensitive assumption is potentially the peak year of mesothelioma claims reporting against the Liable Entities. Shifting the peak year of mesothelioma claims reporting by 5 years from 2010/11 to 2015/2016 for mesothelioma would imply an increase in the future number of mesothelioma claims reported of around 50%.

Table E.7: Summary results of sensitivity analysis

	<u>Undiscounted</u>	<u>Discounted</u>
Central estimate	\$3.03bn	\$1.43bn
Range around the central estimate	-\$1.1bn to \$2.4bn	-\$0.4bn to \$0.7bn
Range of liability estimates	\$1.9bn to \$5.4bn	\$1.0bn to \$2.1bn



Whilst the table above indicates a range around the discounted central estimate of liabilities of -\$400m and +\$700m, the actual cost of liabilities could fall outside that range depending on the out-turn of the actual experience.

Data, Reliances and Limitations

We have been provided with the following information by AICFL:

- Claims database at 31 March 2008 with individual claims listings;
- Accounting database at 31 March 2008 (which includes individual claims payment details);
- Monthly Management Information Reports to 31 March 2008;
- Home Renovator Reports at various dates; and
- Detailed insurance bordereaux information (being a listing of claims filed with the insurers of the Liable Entities) produced by Capita Insurance Services (London) as at 31 March 2008.

While we have tested the consistency of the various data sets provided, we have not otherwise verified the data nor have we undertaken any auditing of the data at source. We have relied on the data provided as being complete and accurate in all material respects. Consequently, should there be material errors or incompleteness in the data, our assessment could be affected materially.

Executive Summary Not Report

Please note that this executive summary is intended as a brief overview of our report. To properly understand our analysis and the basis of our liability assessment requires examination of our report in full.



CONTENTS

1	Scope and Purpose	1
1.1	Introduction	2
1.2	Purpose of this report	3
1.3	Scope of report	4
1.4	Areas of potential exposure not included	9
1.5	Data reliances and limitations	10
1.6	Uncertainty	11
1.7	Distribution and use	11
1.8	Author of the report	12
1.9	Professional standards and compliance	12
2	Areas of Potential Exposure	13
2.1	Overview	13
2.2	Potential changes to the number of future claims	13
2.3	Potential changes to claims costs	16
2.4	Medical developments	17
3	Data	18
3.1	Data provided to KPMG Actuaries	18
3.2	Data limitations	18
3.3	Data verification	19
3.4	Data conclusion	20
4	Valuation Methodology and Approach	22
4.1	Previous valuation work and methodology changes	22
4.2	Overview of current methodology	22
4.3	Disease type and class subdivision	24
4.4	Numbers of future claims notifications	26
4.5	Incidence of claim settlements from future claim notifications	27
4.6	Average claim costs of IBNR claims	28
4.7	Proportion of claims settled for nil amounts	29
4.8	Pending claims	29
4.9	Insurance Recoveries	32
4.10	Cross-claim recoveries	35
4.11	Discounting cashflows	36
5	Analysis of Claims Experience — Claim Numbers	37
5.1	Overview	37
5.2	Mesothelioma claims	38
5.3	Asbestosis claims	44
5.4	Lung cancer claims	47
5.5	ARPD & Other claims	47



*Valuation of the asbestos-related disease liabilities of the
Liable Entities to be met by the AICF Trust
31 March 2008*

5.6 Workers Compensation and wharf claims	47
5.7 Summary of base claims numbers assumptions	48
5.8 Exposure and latency information	49
5.9 Peak year of claims and estimated future notifications	58
5.10 Baryulgil	60
6 Analysis of Experience — Average Claims Costs	61
6.1 Overview	61
6.2 Mesothelioma claims	62
6.3 Asbestosis claims	66
6.4 Lung cancer claims	69
6.5 ARPD & Other claims	70
6.6 Workers Compensation claims	71
6.7 Wharf claims	72
6.8 Large claim size and incidence rates	73
6.9 Average defendant legal cost for non-nil and nil claim settlements	75
6.10 Summary assumptions	78
7 Analysis of Claims Experience — Nil Settlement Rates	79
7.1 Overview	79
7.2 Mesothelioma claims	80
7.3 Asbestosis claims	81
7.4 Lung cancer claims	82
7.5 ARPD & Other claims	83
7.6 Workers Compensation claims	83
7.7 Wharf claims	84
7.8 Summary assumptions	85
8 Economic and Other Assumptions	86
8.1 Overview	86
8.2 Claims inflation	86
8.3 Superimposed inflation	92
8.4 Summary of claims inflation assumptions	94
8.5 Discount rates: Commonwealth bond zero coupon yields	95
8.6 Cross-claim recovery rates	96
8.7 Settlement Patterns	97
9 Product and Public Liability Insurance Programme	100
9.1 Overview	100
9.2 Allowance for Insurance Recoveries	101
9.3 Bad debt allowance on Insurance Recoveries	102
9.4 Expected Insurance Recoveries	103
10 Valuation Results	105
10.1 Central estimate liability	105



10.2 Comparison with previous valuation	106
10.3 Cashflow projections	108
10.4 Amended Final Funding Agreement calculations	110
10.5 Accounting liability calculations: JHINV	111
11 Uncertainty	112
11.1 Overview	112
11.2 Sensitivity testing	113
11.3 Results of sensitivity testing	114

TABLES

Table 1.1: Summary of valuation assessments by KPMG Actuaries	3
Table 3.1: Comparison of amounts from claims and accounting databases	20
Table 5.1: Number of claims reported annually	37
Table 5.2: Base claim numbers assumptions	48
Table 5.3: Assumed latency periods from average date of exposure to notification	57
Table 5.4: Peak year of claim notifications	58
Table 5.5: Number of claim notifications by disease type	59
Table 6.1: Average attritional non-nil claim award (inflated to current money terms)	62
Table 6.2: Average mesothelioma claims assumptions	66
Table 6.3: Average asbestosis claims assumptions	68
Table 6.4: Average lung cancer claims assumptions	70
Table 6.5: Average ARPD & Other claims assumptions	71
Table 6.6: Average Workers Compensation claims assumptions	72
Table 6.7: Average wharf claims assumptions	73
Table 6.8: Summary average claim cost assumptions	78
Table 7.1: Nil settlement rates	79
Table 7.2: Summary nil settlement rate assumptions	85
Table 8.1: Claims inflation assumptions	95
Table 8.2: Zero coupon yield curve by duration	95
Table 8.3: Settlement pattern of claims awards by delay from claim reporting	99
Table 9.1: Value of expected Insurance Recoveries	104
Table 10.1: Comparison of central estimate of liabilities	105
Table 10.2: Analysis of change	107
Table 10.3: Amended Final Funding Agreement calculations	111
Table 11.1: Summary results of sensitivity analysis	116



FIGURES

Figure 4.1: Actual savings achieved on case estimates at settlement	31
Figure 5.1: Proportion of claims by disease type	38
Figure 5.2: Monthly notifications of mesothelioma claims	39
Figure 5.3: Rolling annualised averages of mesothelioma claim notifications	40
Figure 5.4: Number of mesothelioma claims by location of claim filing	41
Figure 5.5: Numbers of mesothelioma claims settlements by year of notification (nil and non-nil claims)	42
Figure 5.6: Monthly notifications of asbestosis claims	44
Figure 5.7: Rolling annualised averages of asbestosis claim notifications	45
Figure 5.8: Number of asbestosis claims by location of claim filing	46
Figure 5.9: Consumption and production indices — Australia 1920-2002	50
Figure 5.10: Mix of claims by duration of exposure (years)	51
Figure 5.11: Timeline of exposure and claim reporting	51
Figure 5.12: Exposure (person-years) of all Liable Entities' claimants to date	52
Figure 5.13: Exposure (person years) of all claimants to date by report year and exposure year	53
Figure 5.14: Latency of mesothelioma claims	54
Figure 5.15: Latency of asbestosis claims	56
Figure 5.16: Latency of lung cancer claims	56
Figure 5.17: Latency of ARPD & Other claims	57
Figure 5.18: Expected future claim notifications by disease type	59
Figure 6.1: Contribution of individual bands of claims to overall average attritional mesothelioma claim costs (inflated to current money terms)	63
Figure 6.2: Distribution of claims awards for attritional non-nil mesothelioma claims (inflated to current money terms)	64
Figure 6.3: Inflated average awards and number of non-nil claims settlements for mesothelioma claims	65
Figure 6.4: Contribution of individual bands of claims to overall average attritional asbestosis claim costs (inflated to current money terms)	66
Figure 6.5: Distribution of claims awards for attritional non-nil asbestosis claims (inflated to current money terms)	67
Figure 6.6: Inflated average awards and number of non-nil claims settlements for asbestosis claims	68
Figure 6.7: Inflated average awards and number of non-nil claims settlements for lung cancer claims	69
Figure 6.8: Inflated average awards and number of non-nil claims settlements for ARPD & Other claims	70
Figure 6.9: Inflated average awards and number of non-nil claims settlements for Workers Compensation claims	71



Figure 6.10: Inflated average awards and number of non-nil claims settlements for Wharf claims	72
Figure 6.11: Scatter plot of large claims by settlement year	75
Figure 6.12: Inflated average defendant legal costs for non-nil claims by closure year	76
Figure 6.13: Inflated average defendant legal costs for nil claims by closure year	77
Figure 7.1: Mesothelioma nil claims experience	80
Figure 7.2: Asbestosis nil claims experience	81
Figure 7.3: Lung cancer nil claims experience	82
Figure 7.4: ARPD & Other nil claims experience	83
Figure 7.5: Workers Compensation nil claims experience	84
Figure 7.6: Wharf nil claims experience	85
Figure 8.1: Trends in Bond Yields	87
Figure 8.2: Trends in CPI and AWOTE	89
Figure 8.3: Age profile of mesothelioma claimants by report year	90
Figure 8.4: Age cohorting of average mesothelioma awards by decade of age	91
Figure 8.5: Average mesothelioma awards	93
Figure 8.6: Cross-claim recovery experience	96
Figure 8.7: Settlement pattern derivation for mesothelioma claims	97
Figure 8.8: Settlement pattern derivation for non-mesothelioma claims	98
Figure 10.1: Past claim-related expenditure of the Liable Entities: 1 January 2003 to 31 March 2008	108
Figure 10.2: Annual cashflow projections (\$m)	109
Figure 11.1: Sensitivity testing results — Impact around the Discounted Central Estimate (in \$m)	115

APPENDICES

A. Credit rating default rates by duration	118
B. Projected cashflows (\$m)	120
C. Projected discounted cashflows (\$m)	121
D. Derivation of US GAAP net accounting liability of JHINV	122
E. Allocation of central estimate liabilities to AICFL entities	126
F. Australian asbestos consumption and production data: 1920-2002	128
G. Glossary of terms	129



1 SCOPE AND PURPOSE

Important Note: Basis of Report

This valuation report ("the Report") has been prepared by KPMG Actuaries Pty Limited (A.B.N. 77 002 882 000) ("KPMG Actuaries") in accordance with an "Amended and Restated Final Funding Agreement in respect of the provision of long-term funding for compensation arrangements for certain victims of Asbestos-related diseases in Australia" (hereafter referred to as "the Amended Final Funding Agreement") between James Hardie Industries NV ("JHINV"), James Hardie 117 Pty Limited, the State of New South Wales and Asbestos Injuries Compensation Fund Limited ("AICFL"), which was signed on 21 November 2006.

This Report is intended to meet the requirements of the Amended Final Funding Agreement and values the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

This Report is not intended to be used for any other purpose and may not be suitable, and should not be used, for any other purpose. Opinions and estimates contained in the Report constitute our judgement as of the date of the Report.

In preparing the Report, KPMG Actuaries has relied on information supplied to it from various sources and has assumed that that information is accurate and complete in all material respects. KPMG Actuaries has not independently verified the accuracy or completeness of the data and information used for this Report.

Except insofar as liability under statute cannot be excluded, KPMG Actuaries, its directors, employees and agents will not be held liable for any loss or damage of any kind arising as a consequence of any use of the Report or purported reliance on the Report including any errors in, or omissions from, the valuation models.

The Report must be read in its entirety. Individual sections of the Report, including the Executive Summary, could be misleading if considered in isolation. In particular, the opinions expressed in the Report are based on a number of assumptions and qualifications which are set out in the full Report.



1.1 Introduction

1.1.1 Chronology of events

In February 2001, the Medical Research & Compensation Foundation (“MRCF”) was established as a charitable trust to meet the asbestos-related liabilities of two former subsidiaries of the James Hardie Group of Companies, namely Amaca Pty Ltd and Amaba Pty Ltd.

In February 2004, the NSW Government established the Special Commission of Inquiry into the Establishment of the MRCF. In September 2004, one of the findings of the Inquiry was that the MRCF was under-funded insofar as it would not have sufficient assets to meet its expected future liabilities.

During the Special Commission of Inquiry, JHINV made an offer to fund the liabilities of the Liable Entities subject to certain conditions and shareholder approval. Subsequent to the Special Commission of Inquiry’s findings, negotiations began to establish the basis on which the funding may take place.

A “Heads of Agreement” was signed on 21 December 2004 between JHINV, the ACTU, a representative of the Asbestos Victims Groups, UnionsNSW and the NSW Government. This was a non-binding agreement which set out the principles upon which the Final Funding Agreement would be based.

The Final Funding Agreement was signed by JHINV and the NSW Government on 1 December 2005 and on 21 November 2006 the parties executed the Amended Final Funding Agreement.

On 7 February 2007, at an Extraordinary General Meeting held in Amsterdam, JHINV security holders approved the Amended Final Funding Agreement and the voluntary funding proposal. An initial payment of \$184.3m was made by JHINV on 9 February 2007.

1.1.2 Liability assessments undertaken by KPMG Actuaries

KPMG Actuaries was retained by JHINV and Allens Arthur Robinson (“AAR”) during the Special Commission of Inquiry to provide an assessment of the asbestos-related disease liabilities of the MRCF at 30 June 2003.

Within the valuation as at 30 June 2003, KPMG Actuaries estimated the discounted value of the quantifiable liabilities of the MRCF on a “central estimate” basis as \$1,573.4m (equivalent to an undiscounted estimate of \$3,403.1m), based on the then current economic and legal environment, net of insurance recoveries and after allowance for claims-related legal costs.



Since that time, KPMG Actuaries has been retained to provide updated assessments of the liabilities at various dates.

The following table shows the valuation assessments made by KPMG Actuaries.

Table 1.1: Summary of valuation assessments by KPMG Actuaries

Valuation Date	Based on data as at	Report release date	Discounted Central Estimate (\$m)	Undiscounted central estimate (\$m)
30/06/03	30/06/03	07/06/04	1,573.4	3,403.1
30/06/04	18/10/04	21/11/04	1,536.0	3,585.6
31/03/05	31/03/05	14/05/05	1,684.9	3,603.7
30/06/05 (a)	24/06/05	01/12/05	1,568.4	3,131.0
31/03/06 (a)	28/02/06 (b)	15/05/06	1,517.0	3,079.2
30/09/06 (a)	30/09/06	13/11/06	1,554.8	3,168.9
31/03/07 (a)	31/03/07	28/05/07	1,355.1	2,810.8
31/03/08 (a)	31/03/08	22/05/08	1,426.3	3,027.3

Notes:

(a) The valuations since 30 June 2005 have included an allowance for cost savings in NSW.

(b) The valuation at 31 March 2006 included supplemental claims and accounting information to 31 March 2006.

The precise scope of the liability assessment of the various historic reports has varied, including varying from the scope of this Report which quantifies the liabilities which are to be met by the AICF Trust as set out in the Amended Final Funding Agreement. The reports since 30 June 2005 were prepared in accordance with the Final Funding Agreement.

Accordingly, comparison between the various estimates of liabilities requires some care and should be regarded as indicative only.

1.2 Purpose of this report

The Amended Final Funding Agreement requires the completion of an Annual Actuarial Report evaluating the potential asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

1.2.1 Liable Entities

The Liable Entities are defined as being the following entities:

- Amaca Pty Ltd (formerly James Hardie & Coy);
- Amaba Pty Ltd (formerly Jsekarb, James Hardie Brakes and Better Brakes); and
- ABN60 Pty Ltd (formerly James Hardie Industries Ltd).

In addition, the Board of JHINV agreed that Personal Asbestos Claims arising out of mining activities at Baryulgil would also be met by the AICF Trust (these liabilities are referred to in the Amended Final Funding Agreement as liabilities in relation to Marlew Claims and are deemed to be liabilities of Amaca).

1.2.2 Personal asbestos claims

Under the Amended Final Funding Agreement, the liabilities to be met by the AICF Trust relate to personal asbestos-related disease liabilities of the Liable Entities.

Such claims must relate to exposure which took place in Australia and which have been brought in a Court in Australia.

The precise scope of the liabilities is detailed in Section 1.3 and in Appendix G.

1.2.3 Purpose of report

KPMG Actuaries has been retained by AICFL to provide an actuarial valuation report as required under the Amended Final Funding Agreement and this is detailed in our Engagement Letter dated 29 January 2008.

The prior written consent of KPMG Actuaries is required for any other use of this report or the information contained in it.

Our valuation is intended to be effective as at 31 March 2008 and has been based on claims data and information as at 31 March 2008 provided to us by AICFL.

1.3 Scope of report

We have been requested to provide an actuarial assessment as at 31 March 2008 of the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust, consistent with the terms of the Amended Final Funding Agreement.

The assessment is on a central estimate basis and is based on the claims experience as at 31 March 2008.

A “central estimate” liability assessment is an estimate of the expected value of the range of potential future liability outcomes. In other words, if all the possible values of the liabilities are expressed as a statistical distribution, the central estimate is an estimate of the mean of that distribution.

It is of note that our liability assessment:

- Relates to the Liable Entities and Marlew (in relation to Marlew Claims arising from asbestos mining activities at Baryulgil).
- Is intended to cover:
 - The amount of settlements, judgments or awards for all Personal Asbestos Claims.
 - Claims Legal Costs incurred by the AICF Trust in connection with the settlement of Personal Asbestos Claims.
- Is not intended to cover:
 - Personal injury or death claims arising from exposure to asbestos which took place outside Australia.
 - Personal injury or death claims, arising from exposure to Asbestos, which are brought in Courts outside Australia.
 - Claims for economic loss, other than any economic loss forming part of an award for damages for personal injury and/or death.
 - Claims for loss of property, including those relating to land remediation.
 - The costs of asbestos or asbestos product removal relating to asbestos or asbestos products manufactured or used by or on behalf of the Liable Entities.
- Includes an allowance for:
 - Compensation to the NSW Dust Diseases Board or a Workers Compensation Scheme by way of a claim by such parties for contribution or reimbursement from the Liable Entities, but only to the extent that the cost of such claims is less than the limits of funding for such claims as outlined within the Amended Final Funding Agreement.



- Workers Compensation claims, being claims from current and former employees of the Liable Entities, but only to the extent that such liabilities are not met by a Workers Compensation Scheme or Policy (see section 1.3.1).
- Assumes that the product and public liability insurance policies of the Liable Entities will continue to respond to claims as and when they fall due. We have not made any allowance for the impact of any disputation concerning Insurance Recoveries nor of any legal costs that may be incurred in resolving such disputes.
- Makes no allowance for potential Insurance Recoveries that could be made on product and public liability insurance contracts placed from 1986 onwards which were placed on a “claims made” basis.
- Makes no allowance for the future Operating Expenses of the Liable Entities or the AICF Trust. Separate allowance for future Operating Expenses needs to be made by the management of AICFL.
- Assumes a continuation of the existing legal environment in relation to claims settlements.
- Makes no additional allowance for the inherent uncertainty of the liability assessment. That is, no additional provision has been included in excess of a central estimate.

Readers of this report may refer to our previous reports (as set out in Section 1.1.2) which are available at www.ir.jameshardie.com.au.

1.3.1 Workers Compensation

Workers Compensation claims are claims made by current and former employees of the Liable Entities. Such past, current and future reported claims were insured with, amongst others, Allianz Australia Limited (“Allianz”) and the various State-based Workers Compensation Schemes.

Under the Amended Final Funding Agreement, the part of future Workers Compensation claims that are met by a Workers Compensation Scheme or Policy of the Liable Entities are outside of the AICF Trust. The AICF Trust is, however, to provide for any part of a claim not covered by a Workers Compensation Scheme or Policy (e.g. as a result of the existence of limits of indemnity and policy deductibles on those contracts of insurance).



On this basis our liability assessment in relation to Workers Compensation claims and which relates to the AICF Trust, includes only the amount borne by the Liable Entities in excess of the anticipated recoveries due from a Workers Compensation Scheme or Policy.

In making our assessment we have assumed that the Workers Compensation insurance programme will continue to respond to claims by current and former employees of the Liable Entities as and when they fall due. To the extent that they were not to respond owing to (say) insurer insolvency, Insurer Guarantee Funds should be available to meet such obligations.

1.3.2 Dust Diseases Board and Other Reimbursements

There exists a right under Section 8E (Reimbursement Provisions) of the Dust Diseases Act 1942 for the NSW Dust Diseases Board (“DDB”) to recover certain costs from common law defendants, excluding the employer of the claimant.

This component of cost is implicitly included within our liability assessment as the claims awards made in recent periods and in recent settlements contain allowance for DDB reimbursement where applicable. Furthermore, currently reported open claims have allowance within their case estimates for the costs of DDB reimbursement where relevant and applicable.

The Amended Final Funding Agreement indicates that the AICF Trust is intended to meet Personal Asbestos Claims and that claims by the DDB or a Workers Compensation Scheme for reimbursement will only be met up to a certain specified limit, being:

- In the first financial year (2006/07) a limit of \$750,000 applied;
- In respect of each financial year thereafter, that limit will be indexed annually in line with the Consumer Price Index;
- There will be an overall unindexed aggregate cap of \$30m.

The cashflow and liability figures contained within this report have already removed that component of reimbursements that will not be met by the AICF Trust owing to the application of these caps.

1.3.3 Baryulgil (“Marlew Claims”)

In light of the agreement by the Board of JHINV to incorporate claims arising from mining activities at Baryulgil (called “Marlew Claims” in the Amended Final Funding Agreement) into the AICF Trust, where they are not otherwise recoverable from other sources, we have made separate allowance for the potential liabilities arising from exposure at Baryulgil, specifically:

- Claims made against Amaca Pty Ltd or ABN60 resulting from their past ownership of the mine, or in the case of Amaca also in relation to their joint venture with Wunderlich, are to be covered by the AICF Trust.
- Claims made against the subsequent owner of the mine (following its sale by James Hardie Industries to Woodsreef in 1976), being Marlew Mining Pty Ltd (“Marlew”) which is in liquidation, are to be met by the AICF Trust except where such claims are Excluded Marlew Claims, which are recoverable by the Claimant from other sources.

These claims are discussed further in Section 5.10.

1.3.4 Risk Margins

Australian-licensed insurance companies are required to, and non-insurance companies may elect to, hold claims provisions at a level above the central estimate basis to reflect the uncertainty attaching to the liability assessment and to include an allowance in respect of that uncertainty.

A risk margin is an additional amount held, above the central estimate, which is held so as to increase the likelihood of adequacy of the provisions to meet the ultimate cost of settlement of those liabilities.

We note that the Amended Final Funding Agreement envisages the ongoing financing of the AICF Trust is to be based on a “central estimate” approach and that the Annual Actuarial Report should provide a Discounted Central Estimate valuation.

Accordingly, we have made no allowance for any risk margins within this Report.

1.3.5 Discounting

We have determined a Discounted Central Estimate in this report by discounting the projected future cashflows to 31 March 2008 using yields on Commonwealth Government Bonds.



Conceptually, the Discounted Central Estimate therefore represents an amount of money which, if fully provided in advance (i.e. as of 31 March 2008) and invested in risk-free assets (such as Commonwealth Government Bonds) of term and currency appropriate to the liabilities, would generate the necessary investment income such that (together with the capital value of those assets) would be expected to be sufficient to pay for the liabilities as they fall due.

To the extent that the actual investments are:

- of different terms; and/or
- in different currencies; and/or
- provide different expected rates of return

investment profits or losses would emerge.

In this regard, we also note that the actual funding mechanism under the Amended Final Funding Agreement only provides for three years' worth of projected Claims and Claims Legal Costs expenditure and one year's worth of Operating Expenses at any one time.

1.4 Areas of potential exposure not included

As identified in Section 1.3, there are other potential sources of claims exposure beyond those directly considered within this report. However, while many of them are possible they are by no means certain and in a number of cases they are unquantifiable even if they have the potential to generate claims. This is especially the case for those sources of future claim where there has been no evidence of claims to date.

Areas of potential changes in claims exposure we have not explicitly allowed for in our valuation include:

- Future significant individual landmark and precedent-setting judicial decisions;
- Significant medical advancements;
- Unimpaired claims, i.e. claims for fear, stress, pure nervous shock or psychological illness;
- A change in the basis of compensation for asymptomatic pleural plaques for which no associated physical impairment is exhibited;

- A proliferation of “third-wave” claims, i.e. claims arising as a result of indirect exposure such as home renovation, washing clothes of family members that worked with asbestos, or from workers involved in removal of asbestos or demolition of buildings containing asbestos;
- Changes in legislation, especially those relating to tort reform for asbestos sufferers;
- Introduction of new, or elimination of existing, heads of damage;
- Exemplary and aggravated or punitive damages (being damages awarded for personal injuries caused as a result of negligence or reckless conduct);
- Changes in the basis of apportionment of awards for asbestos-related diseases for claimants who have smoked;
- Any changes to GST or other taxes; and
- Future bankruptcies of other asbestos claim defendants (i.e. other liable manufacturers or distributors).

Nonetheless, some implicit allowance is made in respect of some of these items in the allowance for superimposed inflation included in our liability assessment and to the extent that some of these have emerged in past claims experience.

We have made no allowance for the risk of further development in relation to New Zealand exposures and the rights of claims from New Zealand claimants in Australian courts (as per *Frost vs. Amaca Pty Ltd*(2005), NSWDDT 36 although this decision was successfully appealed by Amaca in August 2006) nor for the risk of additional exposures from overseas. This is because, as noted in Section 1.3, the AICF Trust will not meet the cost of these claims as they are Excluded Claims.

We discuss these matters further in Section 2.

1.5 Data reliances and limitations

KPMG Actuaries has relied upon the accuracy and completeness of the data with which it has been provided. KPMG Actuaries has not verified the accuracy or completeness of the data, although we have undertaken steps to ensure its consistency with data previously received. However, KPMG Actuaries has placed reliance on the data previously received, and currently provided, as being accurate and complete in all material respects.



1.6 Uncertainty

It must be understood that estimates of asbestos-related disease liabilities are subject to considerable uncertainty.

This is due to the fact that the ultimate disposition of future claims will be subject to the outcome of events that have not yet occurred. Examples of these events, as noted in Section 1.4, include jury decisions, court interpretations, legislative changes, epidemiological developments, medical advancements, public attitudes, potential third-wave exposures and social and economic conditions such as inflation.

It should therefore be expected that the actual emergence of the liabilities will vary, perhaps materially, from any estimate. Thus, no assurance can be given that the actual liabilities of the Liable Entities to be met by the AICF Trust will not ultimately exceed the estimates contained herein and any such variation may be significant.

Nonetheless, we provide our liability estimate based on our current expectations of future such events.

1.7 Distribution and use

The purpose of this report is as stated in Sections 1.2 and 1.3. This report should not be used for any purpose other than those specified.

This report is to be provided to the Board and management of AICFL. This report will also be provided to the Board and management of JHINV, the NSW Government, and to PricewaterhouseCoopers in their capacity as auditors to both JHINV and AICFL.

We understand that this report will be filed with the ASX and placed on JHINV's website in its entirety.

KPMG Actuaries provide our consent for this report to be made available to the above-mentioned parties and for the report to be distributed in the manner described above.

To the extent permitted by law, KPMG Actuaries will not be responsible to third parties for the consequences of any actions they take based upon the opinions expressed within this report, including any use of or purported reliance upon this report not contemplated in Sections 1.2 and 1.3.



Where distribution of this report is permitted by KPMG Actuaries, the report may only be distributed in its entirety and judgements about the conclusions and comments drawn from this report should only be made after considering the report in its entirety and with necessary consultation with KPMG Actuaries.

1.8 Author of the report

This report is signed by Neil Donlevy, a Director of KPMG Actuaries, a Fellow of the Institute of Actuaries (London) and a Fellow of the Institute of Actuaries of Australia.

This report is co-signed by Richard Wilkinson, a Director of KPMG Actuaries, a Fellow of the Institute of Actuaries (London) and a Fellow of the Institute of Actuaries of Australia.

1.9 Professional standards and compliance

This report details a valuation of the outstanding claims liabilities of entities which hold liabilities with features similar to general insurance liabilities as self-insured entities, and which have purchased related insurance protection.

In preparing this report, we have complied with the revised version of Professional Standard 300 of the Institute of Actuaries of Australia ("PS300"), "Valuation of General Insurance Claims". The commencement date of PS300 was 1 January 2008.

However, as we note in Section 1.3, this report does not include an allowance for the future Operating Expenses of the AICF Trust and nor does it include any allowance for a risk margin to reflect the inherent uncertainty in the liability assessment.

2 AREAS OF POTENTIAL EXPOSURE

2.1 Overview

In Section 1.4, we identified some sources of potential exposure that may not explicitly, or implicitly, be factored into our valuation. The impact of the emergence of these might be to increase, or decrease, the future number of claims or the overall costs in relation to the liabilities of the Liable Entities.

2.2 Potential changes to the number of future claims

2.2.1 Overseas exposures

Whilst overseas exposures remain a source of potential exposure for the Liable Entities, they will not impact the liabilities of the Liable Entities to be met by the AICF Trust as the AICF Trust will not meet claims relating to:

- Exposure to asbestos to the extent it took place overseas; and/or
- Claims made overseas relating to asbestos exposure (regardless of the place of exposure).

We note, in any event, that there have been few claims reported to date and that it is currently envisaged that the number of claims from overseas exposures should remain low given the significantly lower levels of asbestos products produced by the Liable Entities which were exported overseas.

In 2007/08, there have been no new US or NZ claims reported against the Liable Entities.

2.2.2 Third-wave claims

We have made some implicit allowance for so-called “third-wave” claims. These are claims for personal injury and / or death arising from asbestos exposure during home renovations by individuals or to builders involved in such renovations. Such claims are allowed for within the projections to the extent to which they have arisen to date and to the extent our exposure model factors in such tertiary exposures in its extrapolation.

Over the last five years, pure home renovator claims have made up approximately 14% of mesothelioma claims by number, with around 30 claims being reported annually. The reporting activity of home renovator claims has not shown any significant upward trend over the period.

We have not allowed for a surge in such claims in the future arising from renovations, but conversely we have not allowed for a tempering of those third-wave claims already included within our projection as a result of improved education of individuals of the risks of such home renovations, or of any local Councils or State Governments passing laws in this regard.

It should be noted that claims for the cost of asbestos or asbestos product removal from homes and properties or any claims for economic loss arising from asbestos or asbestos products being within such homes and properties will not be met by the AICF Trust.

2.2.3 *Unimpaired claims*

Unimpaired claims are claims made by plaintiffs where the plaintiff does not exhibit any physical symptoms of injury or damage. This would include claims for fear and stress.

In the case of *Thompson vs. CSR* (NSWDDT 7/2003), the estate of Mr Thompson made a retrospective claim for fear of contracting mesothelioma 14 years before onset. In this case, Judge O'Meally ruled that the fear was not compensable. The NSW Court of Appeal ((2003) 59 NSWLR 77) upheld that fear was not compensable.

This case was appealed by the estate of Mr Thompson to the High Court of Australia (where it became *CSR vs. Eddy*) but the issue of whether fear was compensable was not the subject of that appeal.

We have not allowed for the admissibility of "unimpaired claims" within the Australian Court system.

2.2.4 *Pure nervous shock claims*

"Pure" nervous shock claims are claims which are unrelated to an underlying disease. Where there is a psychiatric illness, general damages may be payable and economic loss may also be payable where the inability to work is a result of the psychiatric illness.

In Western Australia in October 2004, an appeal case concerning Arturo Della Maddalena, a past employee of CSR at Wittenoom mine was heard. Mr Della Maddalena worked at Wittenoom, owned by CSR, from 1961 until it closed in 1966. During this period he was exposed to blue asbestos dust.

An investigation of 42 of Mr Della Maddalena's former workmates found 39 of them had died from asbestos-related diseases.

In the first Court hearing, the primary judge's determination was that he did not accept there to be evidence of psychiatric illness, or evidence that it arose from asbestos exposure.

However, on appeal the second judge rejected the primary judge's decision as to the acceptability of the evidence placed before him. The Court of Appeal accepted Mr Maddalena's claim for psychiatric illness.

The defendants to the claim appealed the case to the High Court of Australia on two narrow points of law:

- Whether an appellate court is entitled to substitute its own findings as to the credibility of a witness for that of the trial judge; and
- Whether the appellate court had breached procedural fairness in expressing a preference for evidence of a particular expert witness described as being "well known to the Court".

On 2 February 2006, the High Court of Australia ordered that a new trial be held. We understand the case was settled out of court in October 2006, although the terms of the settlement were confidential.

To the extent that other such cases arise in the future, in many cases they would likely represent a bringing forward of some future eventual claims, rather than outright additional claims.

We have assumed that stress or fear from potential exposure, which is not accompanied by a disease, will not result in a material additional net cost of claims for compensation.

2.2.5 Pleural plaques

Pleural plaques are formations of scarred tissue which form on the inside of the chest wall. They are usually benign and take about 20 years to emerge following exposure to asbestos but symptoms are rarely associated with pleural plaques. Current medical opinion is that pleural plaques do not shorten life and that their existence does not increase the possibility of developing an asbestos-related disease but rather acts as an indicator that exposure to asbestos has taken place.

If an individual presents benign pleural plaques without any demonstrable physical impairment, the individual would not currently be compensated within Australia for the existence of pleural plaques (see for example *Torrens vs. James Hardie* [1990] NSWDDT 6).

Pleural plaques which are associated with a certain level of physical impairment, such as reduced “total lung capacity” or “forced vital capacity”, diffuse pleural thickening or where the plaques cause pain could be compensated within Australia (see for example *Abraham vs. Wallaby Grip & Ors* [2006] NSWDDT 22).

Our liability assessment makes no allowance for benign pleural plaque claims without any associated physical impairment.

In relation to pleural plaques with associated physical injury, such claims have arisen in the past and are included within our disease category “ARPD & Other”. Accordingly, we have allowed for these within our liability assessment based on past experience of such claims activity.

2.3 Potential changes to claims costs

2.3.1 Legal environment

We have not explicitly allowed for the emergence of new heads of damage or the significant extension of current heads of damage, or for any overturn or restriction of current heads of damage.

However, allowance for these is, in part, implicit within the rate of superimposed inflation we have assumed.

2.3.2 Exemplary and aggravated or punitive damages

The Dust Diseases Act 2005 (SA) Bill, directs the Courts to consider exemplary damage awards.

We have therefore made some allowance for the potential for exemplary damages awards in South Australia through our assumed average award size. This has been based on anecdotal evidence and views as to the potential size of exemplary awards were such awards to be made.

However, we have made no allowance for exemplary damages awards in other States. To the extent that such awards are possible and could arise in the future such awards would increase the liability assessment.

2.3.3 Smoking-related diseases

There are two prevailing views of the interaction of smoking and asbestos exposure:

- That the emergence of asbestosis is a necessary precursor to lung cancer caused by asbestos exposure (“the necessary precursor hypothesis” as put forward by Hans Weill amongst others).

- That providing there has been exposure to asbestos sufficient to cause asbestosis it is reasonable to attribute a causal contribution to the asbestos exposure (“the fibre burden hypothesis”).

It is generally accepted that the risk of developing cancer after asbestos exposure is increased in the case of a smoker (see papers by Sir Richard Doll in 1985 amongst others).

We have continued to assume that the precedents set in *Judd vs. Amaca* (2002) (NSWDDT 25) and *McDonald vs. State Rail Authority* (1998) (16 NSWCCR 695) will continue and also that the thresholds required to attribute lung cancer to asbestos exposure will be maintained. In these circumstances we have assumed continuation of the current level of awards for asbestos-related lung cancer claims.

2.3.4 Future bankruptcies

As bankruptcies and insolvencies amongst defendants occur, there is a concentration of the costs of claims amongst a decreasing pool of defendants. This would be expected to lead to an increase in the proportion of claims borne by each of the remaining solvent defendants.

Allowance might be made for such bankruptcies by way of using general credit risk methods, or by reduction in the discount rate, but such allowance would require a full model of the liabilities of Australia by entity, including the interactions between entities. This is not adequately determinable at present.

Consequently, within our central estimate assessment, we have not allowed for the future failure of any of the substantial asbestos defendants, insurers or governments who bear a share of the asbestos-related liabilities of Australia.

2.4 Medical developments

Medical developments have the potential to affect claim costs, although it is uncertain as to whether such developments would likely increase or decrease claims costs.

For example, there may be drugs developed which increase costs and extend life without curing mesothelioma: this might increase overall claim amounts. On the other hand, a total cure for mesothelioma would be more likely to reduce overall claim amounts.

At this stage there is no evidence of the success of any treatments to cure mesothelioma and we have therefore made no allowance for the potential impact of such diagnostic or medical developments within the current valuation.

3 DATA

3.1 Data provided to KPMG Actuaries

We have been provided with the following information:

- Claims database at 31 March 2008 with individual claims listings;
- Accounting database at 31 March 2008 (which includes individual claims payment details);
- Monthly Management Information Reports to 31 March 2008;
- Home Renovator Reports at various dates;
- Past exposure history of the Liable Entities and their association with asbestos (this has been covered in our previous valuation reports and we have not repeated it in this report); and
- Detailed insurance bordereaux information (being a listing of claims filed with the insurers of the Liable Entities) produced by Capita Insurance Services (London) as at 31 March 2008.

We have allowed for the benefits of the product and public liability insurance policies of the Liable Entities based on information provided to us by AICFL relating to the insurance programme's structure, coverage and layers.

We have also considered the claims data listings which formed the basis of our previous valuation assessments.

3.2 Data limitations

We have tested the consistency of the various data sets provided to us at different valuation dates, as noted in Section 3.3 which outlines the nature of the testing and verification process undertaken. However, we have not otherwise verified the data and have instead relied on the data provided as being complete and accurate in all material respects. We have relied upon the robustness of AICFL's operational processes and systems as to the completeness of the data provided.

Consequently, should there be material errors or incompleteness in the data, our assessment could also be affected materially.

3.3 Data verification

We have undertaken a number of tests and reconciliations to verify the accuracy of the data to the extent possible, noting the limitations outlined above.

3.3.1 Reconciliation with previous valuation's data

We have performed a reconciliation of the claims database as at 31 March 2008 with that provided at 31 March 2007.

We have reviewed the consistency of a number of key fields, on a claim-by-claim basis, including:

- Claim notification date;
- Claim settlement date;
- Disease type; and
- Settlement amounts (award and legal costs separately).

We note that there are some movements in the historic data between valuations. The following summarise the results of that reconciliation process:

- 24 claims have changed their date of reporting with a number of these being changes by an inconsequential amount. We also observe that all but one of these claims were reported more than 10 years ago so that there is no significant impact to recent claims experience which is a key determinant in setting our valuation assumption for future claims reporting;
- 7 claims have changed their disease type: 4 to lung cancer, 2 to asbestosis and 1 to ARPD & Other; and
- 6 claims have changed their settlement date.

We understand that a change in disease type is often due to the data being updated over time, often as more information comes to light as to the nature of the disease, or through the correcting of any previous data errors which have emerged.

Changes in the date of settlement can often arise because the previous settlement date recorded relates to the settlement with some, but not all, parties to the claim and that this information is updated when all parties have settled.

We also note that there have continued to be additional claims emerging relating to prior years of notification. This is typically due to either additional cross-claims being brought or because of claims “splitting” into two or more claims (e.g. a “Compensation to Relatives” claim and an “Estate” claim). As such, changing and developing data is not unexpected or to be considered as adverse. Indeed, changing data is common to all claims administration systems.

3.3.2 Reconciliation between claims and accounting databases

We have compared the claims awards, the legal costs and the recoveries amounts between the claims database and the accounting database from the earliest date to the current file position. Table 3.1 shows the results of this reconciliation for all claims to date.

Table 3.1: Comparison of amounts from claims and accounting databases

	Claims database \$m	Accounting database \$ m	Difference \$ m	Difference %
Gross settlement amounts	510.3	509.2	1.1	0.2%
Cross claim recoveries	(16.0)	(15.7)	(0.3)	1.9%
Net settlement amounts	494.3	493.5	0.8	0.2%

Overall, the data appears to reconcile reasonably well in aggregate, with the gross claim settlement amounts from the two data sources differing by only 0.2%.

Our approach for each claim record has been to take the maximum value of the two databases for each claim record.

This approach is likely to result in some minor prudence in our overall analysis although the amount of prudence is not material in the context of the size of the potential liabilities and the underlying uncertainty in any valuation estimating future claims costs over the next 40 years or more.

3.4 Data conclusion

We have noted above that we have not verified the underlying data nor undertaken “auditing at source”.



We have assumed that any material data issues emerging from the Statutory Audit will have been identified by the auditors during their testing and would have been notified to us.

However, we have tested the data for internal consistency with the data provided at previous valuations.

Based on that testing and reconciliation, and subject to the limitations described in Section 1.5, we have formed the view that notwithstanding those limitations:

- The data is generally consistent between valuations, with any differences in the data being readily explained;
- The data appears to reconcile reasonably between the two data sources (the claims database and the accounting database);
- Any data issues that have emerged are not material in relation to the size of the liabilities; and
- The data is therefore appropriate for use.

4 VALUATION METHODOLOGY AND APPROACH

4.1 Previous valuation work and methodology changes

We have maintained the core valuation methodology adopted at our previous valuation.

4.2 Overview of current methodology

The methodology involves assessing the liabilities in two separate components, being:

- Allowance for the cost of settling claims which have already been reported but have not yet been settled (“pending claims”); and
- Allowance for the cost of settling claims which have not yet been reported but are expected to arise out of past exposure (“Incurred But Not Reported” or “IBNR” claims).

For pending claims, we have used the case estimates (where available) with some adjustments to reflect the extent to which they tend to overstate the ultimate cost, whilst for IBNR claims we have used what can best be described as an “average cost per claim method”.

In brief, the overall methodology may be summarised as follows:

- Project the future number of claims expected to be reported in each future year by disease type (for product and public liability) and for Workers Compensation and Wharf claims taking into account the past rate of co-joining of the Liable Entities and the expected future incidence of mesothelioma and other diseases;
- Analyse past average attritional claim costs of non-nil claims in current money terms. We have defined attritional claims to be claims which are less than \$1m in **2005/06** money terms. We estimate a baseline attritional non-nil average claim cost in 2007/08 (current) money terms. This represents the Liable Entities’ share of a claim rather than the total claim settlement. For Workers Compensation claims, the average cost represents only that part of a claim which is borne by the Liable Entities (i.e. it is net of any insurance proceeds from a Workers Compensation Scheme or Policy);
- Analyse past historic average plaintiff and defendant legal costs for non-nil claim settlements;

- Analyse past historic average defendant legal costs for nil claim settlements (which includes costs incurred in defending and repudiating liability);
- Estimate a “large claims loading” for mesothelioma claims by estimating the frequency, or incidence rate, and average claim and legal cost sizes of such claims (being claims which are in excess of \$1m in 2005/06 money terms);
- Project the pattern and incidence of future claims settlements from the claims reporting profile projected. This is done by using a settlement pattern derived from consideration of past experience of the pattern of delay between claim reporting and claim settlement for each disease type;
- Estimate the proportion of claims which will be settled with no liability against the Liable Entities by reference to past proportions of claims settled for nil claim cost (we refer to this as the “nil settlement rate”);
- Inflate average claim, plaintiff and defence legal costs and large claim costs to the date of settlement of claims allowing for base inflation and superimposed inflation;
- Multiply the claims numbers which are expected to be settled for non-nil amounts in a period by the inflated average non-nil claim costs (including the “large claims loading”) and plaintiff and defence legal costs for that period;
- Make allowance in defence legal costs for that proportion of settled claims which are expected to be settled for no liability but for which defence costs will be incurred in disputing liability or contribution;
- Inflate average defence legal costs of nil claims to the date of settlement of claims allowing for base inflation and superimposed inflation;
- Multiply the claims numbers which are expected to be settled for nil amounts in a period by the inflated average defence legal costs for nil claims for that period;
- Add the expected claims and legal payments on pending claims (after allowance for the potential savings on case estimates);
- This gives the projected future gross cashflow for each future financial year;

- Adjust projected cashflow for the impact of the cap on DDB reimbursements;
- Estimate the recoveries resulting from cross-claims made by the Liable Entities against other parties (“cross-claim recoveries”);
- Project Insurance Recoveries to establish the net cashflows;
- Discount the cashflows using a yield curve derived from yields on Commonwealth government fixed interest bonds to arrive at our present value liability assessment.

It should be noted that this description is an outline and is not intended to be exhaustive in consideration of all the stages we consider or investigations we undertake. Those other stages are outlined in more detail elsewhere in this report and readers are advised to refer to those sections for a more detailed understanding of the process undertaken.

As discussed elsewhere, the liabilities are established on a central estimate basis.

In our analyses, the “year” we refer to aligns with the financial year of JHINV and runs from 1 April to 31 March, so that a 2005 reported claim would be a claim notified in the period 1 April 2005 to 31 March 2006. Similarly a 2006 settlement would be a claim settled in the period 1 April 2006 to 31 March 2007.

4.3 Disease type and class subdivision

4.3.1 Claims excluded

We have excluded cross-claims brought by the Liable Entities against other defendants. Where the cross-claim is brought as part of the main proceedings the claim is automatically counted in our analysis of the number of claims. However, where the cross-claim by the Liable Entities is severed from the main proceedings, the existence of a separate record on the claims file does not indicate an additional claim (or liability against the Liable Entities). In these circumstances such claims records are not counted in our analysis.

4.3.2 Categories of claim

We have sub-divided the remaining claims into the following groups:

- Product and Public Liability;
- Workers Compensation, being claims by current and former employees of the Liable Entities; and
- Wharf claims.

We have separated the Workers Compensation claims from product and public liability claims because claim payments from Workers Compensation claims do not generate recoveries under the product and public liability insurance cover, so that in order to value those contracts we need to separately identify the cashflows from product and public liability claims and the cashflows from Workers Compensation claims.

We have separated out wharfside workers claims because of their significantly different claim sizes relative to other classes.

4.3.3 Categories of disease

For product and public liability claims, we have separately analysed the individual disease types.

We have split the data by disease because it displays substantially different average claim sizes and because the incidence pattern of future notifications is also expected to vary considerably between the different disease types. As product and public liability claims are financially significant to the overall total of the liabilities and there is significant available data, the sub-division by disease type is appropriate.

We have not divided the Workers Compensation or Wharf claims data by disease type given their relatively low financial significance and the low credibility of the data if sub-divided by disease type.

For the purposes of our analysis, we have allocated each claim once and therefore to one disease. We have selected the following order of priority, based on the relative severity of the disease:

- Mesothelioma;
- Lung cancer / Other cancer;
- Asbestosis; and then
- Asbestos-Related Pleural Disease and Other (“ARPD & Other”).



This means that if a claim has mesothelioma as one of its listed diseases, it is automatically included as a mesothelioma claim. If a claim has lung or other cancer as one of its listed diseases (but not mesothelioma), it is included as a lung cancer claim. If a claim has asbestosis as one of its listed diseases, it is only coded as asbestosis if it has no reference to mesothelioma, lung cancer or other cancer as one of its diseases.

4.4 Numbers of future claims notifications

We begin by first estimating the incidence of future notifications of claims.

We have based this on the use of what we have termed an “exposure model”, which we have constructed in relation to Australian usage of asbestos.

We do not have detailed individual exposure information for the Liable Entities, its products or where the products were used and how many people were exposed to those products. However, given the market share of James Hardie over the years (through to 1987) and its relative stability, we have used a national pattern of usage as a reasonable proxy for the Liable Entities.

We start by constructing an index from the annual consumption of asbestos within Australia from 1900-2002². We split this between the various asbestos types and by year of consumption.

We have not allowed for multiple exposures with respect to the Liable Entities from each unit of asbestos consumed, e.g. where the Liable Entities were both mining and milling the same asbestos. While there was some (moderate) mining at Baryulgil, in relative terms it is not significant. Nonetheless, we have made separate allowance for mining activities at Baryulgil within our liability assessment.

With the exposure index that we have derived, we then allow for the latency period from the average date of exposure to claims notification.

Our model is that claims will:

- emerge proportional to past asbestos exposure measured by asbestos consumption (in metric tonnage); and
- have a latency pattern that is statistically normally distributed.

² World Mineral Statistics Dataset, British Geological Survey, www.mineralsuk.com

US Geological Survey — Worldwide Asbestos Supply and Consumption Trends 1900 to 2000; Robert L. Virta (2003)

Our current assumptions are that:

- The historic asbestos consumption shown in Figure 5.9 gives our assumed past asbestos exposure.
- The latency pattern (from average date of exposure) for mesothelioma has a mean of 35 years and a standard deviation of 10 years. This appears to be generally supported by analyses and comments by Professor Berry et al³, by Jim Leigh et al⁴ and by Yeung et al⁵. Latency pattern assumptions for mesothelioma and other diseases have also been set with consideration of the Liable Entities' own experience to date.

Our methodology is to take each year of exposure, weighted by "average consumption" of asbestos in tonnage for that year, and project an index of the number of claims emerging in each future reporting year resulting from that exposure year using the latency distribution. We then aggregate the index of claims projected across all exposure years to derive an overall index of the number of future claims by report year.

This methodology provides not only the shape of claims reporting as an index but it also derives the peak year of incidence of mesothelioma claims reported to the Liable Entities to be 2010/2011.

For the other claim types, we allow for those diseases having different average latency periods to that of mesothelioma. This results in different projected peak years for the different diseases.

From this claims index we then project the future number of claims by calibrating the index derived to the current level of claims emerging.

Our analysis and assumptions are detailed in Section 5.

4.5 Incidence of claim settlements from future claim notifications

We derive a settlement pattern by considering triangulations of the numbers of settlements by delay from the year of notification.

³ Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia; G Berry, N H de Klerk, et al (2004)

⁴ Malignant Mesothelioma in Australia: 1945-2000; J. Leigh et al (2002)

⁵ Distribution of Mesothelioma Cases in Different Occupational Groups and Industries, 1979-1995; P. Yeung, A. Rogers, A. Johnson (1999)

From these settlement pattern analyses, we have estimated the pace at which claims notified in the future will settle, and used this to project the future number of settlements in each financial year for each disease type.

Our analysis and assumptions selected are detailed in Section 8.7.

4.6 Average claim costs of IBNR claims

4.6.1 Attritional claims

We need to separately consider average settlement costs in respect of future claims and average legal costs of the defendants.

We have estimated the following five components to the average cost assessment:

- Average award (sometimes including plaintiff legal costs) of a non-nil “attritional” claim.
- Average plaintiff legal costs of a non-nil “attritional” claim.
- Average defendant legal costs of a non-nil “attritional” claim.
- Average defendant legal costs of a nil claim.
- Large claim awards and legal cost allowances.

All of our analyses have been constructed using past average awards, which have been inflated to current money terms (i.e. mid 2007/08 money terms) using a base inflation index. This compensates for basic inflation effects when identifying trends in historic average settlements. We then determine a prospective average cost in current money terms.

We perform the same exercise for the defence and plaintiff’s legal costs in respect of non-nil claims, and for defence costs for nil claims (together “Claims Legal Costs”).

Our analysis and assumptions are detailed in Section 6.

4.6.2 Large claims loading

We define a large claim as those for which the award is greater than or equal to \$1m in 2005/06 money terms (this equates to approximately \$1.087m in 2007/08 money terms). We define an attritional claim as a non-nil, non-large claim. We define a nil claim as one for which the award payable by the relevant Liable Entity is zero.



We analyse the historic incidence rate of large claims (being measured as the ratio of the number of large claims to the total number of non-nil claims), and the average claim and legal costs of these claims. We have determined a prospective incidence rate and average cost in current money terms to arrive at a “per claim” loading (being the average cost multiplied by the incidence rate per claim) being the additional amount we need to add to our attritional average claim size to allow for large claims.

Our analysis and assumptions are detailed in Section 6.8.

4.6.3 Future inflation of claim sizes

Allowance for future claim cost inflation is made. This is modelled as a combination of base inflation plus superimposed inflation. This enables us to project future average settlement costs in each future year, which can then be applied to the IBNR claims as they settle in each future year.

Our analysis and assumptions in relation to claims inflation are detailed in Section 8.

4.7 Proportion of claims settled for nil amounts

We apply a “nil settlement rate” to the overall number of settlements to estimate the number of claims which will be settled for nil claim cost (i.e. other than in relation to legal costs) and those which will be settled for a non-nil claim cost.

The prospective nil settlement rate is estimated by reference to past trends in the rate of nil settlements.

Our analysis and assumptions selected are detailed in Section 7.

4.8 Pending claims

4.8.1 Definition of pending claims

At 31 March 2008, there were 564 claims for which claim awards have not yet been fully settled by the Liable Entities. Additionally, there are a number of other claims for which defence legal costs have not yet been settled, even though the awards have been settled.

We have adopted 3 definitions of settlement status:

- Where there is a closure date, there are not expected to be any further award or legal costs incurred.

- When there is no closure date but the claim has a settlement date, there is a possibility of further emerging defendant legal costs, even though the claim award has been settled.
- When there is no settlement date, there is a possibility of award, plaintiff legal costs and defendant legal costs still being incurred.

4.8.2 *Evaluating the liability for pending claims*

The excess amount of the liability for pending claims, over the case estimates held, is what the insurance industry term Incurred But Not Enough Reported (“IBNER”).

Depending on the case estimation procedure of the company and the nature of the liabilities, IBNER can be either positive or negative, with a negative IBNER implying that the ultimate cost of settling claims will be less than case estimates, i.e. that there is some degree of redundancy in case estimates.

In assessing the degree of redundancy in case estimates, we have undertaken a projection of the future settlement cost of pending claims and compared this to the case estimates for such claims. Our projection is based on a blending of the following actuarial techniques:

- Projection of future claim payments by year of notification using triangulation techniques as described in section 4.5 and compare with the case estimates for those claims; and
- Projection of future average cost per claim for reported, but not finalised claims. The average cost is assessed by reference to the delay from when the claim was reported to when the claim settles (this method is known as the PPCF method).

Mesothelioma claims were projected separately from other disease types due to differing reporting and settlement patterns as well as differing average claim awards.

Workers Compensation claims were excluded from the analysis owing to limited data volumes and due to the impact of Workers Compensation insurance upon the data.


4.8.3 *Findings*

Our analysis has indicated that there is a degree of redundancy in case estimates.

The comparison of current case estimates with actuarially-projected future settlement costs for claims reported to date suggests that potential savings from case estimates in relation to the award component could be of the order of 25%.

Amaca's own analysis, as shown in the following chart, suggests that historically there have also been savings. The chart shows the savings averaged over a 3-month, a 12-month and 1-month period.

Figure 4.1: Actual savings achieved on case estimates at settlement



Source: AICF Monthly Management Reports to 31 March 2008

The chart seems to be supportive of our inference that there is some degree of prudence in the existing case estimates.

The level of savings that have eventuated from case estimates have been as high as 35% (averaged over a 12 month period), experienced during 2004, although this was generally stable at around 27% during 2006 and has shown an increase towards 35% during 2007. This recent trend has in part been due to the high levels of savings achieved in December 2006, February 2007 and May 2007 when there were significant numbers of claims settled.

It is also of note that the 12-month average saving has not fallen below 25% since November 2002, and has not been below 20% since the beginning of 2001.



Taking these two different results, and the above observations, into account, we have increased our assumption for the level of redundancy in case estimates on currently reported claims to 25% at this valuation (March 2007: 20%). The impact of this change is less than \$5m in undiscounted money terms.

It should also be noted that making allowance for savings from case estimates is expected to have the most impact on the near term cash flows and a lesser impact on the longer-term cashflows, with 90% of the cost of pending claims expected to be settled within the next six years.

4.9 Insurance Recoveries

Insurance Recoveries are defined as proceeds which are estimated to be recoverable under the product and public liability insurance policies of the Liable Entities, and therefore exclude any such proceeds from a Workers Compensation Scheme or Policy in which the Liable Entities participate or which the Liable Entities hold.

In applying the insurance programme we consider only the projected gross cashflows relating to product and public liability.

We split out product liability cashflows from public liability cashflows as they are covered by different sections of the insurance policy under different bases:

- Product liability claims are covered by an aggregate policy which provides cover for all claims up to an overall aggregate limit; and
- Public liability claims are covered by an “each and every loss” policy which provides cover for each claim up to an individual limit for each claim.

Historical analysis of the claims data suggests that 95% of all liability claims, by number, have been product liability claims.

We make no allowance for the Workers Compensation cashflows in estimating the Insurance Recoveries, as the insurance programme only provides insurance cover to product and public liability exposures.

The insurance cover, for any policy year, consists of a number of consecutive layers of cover. By way of illustration, an insurance programme might be structured as follows:

- Primary \$2m — covering the first \$2m of claims costs; and



- \$3m xs \$2m — covering the next \$3m of claims costs, once the \$2m cover is fully utilised. If the \$2m layer below this cover is not fully utilised then this cover would not be utilised.

4.9.1 Allocation of cashflows

We allocate the gross projected cashflow for Claims and Claims Legal Costs separately to product liability and public liability, assuming that 95% of future cashflows in each year will relate to product liability and 5% of future cashflows in each year will relate to public liability.

We then allocate these costs to each individual exposure year. This is based on a projection of how the pattern of exposure has changed in past years and is estimated to change in future years. In this regard, your attention is drawn to Section 5.8 which shows a recent history of how the allocation to different exposure years and periods has changed with time.

We separate the cashflow into claims costs, plaintiff legal costs and defence legal costs. This is because we understand that defence legal costs do not contribute to the erosion of the insurance cover but that such legal costs are recoverable in addition to recoveries from claims settlements.

For the purposes of the valuation, we have assumed that plaintiff legal costs contribute to the erosion of the insurance cover. Our decision is an actuarial one and is not based on legal opinion, although we note that it appears that plaintiff legal costs may (in common with defence legal costs) not contribute to the erosion of the insurance cover. If this latter view is the case, the value of the insurance assets may increase relative to that which we have assumed within this valuation report.

From this, we then model the future Insurance Recoveries by exposure (policy) year.

We map the Insurance Recoveries to each layer of the historic insurance programme and thereby to each insurer and reinsurer to determine an estimate of the recoveries (both in timing and amount) due from each insurer and reinsurer.

As noted in Section 9, no allowance has been made for any potential Insurance Recoveries in relation to the period from 1986/87 to 1996/97, when insurance was placed on a claims-made basis.



4.9.2 Product liability recoveries

In relation to product liability, given the nature of the cover being on an “in the aggregate” basis, it is likely that the majority of the cover (both the primary and umbrella) covers will be utilised given that we are projecting in excess of \$3.5bn of future gross claim and legal costs in actual money terms.

We anticipate that all insurance covers, other than the highest layer of insurance cover for some of the policy years, will be fully utilised.

4.9.3 Public liability recoveries

In relation to public liability, given that the cover is “each and every loss”, it is not likely that layers above the primary layer (\$1m) will be substantially impacted. It is possible that the non-primary layers could be triggered, although we recognise that this would require:

- a large public liability claim in excess of A\$1m; and
- that the period of exposure be of sufficient brevity or sufficiently concentrated that the allocated cost of the claim to any one year would be in excess of A\$1m.

Whilst it is possible that such claims may arise in the future, to date there has been no such evidence of a claim above \$1m in any one exposure year. Indeed, the largest allocation to any one exposure year has been approximately \$920,000 in relation to a claim with a total cost of \$1,068,000 which was spread over two exposure years.

This is not unsurprising as the average exposure period for mesothelioma claims has historically been approximately 16 years.

Accordingly, at this time we have made no allowance for any layer above the primary layer to generate public liability recoveries.

To the extent that individual public liability claims reported in future years give rise to exposures of more than \$1m to any one exposure year, the value of the Insurance Recoveries would increase.

4.9.4 Bad debt allowance

We have made an allowance for general credit risk based on the credit rating of insurers of the Liable Entities using Standard & Poor’s default rates.



We assume that insurance recoveries from syndicates of Lloyd's of London, which are reinsured by Equitas⁶ (amounting to 45% of the coverage in the claims occurring period), will have 100% recoverability and that no credit risk charge is made against those recoveries. For the remaining companies, we have allowed for credit risk costs on the Insurance Recoveries.

We have estimated this credit risk cost by using the current Standard & Poor's credit ratings of the insurers of the Liable and the Standard & Poor's default rates by credit rating and duration, as shown in Appendix A, to estimate the cost of credit risk for each of the insurers and reinsurers.

Where additional information regarding the expected payout rates of solvent and insolvent Schemes of Arrangement is available we have instead taken the expected payout rates to assess the credit risk allowance to be made in our liability assessment.

4.10 Cross-claim recoveries

A cross-claim can be brought by, or against, one or more Liable Entities. Cross-claims brought against a Liable Entity ("Contribution Claims") are included in our analysis of claims and such claims are treated as if the Liable Entities were joined by the plaintiff in the main proceedings as a joint defendant to the claim, as opposed to being joined as a cross-defendant by another defendant.

Cross-claims brought by a Liable Entity relate to circumstances where the Liable Entity seeks to join (as a cross-defendant) another party to the claim in which the Liable Entity is already joined.

To the extent that the Liable Entities are successful in joining such other parties to a claim, the contribution to the settlement by the Liable Entities will reduce accordingly.

Our approach in the valuation has been to separately value the rate of recovery ("cross-claims recovery rate") as a percentage of the gross award based on historic experience of such recoveries.

Our analysis and assumptions selected are detailed in Section 8.6.

⁶ The announcement by Berkshire Hathaway on 20 October 2006 that it would take over management of Equitas and provide additional capital (by way of a \$7bn reinsurance contract from Berkshire Hathaway to Equitas) appears to reduce the risk of insolvency to Equitas considerably at this time. Berkshire Hathaway is AAA rated by Standard & Poor's. Indications are that Berkshire Hathaway will ultimately assume the liabilities of Equitas, subject to regulatory and Court approval.



4.11 Discounting cashflows

Cashflows are discounted on the basis of yields available on Commonwealth government bonds of varying coupon rates and durations to maturity (matched to the liability cashflows).

It should be recognised that the yield curves and therefore the discount rates applied can vary considerably between valuations and can, and do, contribute significant volatility to the present value of the liability at different assessment dates.

Our analysis and assumptions selected are detailed in Section 8.5.

5 ANALYSIS OF CLAIMS EXPERIENCE — CLAIM NUMBERS

5.1 Overview

We have begun by analysing the pattern of notifications of claims as shown in Table 5.1. This table shows the claim notifications by year.

Table 5.1: Number of claims reported annually

Report Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Wharf	Workers Compensation	All claims
1997/98	112	32	20	17	2	50	233
1998/99	93	25	12	13	3	30	176
1999/00	95	41	16	12	14	39	217
2000/01	126	46	30	21	26	38	287
2001/02	161	92	24	29	17	61	384
2002/03	180	92	36	41	15	51	415
2003/04	187	101	26	27	10	36	387
2004/05	264	120	32	28	6	62	512
2005/06	216	103	31	17	6	33	406
2006/07	215	164	33	28	5	43	488
2007/08	266	169	24	40	7	46	552
All Years (incl. pre-1997)	2,344	1,178	363	408	135	1,071	5,499


Note: Throughout this section the date convention used in tables and charts is that (for example) 2006/07 indicates the financial year running from 1 April 2006 to 31 March 2007. Furthermore, unless clearly identifying a calendar year the label "2006" in charts would indicate the financial year running from 1 April 2006 to 31 March 2007

It can be seen that in recent years, mesothelioma has accounted for more than 40% of claims, and that this percentage increased from 42% in 2001/02 to 53% in 2005/06.

In 2006/07, mesothelioma claims accounted for 44% of claims and in 2007/08 they accounted for 48%.

Asbestosis has shown a significant increase, from less than 20% in 2000/01 to above 30% in the past two years.

Figure 5.1: Proportion of claims by disease type



5.2 Mesothelioma claims

The incidence of mesothelioma claim notifications showed a step change upwards from 1999/00 through to 2001/02 and a steady rate of increase to the 2003/04 financial year, to 187 claims. There was a further upward step in claim numbers during 2004/05 with 264 claims reported in the year, with some of this increase due to a large number of “backlog clearance” claims from WorkCover Queensland and some of the increase arising from uncertainty and concerns as to the MRCF’s financial position.


There were 216 claims reported during 2005/06 and 215 claims reported in 2006/07.

In 2007/08 there have been 266 claims reported.

5.2.1 Monthly analysis of notifications

We have examined the number of mesothelioma claims reported on a monthly basis to better understand the nature of the trends.

Figure 5.2: Monthly notifications of mesothelioma claims




It is observed that:

- The high trend of claims reporting of 2004/05 has returned during 2007/08 after two years when reporting activity had been considerably lower.
- In 2007/08, there have been 3 months where there have been 25 or more claims reported in that month; and only 4 months where claims activity has been less than 20 claims per month.
- There were 37 claims reported in November 2007.
- There is typically a degree of late development which takes place in the following financial year (e.g. the number of claims reported in 2006/07 has increased by 13 since the end of that financial year, and since the figures quoted in our previous valuation report).

5.2.2 Rolling averages

We have also reviewed the number of mesothelioma claims reported on a monthly basis and reviewed the rolling 3-month, 6-month and 12-month averages in recent periods.

Figure 5.3: Rolling annualised averages of mesothelioma claim notifications



It can be seen that the current annualised rolling averages are between 240 (3-month average) and 274 (6-month average).


Generally, over the last two years, the 6-month and 12-month averages have remained within the range of 220 to 270 claims per annum.

The 3-month averages have, not surprisingly, shown more volatility, varying between 210 and 330 over the last twelve months.

5.2.3 Claims notifications by State

We have monitored the number of claim notifications by State in which the claim is filed. Figure 5.4 shows the number of claims notified by year by State.

Figure 5.4: Number of mesothelioma claims by location of claim filing



It is of note that for 2007/08:

- Experience in NSW is slightly higher (by 10 claims) than 2006/07, although lower than the levels of activity in 2004/05 and 2005/06.
- Claim activity in Victoria, Western Australia, South Australia and Queensland has increased significantly (by 41 claims in total).
- Claim activity in Queensland has shown a substantial increase. Our analysis suggests this has been due to a large number of cross-claims (23) being issued by WorkCover Queensland in relation to claims where the claim with the plaintiff has already been settled. Analysis also shows that these claims were reported in “bulk”. This therefore suggests some element of “backlog clearance” by WorkCover Queensland.

In part these trends in claims activity in the various States will also have been contributed to by the decisions of *BHP vs. Schultz*, which will lead to claims being more regularly heard in the State of exposure rather than NSW.

5.2.4 Increases in claims settling for nil amount

One of the possible explanations to the increase in claims reporting is that it reflects an increased rate of joining of the Liable Entities by plaintiff lawyers.

We have reviewed whether this increased joining has been associated with increased repudiation of claims (i.e. reflecting that some of the extra claims in which they have been joined were shown to not involve asbestos products of the Liable Entities).

Figure 5.5: Numbers of mesothelioma claims settlements by year of notification (nil and non-nil claims)

Notification Year	Number of claims reported	Number of claims settled, by delay (in years) from year of notification to year of settlement									Settled to date
		0	1	2	3	4	5	6	7		
2000	126	75	37	6	3	0	0	1	1	123	
2001	161	85	53	7	5	1	5	0		156	
2002	180	99	62	12	0	0	1			174	
2003	187	104	57	12	5	0				178	
2004	264	143	78	10	4					235	
2005	216	110	69	13						192	
2006	215	104	75							179	
2007	266	139								139	

Notification Year	Number of Claims reported	Number of claims settled for NIL, by delay (in years) from year of notification to year of settlement									Settled to date
		0	1	2	3	4	5	6	7		
2000	126	1	10	3	0	0	0	1	0	15	
2001	161	3	3	2	2	1	4	0		15	
2002	180	4	3	2	0	0	1			10	
2003	187	5	4	2	1	0				12	
2004	264	7	8	3	2					20	
2005	216	3	10	6						19	
2006	215	6	12							18	
2007	266	21								21	

The figure above shows that 104 out of 215 in 2006/07). This is to be expected, given the nature of the disease.

The figure also shows that of these 139 claim settlements, 21 have been settled for nil value (a nil settlement rate of 15%). This is substantially more than has typically been observed at the end of the first financial year after notification.

By comparison, in 2006/07 there had been 6 claims settled for nil by the end of the notification year from 104 settlements (a nil settlement rate of 6%) relating to 215 reported claims.

Comparing with 2004/05 which had similar claims reporting activity, by the end of the financial year 143 claims had settled and only 7 of these had settled for nil amount.

The number of nil settlements for 2007/08 (21) is therefore substantially higher than previously observed for other notification years at the same point in the claims settlement process.



We believe that this information suggests that some of the extra claims in which the Liable Entities have been joined have been shown not to involve the Liable Entities and that trend for the 2007/08 notification year will continue, albeit at a more moderate pace than so far observed.

Accordingly, whilst there has been an increase in claims notified to the Liable Entities, a significant part of the increase is not expected to generate any additional liability. That is, higher claims reporting will likely be associated with higher repudiation and lower average claim awards, such that cashflow is not affected to as great an extent as changes in claim reporting activity.

5.2.5 Base valuation assumption

In setting a base valuation assumption for 2008/09, we need to consider whether the observations in the most recent year were one-off fluctuations or were part of a new trend.

The sharp increase in claims reporting in 2007/08 has in part been a function of accelerated reporting (which has seen a further reduction in the average delay from diagnosis to reporting which has fallen from 8 months to 7 months), and “backlog clearance” from WorkCover Queensland.

At our previous valuation, we were faced with 2 years of considerably lower experience and we gave some credibility to that recent emerging experience. However, at this valuation, claims experience has returned to levels last seen in 2004/05.

In setting our valuation assumption for 2008/09 we have therefore given increased credibility to the emerging experience in the latest year together with the experience in the previous 3 years.

We have also recognised that in relation to the WorkCover Queensland claims reporting in 2007/08, 23 claims are essentially “backlog claims”.

This means that the underlying claims reporting in 2007/08 (net of backlog clearance by WorkCover Queensland) is 243 claims, although there may be some further upward development next year due to late development of claims (e.g. due to claims splitting or additional cross claims).

As observed previously, the experience in the third quarter of the most recent financial year can be attributed to a large number of claims from Victoria, above normal reporting levels. This was due to a large number of claims being received from the State Government (effectively the State Electricity Commission of Victoria).

Based on the above observations, we have assumed 252 claims for 2008/09, which equates to 21 claims per month. This effectively assumes there will be no further significant “backlog clearances” emerging from one of the WorkCover schemes or the State Governments next year.

5.3 Asbestosis claims


It can be seen in Table 5.1 that for asbestosis, the incidence of notifications has shown a step change upwards since 2000/01 and then a gradual increase to 2003/04.

There were 164 claims reported in 2006/07 and 169 claims reported in 2007/08, considerably higher than previous years.

5.3.1 Monthly analysis of notifications

We have examined claims on a monthly basis to better understand the nature of the trends.

Figure 5.6: Monthly notifications of asbestosis claims



It is observed that:

- The first and second quarters of 2007/08 showed a significant increase in claims reporting compared to 2006/07;
- The third quarter of 2007/08 showed a degree of slow-down and this has continued further during the fourth quarter; and

- There is typically a degree of late development which takes place in the following financial year (e.g. the number of claims reported in 2006/07 has increased by 9 since the end of that financial year, and since the figures quoted in our previous valuation report).

5.3.2 *Rolling averages*

As with mesothelioma, we have considered rolling 3-month, 6-month and 12-month averages in considering the projected level of claims activity in 2008/09.

Figure 5.7: Rolling annualised averages of asbestosis claim notifications



It can be seen that recent 3-month averages have varied between 140 and 208 claims per annum, with it currently running at 140 claims per annum.

The 6-month and 12-month averages are currently running at 156 and 169 claims per annum respectively.


The 3-month average has reduced from the high-points of early 2007/08 (when it was more than 200) and this reflects that accelerated claims reporting that took place in the early part of 2007/08.

5.3.3 *Claims notifications by State*

It has been observed that the number of claims being filed in Victoria (see below) showed a considerable increase in 2005/06 and has remained broadly stable since that time.

Claims activity in Queensland in 2006/07 and 2007/08 has been considerably greater than in previous years, whilst South Australia has also shown an increase in reporting activity (noting that it currently contributes around 12% of claims by number).

Figure 5.8: Number of asbestosis claims by location of claim filing



There was a step-change in the level of asbestosis claims activity from 2000/01 to 2001/02 in NSW with claims activity more than doubling in that year.

Activity in NSW fell considerably in 2005/06 although it appears that part of that reduction could be explained as being the impact of *BHP vs. Schultz*, such that claims were increasingly filed in Victoria, Queensland or South Australia as opposed to the previous practice of such claims being heard in the NSW Dust Diseases Tribunal.

However, whilst claims activity in NSW has shown a significant increase in 2006/07 and 2007/08 over 2005/06 it still remains considerably lower than observed in the period from 2001/02 to 2004/05.

Queensland has shown a significant increase in 2007/08. In contrast to mesothelioma, these claims have not generally resulted from cross-claiming activity by WorkCover Queensland and do not appear to reflect any “backlog clearance” by third parties.

5.3.4 Base valuation assumption

For 2006/07, there were 164 claims reported and for 2007/08 there were 169 claims reported.

It is not clear whether such a trend in increased emergence of claims will continue in the future but at this time we feel it appropriate to assume there will be some continuation of this higher level of reporting activity in the near term.

In setting our valuation assumption, we have also recognised that, unlike mesothelioma, the increased reporting activity from Queensland does not reflect any “backlog clearance”.

We have therefore estimated 168 claims to be reported in 2008/09.

5.4 Lung cancer claims

For lung cancer claims, claim notifications have been reasonably steady and do not appear to have shown the same pattern of notification as mesothelioma and asbestosis. There were 31 claims reported during 2005/06 and 33 reported in 2006/07.

There were 24 claims reported in 2007/08.

We have estimated 30 claims to be reported in 2008/09.

5.5 ARPD & Other claims

For ARPD & Other claims, the number of claims reported has been volatile, with 41 reported in 2002/03, 17 claims reported in 2005/06 and 28 claims reported in 2006/07.

There were 40 claims reported in 2007/08.

We have estimated 36 claims to be reported in 2008/09.

5.6 Workers Compensation and wharf claims

The number of Workers Compensation claims, including those met in full by the Liable Entities’ Workers Compensation insurers, has exhibited some degree of volatility ranging from 33 claims to 62 claims in the last six years.

In 2005/06, there were 33 claims reported and in 2006/07 there were 43 claims reported.

In 2007/08 there have been 46 claims reported.

We have estimated 48 claims to be reported in 2008/09.



It should be noted that the financial impact of this source of claim is not substantial given the proportion of claims which are settled for nil liability against the Liable Entities (typically around 90%), which results from the insurance arrangements in place.

For wharf claims, we have projected 6 claims to be notified in 2008/09. Again, the financial impact of this source of claim is not material.

5.7 Summary of base claims numbers assumptions

In forming a view on the numbers of claims projected to be reported in 2008/09, we have taken into account the emerging experience in the latest financial year (2007/08) and a revised view of the expected numbers of claims reported monthly based on recent trends.

We have also considered the extent to which the experience in the previous 3 financial years, and trends in those claims numbers, will continue.

As outlined in Sections 5.2 to 5.6, our assumptions as to the levels of claims numbers to assume are as follows:

Table 5.2: Base claim numbers assumptions

	Average 2005/06 and 2006/07	First half- year of 2007/08 (annualised)	Second half- year of 2007/08 (annualised)	2008/09 (projected)
Mesothelioma	215	258	274	252
Asbestosis	134	182	156	168
Lung Cancer	32	20	28	30
ARPD & Other	22	50	30	36
Wharf claims	6	8	6	6
Workers Compensation	38	42	50	48
Total	447	560	544	540

Note: Annualised figures do not make allowance for any seasonality of reporting or for late development adjustments. They are calculated by multiplying the half-year experience by a factor of 2.

It can be seen that the first half and second half of 2007/08 have been similar in terms of overall activity, although the mix of claims by disease type has shown a degree of variation.

Our projection for 2008/09 compares with a previous projection (as at 31 March 2007) for 493 claims in 2008/09.

The increase in the assumption predominantly reflects the higher reporting activity for both mesothelioma and asbestosis and credibility being attached to that experience, thereby resulting in a reconsideration of our previous views.

5.8 Exposure and latency information


To project the pattern of incidence of claims against the Liable Entities, we have constructed a model which utilises the following inputs:

- The exposure to asbestos in Australia, adjusted to allow for the Liable Entities particular incidence of usage, noting that for the period to 1987 they had approximately a uniform market share but thereafter were not involved in asbestos products;
- The average period over which claimants are typically exposed; and
- The distribution of the latency period from average exposure for each disease type.

5.8.1 Australian use of asbestos

Figure 5.9 shows measures of the production and consumption of asbestos in Australia in the period 1920 to 2002. It can be seen that the exposure, being measured in net consumption, appeared to peak in the early to mid 1970s. It can also be seen that for Australia as a whole, asbestos consumption continued at significant levels until the mid 1980s and then began to fall, but nonetheless continued through to 2002.

Figure 5.9: Consumption and production indices — Australia 1920-2002




Source: *World Mineral Statistics Dataset, British Geological Survey, www.mineralsuk.com R Virta, USGS Website Annual Yearbook*
 The data underlying this chart is shown in Appendix E.

The “averaged consumption” is derived as the consumption averaged over the prior 16-year period. The 16-year assumption for “averaging” the exposure is based on experience specific to the Liable Entities and reflects that, for the Liable Entities, claims have (on average) related to 16 years of exposure.

It is the averaged consumption which is used as a basis for projecting future mesothelioma claims numbers.

The following chart show the derivation and support for the assertion that claims have resulted from, on average, 16 years of exposure.


Figure 5.10: Mix of claims by duration of exposure (years)



It can be seen that the average duration of exposure has generally varied between 16 years and 19 years, with an average of 16.6 years over the last five years and 17.3 years over the last ten years.

The following chart shows the timeline of exposure, diagnosis and claims reporting.


Figure 5.11: Timeline of exposure and claim reporting



5.8.2 Exposure information from current claims

We have also reviewed the actual exposure information available in relation to claims notified to date. This has been conducted by using the exposure dates stored in the claims database at an individual claim level and identifying the number of person-years of exposure in each exposure year. We have reviewed the pattern of exposure for each of the disease types separately, although we note that they tend to follow similar patterns for each disease type.

**Figure 5.12: Exposure (person-years) of all
 Liable Entities' claimants to date**



The chart shows that the peak of exposure from claims reported to date has so far arisen in 1968. It should be recognised that there is a significant degree of bias in this analysis in that the claims notified to date will tend to have arisen from the earlier periods of exposure.

Over time, one would expect this curve to develop to the right hand side and the peak year of exposure to trend towards the early to mid 1970s, whilst also increasing in absolute levels at all periods of exposure as more claims are notified and the associated exposures from these are included in the analysis.


The relatively low level of exposure from 1987 onwards (about 3% of the total) is not unexpected given that all products ceased to be manufactured by 1987 but the exposure after that date likely results from usage of products already produced and sold before that date.

This chart is a cumulative chart of the position to date and does not show temporal trends in the allocation of claims to exposure years.

For example, one would expect that more recently reported claims should be associated with, on average, later exposures; and that claims reported in future years would continue that trend to later exposure periods. If this did not occur, it would suggest mean latency periods would increase substantially over time and that the claimant's age at diagnosis would also rise considerably. This does not appear to be commensurate with trends to date or with epidemiological research of mesothelioma.

To understand better these temporal trends, we have modelled claimants' exposures for each past claim report year since 1997/98.

Figure 5.13: Exposure (person years) of all claimants to date by report year and exposure year



As can be seen in the above chart, there has been a general increasing shift towards the period after 1975, evident by the downwards trends in the chart from left to right indicating that an increasing proportion of the claimants' exposure relates to more recent exposure periods.

We would expect that such a trend should continue for some time to come and that an increasing proportion of the exposure will relate to the period 1981/82 to 1985/86.

5.8.3 Latency model

Our method for projecting claim numbers is described in Section 4.4.

In brief terms, we use the exposure curve (averaged consumption) together with a model of the latency period of claims to derive an index of future claim notifications. We then calibrate this index to a base number of claims notifications to estimate the future incidence of claims reporting.

Our latency model for mesothelioma is for latency from the average date of exposure to be normally distributed with a mean latency of 35 years and a standard deviation of 10 years.

We have monitored the latency period of the claims of the Liable Entities in order to test the validity of those assumptions.

We have measured the mean latency period from the average date of exposure to the date of notification of a claim.

In strict epidemiological terms, the latency period should be measured from the date of first exposure to the date of diagnosis.


Because our model utilises latency assumptions from the average date of exposure, the latency period reported in the following charts is not directly comparable with that referred to in epidemiological literature.

As indicated in Figure 5.11, the average period of exposure for claimants against the Liable Entities is around 16 years. This means the actual latency period from the date of first exposure is around 8 years more than indicated in the following charts.

Furthermore, given that the date of notification lags the date of diagnosis by around 8 months for mesothelioma and by about 2 to 3 years for non-mesothelioma disease types, the latency trends shown in the following charts might slightly overstate the latency to diagnosis.

The charts below show the average (mean) latency and the 25th percentile and 75th percentile observations.

Figure 5.14: Latency of mesothelioma claims



The above chart indicates that the average latency period from the average exposure is currently around 35 years for mesothelioma.



Epidemiological studies tend to suggest that the observed latency period (from first exposure) for mesothelioma is between 4 and 75 years, with an average latency of around 35 to 40 years and an implied standard deviation of around 11 years.

Given that the average period of exposure is 16 years, this implies our latency assumption from the date of first exposure is approximately 43 years (being $35^{+1/2} \times 16$). Our model therefore generally accords with epidemiological literature and, if anything, assumes slightly longer latencies than epidemiological studies suggest.

At present, given that we are some 30 to 40 years after the main period of exposure, claims currently being reported reflect a broad mix of claims of varying latencies. Accordingly, any analysis of the latency period during the most recent 5 to 10 years:

- Should provide a good indicator of the underlying average latency period of each disease type; and
- Should have shown upwards trends given the fall-off in exposure in the late 1970s and 1980s.

The average observed latency should also therefore be expected to show some further slight upward trends in the coming years, albeit at a slower rate of increase than observed in the past.

The average observed latency period for mesothelioma has shown some upwards trends over time but has remained relatively stable for the last three years, at around 37 years.

The currently observed standard deviation of the latency period is 8.6 years.

The claims experience to date and the assumptions selected seem to accord with epidemiological research in relation to mesothelioma, once the relevant adjustments to standardise onto a consistent terminology are made.

Figure 5.15: Latency of asbestosis claims




Figure 5.16: Latency of lung cancer claims





Figure 5.17: Latency of ARPD & Other claims



The latency periods for the other disease types shows a more surprising trend, appearing to be longer than epidemiological literature has tended to suggest (particularly when adjusting our information to the latency from first exposure).

A summary of our latency assumptions by disease type are shown below.

Table 5.3: Assumed latency periods from average date of exposure to notification

	Mean (years)	Std Dev (years)
Mesothelioma	35	10
Asbestosis	35	8
Lung Cancer	35	10
ARPD & Other	32	10
Wharf	n/a	n/a
Workers Compensation	n/a	n/a

5.9 Peak year of claims and estimated future notifications

Based on the application of our exposure model and our latency model, and also taking into account various epidemiological views from both Australia and the UK, recognising that there are conflicting and widely diverging views as to when the peak might arise, the peak year of notification of claims reporting against the Liable Entities for each disease type is assumed to be as follows:

Table 5.4: Peak year of claim notifications


	<u>Current valuation assumption</u>	<u>Previous valuation assumption</u>
Mesothelioma	2010/11	2010/11
Asbestosis	2008/09	2006/07
Lung Cancer	2010/11	2010/11
ARPD & Other	2007/08	2006/07
Wharf claims	2000/01	2000/01
Workers Compensation	2007/08	2006/07

The changes to the assumed peak year of notification for asbestosis and ARPD & Other claims are a function of the revised latency assumptions for these diseases.

We have projected the future number of claim notifications from the curve we have derived using our exposure model and our latency model. We have applied this curve to the base number of claims we have estimated for 2008/09 as summarised in Section 5.7.

Figure 5.18 shows the pattern of future notifications which have resulted from the application of our exposure and latency model and the recalibration of the curve to our revised expectations for 2008/09.

Figure 5.18: Expected future claim notifications by disease type



The number of future claim notifications and the ultimate number of claims is shown below, both at our previous valuation and at this valuation.

Table 5.5: Number of claim notifications by disease type

	Current number projection		Previous number projection	
	2008 onwards	Ultimate	2008 onwards	Ultimate
Mesothelioma	4,247	6,591	3,801	6,080
Asbestosis	2,462	3,640	1,982	3,134
Lung Cancer	506	869	514	879
ARPD & Other	493	901	381	778
Wharf claims	54	189	51	185
Workers Compensation	658	1,729	610	1,682
All claim types	8,421	13,920	7,340	12,739

Note: "Ultimate" is the number of claims we project will be reported to the Liable Entities from 1967 to 2060.



It can be seen that the recognition of the emerging experience to 31 March 2008 has increased our projected ultimate number of claims compared with our previous valuation by 1,181 claims, the majority of which results from mesothelioma (511) and asbestosis (506) and other more minor changes in relation to the other disease types.

5.10 Baryulgil

During the last financial year, there have been no new claims reported. Of the 5 claims reported in 2006, 4 remain unsettled with the other claim having been settled with no liability attaching to the Liable Entities.

As previously noted, almost half of the claims settled have been settled with no liability against the Liable Entities; and for the remaining settled claims, the Liable Entities have typically borne around one-third to one-half of the settlement amount, reflecting the contribution by other defendants to the overall settlement (including those which have since been placed in liquidation).

For the purposes of our valuation, we have estimated there to be a further 25 future claims, comprising 9 mesothelioma claims, 8 other product and public liability claims and 8 Workers Compensation claims.

We have assumed average claims and legal costs, net of Workers Compensation insurances, broadly in line with those described in Section 6.

Our liability assessment at 31 March 2008 of the additional provision (for claims not yet reported) that could potentially be required is an undiscounted liability of \$8.0m and a discounted liability of \$5.1m, all of which is deemed to be a liability of Amaca.



6 ANALYSIS OF EXPERIENCE — AVERAGE CLAIMS COSTS

6.1 Overview

We have modelled the average claim awards and plaintiff and defendant legal costs (where separately disclosed) by disease type in arriving at our valuation assumptions.

Average attritional claim awards (which we have defined to be claims below \$1m in 2005/06 money terms) may vary considerably with the development of new heads of damage.

Table 6.1 shows how the average settlement costs for non-nil attritional claims have varied by plaintiff settlement year. All data have been converted into current money terms (i.e. mid 2007/08 money terms) using base inflation at 4% per annum.

The reader's attention is drawn to the fact that the average amounts shown hereafter relate to the average amounts of the contribution made by the Liable Entities, and do not reflect the total award payable to the plaintiff unless this is clearly stated to be the case.

In particular, for Workers Compensation the average awards reflect the average contribution by the Liable Entities for claims in which they are joined but relate only to that amount of the award determined against the Liable Entities which is not met by a Workers Compensation Scheme or Policy.

**Table 6.1: Average attritional non-nil claim award
 (inflated to current money terms)**

Plaintiff settlement Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Wharf	Workers Compensation
1997/98	180,776	73,434	44,669	75,513	74,012	126,332
1998/99	193,244	46,252	33,962	121,696	0	50,289
1999/00	215,082	72,655	77,396	129,065	74,872	119,072
2000/01	242,852	76,027	95,408	83,222	80,836	66,907
2001/02	283,395	90,000	117,460	107,254	51,608	53,776
2002/03	255,514	97,076	80,727	81,755	115,423	112,743
2003/04	239,669	109,814	101,951	94,980	112,215	97,328
2004/05	253,653	84,654	152,968	83,471	80,374	143,040
2005/06	242,866	88,635	88,222	89,759	77,467	103,871
2006/07	251,484	93,608	116,796	74,752	122,268	96,373
2007/08	236,635	80,343	117,184	46,461	31,633	243,749

Note: Throughout this section the date convention used in tables and charts is that (for example) 2006/07 indicates the financial year running from 1 April 2006 to 31 March 2007. Furthermore, the label "2006" (for example) in charts would indicate the financial year running from 1 April 2006 to 31 March 2007

6.2 Mesothelioma claims

For mesothelioma, the year 2001/02 resulted in the highest annual average cost. The step changes in 1999/00 through 2001/02 would appear to reflect in part legislative changes that occurred as well as in the percentage of the total award which the Liable Entities were required to contribute.

6.2.1 Distribution of claim sizes for mesothelioma claims

We have analysed the make-up of the average costs for mesothelioma claims by banding claims into cohorts of 10% groups. That is, identifying the contribution to the overall average cost from the smallest 10% of non-nil claims by size, then the contribution from the smallest 20% of claims by size etc.


By way of illustration, the amount for the 10%-20% band is measured as the average cost of the smallest 20% of claims less the average cost of the smallest 10% of claims.

The aim of this is two-fold:

- To understand the trends in the average costs; and
- To identify if the change in mix of claims by size has contributed to the observed level of superimposed inflation.

Figure 6.1 shows the relative contribution of the various bands to the overall average costs identified in Table 6.1.


Figure 6.1: Contribution of individual bands of claims to overall average attritional mesothelioma claim costs (inflated to current money terms)



This chart shows that for the most recent five years, the mix of claims has been relatively stable.

An alternative way of looking at this is to consider the distribution of claims by size.

Figure 6.2: Distribution of claims awards for attritional non-nil mesothelioma claims (inflated to current money terms)




The chart confirms that the primary driver for the high average award in 2001 was the high proportion of larger claims (i.e. around 35% of non-nil claims were over \$350k).

6.2.2 Trends in average awards

In setting our assumption for mesothelioma, we have considered average awards over the last 3, 4 and 5 years in arriving at our valuation assumption.

Figure 6.3: Inflated average awards and number of non-nil claims settlements for mesothelioma claims



The chart above shows the historic variability in average claim sizes for mesothelioma varying from \$180,000 to \$280,000 in 2007/08 money terms.

The last six years' experience has shown a considerable degree of stability after the significant escalation in claim awards that took place over the previous five years.

The average of the last three years (to 2007/08) is \$243,000; the average of the last four years is \$246,000 and the average of the last five years is \$245,000.

Analysis of the contribution rate by the Liable Entities to the overall award settlement suggests that the reduction in average awards in the latest financial year has been primarily due to a fall in contribution rates (i.e. the share of the total award which the Liable Entities have to contribute). In 2006/07 the contribution rate was 82%, whilst in 2007/08 it fell to 71%.

Taking the above averages and the underlying trends into consideration, we have adopted a valuation assumption of \$250,000 for mesothelioma claims in 2007/08 money terms.

This compares with our previous valuation assumption of \$266,500 in 2007/08 money terms. This represents a 6% reduction in inflation-adjusted terms.

Table 6.2: Average mesothelioma claims assumptions

Valuation Report	Claim settlement year	
	2006/07	2007/08
31 March 2007	250,000	266,500
31 March 2008	n/a	250,000

Note: 2006/07 settlements are in 2006/07 dollars whilst 2007/08 settlements are in 2007/08 dollars.

6.3 Asbestosis claims


For asbestosis, it can be seen from Table 6.1 that in 2003 the average settlement was high relative to recent experience.

6.3.1 Distribution of claim sizes for asbestosis claims

We have analysed the make-up of the average costs for asbestosis claims by banding claims into cohorts of 10% groups.


Figure 6.4 shows the relative contribution of the various bands to the overall average costs identified in Table 6.1.

Figure 6.4: Contribution of individual bands of claims to overall average attritional asbestosis claim costs (inflated to current money terms)



An alternative way of looking at this is to consider the distribution of claims by size.

**Figure 6.5: Distribution of claims awards for attritional non-nil asbestosis claims
 (inflated to current money terms)**




The average size for asbestosis is considerably lower than for mesothelioma and this is mainly due to the absence of claims above \$250,000.

The chart also shows that the reason for the high average award in 2003 was due to a relatively large number of claims costing between \$250,000 and \$350,000.

6.3.2 Trends in average awards

In setting our assumption for asbestosis, we have considered average awards over the last 3, 4 and 5 years in arriving at our valuation assumption.

Figure 6.6: Inflated average awards and number of non-nil claims settlements for asbestosis claims



The chart shows the substantial variation in average awards though in part this is affected by the low numbers of claims settled in the earlier years.

The average of the last three years is \$87,000; the average of the last four years is \$86,000 and the average of the last five years is \$91,000. These are not surprising given the relatively high average cost in 2003 and the substantial increase in claim numbers thereby giving greater weight to the recent years' experience.

We have reduced our assumption to \$92,500 in light of the recent experience, whilst still giving some credibility to the experience in 2003. This represents a 9% reduction in inflation-adjusted terms.

Table 6.3: Average asbestosis claims assumptions

Valuation Report	Claim settlement year	
	2006/07	2007/08
31 March 2007	95,000	101,300
31 March 2008	n/a	92,500


Note: 2006/07 settlements are in 2006/07 dollars whilst 2007/08 settlements are in 2007/08 dollars.

6.4 Lung cancer claims

Lung cancer average claims costs appear to have experienced some volatility in the last five years, although this is not unexpected given the small volume of claim settlements (usually approximately 20 per annum).

Average claim costs observed in 2004, 2006 and 2007 were high relative to previous and more recent experience, mainly due to a number of claims settlements being made which were in excess of \$200,000.

Figure 6.7: Inflated average awards and number of non-nil claims settlements for lung cancer claims



The average of the last three years is \$108,000; the average of the last four years is \$121,000 and the average of the last five years is \$117,000.

At this valuation, we have adopted an average award size of \$120,000, taking into account the recent downward trend in experience but recognising the volatility in past experience and the high average award sizes in 2004. This represents a 10% reduction in inflation-adjusted terms.

Table 6.4: Average lung cancer claims assumptions


Valuation Report	Claim settlement year	
	2006/07	2007/08
31 March 2007	125,000	133,300
31 March 2008	n/a	120,000

Note: 2006/07 settlements are in 2006/07 dollars whilst 2007/08 settlements are in 2007/08 dollars.

6.5 ARPD & Other claims

Historically, average awards have been volatile owing to the low number of claims.

Figure 6.8: Inflated average awards and number of non-nil claims settlements for ARPD & Other claims



For ARPD & other claims, the average of the last three years is \$72,000; the average of the last four years is \$75,000 and the average of the last five years is \$80,000.

We have adopted an average award size of \$85,000 recognising the experience between 2002 and 2005 (and largely ignoring the experience in 2006 and 2007 owing to the lower number of claim settlements). This is a 11% reduction in inflation-adjusted terms.

Table 6.5: Average ARPD & Other claims assumptions

Valuation Report	Claim settlement year	
	2006/07	2007/08
31 March 2007	90,000	95,900
31 March 2008	n/a	85,000

Note: 2006/07 settlements are in 2006/07 dollars whilst 2007/08 settlements are in 2007/08 dollars.


6.6 Workers Compensation claims

The average award for non-nil Workers Compensation claims has shown a degree of volatility and reduced from the level observed in 2004/05 through to 2006/07.

In 2007/08 there has been a significant increase in average awards, although this is largely due to the impact of one large claim.

With 7 claims settled this year, and typically around 3 claims settled in previous years, an individual claim can have a significant influence on the observed average claim size.

Figure 6.9: Inflated average awards and number of non-nil claims settlements for Workers Compensation claims



The average of the last three years is \$177,000; the average of the last four years is \$171,000 and the average of the last five years is \$153,000.



We have adopted \$150,000 as our valuation assumption for Workers Compensation claims in 2007/08 money terms, giving some credibility to the latest year (after adjusting for the impact of the large claim).

This represents a 12% increase in the assumption in inflation-adjusted terms.

Table 6.6: Average Workers Compensation claims assumptions


Valuation Report	Claim settlement year	
	2006/07	2007/08
31 March 2007	125,000	133,300
31 March 2008	n/a	150,000

Note: 2006/07 settlements are in 2006/07 dollars whilst 2007/08 settlements are in 2007/08 dollars.

6.7 Wharf claims

For wharf claims, the average of the last three years has been \$87,000; the average of the last four years has been \$86,000 and the average of the last five years has been \$91,000.

Figure 6.10: Inflated average awards and number of non-nil claims settlements for Wharf claims



The experience in 2006/07 was affected significantly by one large claim of more than \$350,000.



We have adopted a valuation assumption of \$90,000 in 2007/08 money terms. This is a reduction of 15% in inflation-adjusted terms. This assumption is not material to the overall liability.

Table 6.7: Average wharf claims assumptions

Valuation Report	Claim settlement year	
	2006/07	2007/08
31 March 2007	100,000	106,600
31 March 2008	n/a	90,000

Note: 2006/07 settlements are in 2006/07 dollars whilst 2007/08 settlements are in 2007/08 dollars.

6.8 Large claim size and incidence rates

There have been 27 settled claims with claims awards in excess of \$1m in 2005/06 money terms. All of these claims are product and public liability claims and the disease diagnosed in every case is mesothelioma.

In aggregate they have been settled for \$41m in current money terms, at an average cost of approximately \$1.58m. We have noted one claim of more than \$4m in current money terms.

The incidence rate of large claims to non-nil settlements in any one year has been variable, dependent on the random incidence of large claims by settlement year:

- Over the period 1994-2007 there have been 26 large claims compared with 1,712 non-nil non-large claims settlements. This gives an incidence rate of 1.50%.
- Over the period 2000-2007 there have been 21 large claims compared with 1,328 non-nil non-large settlements, an incidence rate of about 1.56%.
- Both of these figures have been affected by the relatively light large claims incidence in 2007 when there has been just one large claim compared with 190 non-nil non-large settlements.

We have assumed that there will be a large claim incidence rate of 2.00% prospectively over all future years. This is unchanged from our previous valuation assumption.



With approximately 250 mesothelioma claims settlements per annum, we are therefore projecting to observe approximately 5 large claims per annum, or \$8m in claim awards.

In setting this assumption, we have had regard to the experience in 2005/06 and 2006/07 more than the experience in 2007/08; and we have also had regard to the number of large pending claims.

There remain five mesothelioma claims open with award sizes case-estimated at in excess of \$900,000, four of which were reported in 2007/08. Case estimates for these five claims amount to more than \$8m.


We have taken the average costs experienced over all years as our base assumption, given the small volume of such claims. This has resulted in an assumption of \$1.6m for the claim award and \$50,000 for plaintiff legal costs with separate allowance also made for defendant legal costs of \$100,000 per claim. Implicitly this allows for the occasional \$4m claim at an incidence rate broadly equivalent to past experience.

As a consequence, the overall loading per non-nil mesothelioma claim (including plaintiff legal costs) to make allowance for large claims is \$33,000 (being 2.0% x \$1,650,000).

We note that the actual incidence of, and settlement of, large claims is not readily predictable and it should be expected that deviations will occur from year to year due to random fluctuations because of the small numbers of large claims (about 5 per annum): this has been the case for the 2007/08 financial year.

For other disease types, there have been no claims settled which have exceeded \$650,000 in actual money terms. Therefore we have made no allowance for large claims for other disease types.

Figure 6.11: Scatter plot of large claims by settlement year



6.9 Average defendant legal cost for non-nil and nil claim settlements

As with the average awards, we have modelled defendant legal costs separately. We have also modelled nil claims and non-nil claims separately as they should portray different characteristics in relation to their legal costs.


We have removed large claims from the analysis and treated them separately, applying a large claim loading and an incidence rate consistent with the underlying large claims.

We have used closure year as the base definition to allocate costs into years and given the lag between the award settlement and the closure year, distortions can arise from year to year depending on closure activity of claims files.

6.9.1 Non-nil claims

The following chart shows the pattern of average defendant legal costs of the Liable Entities by disease type for non-nil claims, inflated to 2007/08 money terms over recent years. We have not included Wharf claims or Workers Compensation claims in the chart as the data is more sparse and exhibits considerable volatility.

Figure 6.12: Inflated average defendant legal costs for non-nil claims by closure year



For mesothelioma, we have determined an average base defendant legal cost of \$22,500. This is unchanged from our previous assumption.

For asbestosis, we have determined an average of \$22,500 again unchanged from our previous assumption.

For lung cancer, we have selected \$20,000 although there is sparse data from which to estimate this amount. We recognise that there have been substantial average defence costs incurred in some years, especially in 1993 and 1996, but we are aware that these have been a result of precedent-setting cases, or matters involving key principles of law. It should also be recognised that the financial materiality of such an assumption is not expected to be significant given the low number of lung cancer claims and the relatively high nil settlement rate.

For ARPD & Other claims, we have selected \$25,000 based on an average of the last three years.


For Workers Compensation we have selected \$15,000.

For Wharf claims, we have selected \$20,000.

6.9.2 Nil claims

The following chart shows the pattern of average defendant legal costs of the Liable Entities by disease type for nil claims, inflated to 2006/07 money terms over recent years. We have not included Wharf claims or Workers Compensation claims in the chart as the data is more sparse and exhibits considerable volatility.

Figure 6.13: Inflated average defendant legal costs for nil claims by closure year



For mesothelioma, we have selected an average of \$10,000, a reduction from the previous valuation assumption.

For asbestosis, we have selected an average of \$10,000 a reduction from the previous valuation assumption.

For lung cancer, again there is scarcity of data, but we have selected \$7,000 as our assumption, a reduction from our previous valuation. We note that there have been a small number of precedent-setting cases for which significant legal costs have been incurred but where the claim has not been closed.

For ARPD & Other claims, we have selected \$5,000, a reduction from our previous valuation assumption.

For Workers Compensation and Wharf claims we have selected \$2,500 as our assumption. These are unchanged from our previous valuation.



6.10 Summary assumptions

The following table provides a summary of our average claim cost assumptions at this valuation, and those assumed at the previous valuation.

Table 6.8: Summary average claim cost assumptions

	Current valuation assumption	Previous valuation assumption
Mesothelioma	250,000	266,500
Asbestosis	92,500	101,300
Lung Cancer	120,000	133,300
ARPD & Other	85,000	95,900
Wharf	90,000	106,600
Workers Compensation	150,000	133,300
Mesothelioma large claims allowance (excl. defendant legal costs)	Average size = \$1.65m Frequency = 2.0% Loading = \$33,000 per claim	Average size = \$1.76m Frequency = 2.0% Loading = \$33,000 per claim

Note: Both the current valuation assumption and the previous valuation assumption are expressed in 2007/08 money terms.

7 ANALYSIS OF CLAIMS EXPERIENCE — NIL SETTLEMENT RATES

7.1 Overview

We have modelled the nil settlement rates, being the number of nil settlements expressed as a percentage of the total number of settlements (nil and non-nil). The following table shows the observed nil settlement rates by disease type and by settlement year.

Table 7.1: Nil settlement rates

Plaintiff Settlement Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Wharf	Workers Compensation
1997/98	34%	22%	23%	56%	0%	84%
1998/99	26%	50%	11%	30%	100%	90%
1999/00	10%	15%	27%	17%	17%	77%
2000/01	6%	11%	6%	14%	36%	83%
2001/02	15%	12%	30%	13%	17%	86%
2002/03	9%	3%	21%	11%	33%	80%
2003/04	9%	2%	26%	7%	46%	95%
2004/05	8%	12%	27%	10%	0%	94%
2005/06	8%	9%	40%	24%	25%	93%
2006/07	19%	13%	34%	51%	0%	95%
2007/08	18%	12%	28%	21%	33%	72%

Note: Throughout this section the date convention used in tables and charts is that (for example) 2006/07 indicates the financial year running from 1 April 2006 to 31 March 2007. Furthermore, the label "2006" (for example) in charts would indicate the financial year running from 1 April 2006 to 31 March 2007


It should be noted that some of the nil settlement rate in these tables have changed since the last valuation report (particularly for the more recent years). This reflects ongoing activity on the claims files that can be re-opened with settlement and recovery amounts modified over time.

7.2 Mesothelioma claims

The nil settlement rates for mesothelioma have shown some degree of volatility between settlement years.

Figure 7.1 shows the number of claims settled for nil cost, the total number of claims settled and the implied nil settlement rate for each settlement year.

Figure 7.1: Mesothelioma nil claims experience



During the last six years, the rate has varied between 8% and 19%.

In considering the future nil settlement rate assumption, we note the following:


- Based on the current data, the last three years (to 2007/08) have averaged 15%, the last four years have averaged 13% and the last five years have averaged 13%;
- The experience in 2006/07 and 2007/08 has shown an increased nil settlement rate to around 19%;
- Data generally develops in such a way that the nil settlement rate typically trends downwards over time; and
- We have noted in Section 5 that the increased claims reporting activity in 2007/08 appears to have been associated with higher nil settlement rates compared with previous years at the same point in time.

Taking all of these factors into consideration we have increased the assumed future nil settlement rate to 12.5%. An increase in the nil settlement rate reduces the liability.

7.3 Asbestosis claims

As with mesothelioma, the historic asbestosis nil settlement rates have been fairly volatile.

Figure 7.2: Asbestosis nil claims experience



We have reviewed the averages rate over the last 3, 4 and 5 years in determining our assumption.


The last three years (to 2007/08) have averaged 12%, the last four years have averaged 12% and the last five years have averaged 10%.

In these circumstances we have assumed a nil settlement rate of 10.5%, increased from our previous valuation assumption of 9.5%.

7.4 Lung cancer claims

Given the small volumes of claims, volatility in nil settlement rates for lung cancer claims is to be expected.

Figure 7.3: Lung cancer nil claims experience



The average of the last three years (to 2007/08) for lung cancer claims has been 35%, the last four years have averaged 33% and the last five years have averaged 31%.


The nil settlement rate trend observed in these averages is influenced by the high nil settlement rate for 2005/06 (40%). In these circumstances we have selected 32% as the future nil settlement rate. This is unchanged from the previous valuation.

We note that this rate could be affected in the future by legal changes to the division and acceptability of claims in relation to claimants who have also smoked and the contribution of smoking to the incidence of lung cancer. At this time, we have no evidence to make any specific adjustment to the assumption for that factor.

7.5 ARPD & Other claims

As with other disease types, there has been significant volatility in the historic nil settlement rates, given the low numbers of claims for this disease.

Figure 7.4: ARPD & Other nil claims experience



The average for the last three years (to 2007/08) for ARPD & Other claims has been 33%, the average for the last four years has been 27% and the average for the last five years has been 24%.

We have not placed significant credibility on the 2006/07 year's experience in selecting our nil settlement rate assumption at this stage.


In these circumstances, we have selected 22% as our nil settlement rate assumption for this class of disease. This is an increase from our previous valuation assumption of 20%.

7.6 Workers Compensation claims

The nil settlement rates for Workers Compensation are high and are reflective of the portion of claims whose costs are fully met by a Workers Compensation Scheme or Policy. The proportion of such claims which are fully met by insurance will have increased over time and are likely to continue to do so in the future.

This trend can be observed in the following chart. The nil settlement rate has risen from 50% in 1994 to in excess of 90% for four of the last five years.

Figure 7.5: Workers Compensation nil claims experience



Whilst the nil settlement in 2007/08 has shown a significant reduction to 72%, it should be noted that the number of settlements have been very low, at approximately half the normal level of settlements.

The average nil settlement rate of the last three years (to 2007/08) is 90%, the average of the last four years is 91% and the average of the last five years is 93%.

As a result, whilst we have reduced the nil settlement rate assumption, we have not placed significant credibility on the most recent year at this valuation.


In these circumstances, we have selected a rate of 90% at this valuation, reduced from our previous valuation assumption of 93%.

7.7 Wharf claims

For wharf claims, the average of the last three years is 19%, the average of the last four years is 15% and the average of the last five years is 24%. We have selected 25% as our valuation assumption which is unchanged from our previous valuation assumption.

Given the extremely low volume of claims activity for Wharf claims, this assumption is highly subjective but is also not material to the liability assessment.

Figure 7.6: Wharf nil claims experience



7.8 Summary assumptions

The following table provides a summary of our nil settlement rate assumptions at this valuation, and those assumed at the previous valuation.

Table 7.2: Summary nil settlement rate assumptions

	Current valuation assumption	Previous valuation assumption
Mesothelioma	12.5%	11.5%
Asbestosis	10.5%	9.5%
Lung Cancer	32%	32%
ARPD & Other	22%	20%
Wharf	25%	25%
Workers Compensation	90%	93%

8 ECONOMIC AND OTHER ASSUMPTIONS

8.1 Overview

The two main economic assumptions required for our valuation are:

- The underlying claims inflation assumptions adopted to project the future claims settlement amounts and related costs.
- The discount rate adopted for the present value determinations.

These are considered in turn in Sections 8.2 to 8.5.

We also discuss the basis of derivation of other assumptions, being:

- The cross-claim recovery rate; and
- The pattern of settlement of reported claims.

8.2 Claims inflation

We are required to make assumptions about the future rate of inflation of claims costs. We have adopted a standard Australian actuarial claims inflation model for liabilities of the type considered in this report that is based on:

- An underlying, or base, rate of general economic inflation relevant to the liabilities, in this case based on wage/salary (earnings) inflation; and
- A rate of superimposed inflation, i.e. the rate at which claims costs inflation exceeds base inflation.

8.2.1 Base inflation basis

Ideally, we would aim to derive our long term base inflation assumptions based on observable market indicators or other economic benchmarks. Unfortunately, such indicators and benchmarks typically focus on inflation measures such as CPI (e.g. CPI index bond yields and RBA inflation targets).

We have therefore derived our base inflation assumption from CPI based indicators and long term CPI / AWOTE⁷ relativities.

⁷ AWOTE = Average Weekly Ordinary Time Earnings

8.2.2 CPI assumption


We have considered two indicators for our CPI assumption:

- Market implied CPI measures.
- RBA CPI inflation targets.

We have measured the financial market implied expectations of the longer-term rate of CPI by reference to the gap between the yield on government bonds and the real yield on government CPI index-linked bonds.

The chart below shows the yields available for 10-year Commonwealth Bonds and Index-linked bonds. The gap between the two represents the implied market expectation for CPI at the time.

Figure 8.1: Trends in Bond Yields



Source: <http://www.rba.gov.au/Statistics/Bulletin/index.html>

It can be seen that the implied rate of CPI has varied between 1.5% per annum and 4% per annum during the last 11 years, although it broadly remained between 2% and 3% per annum from March 2000 to January 2006.

Currently, the effective annual yield on long-term government bonds is approximately 6.1% p.a. and the equivalent effective real yields on long-term index-linked bonds is approximately 2.3% per annum. This would imply current market expectations for the long-term rate of CPI were of the order of 3.8% per annum.

In considering this result we note that:

- The implied CPI rate has stayed consistently above 3.2% per annum since March 2006.


- The yields on both nominal and CPI-linked government bonds are driven by supply and demand, and both are in increasingly short supply in the market. The yields on both, and their relativities, are subject to some volatility and likely some short term distortion.
- The RBA's long term target is for CPI to be maintained between 2% and 3% per annum.
- The implied rate of CPI has shown a prolonged trend upwards since the early part of 2003, which coincides when it last was towards the bottom end of the RBA's target range.
- While the RBA has been relatively successful with this target, over the longer term future the risk of events leading to inflation emerging occasionally outside this range needs to be allowed. Given a likely upside bias to such events, longer term inflation at the higher end of the RBA's range would not be unexpected.

Weighing this evidence together, this suggests a long term CPI inflation benchmark of 2.75% to 3.00% per annum.

8.2.3 *Wages (AWOTE) / CPI relativity*

The following chart summarises the annualised rates of AWOTE and CPI inflation, and their relativities, for the 1970 to 2007 period.

Figure 8.2: Trends in CPI and AWOTE



In considering the above, we note:

- The last period from 1995 reflects largely a continuous period of economic growth which may not be reflective of longer term trends.
- The longer periods cover a range of business cycles, albeit that the period from 1970 includes the unique events of the early 1970's (i.e. general inflationary pressures, both locally and worldwide, and the impact of high oil prices owing to the Oil Crisis in 1973).

Allowing for these factors, the historic data suggests a CPI / AWOTE relativity, or gap, of approximately 1.75% to 2.00% per annum.

On this basis, given a longer term CPI benchmark of 2.75% to 3.00%, it would suggest a longer-term wage inflation (AWOTE) assumption of 4.50% to 5.00% p.a.

We note that such an assumption is not inconsistent with actual wage inflation over recent years (see Figure 8.2 above) which has arisen during economic conditions not dissimilar to those reflected in the current market interest rates looking forward.


8.2.4 Impact of claimant ageing and non-AWOTE inflation effects

The overall age profile of claimants is expected to rise over future years with the consequent impact that, other factors held constant, claims amounts should tend to increase more slowly than average wage inflation (excluding any societal changes, e.g. changes in retirement age). This is due to both reduced compensation for years of income or life lost and a tendency for post retirement age benefits to possibly increase closer to CPI than AWOTE.

Furthermore, we note that some heads of damage would be expected to rise at CPI or lower, such as general damages and compensation for loss of expectation of life, owing to the age profile of claimants showing a continuing upward trend in average ages. Other heads of damage, including loss of earnings, would be expected to rise at AWOTE (ignoring the ageing effect); whilst medical expenses and care costs would be expected to rise in line with medical cost inflation which in recent times has been in excess of AWOTE.

We have analysed the age pattern of the claimants to understand how this is trending over time. This is important in consideration of the extent of both base and superimposed inflation in claims costs as a result of the age of claimants.

Figure 8.3: Age profile of mesothelioma claimants by report year




The chart indicates that claimants are generally continuing to age. The claims experience does not indicate a considerable increase in the number (and proportion) of younger claimants. We note the claim reported in 2006/07 involving a 25-year old claimant. However, the chart indicates that the trend for all of the lines in the graph (other than the minimum age) is upwards indicating that there is a gradual ageing of the population of claimants.

The chart also indicates that the average age of claimants is increasing by around 0.5 years each year, with the average age now about 70 years.

This has the effect of negating some aspects of emerging claims inflation. This is because part of the award relates to economic loss and loss of expectation of life and awards for these are in part a function of age.

We have reviewed how average claim sizes vary by decade of age.

Figure 8.4: Age cohorting of average mesothelioma awards by decade of age



The analysis suggests that average mesothelioma awards reduce by around 15%-20% for each increasing decade of age when considering the typical age range of the claimants (i.e. over 60 years of age).

For asbestosis, analysis suggests that average awards change by less, typically around 10% for each decade of age.

Analysis also suggests that mesothelioma claimants are typically ageing by around 0.5 years every year; whilst asbestosis claimants are ageing by around 0.3 years every year and are also typically older than mesothelioma claimants.

Weighing these various factors together, and allowing for the relative mix of claims between mesothelioma and asbestosis, we consider that a reasonable assumption for the deflationary allowance for the impact of ageing on average sizes is 0.50% to 0.75% per annum.

Taking all of these factors into account, we have adopted a base inflation assumption of 4.25% per annum.

8.3 Superimposed inflation

8.3.1 Overview

At our previous valuation, we indicated that an allowance of 2.25% per annum for superimposed inflation was appropriate. We identified a number of factors we considered in setting this assumption.

These included:

- The rate of pure (judicial) inflation reflecting the natural tendency for personal injury claim awards to rise at a rate higher than wage inflation;
- The impact of medical or other developments;
- The emergence of new heads of damage, or the expansion of existing heads of damage; and
- The mix of claims costs by different heads of damage.

Additionally, we have considered the potential for these factors to be offset to some extent by:


- The potential for existing heads of damage to be removed, or for the contraction of these heads of damage (e.g. *CSR vs. Eddy*); and
- The effect of an ageing population of claimants on the rate of inflation of overall damages, a component of which relates to economic loss.

Whilst the future rate of superimposed inflation is uncertain, and not predictable from one year to the next, it is of note that the average claim costs appear to have been stable in the last few years, although the emergence of new or expanding heads of damage does not tend to proceed smoothly but rather is more “lumpy”.

8.3.2 Analysis of past rates of superimposed inflation

We have reviewed the rate of inflation of claims costs by settlement year for the last 10 years for mesothelioma claims. We have assessed this by using uninflated claim costs and therefore the chart can be used to imply the total rate of inflation.

Figure 8.5: Average mesothelioma awards



The chart can be used to imply the rate of inflation of claim awards over and above base inflation (i.e. it measures the rate of superimposed inflation) in any one year or an annualised rate of superimposed inflation over a longer-term.

The chart shows the “best fit” of the rate of growth of inflated claim awards using two possible models:

- A linear fit — which assumes that the average inflated award is a linearly increasing function (such that the monetary increase from year to year is fixed); and
- An exponential fit — which assumes that the rate of increase in the average inflated awards (i.e. the rate of superimposed inflation) is constant.

The actual rate of inflation within any one year, and the extent to which superimposed inflation arises in any one year, is not in itself readily estimable but rather is a function of a whole range of factors. It can be inferred from Table 6.1 and Figure 8.5, that the average rate of claim inflation can be extremely volatile from year to year, with figures as low as -20% and as high as +20% observed since 1995.

The actuarial approach for this report is to take an average view to be applied over the long-term noting that there will necessarily be deviations from this average on an annual basis.

Using the chart and these models of best fit, we have the following observations in relation to the rate of claim inflation:

- The linear fit of the last 10 years' experience implies a rate of claim inflation of around 4.6% per annum. This implies superimposed inflation of around 0.3% per annum;
- The exponential fit of the last 10 years' experience implies the rate of claim inflation to be around 6.6% per annum. This implies superimposed inflation of around 2.25% per annum;
- Over the last five years, the annualised rate of claim inflation has been 3% per annum; and
- Step changes in average claim costs typically reflect the impact of:
 - Emerging new heads of damage (such as Sullivan vs. Gordon and Griffiths vs. Kerkemeyer); and
 - Changes in the contribution rate of the Liable Entities to the overall settlements.

Weighing all of this evidence together, we have adopted an assumed rate of future superimposed inflation of 2.25% per annum, noting in particular that this rate is intended to be a longer-term rate of inflation.

8.4 Summary of claims inflation assumptions

The table below summarises the claims inflation assumptions we have used within our current and previous liability assessments.

Table 8.1: Claims inflation assumptions

	Current valuation	Previous valuation
Base inflation	4.25%	4.25%
Superimposed inflation	2.25%	2.25%
Claim cost inflation*	6.60%	6.60%

* *Base and superimposed Inflation are applied multiplicatively in our models so that claim cost inflation is calculated as 1.0425 * 1.0225 — 1*

8.5 Discount rates: Commonwealth bond zero coupon yields

We have adopted the zero coupon yield curve at 31 March 2008, underlying the prices, coupons and durations of certain Australian government bonds for the purpose of discounting the liabilities for this report.

The use of such discount rates is consistent with standard Australian actuarial practice for such liabilities, is in accordance with Professional Standard PS300 and is also consistent with our understanding of the Australian accounting standards.

Table 8.2: Zero coupon yield curve by duration

Year	Current valuation	Previous valuation
1	6.57%	6.36%
2	6.10%	6.27%
3	6.09%	6.14%
4	6.09%	6.02%
5	6.09%	5.91%
6	6.09%	5.82%
7	6.09%	5.76%
8	6.09%	5.71%
9+	6.09%	5.67%

The equivalent single uniform discount rate, based on cashflows weighted by term, is 6.14% per annum at 31 March 2008 (March 2007: 5.88% per annum).


8.6 Cross-claim recovery rates

Cross-claim recoveries have totalled \$16m to date. This represents 3.1% of gross claim costs.

The majority of cross-claim recoveries have been in relation to the Hardie-BI Joint Venture with CSR, including more than \$4m paid in 2005/06 and \$2m paid in 2006/07 in relation to cross-claims against CSR and Bradford Insulation in relation to the Hardie-BI Joint Venture.

The following chart shows how the experience of cross-claim recoveries has varied over time, both in monetary terms and expressed as a percentage of gross payments.

Figure 8.6: Cross-claim recovery experience



Given the observations that 2005/06 (\$5.8m) and 2006/07 (\$3.4m) have been impacted by significant recoveries from CSR and also due to the impact of the Hardie-BI Joint Venture, and given that such recoveries in part relate to recoveries that ought to have been made earlier, the rate of recovery exhibited in those two years is currently not believed to be a good guide to the future level of recovery.

In 2007/08 the level of cross-claim recoveries has reduced to \$1.4m (2.1% of gross awards).

We understand that this reduction is in part a function of the revised claim process in NSW which has resulted in more of the defendants being joined as part of the main proceedings, as opposed to the previous practice of a separate cross-claim being filed and recoveries being sought at a later date.

This change in process would have the effect of reducing the gross award payable by AICFL but also reducing the cross-claim recoveries available. In theory, the net effect of the changes should be nil.

Taking all of the above factors into account, we have assumed that future levels of cross-claim recoveries will be 2.2% of the average award. This is a reduction from our previous assumption of 3.0% of the average award.

8.7 Settlement Patterns

Triangulation methods are used to derive the past pattern of settlement of claims and are used in forming a view on future settlement patterns.

The following triangles provide an illustrative example of how we perform this:

Figure 8.7: Settlement pattern derivation for mesothelioma claims

Number of claims settled by the end of each year														
Reporting year	Delay to settlement (years)											Number of claims reported		
	Y	0	1	2	3	4	5	6	7	8	9		10	11
1996	45	77	92	103	105	103	103	103	103	103	103	103	103	103
1997	60	94	94	96	97	100	100	101	103	103	104	104	105	105
1998	57	78	82	84	86	86	88	88	88	88	88	88	88	88
1999	51	65	66	66	66	66	66	66	66	66	66	66	66	66
2000	75	112	118	118	121	121	121	122	123	123	123	123	123	123
2001	85	138	145	150	151	156	156	156	156	156	156	156	156	156
2002	89	161	173	173	173	173	174	174	174	174	174	174	174	174
2003	104	161	173	173	178	178	178	178	178	178	178	178	178	178
2004	143	221	231	235	235	235	235	235	235	235	235	235	235	235
2005	110	179	182	182	182	182	182	182	182	182	182	182	182	182
2006	104	179	182	182	182	182	182	182	182	182	182	182	182	182
2007	139	182	182	182	182	182	182	182	182	182	182	182	182	182

Proportion of claims settled by the end of each year														
Reporting year	Delay to settlement (years)											Number of claims reported		
	Y	0	1	2	3	4	5	6	7	8	9		10	11
1996	54.2%	62.0%	66.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
1997	58.0%	63.9%	63.9%	65.7%	66.6%	68.3%	68.3%	69.3%	69.3%	69.3%	69.3%	69.3%	69.3%	69.3%
1998	61.3%	63.9%	62.2%	60.3%	62.5%	62.5%	64.6%	64.6%	64.6%	64.6%	64.6%	64.6%	64.6%	64.6%
1999	53.7%	66.5%	62.6%	60.7%	64.7%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%
2000	58.5%	68.0%	63.7%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%
2001	52.0%	65.7%	60.1%	60.2%	63.0%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%
2002	55.0%	69.4%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%	66.1%
2003	55.6%	66.1%	62.5%	65.2%	65.2%	65.2%	65.2%	65.2%	65.2%	65.2%	65.2%	65.2%	65.2%	65.2%
2004	64.2%	63.7%	67.5%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%	66.6%
2005	50.5%	62.5%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%	65.9%
2006	48.4%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%
2007	52.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%	63.3%
Pattern assumed	51.4%	64.2%	60.6%	62.4%	64.2%	66.1%	67.5%	68.5%	69.0%	69.5%	69.5%	69.5%	69.5%	69.5%

Owing to limited data volumes, we have modelled “non-mesothelioma” claims as one cohort for determining claims settlement patterns.

Figure 8.8: Settlement pattern derivation for non-mesothelioma claims

Number of claims settled by the end of each year

Reporting year	Delay to settlement (years)											Number of claims reported	
	Y 0	1	2	3	4	5	6	7	8	9	10		11
1996	31	60	80	91	96	97	99	102	105	107	108	108	111
1997	32	68	91	103	109	110	115	117	117	117	117	117	121
1998	28	47	59	67	70	73	74	76	77	77	77	77	83
1999	38	62	69	104	114	116	117	118	119				123
2000	39	61	112	143	144	147	154	154					161
2001	67	125	181	198	307	312	214						223
2002	51	148	185	201	218	222							235
2003	45	125	163	177	189								200
2004	57	143	189	218									248
2005	37	135	152										180
2006	55	161											273
2007	76												288

Proportion of claims settled by the end of each year

Reporting year	Delay to settlement (years)											
	Y 0	1	2	3	4	5	6	7	8	9	10	11
1996	37.9%	54.1%	72.1%	82.0%	85.9%	87.4%	89.2%	91.6%	94.6%	95.4%	97.3%	97.3%
1997	36.4%	58.2%	75.2%	85.1%	90.1%	90.9%	92.0%	93.7%	94.6%	95.7%	96.3%	97.3%
1998	33.7%	56.6%	71.1%	80.7%	84.3%	88.0%	89.2%	91.6%	92.6%	92.9%		
1999	31.1%	67.2%	61.1%	65.2%	83.4%	85.1%	85.0%	90.7%	90.7%			
2000	23.6%	56.0%	69.6%	88.8%	89.4%	91.3%	95.7%	95.7%				
2001	30.0%	56.1%	65.7%	68.8%	92.8%	95.1%	96.0%	96.7%				
2002	21.7%	63.0%	78.7%	82.5%	82.6%	84.5%						
2003	22.0%	62.0%	81.5%	88.6%	91.6%							
2004	23.6%	57.7%	79.8%	87.8%								
2005	19.5%	71.1%	80.0%									
2006	20.9%	66.3%										
2007	26.0%											
Pattern assumed	22.9%	61.9%	78.9%	83.7%	89.9%	92.6%	95.0%	96.4%	97.3%	98.0%	98.5%	99.0%



We have therefore estimated the settlement pattern from future claim reporting as follows:

Table 8.3: Settlement pattern of claims awards by delay from claim reporting

Delay (years)	Mesothelioma	Other
0	51.4%	22.9%
1	32.9%	39.0%
2	6.3%	17.0%
3	1.8%	6.7%
4	1.8%	4.3%
5	1.9%	2.7%
6	1.4%	2.3%
7	1.0%	1.4%
8	0.5%	1.0%
9	0.5%	0.7%
Future	0.5%	2.0%

These assumed settlements patterns have been modified since our previous valuation.

9 PRODUCT AND PUBLIC LIABILITY INSURANCE PROGRAMME

9.1 Overview

Until 31 March 1985, the Liable Entities had in place General and Products liability insurance covers with a \$1m primary policy layer.

In addition, until 31 May 1986, the Liable Entities maintained further “umbrella” insurance contracts, with varying retentions and policy limits. That is, the contracts paid all costs arising from claims with exposure in a specified year from the retention up to the relevant policy limit. All claim costs in relation to a given exposure year in excess of the limit would be retained by the Liable Entities.

Product liability claims were insured under these contracts on an “in the aggregate” basis whilst public liability claims were insured on an “each and every loss” basis.

These contracts were placed amongst a number of insurance providers on a claims occurring basis.

From 31 May 1986, the insurance contracts were placed on a claims made basis in relation to asbestos-related product and public liability cover.

The umbrella policies were placed as follows:

- For the period up to June 1976, the insurance policies were written on a claims occurring basis. The insurance was provided by QBE but the cover provided by these policies was commuted in June 2000 for a consideration of \$3.1m per annum for the following 15 years.
- For the period from June 1976 to 31 May 1986, the insurance policies were written on a claims occurring basis. CE Heath acted as the underwriting agent and insured the risk in Australia and also into Lloyd’s of London and the London Market. However, during this period both CE Heath Underwriting Agencies Pty Ltd (CEHUA) and CE Heath Underwriting & Insurance (Australia) Pty Ltd (CEH U&I) also insured some of the risk, reinsuring their placement on a facultative basis.



- For the period 31 May 1986 to 31 March 1990, the insurance policies were written on a claims-made basis. CE Heath acted as the underwriting agent and insured the risk into Lloyd's of London and the London Market.
- For the period 31 March 1990 to 31 March 1997, the insurance policies were written on a claims-made basis. However, CE Heath Casualty & General Insurance Ltd (later HIH Casualty & General) acted as the insurer of the programme and reinsured it on a facultative basis into Lloyd's of London and the London Market. CE Heath Casualty & General retained some share on some of the layers.

For the claims occurring period, we understand that defence legal costs are additional to the cover.

The methodology describing our approach for valuing the Insurance Recoveries is detailed in Section 4.9.

9.2 Allowance for Insurance Recoveries

It should be noted that only product and public liability Insurance Recoveries are allowed for within our liability assessment, and only in relation to the period of exposure and insurance placement up to 31 May 1986.

Insurance protection purchased from 31 May 1986 onwards was placed on a "claims made" basis and as such may not provide protection or recoveries against the cost of future claim notifications made by claimants against the Liable Entities. We have therefore, for the purposes of this report, made no allowance for the value of insurance contracts placed from 1986 onwards in our liability assessment.

We note that a claim of approximately \$70m has been made by Amaca on behalf of the Liable Entities against HIH and related entities in relation to the insurance programme for the 1990/91 to 1996/97 years. This claim is presently being considered by the liquidators of HIH and we have not, for the purposes of this report, attempted to estimate any recovery for it at this time.

It should be noted that our decision is an actuarial one and is not based on consideration of the legal arguments that might be presented by Amaca, by HIH or by the reinsurers. We present no legal opinion, and have not based our assessment on any such legal opinion, as to the admissibility of the claim or the expected recovery under the claim.



To the extent recovery is made against this claim, the net asset position of the AICF Trust would improve and this would reduce the future funding requirement by JHINV.

We have allowed for the value of the QBE commutation entered into in June 2000 which involves the payment of a consideration of \$3.1m per annum for 15 years to 30 June 2014.

For the claims occurring period, where a claim filed under a Scheme of Arrangement has been accepted and payment made, we have assumed that the insurance liabilities of that entity to the Liable Entities have been fully discharged and no further recoveries fall due.

We have not included within our estimate any allowance for insurance recoveries that are due but have not yet been collected ("unpaid balances") as these are more appropriately dealt with as a debtor of AICFL.

9.3 Bad debt allowance on Insurance Recoveries

We have made allowance for bad debts on future Insurance Recoveries within our valuation by use of the default rates in Appendix A. These have been sourced from Standard & Poor's Global Fixed Income Research, February 2008 and are based on bond default rates.

We have considered the credit rating of the insurers of the Liable Entities as at March 2008 and applied the relevant credit rating default rates to the expected future cashflows by year, treaty and insurer.

Where additional information regarding the expected payout rates of solvent and insolvent Schemes of Arrangement is available we have instead taken the expected payout rates to assess the credit risk allowance to be made in our liability assessment.

In relation to those claims occurring contracts where CEHUA or CEH U&I insured some of the risks (and then facultatively reinsured that risk), we have assumed, for the purposes of this report, that cut-through from the reinsurers directly to the Liable Entities will not take place and that these Insurance Recoveries will therefore rank alongside other creditors of the HIH Group. We note that this assumption is an actuarial valuation assumption and is not based on legal opinion and we pass no such opinion.



We note the recent House of Lords decision (McGrath and Ors and another vs. Riddell and Ors, [2008] UKHL21) passed down in April 2008 which has had the effect of remitting the reinsurance assets of HIH Group to Australia. Those assets will then be available for distribution in accordance with Australian law.

Whilst this decision assists in any potential applicability of Section 562A(4) of the Corporations Act to the reinsurance recoveries of the HIH Liquidator, the decision does not in itself enshrine or impose cut-through (any such application would be at the Court's discretion).

Accordingly, given the obstacles that still remain (in relation to any potential cut-through) we have not allowed for this beneficial decision to alter the value we have assigned to these insurance and reinsurance contracts at this valuation.

Were cut-through to be achieved, whether under Section 562A(4) of the Corporations Act or under Section 6 of the Law Reform (Miscellaneous Provisions) Act or on some other basis, this would be expected to increase the level of Insurance Recoveries, as the financial health of the reinsurers to the HIH Group is generally better than that of the HIH Group itself, so that a lower bad debt charge would apply.

9.4 Expected Insurance Recoveries

The following table shows the Insurance Recoveries and the bad debt allowances that we have made within our valuation assessment on both a discounted and an undiscounted basis.

Table 9.1: Value of expected Insurance Recoveries

	Undiscounted (\$m)	Discounted (\$m)
Gross Liability	3,525.2	1,645.7
QBE Recoveries	(21.7)	(17.7)
Product and Public liability recoveries	(548.8)	(236.9)
Bad Debt Allowance	72.7	35.3
Net Liability after Bad Debt	3,027.3	1,426.3

As such, non-QBE Insurance Recoveries (after allowing for bad debt) support approximately 12% of the discounted gross liabilities. The overall bad debt allowance amounts to around 15% of the expected Insurance Recoveries.

In determining our net liability assessment, we have assumed that the insurance policies of the Liable Entities will continue to respond to relevant claims we have projected as they fall due. Other than making a general credit risk (“bad debt”) allowance in valuing the Insurance Recoveries, we have assumed they will otherwise be fully recovered.

To the extent that:

- One or more significant insurers fail in the future; and/or
- insurers dispute payments due to the Liable Entities; and/or
- legal cases change the way in which insurances respond to claims (e.g. due to changing legal interpretations of the “date of loss”); and/or
- insurance assets may be subject to claims by non-Australian claimants; and/or
- insurers negotiate commutations of their obligations to the Liable Entities for more or less than our valuation allowance;

the net liabilities of the Liable Entities would vary accordingly. For example an event resulting in a loss of 10% of the anticipated Insurance Recoveries included in our valuation (in addition to the general bad debt allowance) would increase the net liability by approximately \$20 million.



10 VALUATION RESULTS

10.1 Central estimate liability

At 31 March 2008, our central estimate of the liabilities of the Liable Entities (the Discounted Central Estimate) to be met by the AICF Trust is \$1,426.3m (March 2007: \$1,355.1m).

We have not allowed for the future Operating Expenses of the AICF Trust or the Liable Entities in the liability assessment.

The following table shows a summary of our central estimate liability assessment and compares the current assessment with our previous valuation.

Table 10.1: Comparison of central estimate of liabilities

	March 2008 \$m		March 2007 \$m
	Gross of insurance recoveries	Insurance recoveries	Net of insurance recoveries
Total projected cashflows (uninflated)	1,614.3	228.1	1,386.2
Future inflation allowance	1,910.8	269.7	1,641.1
Total projected cash-flows with inflation	3,525.2	497.8	3,027.3
Discounting allowance	(1,879.5)	(278.5)	(1,601.0)
Net present value liabilities	1,645.7	219.4	1,426.3

10.2 Comparison with previous valuation

In the absence of any change to the claim projection assumptions from our 31 March 2007 valuation, other than allowing for the changes in the discount rate, we would have projected a Discounted Central Estimate liability of \$1,334.6m as at 31 March 2008.

Consequently, our revised assessment at 31 March 2008 represents an increase of \$91.7m from that assessment.

The increase in that net liability estimate is principally a consequence of:

- An increase in the projected number of future mesothelioma and asbestosis claims recognising the higher reporting activity in the last year;
- Increases to the incidence pattern of notifications, particularly in relation to the assumed peak year of notification for asbestosis; and
- A reduction in the assumed cross-claim recovery rate.

offset by

- A reduction in average claim awards and legal costs for some disease types;
- An increase in the assumed rate of nil settlements;
- A change to the settlement pattern of claims; and
- Actual experience in the 12-month period being better than forecast, with savings being achieved on claims which were not settled as at the previous valuation.

The following table shows an analysis of the change in our liability assessments from March 2007 to March 2008.

Table 10.2: Analysis of change

	<u>\$m</u>
Net liability at start of valuation period	<u>1,355.1</u>
Expected net claims payments	(64.3)
Unwind of discount / interest charge	84.2
Expected liability at end of valuation period	<u>1,375.0</u>
Change in discount rate	(40.4)
Expected net liability at end of valuation period adjusted for discount rate	<u>1,334.6</u>
Impact of Change in valuation bases:	
- Claim numbers	144.5
- Incidence pattern of notifications (change in peak year)	29.6
- Nil settlement rate	(12.7)
- Average claims costs and legal costs	(72.2)
- Settlement Patterns	(6.9)
- Insurance recoveries	0.2
- Cross-claim recoveries	12.0
- Emerging experience on reported claims and pending claims	(2.8)
Total development in net liability	<u>91.7</u>
Net liability at end of valuation period	<u>1,426.3</u>


10.3 Cashflow projections

10.3.1 Past cashflow expenditure

It is worth comparing the projected rate of future expenditure with that exhibited in the past.

The following chart shows the monthly rate of expenditure relating to asbestos-related claim settlements over the last five years.

**Figure 10.1: Past claim-related expenditure of the Liabe Entities:
 1 January 2003 to 31 March 2008**



Cashflow payments in the 12 months to 31 March 2008 were approximately \$74m gross of insurance and other recoveries and \$55m net of insurance and other recoveries.

By comparison, cashflow payments in the 12 months to 31 March 2007 were approximately \$75m gross of insurance and other recoveries and \$57m net of insurance and other recoveries; whilst in the 12-month period to 31 March 2006, the comparative cashflow figures were \$75m and \$48m respectively.

On a gross basis, cashflow has therefore been reasonably stable across the last three financial years.


Insurance and other recoveries continue to remain strong, albeit at a slightly lower level than that observed in 2005/06 and 2006/07. Those years included, in part, some element of catch-up resulting from the absence of collections taking place in 2004/05 and earlier.

It should be noted that the above chart is compiled on a "cash basis" rather than an "accruals basis" so that the figures are not directly applicable to the actuarial basis of projection. However, the difference in timing should be relatively small (i.e. of the order of 1-2 months generally).

10.3.2 Future cashflow projections

Figure 10.2 shows a comparison of the actual annual net cashflows for all financial years since 2000/01, the projected net cashflows underlying our current valuation and the projected net cashflow projection underlying our previous valuation.

Figure 10.2: Annual cashflow projections (\$m)



The underlying projected cashflows for this chart are detailed in Appendix B.

The increase in projected future cashflow between the previous valuation and our current valuation is predominantly a result of the higher number of future mesothelioma and asbestosis claims which we are now assuming.

With (for example) a 13% increase in the projected future number of mesothelioma claims offset by a 7% reduction in average claim sizes, it is not surprising that the proportionate increase in cashflow across most future years is broadly 5%.

The peak cashflow is projected to arise in around 2020/21, which is later than the projected peak in reporting of claims (2010/11 for mesothelioma). This lag reflects:



- the delay between claims reporting and claims settlement of approximately 1 year for mesothelioma and 2.5 years for non-mesothelioma; and
- the impact of claims inflation upon cashflow. Cashflow is a function of claim numbers and average costs. Until 2018/19, claim numbers reduce at a rate less than 6.6%, so that claims inflation of average claim sizes more than offsets the fall in claim numbers and projected cashflow therefore still increases.

Given the extremely long-tail nature of asbestos-related liabilities, a small change in an individual assumption can have a significant impact upon the cashflow profile of the liabilities.

10.4 Amended Final Funding Agreement calculations

The Amended Final Funding Agreement sets out the basis on which payments will be made to the AICF Trust.

Additionally, there are a number of other figures specified within the Amended Final Funding Agreement that we are required to calculate. These are ⁸:

- Discounted Central Estimate;
- Term Central Estimate; and
- Period Actuarial Estimate.

⁸ See Glossary of Terms in Appendix G for description of these items



Table 10.3: Amended Final Funding Agreement calculations

	\$m
Discounted Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,426.3
Period Actuarial Estimate (net of cross-claim recoveries, gross of Insurance and Other Recoveries) comprising:	249.8
Discounted value of cashflow in 2008/09	81.0
Discounted value of cashflow in 2009/10	83.1
Discounted value of cashflow in 2010/11	85.7
Term Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,422.4

It should be noted that the actual funding required at a particular date will depend upon a number of factors, including:

- the net asset position of the AICF Trust at that time;
- the free cash flow amount of the JHINV Group in the preceding financial year; and
- the Period Actuarial Estimate in the latest Annual Actuarial Report.

10.5 Accounting liability calculations: JHINV

The accounting liabilities for JHINV are determined in accordance with US GAAP which differs from Australian actuarial standards of liability determination.

The determination of the accounting liability to be established by JHINV is ultimately a decision for the Board of JHINV.

However, the Board of JHINV have indicated that the calculation of the accounting liability will, in part, be based upon the liabilities we have estimated within this report.

The basis upon which we have calculated the US GAAP accounting liability is set out in Appendix D.

11 UNCERTAINTY

11.1 Overview

There is uncertainty involved in any valuation of the liabilities of an insurance company or a self-insurer. The sources of such uncertainty include:

- Parameter error — this is the risk that the parameters and assumptions chosen ultimately prove not to be reflective of future experience.
- Model error — this is the risk that the model selected for the valuation of the liabilities ultimately proves not to be adequate for the projection of the liabilities.
- Legal and social developments — this is the risk that the legal environment in which claims are settled changes relative to its current and historic position thereby causing significantly different awards.
- Future actual rates of inflation.
- The general economic environment.
- Potential sources of exposure — this is the risk that there exist sources of exposure which are as yet unknown or unquantifiable, or for which no liabilities have yet been observed, but which may trigger future claims.

In the case of asbestos liabilities, these uncertainties are exacerbated by the extremely long latency period from exposure to onset of disease and notification of a claim. Asbestos-related claims often take in excess of 40 years from original exposure or event to become notified and then settled, compared with an average of 4-5 years for many other compensation-type liabilities such as Comprehensive Third-Party injury liabilities or other Workers Compensation liabilities. Specific forms of uncertainty relating to asbestos-related disease liabilities include:

- The difficulty in quantifying the extent and pattern of past asbestos exposures and the number and incidence of the ultimate number of lives that may be affected by asbestos related diseases arising from such past asbestos exposures;
- The propensity of individuals affected by diseases arising from such exposure to file common law claims against defendants;

- The extent to which the Liable Entities will be joined in such future common law claims;
- The fact that the ultimate severity of the impact of the disease and the quantum of the claims that will be awarded will be subject to the outcome of events that have not yet occurred, including:
 - medical and epidemiological developments;
 - court interpretations;
 - legislative changes;
 - changes to the form and range of benefits for which compensation may be awarded (“heads of damage”);
 - public attitudes to claiming;
 - the potential for future procedural reforms in NSW and other States affecting the legal costs incurred in managing and settling claims;
 - potential third-wave exposures; and
 - social and economic conditions such as inflation.

11.2 Sensitivity testing

As we have noted above, there are many sources of uncertainty. Actuaries often perform “sensitivity testing” to identify the impact of different assumptions as to future experience, thereby providing an indication of the degree of parameter error risk to which the valuation assessment is exposed.

Sensitivity testing may be considered as being a mechanism for testing “what will the liabilities be if instead of choosing [x] for assumption [a] we chose [y]?” It is also a mechanism for identifying how the result will change if experience turns out different in a particular way relative to that which underlies the central estimate expectations. As such, it provides an indication of the level of variability inherent in the valuation.

We have performed some sensitivity tests of the results of our central estimate valuation. We have sensitivity tested the following factors:

- *nil settlement rate*: 5 percentage points above and below our best estimate assumption.
- *average claim cost of a non-nil claim*: 10% above and below our best estimate assumption.

- **peak year of claims:** increase/decrease by 1, 3 and 5 years.
- **number of claims notified:** 5% above and below our best estimate assumption.
- **superimposed inflation:** 2.25% per annum superimposed inflation for 5 years reducing to 0% per annum after a further five years and remaining at 0% per annum thereafter; and 6.25% per annum superimposed inflation for the next five years, linearly reducing to 2.25% per annum after a further five years and remaining at 2.25% per annum thereafter.
- **discount rates:** 1 percentage point above and below our best estimate assumption.
- **base inflation:** 1 percentage point above and below our best estimate assumption.

There are other factors which influence the liability assessment and which could be sensitivity tested, including:

- The cross-claim recovery rate;
- The pattern of claim notifications; and
- The pattern and delay of claim settlements from claim notification.

We have not sensitivity tested these factors noting them to be of less financial significance or uncertainty individually, although in aggregate they could be of more significance.

We have not sensitivity tested the value of Insurance Recoveries as these uncertainties relate to legal risks and disputation risks, and it is not possible to parameterise a sensitivity test in an informed manner.


11.3 Results of sensitivity testing

Figure 11.1 shows the impact of various individual sensitivity tests on the Discounted Central Estimate of the liabilities, and of a combined sensitivity test of a number of factors.

It should be noted that although we have tested multiple scenarios of each assumption, one cannot gauge an overall potential range by simply adding these tests together.

It should also be noted that because of the interactions between assumptions, the maximum range will not be the sum of the constituent parts. Rather it is important to recognise that it is unlikely that all assumptions would deteriorate together, and there are often compensating upsides to the downsides that can arise. This is especially so when considering the inter-dependencies and correlations between parameters, such as higher inflation often being associated with higher discount rates: the former would increase the liabilities whilst the latter would decrease the liabilities.

Figure 11.1: Sensitivity testing results — Impact around the Discounted Central Estimate (in \$m)



* The superimposed inflation sensitivity tests are for 6.25% per annum for 5 years reducing to 2.25% per annum; and 2.25% per annum for 5 years reducing to 0% per annum.

Whilst our combined sensitivity test of a number of factors (including superimposed inflation, average claim costs and numbers of claims) indicates a range around the Discounted Central Estimate of liabilities of -\$400m to +\$700m (i.e. \$1.0bn to \$2.1bn), the actual cost of liabilities could fall outside that range depending on the out-turn of the actual experience.

The above chart implies that the single most sensitive assumption is potentially the peak year of mesothelioma claims reporting against the Liable Entities. Shifting the peak year of mesothelioma claims reporting by 5 years from 2010/11 to 2015/2016 for mesothelioma would imply an increase in the future number of mesothelioma claims reported of around 50%.



Table 11.1: Summary results of sensitivity analysis

	Undiscounted	Discounted
Central estimate	\$3.03bn	\$1.43bn
Range around the central estimate	-\$1.1bn to \$2.4bn	-\$0.4bn to \$0.7bn
Range of liability estimates	\$1.9bn to \$5.4bn	\$1.0bn to \$2.1bn



APPENDICES



A. Credit rating default rates by duration

Rating	Yr. 1	Yr. 2	Yr. 3	Yr. 4	Yr. 5	Yr. 6	Yr. 7	Yr. 8	Yr. 9	Yr. 10	Yr. 11	Yr. 12	Yr. 13	Yr. 14	Yr. 15
AAA	0.00%	0.00%	0.09%	0.18%	0.28%	0.41%	0.48%	0.59%	0.63%	0.67%	0.67%	0.67%	0.67%	0.73%	0.79%
AA+	0.00%	0.06%	0.06%	0.13%	0.20%	0.28%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%
AA	0.00%	0.00%	0.00%	0.09%	0.18%	0.25%	0.35%	0.48%	0.60%	0.72%	0.81%	0.88%	1.03%	1.10%	1.14%
AA-	0.02%	0.09%	0.20%	0.32%	0.45%	0.61%	0.76%	0.86%	0.96%	1.08%	1.21%	1.35%	1.41%	1.53%	1.60%
A+	0.05%	0.10%	0.25%	0.45%	0.61%	0.77%	0.95%	1.10%	1.29%	1.46%	1.66%	1.88%	2.08%	2.31%	2.51%
A	0.07%	0.18%	0.30%	0.42%	0.60%	0.80%	1.00%	1.21%	1.42%	1.73%	1.98%	2.12%	2.26%	2.35%	2.61%
A-	0.06%	0.20%	0.32%	0.49%	0.73%	1.02%	1.44%	1.71%	1.95%	2.12%	2.19%	2.32%	2.42%	2.53%	2.65%
BBB+	0.15%	0.46%	0.91%	1.30%	1.74%	2.22%	2.58%	2.91%	3.36%	3.71%	4.07%	4.27%	4.62%	5.14%	5.72%
BBB	0.23%	0.54%	0.85%	1.39%	1.95%	2.47%	2.95%	3.48%	3.93%	4.44%	5.00%	5.44%	5.93%	6.12%	6.50%
BBB-	0.31%	1.02%	1.78%	2.78%	3.74%	4.60%	5.25%	5.87%	6.33%	6.91%	7.42%	7.94%	8.54%	9.37%	10.03%
BB+	0.52%	1.41%	2.85%	4.20%	5.41%	6.71%	7.88%	8.41%	9.36%	10.21%	10.82%	11.41%	11.85%	12.35%	13.07%
BB	0.81%	2.50%	4.62%	6.53%	8.38%	10.13%	11.52%	12.79%	13.82%	14.62%	15.71%	16.63%	17.10%	17.19%	17.28%
BB-	1.44%	4.16%	7.04%	9.90%	12.32%	14.66%	16.52%	18.35%	19.87%	21.03%	21.93%	22.62%	23.51%	24.22%	24.87%
B+	2.53%	6.97%	11.22%	14.92%	17.65%	19.74%	21.64%	23.29%	24.70%	26.11%	27.32%	28.29%	29.29%	30.31%	31.19%
B	6.27%	12.74%	17.75%	21.27%	23.84%	26.03%	27.44%	28.52%	29.43%	30.43%	31.40%	32.36%	33.42%	34.20%	35.04%
B-	9.06%	16.94%	22.75%	26.66%	29.44%	31.56%	33.38%	34.53%	35.25%	35.73%	36.26%	36.64%	36.84%	37.07%	37.32%
CCC+	25.59%	34.06%	39.04%	41.86%	44.50%	45.62%	46.67%	47.25%	48.86%	49.76%	50.50%	51.26%	51.87%	52.50%	52.50%
L	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NR	2.81%	6.54%	10.00%	12.92%	15.23%	17.23%	18.87%	20.25%	21.46%	22.54%	23.52%	24.34%	25.12%	25.79%	26.43%
CEHUA	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%	80.00%
CEHU&I	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%	92.50%
CIC	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%	55.00%
R	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Source: Standard and Poor's 2007 Annual Global Corporate Default Study and Rating Transitions, February 2008.

CEHUA, CEHU&I and CIC default rates have been estimated by KPMG Actuaries based on HIH Scheme Information at 30 June 2007, available at www.hih.com.au



Notes:

These rates are not used for those solvent and insolvent Schemes of Arrangement where the payout rates are known or have been estimated. In those cases, the payout rate has been used to determine the credit rating default rates.

L relates to Lloyds' of London and Equitas.

NR relates to companies which are Not Rated.

R relates to companies which have been subject to Regulatory Action regarding solvency.

The credit ratings used for individual companies are as at March 2008.



Valuation of the asbestos-related disease liabilities of the
 Liable Entities to be met by the AICF Trust
 31 March 2008

B. Projected cashflows (\$m)

Payment Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Defendant Legal Costs	Workers Compensation		Workers Legal		Wharf Claims	Wharf Legal Costs	Baryulgil	Cross Claim Recoveries	Gross	Insurance	Net
						Claims	Costs	Claims	Costs							
2008 / 2009	60.3	12.6	3.3	3.0	4.0	1.1	0.1	0.3	0.0	0.6	1.7	83.6	12.5	71.2		
2009 / 2010	66.2	14.3	3.0	2.8	4.7	0.9	0.1	0.4	0.0	0.6	1.9	91.2	13.1	78.1		
2010 / 2011	72.3	15.7	3.2	2.9	5.7	0.9	0.1	0.4	0.1	0.6	2.1	99.8	14.1	85.7		
2011 / 2012	78.0	17.0	3.4	3.0	6.5	0.9	0.1	0.4	0.1	0.6	2.2	107.8	14.8	93.0		
2012 / 2013	83.6	18.1	3.6	3.1	7.4	1.0	0.1	0.4	0.1	0.5	2.4	115.7	15.0	100.7		
2013 / 2014	88.9	19.1	3.8	3.3	8.2	1.0	0.2	0.4	0.1	0.5	2.5	122.9	15.7	107.2		
2014 / 2015	93.5	19.9	4.0	3.4	8.9	1.0	0.2	0.4	0.1	0.5	2.6	129.3	16.5	112.9		
2015 / 2016	97.6	20.6	4.2	3.4	9.7	1.0	0.2	0.4	0.1	0.4	2.8	134.9	14.4	120.6		
2016 / 2017	100.9	21.1	4.3	3.5	10.4	1.1	0.2	0.4	0.1	0.4	2.8	139.6	15.5	124.2		
2017 / 2018	103.5	21.5	4.4	3.5	11.1	1.1	0.2	0.4	0.1	0.4	2.9	143.3	16.4	126.9		
2018 / 2019	105.3	21.7	4.5	3.5	11.7	1.1	0.2	0.4	0.1	0.4	3.0	145.9	17.3	128.6		
2019 / 2020	106.1	21.7	4.6	3.5	12.3	1.1	0.2	0.4	0.1	0.3	3.0	147.2	17.9	129.3		
2020 / 2021	106.0	21.6	4.6	3.5	12.8	1.0	0.2	0.3	0.1	0.3	3.0	147.4	18.5	128.9		
2021 / 2022	105.1	21.3	4.6	3.4	13.2	1.0	0.2	0.3	0.1	0.3	2.9	146.5	16.4	130.0		
2022 / 2023	103.3	20.8	4.6	3.3	13.4	1.0	0.2	0.3	0.1	0.2	2.9	144.3	16.8	127.5		
2023 / 2024	100.8	20.2	4.5	3.1	13.4	1.0	0.2	0.3	0.1	0.2	2.8	140.9	17.3	123.6		
2024 / 2025	97.5	19.4	4.4	3.0	13.1	0.9	0.2	0.2	0.1	0.2	2.7	136.3	17.4	118.9		
2025 / 2026	93.6	18.5	4.3	2.8	12.8	0.9	0.2	0.2	0.0	0.2	2.6	130.8	17.3	113.5		
2026 / 2027	89.1	17.4	4.1	2.7	12.4	0.8	0.2	0.2	0.0	0.1	2.5	124.5	17.0	107.4		
2027 / 2028	84.1	16.3	3.9	2.5	12.6	0.7	0.2	0.2	0.1	0.1	2.3	118.3	16.8	101.5		
2028 / 2029	78.8	15.2	3.7	2.3	12.1	0.7	0.2	0.1	0.0	0.1	2.2	111.0	16.4	94.6		
2029 / 2030	73.1	14.0	3.4	2.1	11.5	0.6	0.2	0.1	0.0	0.1	2.0	103.1	15.9	87.3		
2030 / 2031	67.2	12.8	3.2	1.9	10.9	0.6	0.1	0.1	0.0	0.1	1.9	95.1	15.2	79.8		
2031 / 2032	61.3	11.6	2.9	1.7	10.2	0.5	0.1	0.1	0.0	0.1	1.7	86.9	14.7	72.2		
2032 / 2033	55.4	10.5	2.7	1.5	9.5	0.5	0.1	0.1	0.0	0.1	1.5	78.8	14.1	64.8		
2033 / 2034	49.7	9.3	2.4	1.3	8.8	0.4	0.1	0.1	0.0	0.0	1.4	70.9	13.3	57.5		
2034 / 2035	44.2	8.3	2.2	1.2	8.1	0.4	0.1	0.1	0.0	0.0	1.2	63.3	12.6	50.6		
2035 / 2036	38.9	7.3	2.0	1.0	7.4	0.3	0.1	0.0	0.0	0.0	1.1	56.0	11.8	44.2		
2036 / 2037	34.0	6.3	1.7	0.9	6.7	0.3	0.1	0.0	0.0	0.0	0.9	49.2	11.0	38.1		
2037 / 2038	29.5	5.5	1.5	0.8	6.1	0.2	0.1	0.0	0.0	0.0	0.8	42.8	10.2	32.6		
2038 / 2039	25.3	4.7	1.3	0.6	5.5	0.2	0.1	0.0	0.0	0.0	0.7	37.0	7.7	29.3		
2039 / 2040	21.6	4.0	1.1	0.5	4.8	0.2	0.1	0.0	0.0	0.0	0.6	31.7	6.9	24.9		
2040 / 2041	18.2	3.4	1.0	0.5	4.3	0.1	0.1	0.0	0.0	0.0	0.5	27.0	6.2	20.8		
2041 / 2042	15.3	2.8	0.8	0.4	3.8	0.1	0.0	0.0	0.0	0.0	0.4	22.8	4.2	18.6		
2042 / 2043	12.7	2.3	0.7	0.3	3.3	0.1	0.0	0.0	0.0	0.0	0.4	19.1	3.7	15.3		
2043 / 2044	10.4	1.9	0.6	0.3	2.8	0.1	0.0	0.0	0.0	0.0	0.3	15.9	3.1	12.8		
2044 / 2045	8.5	1.6	0.5	0.2	2.4	0.1	0.0	0.0	0.0	0.0	0.2	13.1	2.1	11.0		
2045 / 2046	6.9	1.3	0.4	0.2	2.1	0.1	0.0	0.0	0.0	0.0	0.2	10.7	1.7	9.0		
2046 / 2047	5.5	1.0	0.3	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.2	8.7	1.4	7.3		
2047 / 2048	4.4	0.8	0.3	0.1	1.5	0.0	0.0	0.0	0.0	0.0	0.1	7.0	1.1	5.9		
2048 / 2049	3.5	0.7	0.2	0.1	1.2	0.0	0.0	0.0	0.0	0.0	0.1	5.6	0.9	4.7		
2049 / 2050	2.7	0.5	0.2	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.1	4.4	0.7	3.8		
2050 / 2051	2.1	0.4	0.1	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.1	3.5	0.5	3.0		
2051 / 2052	1.6	0.3	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.4	2.3		
2052 / 2053	1.2	0.2	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.3	1.8		
2053 / 2054	0.9	0.2	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.3	1.4		
2054 / 2055	0.7	0.1	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.2	1.1		
2055 / 2056	0.5	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.2	0.8		
2056 / 2057	0.4	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.6		
2057 / 2058	0.3	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.5		
2058 / 2059	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.3		
2059 / 2060	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.3		
2060 / 2061	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2		
2061 / 2062	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1		
2062 / 2063	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1		
2063 / 2064	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1		
2064 / 2065	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2065 / 2066	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2066 / 2067	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2067 / 2068	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2068 / 2069	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2069 / 2070	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2070 / 2071	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2071 / 2072	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
TOTAL	2,511.6	506.3	115.3	81.4	333.9	25.0	4.9	7.7	1.6	8.0	70.4	3,525.2	497.8	3,027.3		



*Valuation of the asbestos-related disease liabilities of the
Liable Entities to be met by the AICF Trust
31 March 2008*

C. Projected discounted cashflows (\$m)

Payment Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Defendant Legal Costs	Workers Compensation		Workers Legal		Wharf Claims	Wharf Legal Costs	Baryulgil	Cross Claim Recoveries	Gross	Insurance	Net
						Claims	Costs	Claims	Costs							
2008 / 2009	58.4	12.2	3.2	2.9	3.9	1.1	0.1	0.3	0.0	0.6	1.6	81.0	12.1	69.0		
2009 / 2010	60.3	13.0	2.8	2.6	4.3	0.8	0.1	0.3	0.0	0.5	1.7	83.1	11.9	71.2		
2010 / 2011	62.1	13.5	2.8	2.5	4.9	0.8	0.1	0.4	0.0	0.5	1.8	85.7	12.1	73.6		
2011 / 2012	63.2	13.7	2.8	2.4	5.3	0.8	0.1	0.4	0.1	0.4	1.8	87.2	12.0	75.2		
2012 / 2013	63.8	13.8	2.8	2.4	5.7	0.7	0.1	0.3	0.1	0.4	1.8	88.3	11.4	76.8		
2013 / 2014	63.9	13.7	2.7	2.3	5.9	0.7	0.1	0.3	0.1	0.4	1.8	88.3	11.3	77.1		
2014 / 2015	63.4	13.5	2.7	2.3	6.1	0.7	0.1	0.3	0.0	0.3	1.8	87.6	11.2	76.5		
2015 / 2016	62.4	13.2	2.7	2.2	6.2	0.7	0.1	0.3	0.0	0.3	1.8	86.2	9.2	77.0		
2016 / 2017	60.8	12.7	2.6	2.1	6.3	0.6	0.1	0.3	0.0	0.2	1.7	84.1	9.3	74.8		
2017 / 2018	58.7	12.2	2.5	2.0	6.3	0.6	0.1	0.2	0.0	0.2	1.7	81.3	9.3	72.0		
2018 / 2019	56.4	11.6	2.4	1.9	6.3	0.6	0.1	0.2	0.0	0.2	1.6	78.1	9.3	68.8		
2019 / 2020	53.5	11.0	2.3	1.8	6.2	0.5	0.1	0.2	0.0	0.2	1.5	74.3	9.1	65.2		
2020 / 2021	50.4	10.3	2.2	1.6	6.1	0.5	0.1	0.2	0.0	0.1	1.4	70.1	8.8	61.3		
2021 / 2022	47.1	9.5	2.1	1.5	5.9	0.5	0.1	0.1	0.0	0.1	1.3	65.6	7.4	58.3		
2022 / 2023	43.7	8.8	1.9	1.4	5.7	0.4	0.1	0.1	0.0	0.1	1.2	60.9	7.1	53.9		
2023 / 2024	40.1	8.0	1.8	1.3	5.3	0.4	0.1	0.1	0.0	0.1	1.1	56.1	6.9	49.2		
2024 / 2025	36.6	7.3	1.7	1.1	4.9	0.3	0.1	0.1	0.0	0.1	1.0	51.1	6.5	44.6		
2025 / 2026	33.1	6.5	1.5	1.0	4.5	0.3	0.1	0.1	0.0	0.1	0.9	46.3	6.1	40.1		
2026 / 2027	29.7	5.8	1.4	0.9	4.1	0.3	0.1	0.1	0.0	0.0	0.8	41.5	5.7	35.8		
2027 / 2028	26.4	5.1	1.2	0.8	4.0	0.2	0.1	0.1	0.0	0.0	0.7	37.2	5.3	31.9		
2028 / 2029	23.3	4.5	1.1	0.7	3.6	0.2	0.0	0.0	0.0	0.0	0.6	32.9	4.9	28.0		
2029 / 2030	20.4	3.9	1.0	0.6	3.2	0.2	0.0	0.0	0.0	0.0	0.6	28.8	4.4	24.4		
2030 / 2031	17.7	3.4	0.8	0.5	2.9	0.1	0.0	0.0	0.0	0.0	0.5	25.0	4.0	21.0		
2031 / 2032	15.2	2.9	0.7	0.4	2.5	0.1	0.0	0.0	0.0	0.0	0.4	21.6	3.6	17.9		
2032 / 2033	13.0	2.4	0.6	0.4	2.2	0.1	0.0	0.0	0.0	0.0	0.4	18.4	3.3	15.1		
2033 / 2034	11.0	2.1	0.5	0.3	1.9	0.1	0.0	0.0	0.0	0.0	0.3	15.6	2.9	12.7		
2034 / 2035	9.2	1.7	0.5	0.2	1.7	0.1	0.0	0.0	0.0	0.0	0.3	13.1	2.6	10.5		
2035 / 2036	7.6	1.4	0.4	0.2	1.5	0.1	0.0	0.0	0.0	0.0	0.2	11.0	2.3	8.6		
2036 / 2037	6.3	1.2	0.3	0.2	1.2	0.0	0.0	0.0	0.0	0.0	0.2	9.1	2.0	7.0		
2037 / 2038	5.1	0.9	0.3	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.1	7.5	1.8	5.7		
2038 / 2039	4.2	0.8	0.2	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.1	6.1	1.3	4.8		
2039 / 2040	3.3	0.6	0.2	0.1	0.7	0.0	0.0	0.0	0.0	0.0	0.1	4.9	1.1	3.8		
2040 / 2041	2.7	0.5	0.1	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.1	3.9	0.9	3.0		
2041 / 2042	2.1	0.4	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.1	3.1	0.6	2.6		
2042 / 2043	1.6	0.3	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.5	2.0		
2043 / 2044	1.3	0.2	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.4	1.6		
2044 / 2045	1.0	0.2	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.2	1.3		
2045 / 2046	0.7	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.2	1.0		
2046 / 2047	0.6	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.1	0.7		
2047 / 2048	0.4	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.6		
2048 / 2049	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.4		
2049 / 2050	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.3		
2050 / 2051	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2		
2051 / 2052	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2		
2052 / 2053	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1		
2053 / 2054	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1		
2054 / 2055	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1		
2055 / 2056	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0		
2056 / 2057	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2057 / 2058	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2058 / 2059	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2059 / 2060	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2060 / 2061	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2061 / 2062	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2062 / 2063	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2063 / 2064	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2064 / 2065	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2065 / 2066	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2066 / 2067	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2067 / 2068	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2068 / 2069	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2069 / 2070	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2070 / 2071	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
2071 / 2072	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
TOTAL	1,181.8	243.5	53.2	41.0	134.2	12.7	2.2	4.4	0.8	5.1	33.2	1,645.7	219.4	1,426.3		



D. Derivation of US GAAP net accounting liability of JHINV

The cashflows used in the derivation of the accounting liability are “uninflated and undiscounted” (“UIUD”).

No credit is taken within the determination of the accounting liability under US GAAP for “cross claim recoveries” from third parties until such recoveries have been received.

Adjustments are then made by to allow for:

- The expected future direct claims handling costs projected to be incurred in settling all future claims;
- The net assets or liabilities of the AICF; and
- Tax deductibility of contributions by JHINV.

The following tables show how the net US GAAP accounting liability established by JHINV is derived from the valuation estimates contained within this report.

For comparison, we have shown the derivation of the net liability figures for 31 March 2007.

Note that the tables do not show the split between current and non-current liabilities and nor do they show the breakdown of the exact composition of the accounting liability between the gross liability and any corresponding insurance assets.

Readers are referred to the financial statements of JHINV for specific details of the required US GAAP disclosures.



Step 1 — KPMGA estimate of uninflated and undiscounted liabilities (AUD)

The first step is to derive the uninflated and undiscounted liability from the Discounted Central Estimate.

This is shown in Section 11 of this report to be derived as follows:

	31 March 2008 Valuation			31 March 2007	Change
	Gross	Insurance	Net	Net	Net
Discounted Central Estimate	1,645.7	219.4	1,426.3	1,355.1	71.2
Discounting allowance	1,879.5	278.5	1,601.0	1,455.6	145.4
Inflated, Undiscounted Central Estimate	3,525.2	497.8	3,027.3	2,810.8	216.5
Inflation allowance	(1,910.8)	(269.7)	(1,641.1)	(1,537.8)	(103.3)
Uninflated and Undiscounted liability	1,614.3	228.1	1,386.2	1,273.0	113.2



Step 2 — US GAAP adjustments (AUD)

These include adjustments for:

- Adjustment to value QBE receivables on a discounted basis as the timing and monetary amounts of the receivables are known;
- Removal of recoveries arising from cross-claims;
- Future direct claims handling allowance on uninflated & undiscounted basis;
- Gross-up for recoveries from workers compensation insurers — although the net liability impact is zero; and
- Net assets (or net liabilities) of AICF.

	31 March 2008 Valuation			31 March 2007	Change Net
	Gross	Insurance	Net	Net	
Uninflated, Undiscounted liabilities	1,614.3	228.1	1,386.2	1,273.0	113.2
Adjustment for discounting QBE receivable (as timing of receipts is fixed)	0.0	(4.0)	4.0	0.0	4.0
Other insurance receivable adjustments	0.0	3.1	(3.1)	0.0	(3.1)
Cross-claim recoveries (on UIUD basis)	31.1	0.0	31.1	39.6	(8.5)
Claims handling costs	73.5	0.0	73.5	69.2	4.3
Asbestos liability	1,718.9	227.2	1,491.7	1,381.8	109.9
Workers Compensation Additional Liability	93.1	93.1	0.0	0.0	0.0
Accounting Liability (pre-tax)	1,812.0	320.3	1,491.7	1,381.8	109.9



Step 3 — Conversion to US Dollars

	31 March 2008 Valuation			31 March 2007 Net	Change Net
	Gross	Insurance	Net		
Net accounting liability (pre tax) — AUD	1,812.0	320.3	1,491.7	1,381.8	109.9
<i>Exchange rate</i>	<i>1.0903</i>	<i>1.0903</i>	<i>1.0903</i>	<i>1.2395</i>	
Net accounting liability (pre tax) — USD	1,661.9	293.8	1,368.1	1,114.8	253.3

Further adjustments are then required to establish the liability, allowing for:

- Deferred Income Tax Assets (USD426.6m); and
- Other net liabilities (primarily reflecting commitments in the FFA to provide certain educational and medical research funding) (USD3.4m).

This results in a net liability of USD944.9m. In arriving at the unfunded liability, allowance is then made for the existing net assets of the AICF (USD115.1m) at 31 March 2008 to leave an unfunded net liability of USD829.8m.

E. Allocation of central estimate liabilities to AICFL entities

The accounting liabilities for AICFL are determined in accordance with Australian GAAP which differs from US GAAP and is more closely aligned with the Australian actuarial standards of liability determination.

The determination of the accounting liabilities of AICFL is ultimately a decision for the Board of AICFL.

However, we have been requested to provide an actuarially-assessed allocation of the central estimate liabilities set out in this report to each of the three entities (namely Amaca, Amaba and ABN60) to assist AICFL in completing their statutory financial statements.

The central estimate liabilities for each entity have been assessed on the basis of the overall figures contained within this report, with a separate allocation to each entity as follows:

- Gross liabilities (net of cross-claim recoveries),
- Allocation of insurance recoveries (separating QBE and other insurance recoveries); and
- Split between current and non-current liabilities.

Our allocation assumptions (based on a review of past experience) for each of the categories of claim are as follows:

Table 1: Mix of claims costs by Liable Entity

	<u>Open claims</u>	<u>Gross IBNR</u>	<u>Baryulgil</u>	<u>QBE recoveries</u>
Amaca Pty Ltd	98.49%	97.40%	100.00%	96.00%
Amaba Pty Ltd	1.49%	2.50%	0.00%	4.00%
ABN60 Pty Ltd	0.02%	0.10%	0.00%	0.00%

This allocation results in the following allocation of the assets and liabilities of the Liable Entities (Note: these figures do not include any claims handling expenses and separate allowance for this is required to be made by AICFL.)



Table 2: Allocation of central estimate liabilities by Liable Entity (A\$m)

		Amaca	Amaba	ABN 60	Total
Current liabilities	Gross	79.4	1.6	0.0	81.0
	QBE	2.9	0.1	0.0	3.0
	Insurance	8.9	0.2	0.0	9.1
	Net	67.6	1.3	0.0	69.0
Non- current liabilities	Gross	1,524.6	38.5	1.5	1,564.7
	QBE	14.1	0.6	0.0	14.7
	Insurance	187.7	4.8	0.2	192.6
	Net	1,322.8	33.2	1.3	1,357.4
Total liabilities	Gross	1,604.0	40.1	1.6	1,645.7
	QBE	17.0	0.7	0.0	17.7
	Insurance	196.5	4.9	0.2	201.7
	Net	1,390.5	34.5	1.4	1,426.3

Note: Owing to rounding, the above table may not necessarily reconcile exactly to figures contained earlier in the report; nor may the total column equal the sum of the individual entities. Such differences will, however, only be +/- \$0.1m.

As already indicated within this report, the projection of future asbestos liabilities is subject to significant uncertainty.

The allocation of the overall liability projections between individual entities adds an additional level of uncertainty, which arises because the subdivision of data to each entity reduces the credibility of the projection even further and because the projection of which of the Liable Entities will be joined in future claims is uncertain as it is influenced by the action of plaintiff lawyers as to whom they name in a "Statement of Claim".

Accordingly, such estimates are less readily predictable and deviations from the estimates by entity as contained above should therefore be expected.



F. Australian asbestos consumption and production data: 1920-2002

Figures in this table are in 000's metric tonnes

Year	Production	Import	Export	Consumption
1920	0	0	0	0
1921	1,182	0	0	1,182
1922	742	0	0	742
1923	217	0	0	217
1924	78	0	0	78
1925	51	0	0	51
1926	0	0	0	0
1927	11	0	0	11
1928	12	0	0	12
1929	255	3,679	0	3,934
1930	82	0	0	82
1931	128	1,200	0	1,328
1932	130	0	0	130
1933	279	2,676	0	2,955
1934	170	2,471	0	2,641
1935	170	4,423	0	4,593
1936	239	7,817	0	8,056
1937	298	6,199	0	6,497
1938	173	11,179	0	11,352
1939	78	10,081	0	10,159
1940	489	14,097	0	14,586
1941	251	14,220	0	14,471
1942	331	20,176	0	20,507
1943	678	14,229	0	14,907
1944	764	14,091	0	14,855
1945	1,629	9,131	32	10,728
1946	620	18,697	496	18,821
1947	1,377	14,246	652	14,971
1948	1,327	14,857	278	15,906
1949	1,645	14,767	346	16,066
1950	1,617	29,536	385	30,768
1951	2,558	25,289	588	27,259
1952	4,059	24,686	868	27,877
1953	4,970	28,784	1,631	32,123
1954	4,713	26,406	2,298	28,821
1955	5,352	42,677	3,287	44,742
1956	8,670	32,219	6,859	34,030
1957	13,098	23,235	11,644	24,689
1958	13,900	34,721	9,315	39,306
1959	15,959	34,223	11,584	38,598
1960	13,940	36,609	7,410	43,139
1961	14,952	32,947	7,196	40,703
1962	16,443	34,915	8,695	42,663
1963	11,941	32,704	2,347	42,298
1964	12,191	38,299	6,500	43,990
1965	10,326	46,179	4,295	52,210
1966	12,024	49,243	4,146	57,121
1967	647	46,950	2,254	45,343
1968	799	59,590	718	59,671
1969	734	52,739	162	53,311
1970	739	57,250	367	57,622
1971	756	71,777	174	72,359
1972	16,884	61,682	2,387	76,179
1973	43,529	61,373	27,810	77,092
1974	30,863	57,051	29,191	58,723
1975	47,922	69,794	24,524	93,192
1976	60,642	60,490	40,145	80,987
1977	50,601	54,267	20,510	84,358
1978	62,383	42,061	37,094	67,350
1979	79,721	23,735	54,041	49,415
1980	92,418	25,239	51,172	66,485
1981	45,494	20,960	38,576	27,878
1982	18,587	20,853	15,578	23,862
1983	3,909	10,113	4,460	9,562
1984	0	14,432	22	14,410
1985	0	12,194	0	12,194
1986	0	10,597	0	10,597
1987	0	6,294	0	6,294
1988	0	2,072	0	2,072
1989	0	2,128	0	2,128

1990	0	1,706	0	1,706
1991	0	1,342	0	1,342
1992	0	1,533	0	1,533
1993	0	2,198	0	2,198
1994	0	1,843	0	1,843
1995	0	1,488	0	1,488
1996	0	1,366	0	1,366
1997	0	1,556	0	1,556
1998	0	1,471	0	1,471
1999	0	1,316	0	1,316
2000	0	1,246	0	1,246
2001	0	945	0	945
2002	0	515	0	515

G. Glossary of terms

The following provides a glossary of terms upon which we have relied in preparing our report.

The operation of these definitions cannot be considered in isolation but instead need to be considered in the context of the totality of the Amended Final Funding Agreement.

AICF means the trustee of the Asbestos Injuries Compensation Fund from time to time, in its capacity as trustee, initially being Asbestos Injuries Compensation Fund Limited.

AICF Funded Liability means:

- (a) any Proven Claim;
- (b) Operating Expenses;
- (c) Claims Legal Costs;
- (d) any claim that was made or brought in legal proceedings against a Former James Hardie Company commenced before 1 December 2005;
- (e) Statutory Recoveries within the meaning and subject to the limits set out in the Amended Final Funding Agreement;
- (f) a claim or category of claim which James Hardie and the NSW Government agree in writing is a "AICF Funded Liability" or a category of "AICF Funded Liability".

but in the cases of paragraphs (a), (c) and (d) excludes any such liabilities or claims to the extent that they have been recovered or are recoverable under a Worker's Compensation Scheme or Policy

Claims Legal Costs means all costs, charges, expenses and outgoings incurred or expected to be borne by AICF or the Former James Hardie Companies, in respect of legal advisors, other advisors, experts, court proceedings and other dispute resolution methods in connection with Personal Asbestos Claims and Marlew Claims but in all cases excluding any costs included as a component of calculating a Proven Claim.

Concurrent Wrongdoer in relation to a personal injury or death claim for damages under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with Amended Final Funding Agreement), means a person whose acts or omissions, together with the acts or omissions of one or more Former James Hardie Companies or Marlew or any member of the James Hardie Group (whether or not together with any other persons) caused, independently of each other or jointly, the damage or loss to another person that is the subject of that claim.

Contribution Claim means a cross-claim or other claim under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with Amended Final Funding Agreement):

- (a) for contribution by a Concurrent Wrongdoer against a Former James Hardie Company or a member of the James Hardie Group in relation to facts or circumstances which give rise to a right of a person to make a Personal Asbestos Claim or a Marlew Claim; or
- (b) by another person who is entitled under common law (including by way of contract) to be subrogated to such a first mentioned cross-claim or other claim;

Discounted Central Estimate means the central estimate of the present value (determined using the discount rate used within the relevant actuarial report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs, calculated in accordance with the Amended Final Funding Agreement.

Excluded Claims are any of the following liabilities of the Former James Hardie Companies:

- (i) personal injury or death claims arising from exposure to Asbestos outside Australia;
- (ii) personal injury or death claims arising from exposure to Asbestos made outside Australia;
- (iii) claims for economic loss (other than any economic loss forming part of the calculation of an award of damages for personal injury or death) or loss of property, including those relating to land remediation and/or Asbestos or Asbestos products removal, arising out of or in connection

with Asbestos or Asbestos products manufactured, sold, distributed or used by or on behalf of the Liable Entities;

- (iv) any Excluded Marlew Claim;
- (v) any liabilities of the Liable Entities other than AICF Funded Liabilities.

Excluded Marlew Claim means a Marlew Claim:

- (a) covered by the indemnities granted by the Minister of Mineral Resources under the deed between the Minister, Fuller Earthmoving Pty Limited and James Hardie Industries Limited dated 11 March 1996; or
- (b) by a current or former employee of Marlew in relation to an exposure to Asbestos in the course of such employment to the extent:
 - (i) the loss is recoverable under a Worker's Compensation Scheme or Policy; or
 - (ii) the Claimant is not unable to recover damages from a Marlew Joint Tortfeasor in accordance with the Marlew Legislation;
- (c) by an individual who was or is an employee of a person other than Marlew arising from exposure to Asbestos in the course of such employment by that other person where such loss is recoverable from that person or under a Worker's Compensation Scheme or Policy; or
- (d) in which another defendant (or its insurer) is a Marlew Joint Tortfeasor from whom the plaintiff is entitled to recover compensation in proceedings in the Dust Diseases Tribunal, and the Claimant is not unable to recover damages from that Marlew Joint Tortfeasor in accordance with the Marlew Legislation.

Former James Hardie Companies means Amaca, Amaba and ABN 60.

Insurance and Other Recoveries means any proceeds which may reasonably be expected to be recovered or recoverable for the account of a Former James Hardie Company or to result in the satisfaction (in whole or part) of a liability of a Former James Hardie Company (of any nature) to a third party, under any product liability insurance policy or public liability insurance policy or commutation of such policy or under any other contract, including any contract of indemnity, but excluding any such amount recovered or recoverable under a Worker's Compensation Scheme or Policy.

Liable Entities see Former James Hardie Companies

Marlew means Marlew Mining Pty Ltd (in liquidation), ACN 000 049 650, previously known as Asbestos Mines Pty Ltd.



Marlew Claim means, subject to the limitation on Statutory Recoveries, a claim which satisfies one of the following paragraphs and which is not an Excluded Marlew Claim:

- (a) any present or future personal injury or death claim by an individual or the legal personal representative of an individual, for damages under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with the Amended Final Funding Agreement) which:
 - (i) arose or arises from exposure to Asbestos in the Baryulgil region from Asbestos Mining Activities at Baryulgil conducted by Marlew, provided that:
 - A. the individual's exposure to Asbestos occurred wholly within Australia; or
 - B. where the individual has been exposed to Asbestos both within and outside Australia, the amount of damages included in the Marlew Claim shall be limited to the amount attributable to the proportion of the exposure which caused or contributed to the loss or damage giving rise to the Marlew Claim which occurred in Australia;
 - (ii) is commenced in New South Wales in the Dust Diseases Tribunal; and
 - (iii) is or could have been made against Marlew had Marlew not been in external administration or wound up, or could be made against Marlew on the assumption (other than as contemplated under the Marlew legislation) that Marlew will not be in the future in external administration;
- (b) any claim made under compensation to relatives legislation by a relative of a deceased individual (or personal representative of such a relative) or (where permitted by law) the legal personal representative of a deceased individual in each case where the individual, but for such individual's death, would have been entitled to bring a claim of the kind described in paragraph (a); or
- (c) a Contribution Claim relating to a claim described in paragraphs (a) or (b).



Marlew Joint Tortfeasor means any person who is or would be jointly and severally liable with Marlew in respect of a Marlew Claim, had Marlew not been in external administration or wound up, or on the assumption that Marlew will not in the future be, in external administration or wound up other than as contemplated under the Marlew Legislation.

Payable Liability means any of the following:

- (a) any Proven Claim (whether arising before or after the date of this deed);
- (b) Operating Expenses;
- (c) Claims Legal Costs;
- (d) any liability of a Former James Hardie Company to the AICFL, however arising, in respect of any amounts paid by the AICFL in respect of any liability or otherwise on behalf of the Former James Hardie Company;
- (e) any claim that was made or brought in legal proceedings against a Former James Hardie Company commenced before 1 December 2005;
- (f) if regulations are made pursuant to section 30 of the Transaction Legislation and if and to the extent the AICFL and James Hardie have notified the NSW Government that any such liability is to be included in the scope of Payable Liability, any liability of a Former James Hardie Company to pay amounts received by it from an insurer in respect of a liability to a third party incurred by it for which it is or was insured under a contract of insurance entered into before 2 December 2005; and
- (g) Statutory Recoveries within the meaning and subject to the limits set out in the Amended Final Funding Agreement,

but in the cases of paragraphs (a), (c) and (e) excludes any such liabilities or claims to the extent that they have been recovered or are recoverable under a Worker's Compensation Scheme or Policy.



Period Actuarial Estimate means, in respect of a period, the central estimate of the present value (determined using the discount rate used in the relevant actuarial report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs (in each case which are reasonably expected to become payable in that period), before allowing for Insurance and Other Recoveries, calculated in accordance with the Amended Final Funding Agreement.

Personal Asbestos Claim means any present or future personal injury or death claim by an individual or the legal personal representative of an individual, for damages under common law or under other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government under the Amended Final Funding Agreement) which:

- (a) arises from exposure to Asbestos occurring in Australia, provided that:
 - (i) the individual's exposure to Asbestos occurred wholly within Australia; or
 - (ii) where the individual has been exposed to Asbestos both within and outside Australia, damages included in the Marlew Claim shall be limited to the amount attributable to the proportion of the exposure which caused or contributed to the loss or damage giving rise to the Personal Asbestos Claim which occurred in Australia;
- (b) is made in proceedings in an Australian court or tribunal; and
- (c) is made against:
 - (i) all or any of the Liable Entities; or
 - (ii) any member of the James Hardie Group from time to time;
- (d) any claim made under compensation to relatives legislation by a relative of a deceased individual (or personal representative of such a relative) or (where permitted by law) the legal personal representative of a deceased individual in each case where the individual, but for such individual's death, would have been entitled to bring a claim of the kind described in paragraph (a); or
- (e) a Contribution Claim made in relation to a claim described in paragraph (a) or (b)

but excludes all claims covered by a Worker's Compensation Scheme or Policy.



Proven Claim means a proven Personal Asbestos Claim in respect of which final judgment has been given against, or a binding settlement has been entered into by, a Former James Hardie Company, to the extent to which that entity incurs liability under that judgment or settlement, or a Proven Marlew Claim.

Statutory Recoveries means any statutory entitlement of the NSW Government or any Other Government or any governmental agency or authority of any such government ("Relevant Body") to impose liability on or to recover an amount or amounts from any person in respect of any payments made or to be made or benefits provided by a Relevant Body in respect of claims (other than as a defendant or in settlement of any claim, including a cross-claim or claim for contribution).

Term means the period

- (i) from the date on which the principal obligations under the Amended Final Funding Agreement will commence to 31 March 2045,
- (ii) as may be extended in accordance with the terms of the Amended Final Funding Agreement.

Term Central Estimate means the central estimate of the present value (determined using the discount rate used in the relevant Annual Actuarial Report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs (in each case reasonably expected to become payable in the relevant period) after allowing for Insurance and Other Recoveries during that period, from and including the day following the end of the Financial Year preceding that Payment Date up to and including the last day of the Term (excluding any automatic or potential extension of the Term, unless or until the Term has been extended).

Workers Compensation Scheme or Policy means any of the following:

- (a) any worker's compensation scheme established by any law of the Commonwealth or of any State or Territory;
- (b) any fund established to cover liabilities under insurance policies upon the actual or prospective insolvency of the insurer (including without limitation the Insurer Guarantee Fund established under the Worker's Compensation Act 1987 (NSW)); and
- (c) any policy of insurance issued under or pursuant to such a scheme.